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Abstract           
Lynch Syndrome (LS) confers an inherited cancer predisposition, particularly for 
colorectal cancer, due to germline mutations in one of the DNA mismatch repair (MMR) 
genes, such as MSH2. MMR is a DNA damage repair pathway involved in the removal of 
base mismatches and insertion/deletion loops, caused by several endogenous and 
exogenous factors. Loss of MMR through somatic alteration of the wild-type MMR allele 
in LS results in defective MMR (dMMR). Lifestyle factors can modify cancer risk for LS 
and sporadic patients. Ethanol and its metabolite acetaldehyde, are classified as group 
one carcinogens by the International Agency for Research on Cancer, and are risk factors 
for sporadic cancers of the upper aerodigestive tract, liver, breast and colorectum. 
Acetaldehyde is metabolised to acetate by the Aldh family of enzymes, particularly 
Aldh1b1 in the intestines. Acetaldehyde is very reactive and may cause a range of DNA 
lesions. However, DNA repair pathways responsible for correcting such lesions remain 
unknown. It was hypothesized that MMR plays a role in protecting intestinal cells from 
ethanol/acetaldehyde-induced DNA damage. This study aimed to determine if there is 
a gene/environment interaction between dMMR and ethanol/acetaldehyde that 
accelerates colorectal tumour development and progression. 
A conditional Msh2 knockout (“Msh2-LS”) mouse model with one deleted and one 
conditional knockout Msh2 allele was used, as it mimics the LS patients’ pattern of MMR 
gene inactivation. The Msh2-LS model mice were fed either with 20% ethanol in drinking 
water or normal drinking water. Long-term ethanol consumption led to large intestinal 
mucosal epithelial hyperproliferation and adenoma formation in 65% (15/23) mice and, 
in some cases, invasive adenocarcinoma (5/23 mice, 21.7%) within 6 months (mostly in 
the proximal and mid-colon), compared with 0% (0/23 mice) at 6 months and only one 
colonic tumour after 15 months in the water-treated mice (p<0.0001). No small 
intestinal tumours were observed. Additionally, a conditional Aldh1b1 knockout 
(Aldh1b1flox/flox) Msh2-LS mouse model and a constitutive Aldh1b1 knockout (Aldh1b1-/-) 
Msh2-LS mouse model were generated, in which the lack of Aldh1b1 enzyme caused 
increased acetaldehyde levels and acetaldehyde-induced DNA damage. In these 
Aldh1b1-deficient mice, long-term ethanol consumption led to increased numbers of 
colorectal adenomas per mouse (4.2, 21 neoplasms in 5 tumour-bearing conditional 
Aldh1b1fl/fl Msh2-LS mice; and 4.8, 35 neoplasms in 8 tumour-bearing constitutive 
iv 
 
Aldh1b1-/- Msh2-LS mice) compared with 2.4 (36 neoplasms in 15 tumour-bearing mice) 
colorectal adenomas per mouse observed in the Msh2-LS mouse model with wild-type 
Aldh1b1 (p=0.0319 and p=0.0103) , but no colonic tumours were observed in water-
treated controls.  
Precursor lesions were observed as dMMR crypts in the murine colon in all of these 
mouse models, and their quantification showed increased numbers of dMMR crypt foci 
in ethanol-treated mice compared with water-treated controls (p=0.0029 in Aldh1b1wt 
Msh2-LS mice, p=0.0006 in Aldh1b1fl/fl  Msh2-LS mice and p<0.0001 in Aldh1b1-/-   Msh2-
LS mice). A significant increase in DNA damage was detected in the large intestinal 
epithelium of ethanol-treated mice of all genotypes compared with the respective 
water-treated controls (p=0.0009 in Aldh1b1wt Msh2-LS mice, p<0.0001 in Aldh1b1fl/fl  
Msh2-LS mice and in Aldh1b1-/-   Msh2-LS mice), along with increased plasma 
acetaldehyde levels in ethanol-treated mice and acetaldehyde levels were higher in the 
plasma of Aldh1b1flox/flox Msh2-LS mice and Aldh1b1-/- Msh2-LS mice than in the plasma 
of Msh2-LS mice.  
In this study, evidence was provided for a role for Msh2 in protecting the MMR-
proficient colonic epithelial cells against ethanol/acetaldehyde-induced DNA damage by 
activating DNA mismatch repair, triggering cell cycle arrest or cell death by apoptosis. A 
key role for Aldh1b1 was confirmed for protecting the large intestines from 
acetaldehyde-induced DNA damage and tumour formation. Long-term 
ethanol/acetaldehyde exposure was shown to accelerate dMMR-driven intestinal 
tumour formation and this is proposed to act via promoting proliferation (mucosal 
epithelial hyperproliferation) and suppressing apoptosis, thus enhancing survival of 
aberrant dMMR intestinal epithelial cells/crypts relative to MMR-proficient intestinal 
epithelial cells/crypts, leading to adenoma development (with microsatellite instability) 
with some progressing to adenocarcinomas.  In conclusion, there is strong evidence for 
a gene/environment interaction between acetaldehyde/dMMR, causing the 




Lay Summary          
Lynch Syndrome (LS) is an inherited genetic disease that increases a person’s risk of 
developing a range of cancers, especially colorectal cancer. Developing tumours are 
known to acquire mutations occurring within the DNA of cells. To combat the 
accumulation of DNA mutations, cells have several DNA repair pathways that can 
accurately identify and repair DNA damage. One such pathway is termed the DNA 
mismatch repair (MMR) pathway and it is this pathway which is defective in LS patients. 
Alcohol consumption, specifically ethanol (and its toxic breakdown intermediate 
acetaldehyde), is a known risk factor for cancer development, as it can induce various 
types of DNA damage. However, as yet the specific DNA repair pathways responsible for 
correcting such DNA damage remain unknown. It was hypothesized that MMR plays a 
role in protecting cells from alcohol-induced DNA damage. This study aimed to 
determine if there is an interaction between defective MMR and alcohol that 
accelerates colorectal tumour development and progression. 
To investigate this hypothesis, a mouse model of LS was used that was previously 
developed, which allows controllable inactivation of one of the MMR genes (called 
Msh2) similar to that known to occur in human LS patients. Long-term alcohol 
consumption by these mice led to increased cell proliferation in the large intestine, with 
benign and malignant intestinal tumour formation within 6 months, compared with no 
tumours in the same time period (and only one intestinal tumour after 15 months) in 
the same mice given normal drinking water instead of alcohol.  
New mouse models were made that had both controllable inactivation of one of the 
MMR genes and abnormal metabolism of alcohol with accumulation of one of its toxic 
breakdown products (acetaldehyde). These mice were fed alcohol to allow study of the 
effects of alcohol and its toxic breakdown product on the mechanism of alcohol-induced 
intestinal tumours. Abnormal alcohol metabolism led to increased DNA damage. Long-
term consumption of alcohol by these model mice caused increased numbers of large 
intestinal tumours, compared with those found in the first mouse model of LS over the 
same time period. No tumour formation was seen in the model mice given normal 
water. 
The results showed that large intestinal tumours arose from those cells unable to 
activate MMR. In all the mouse models used in this study, a significant increase in DNA 
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damage was observed in the mice that received alcohol compared with the mice that 
received water. A significant increase of the toxic breakdown product (acetaldehyde) of 
alcohol was detected in the blood of alcohol-treated mice compared with water-treated 
mice, in the mouse models unable to normally metabolise alcohol and unable to activate 
MMR compared with the mouse model only unable to activate MMR but able to 
metabolise alcohol normally. The results obtained revealed the importance of DNA 
MMR in protecting intestinal cells from alcohol-induced DNA damage and also the 
importance of normal metabolism of alcohol to help reduce DNA damage.  This 
demonstrated that there is an interaction between alcohol and inactive MMR that 
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Chapter 1: Introduction        
1.1 Lynch Syndrome 
1.1.1 Lynch Syndrome, mismatch repair genes and susceptibility to cancer 
Lynch syndrome (LS), previously called hereditary nonpolyposis colorectal cancer (HNPCC), 
is probably the most common major cause of inherited susceptibility to cancer, with an 
estimated prevalence in the general population of between 1/100 and 1/180 (Frankel et al., 
2019). LS is characterised by predisposition to a range of cancers, involving most frequently 
the colorectum and endometrium, and also many other organ sites including ovary, stomach, 
small intestine, hepatobiliary tract, pancreas, urinary tract, prostate, brain, and sebaceous 
skin tumours (Møller et al., 2017, 2018). LS is caused by constitutional (germline) pathogenic 
variants affecting one of four genes encoding the DNA Mismatch Repair (MMR) system 
components: MLH1, MSH2, MSH6, and PMS2, and hence the current commonly accepted 
diagnostic definition of LS is carrying such a variant (Thompson et al., 2014; Vasen et al., 
2010, 2014, 2013; Frankel et al., 2019; Frayling et al., 2016). However, although it is 
acknowledged that (there is an opinion that) LS can only be diagnosed in such individuals 
once cancer has been diagnosed, this is contrary to the hereditary polyposes, which are 
characterised by the macroscopic syndromic feature of multiple pre-malignant tumours 
(Vasen et al., 2008). Allied to this, a major purpose of diagnosis of a cancer predisposing 
condition is to identify those who would benefit from surveillance and prophylactic surgery 
to prevent cancer (Vasen et al., 2010). Hence, the emerging current view is that it is 
inconsistent to discriminate against LS by expecting such individuals to develop cancer in 
order to be diagnosed with the condition, especially as cancer does not always occur 
(Dominguez-Valentin et al., 2020; Møller et al., 2017, 2018). Hence, it has been proposed 
that the definition of LS should incorporate recently identified specific microscopic and 
molecular pre-malignant syndromic features (Cerretelli et al., 2020; Seth et al., 2018). The 
DNA MMR pathway recognises and repairs both mismatched bases (e.g. C opposite T) and 
insertions or deletions in repetitive sequences. In LS patients, an inherited MMR gene 
constitutional variant/mutation, when combined with an acquired second pathogenic 
variant/mutation due to somatic mutation in the wildtype allele of the same MMR gene, 
results in the complete loss of MMR pathway function in the affected cells. Deficiency of 
MMR (dMMR) leads to hypermutability, resulting in an increase in the mutation rate by 100- 
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to 1000-fold due to uncorrected base mismatches, and to microsatellite instability (MSI) due 
to variation in the lengths of repetitive sequences (e.g. AAAAAAA… or CACACACA…. or 
similar, known as microsatellites) due to uncorrected insertion/deletion loops that are prone 
to occur as DNA replication errors in repetitive sequences (Poulogiannis et al., 2010). 
However, crucially, dMMR does not simply fail to repair mismatches, it elicits a reduced 
susceptibility to apoptosis or cell cycle arrest induced by DNA damage recognised by the 
MMR pathway (Poulogiannis et al., 2010; Toft et al., 1999; Tomlinson & Bodmer, 1999; Zhang 
et al., 1999).  
The International Society for Gastrointestinal Hereditary Cancer (InSiGHT) was the first 
expert group to define pathogenicity of gene variants according to an agreed set of criteria 
based upon Bayesian probability, using the five-tier classification system of Plon et al.  (Plon 
et al., 2008; Thompson et al., 2014) . In this system, Class 5 variants are pathogenic and Class 
4 likely pathogenic, with Class 3 being variants of uncertain significance (VUS), and Classes 2 
and 1 being likely benign and benign respectively. InSiGHT maintains the world reference 
database of variants observed in MMR genes, as Leiden Open Variation Databases (LOVDs), 
which are now linked to ClinVar as part of the ClinVar-ClinGen partnership. Interestingly, 82% 
of the Class 4 and 5 variants of MMR genes listed affect MLH1 and MSH2, with 13% affecting 
MSH6 and 5% PMS2 (Landrum & Kattman, 2018; Rehm et al., 2015). It should be noted that 
these pathogenic variants are mostly from cases ascertained by family history. As more cases 
of LS are ascertained from systematic testing of cancer cases and from gene panel testing, 
more patients may be identified with pathogenic variants in MSH6 and PMS2, and thus the 
proportions due to the different MMR genes may alter (Vasen et al., 2013). All types of 
variants can be pathogenic: nonsense, frameshift, splice-site, missense, insertion–deletion, 
and large deletions/rearrangements, the largest so far being a 10 Mb inversion affecting 
MSH2 and which is visible cytogenetically (Li et al., 2006; Taylor et al., 2003; Wagner et al., 
2002). Approximately 60% of all putative pathogenic missense mutations causing LS actually 
disrupt splicing and are thus, in effect, truncating (Thompson et al., 2015). Up to 3% of LS 
cases are due to variants involving the 3’ end of the EPCAM gene (immediately upstream to 
MSH2), that result in hypermethylation of the MSH2 promoter or partial deletion of MSH2 
(Kempers et al., 2011; Niessen et al., 2009). Another infrequent cause of LS is constitutional 
methylation of the MLH1 promoter, which occurs in 1–2% of cases (Hitchins et al., 2005; 
Hitchins & Ward, 2009; Morak et al., 2018). Hypermethylation of the MLH1 promoter is 
usually sporadic in nature, so it is neither inherited nor heritable, and relatives are therefore 
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not at risk. However, in a small number of patients, the hypermethylation may be secondary 
to a large deletion involving LRRFIP2, the gene upstream of MLH1, and it is the deletion that 
is the heritable pathogenic variant, the methylation is secondary (Morak et al., 2018). Given 
the risks to relatives it is therefore important to distinguish such cases, and this is achieved 
by testing both the tumour and constitutional DNA, and finding MLH1 promoter methylation 
in both, perhaps in the context of an LS family history. It has to be borne in mind that 
approximately 15% of sporadic colonic cancers are also dMMR due to somatic, so acquired, 
epimutation of both MLH1 alleles by promoter hypermethylation (Sinicrope & Sargent, 
2009). This is a function of such tumours arising from right-sided serrated lesions (Noffsinger, 
2009). A higher proportion (25-30%) of sporadic endometrial cancers also have bi-allelic 
hypermethylation of MLH1, and as with colonic cancers a small proportion are due to 
constitutional methylation plus a somatic mutation in the normal MLH1 allele (Esteller et al., 
















1.1.2 DNA mismatch repair mechanisms 
The MMR pathway is a highly evolutionarily conserved mechanism responsible for the 
correction of base mismatches (e.g. C or G opposite T or A) and insertion/deletion loops 
(occurring in repetitive sequences such as AAAAAA … or CACACACA … due to insertion or 
deletion of a repeat unit during stalled DNA replication of these repetitive sequences). Such 
stalling is probably mostly due to replication-associated errors, but is also caused by DNA 
damage due to oxidative stress, lipid peroxidation, base deamination, methylation, and 
alkylation (Modrich & Lahue, 1996). A base mismatch or single nucleotide insertion/deletion 
error is recognised by the MutSα complex, which is composed of MSH2 and MSH6 proteins. 
Insertion/deletion loops of 2–8 nucleotides are recognised by the alternative complex 
MutSβ, composed of MSH2 and MSH3 proteins. MutSα complex activation is characterized 
by ATPase activity, which is important for the interaction with the mismatched DNA and 
initiation of repair. The binding of MutSα stimulates ATP hydrolysis, leading to a 
conformational change that subsequently triggers the recruitment of a second complex 
MutLα, composed of MLH1 and PMS2 proteins (although there is redundancy with PMS1 and 
MLH3 in this complex). The tetrameric complex, by sliding on the DNA, searches for the single 
strand DNA mismatch on the new strand (daughter strand). This in turn activates 
proliferating cell nuclear antigen (PCNA) and replication factor C (RFC). MutLα possesses an 
intrinsic ATP-stimulated endonuclease activity that requires activation by PCNA in order to 
create an incision in the recently synthesised daughter strand (containing the error). The 
incision step is followed by the recruitment of exonuclease 1 (EXO1) that removes the newly 
synthesised DNA strand up to and beyond the mismatch or loop. DNA polymerase δ 
resynthesises the DNA, whereas ligase 1 seals the remaining nick (Figure 1.1) (Hsieh & 
Yamane, 2008). 
The MMR pathway is involved in a signalling cascade that leads to either cell cycle arrest 
and/or apoptosis, if DNA damage has occurred (Stojic et al., 2004). It has been observed that 
MMR-deficient cells fail to recruit ataxia-telangiectasia mutated (ATM) and ATM and Rad3-
related (ATR) proteins; and this prevents p53 phosphorylation in response to DNA damage 
(Brown et al., 2003; Toft et al., 1999). The underlying mechanisms by which MMR proteins 
promote DNA damage–induced cell cycle arrest and apoptosis have not been fully 
elucidated. Two models have been hypothesised: the futile cycling model and the direct 
damage signalling model. In the futile cycling model, MMR recognises the mismatch 
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triggering the excision of the newly synthesized strand, although the persistent offending 
damage on the template strand cannot be excised. MMR initiates futile repair cycles, 
eventually resulting in the formation of DNA double-strand breaks and thus activating the 
ATM/ATR/p53 signalling pathway to activate cell cycle arrest and/or apoptosis (Stojic et al., 
2004). In the direct damage signalling model, MutSα and MutLα directly recruit ATM/ATR 
and causes cell cycle arrest and/or apoptosis (Yoshioka et al., 2006). A crucial consequence 
of this is that the low background level of DNA damage in normal cells may stimulate MMR 
and thus inhibit the cell cycle, or if severe may stimulate apoptosis, and so net cell turnover 
does not reach its theoretical maximum. However, if MMR deficiency should occur in such 
cells, there is no such limitation by stalling of the cell cycle or activation of apoptosis and net 
cell division increases in an uncontrollable fashion, allied to which as a secondary 
phenomenon the mutation rate increases, which is manifest as MSI and/or abnormal MMR 
immunohistochemistry (IHC). This is very useful diagnostically, but it is important to 
appreciate that it is not the increased mutation rate per se that is driving the carcinogenic 
process, and neither does it make adenomas progress any quicker than usual (Tomlinson & 
Bodmer, 1999). However, because mutations are strongly biased towards repetitive DNA 
sequences in dMMR cells, this has profound consequences for the biology of such tumours 
and patients with LS due to the strong immunological responses this elicits (Llosa et al., 2015; 
Pfuderer et al., 2019) and the critical consequences of this are manifest in how LS tumours 






Figure 1.1: Schematic diagram of the DNA Mismatch repair pathway, which is strand-specific (adapted 
and modified from Hsieh & Yamane, 2008). During DNA synthesis the newly synthesised (daughter) 
strand (which transiently includes nicks before they are sealed by ligases) may include errors, including 
base mismatches, insertions or deletions. The base mismatch or single nucleotide insertion/deletion 
(red square) error is recognized by the complex MutSα composed of MSH2 and MSH6 (whereas 
insertion/deletion loops of 2-8 nucleotides are recognized by the complex MutSβ composed of MSH2 
and MSH3, not shown). The binding of MutSα stimulates ATP-hydrolysis leading to a conformational 
change triggering the recruitment of a second complex MutLα. MutLα, composed of MLH1 and PMS2, 
induces ATP hydrolysis causing the translocation of MutSα along the DNA and generation of a new 
nick of the affected strand. Excision and repair are performed by other factors, including exonuclease 
1 (EXO1) which excises the affected strand between the two nicks, whereas proliferating cell nuclear 
antigen (PCNA), replication factor C (RFC) and DNA polymerase delta (POLδ) repair the strand and this 
is religated by DNA ligase 1. Replication protein A (RPA) binds to single-stranded DNA, preventing it 
from winding back on itself or forming secondary structures, keeping the DNA unwound for the 
polymerase to replicate it. (Image created with BioRender.com). 
7 
 
1.1.3 Lynch syndrome databases and cancer risks 
In addition to the MMR gene variant database maintained by InSiGHT (https://www.insight-
group.org/), there are other phenotypic databases aimed at understanding the precise risks 
that LS patients face. Initial estimates were liable to ascertainment bias and thus tended to 
overestimate by being necessarily retrospective. The penetrance and expressivity of MMR 
pathogenic variants differs in LS patients according to the MMR gene, age, sex and 
environmental/lifestyle factors (Diergaarde et al., 2007). Several lifestyle factors, such as 
smoking, alcohol, and obesity, are associated with an increased risk of sporadic cancer and 
have been suggested to have similar effects in LS patients. Therefore, as it is fundamental to 
quantify accurately the risks of developing cancer for LS patients, in order to provide 
adequate data for surveillance and care, as well as understand the underlying biology, the 
Prospective Lynch Syndrome Database (PLSD) was established in 2012 by the Mallorca Group 
of InSiGHT (Dominguez-Valentin, 2020; Møller et al., 2017). The PLSD collects data on LS 
patients from expert centres and registries worldwide; these patients are thus undergoing 
colonoscopic surveillance with polypectomy and may also be having therapeutic or 
prophylactic surgery. It therefore provides information on the natural history of the disease 
course and the effects of interventions and lifestyle risk factors. The PLSD is linked to the 
InSiGHT MMR LOVD: all patients on the PLSD must have a Class 4 or 5 MMR variant, so 
pathogenic or likely pathogenic, according to the InSiGHT classification (InSiGHT, 2020e; 
Thompson et al., 2014). The PLSD includes basic information on pathogenic genetic variants, 
sex, and age, plus information such as cancers or pre-cancers diagnosed, age at diagnoses, 
age at prophylactic surgical removal of organs, and information on pre-cancers. Every patient 
is followed as an individual, as the family history is ignored so as not to introduce bias, and 
the database now has >50,000 patient-years of observations (Dominguez-Valentin et al., 
2020). The PLSD website (http://lscarisk.org/) is public and allows anyone to determine the 
risks to an individual of an LS-associated cancer in an interactive graphical form according to 
their affected gene, age, sex, and whether previously affected by cancer (Dominguez-
Valentin, 2020). Important parallel efforts have been made in defining risks in Lynch 
syndrome by the Colon Cancer Family Registry (CCFR) and the International Mismatch Repair 
Consortium (IMRC) (Jenkins et al., 2018; Jenkins et al., 2018). The CCFR is an international 
consortium of six institutes in the United States, Canada, and Australasia formed as a 
resource to support studies on the aetiology, prevention, and clinical management of 
colorectal cancer, and utilises a form of modified segregation analysis to minimise 
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retrospective ascertainment bias (Dowty et al., 2013; Jenkins et al., 2018). It currently has 
data on >42,500 individuals from >15,000 families on its records and has made significant 
advances in demonstrating how environmental and lifestyle factors affect cancer risks in LS, 
such as smoking, increased body mass index, and alcohol consumption (Pande et al., 2010; 
Win et al., 2011). By contrast, reduced cancer risk is seen with, for example, hormone 
replacement therapy, vitamin and mineral supplements, nonsteroidal anti-inflammatory 
drug (NSAID) use, and parity, but there is no change in risk associated with oral contraceptive 
use (Ait Ouakrim et al., 2015; Chau et al., 2016). The IMRC is a worldwide collaboration of 
more than 115 investigators from 59 centres, with 20,000 individuals with LS from 8800 
families, facilitated by InSiGHT and the Collaborative Group of the Americas on Inherited 
Gastrointestinal Cancer (CGAIGC) (Jenkins et al., 2018). Reduced cancer risk has been 

















1.1.4 Pathology of Lynch syndrome cancers  
Typical histological features of LS tumours are best exemplified by colorectal cancer (CRC), 
which often shows a combination of the presence of prominent tumour-infiltrating 
lymphocytes, Crohn-like peritumoural lymphoid aggregates, poor differentiation, frequently 
with areas of mucinous and/or signet-ring cell patterns, sometimes with a medullary growth 
pattern (Alexander et al., 2001; Truta et al., 2008). These characteristics can be seen in both 
Lynch syndrome CRC and sporadic dMMR bowel cancers, but are not sufficiently specific to 
distinguish them from MMR-proficient (pMMR) cancers. Fewer data have been published 
about non-colorectal LS-associated cancers. LS associated gastric carcinomas are mostly of 
the intestinal-type with fewer diffuse-type, and rarely of mucinous type, and an associated 
immune gastritis is reported (Aarnio et al., 1997; Adar et al., 2019; Capelle et al., 2010; Gylling 
et al., 2007). LS-associated small intestinal adenocarcinomas often display mucinous, signet-
ring cell, or medullary differentiation, with tumour-infiltrating lymphocytes and Crohn-like 
reactions, as do ampullary adenocarcinomas (Jun et al., 2017). 
 
1.1.5 Testing for Lynch syndrome cancers 
Testing of (usually selected) patients with CRC, endometrial cancer, and/or other types of LS-
associated cancer is recommended by many guidelines and organisations, generally starting 
with testing the tumours for either the presence of MSI or the absence (or abnormal 
expression) of mismatch repair proteins. There is no consensus regarding whether MMR 
immunohistochemistry or MSI testing is the better first test in CRCs as they have similar test 
performance characteristics in detecting LS: sensitivity of MSI testing is 88 - 100% and MMR 
IHC is 73 - 100%, with specificity of MSI testing is 68 - 84% versus MMR IHC specificity of 78 
- 98% (Snowsill et al., 2014, 2017). They may be used serially, or in combination (National 
Institute for Health and Care Excellence, 2017; Sie et al., 2014; Wedden et al., 2019). 
However, evidence is now emerging that IHC may be the preferred option when testing 
endometrial cancers (systematic testing of which has recently been approved by the UK 
National Institute for Health and Care Excellence (NICE), as a recent UK study has shown that 
while MSI and MMR IHC have similar specificity (83.7 versus 81%), MSI has only 56.3% 
sensitivity compared with 100% for MMR IHC in endometrial cancers (Crosbie et al., 2019; 
Ryan et al., 2020). MMR IHC is the better option for small biopsies, cancers with a low tumour 
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cell proportion, or an intense inflammatory reaction. Subsequent testing for MLH1 promoter 
hypermethylation and somatic (rather than constitutional/germline) mutations can be used 
to clarify the risk of inherited pathogenic variants in suspected LS patients. MLH1 promoter 
hypermethylation testing may be used as an alternative to BRAF V600E mutation analysis in 
colonic cancers (Adar et al., 2017; Bläker et al., 2019; Marks & West, 2020). The use of larger 
targeted gene mutation panels (or whole exome/genome sequencing) that includes MMR 
gene testing with mutation analyses is becoming more widespread (Taylor et al., 2018).  
Immunohistochemical staining for the four major DNA mismatch repair proteins (MLH1, 
MSH2, MSH6, and PMS2) is probably the most common UK test to screen CRCs and other 
tumours for dMMR (Sie et al., 2014; Snowsill et al., 2017; Wedden et al., 2019). The nuclear 
expression of all four MMR proteins suggests mismatch repair proficiency with microsatellite 
stability (Arends et al., 2008; Frayling & Arends, 2015; Mensenkamp et al., 2014). Loss or 
abnormality of nuclear staining for any of the proteins indicates dMMR and suggests the 
most likely MMR gene involved (Frayling & Arends, 2015; Mensenkamp et al., 2014). Loss of 
MSH2 alone, or loss of both MSH2 and MSH6, suggests that a mutation or abnormality in 
MSH2 is most likely. Similarly, loss of MLH1 alone, or loss of both MLH1 and PMS2, suggests 
an underlying mutation, abnormality, or promoter methylation in MLH1. Combined loss of 
both MSH2 and MSH6 (or of both MLH1 and PMS2) reflects the heterodimeric binding of 
MSH2 with MSH6 (or of MLH1 with PMS2) in the mismatch repair complex MutSα (or of 
MutLα), such that loss of the first protein partner generates instability and loss of the second 
(South et al., 2008). Usually, there is nuclear staining in the nuclei of both tumour cells and 
adjacent normal epithelial cells, stromal cells, and lymphocytes. In a dMMR tumour due to 
MSH2 mutation, there is loss of nuclear MSH2 and MSH6 and intact staining for MLH1 and 
PMS2. In a dMMR tumour due to MLH1 mutation, there is loss of nuclear MLH1 and PMS2 
and intact staining for MSH2 and MSH6. This pattern of combined MLH1 and PMS2 loss could 
be seen either in a sporadic tumour (most commonly due to MLH1 promoter methylation) 
or in LS due to constitutional MLH1 mutation. Correct MMR IHC interpretation requires 
adequate internal control staining of the adjacent stromal and lymphoid cells to confirm 
good fixation of the tissue region (Arends et al., 2008; Frayling & Arends, 2015). Patchy intact 
nuclear staining may occur due to variable fixation, tissue hypoxia, or unequal antibody 
diffusion (Chang et al., 2002; Mihaylova et al., 2003). Cytoplasmic staining may occur, but if 
nuclear staining is lost, this is considered abnormal, indicating dMMR (Sekine et al., 2017). 
Weak, patchy nucleolar staining, or sometimes absence of MSH6 has been described in rectal 
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tumours following neoadjuvant treatment without MSI or a mutation confirmed by 
molecular testing (Bao et al., 2010; Radu et al., 2011). Notably, heterogeneous staining or 
loss of MSH6 can be due to secondary (non-germline) acquired somatic mutations in the 
MSH6 coding repetitive mononucleotide tract (Graham et al., 2015; Shia et al., 2013). 
Approximately 3–10% of LS associated dMMR tumours show no abnormality on IHC testing 
(presumably because of variants that disrupt normal MMR protein function but nonetheless 
enable protein detection by IHC) (Bartley et al., 2012). 
Testing DNA extracted from tumours for MSI involves investigating the presence of extra 
alleles (longer or shorter) at a microsatellite locus compared with normal tissue or blood 
from the same individual (Frayling, 1999). Microsatellites vary in their propensity to show 
instability, and thus the frequency with which the same microsatellite is altered varies in 
different tumour types. Instability is more likely to be observed at mononucleotide repeats 
(e.g. AAAAA …) than at dinucleotide repeats (e.g. CACACA …). Microsatellite loci or markers 
used in colonic cancer MSI testing are known to have reduced sensitivity at detecting MSI in 
non-colonic cancers, including endometrial, small intestinal, or gastric cancers; in tumours 
from LS patients with MSH6 or PMS2 mutations; and in colonic adenomas (Hause et al., 
2016). Therefore, a proportion of LS-associated tumours may not appear to have MSI using 
the standard test but might be identified by abnormal MMR immunohistochemistry. The 
efficacy of MMR IHC and MSI testing may be significantly enhanced by testing more than one 
tumour from the same individual or family, particularly if there are tumours that are multiple 
or rarely seen in LS (e.g. colorectal adenomas, small intestinal cancers, hepatobiliary, upper 
urinary tract, and cutaneous sebaceous tumours) (InSiGHT, 2020e; Ju et al., 2018). Consistent 
IHC abnormality of one mismatch repair protein in more than one tumour from an individual 
or family represents very good evidence for variant pathogenicity (InSiGHT, 2020e; Loukola 
et al., 1999). Some CRCs due to MUTYH associated polyposis (MAP) or proofreading 
polymerase-associated polyposis (PPAP) may exhibit MSI and/or abnormal IHC due to 
somatically acquired MMR gene mutations. Approximately 13–15% of sporadic colonic 
cancers have dMMR, usually due to epigenetic silencing of both alleles of MLH1 by promoter 
hypermethylation. Hence, although overall unselected dMMR colonic cancers have a 
relatively poor positive predictive value for LS, because the proportion of colonic cancers 
with MSI due to LS varies with age this can be exploited clinically. In individuals younger than 
the age of 57, more than half of all dMMR colonic cancers will be due to LS, whereas over 
this age less than half will be, although even at age 70 approximately 25% dMMR colonic 
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cancers will be due to LS (Frayling et al., 2016; Mensenkamp et al., 2014; van Lier et al., 2012). 
In contrast, proficient mismatch repair (pMMR) tumours have a good negative predictive 
value for LS. Further tests (BRAF mutation and MLH1 methylation tests) are required for 
MLH1-negative cancers to distinguish between LS and sporadic origin (National Institute for 
Health and Care Excellence, 2017; Snowsill et al., 2014, 2017). Another important practice 
point is that rectal cancers are distinct from colonic cancers in the diagnosis of LS. Because 
sporadic colonic cancers with dMMR arise largely from right-sided serrated lesions, sporadic 
rectal cancers with dMMR are correspondingly rare, if they occur at all, and hence a rectal 
cancer with dMMR at any age are considered to be due to LS until proven otherwise (de Rosa 
et al., 2016; Nilbert et al., 1999). The activating missense variant BRAF p.V600E occurs in 
sporadic colonic cancers with dMMR, but not in those due to LS; therefore, BRAF p.V600E is 
highly predictive of the tumour being of sporadic origin rather than LS (National Institute for 
Health and Care Excellence, 2017; Noffsinger, 2009; Snowsill et al., 2014, 2017; Thiel et al., 
2013). However, sporadic tumours may occasionally occur in patients with LS, so the absence 
of BRAF p.V600E does not definitively diagnose LS but does indicate that LS is more likely. 
Alternatively, detection of MLH1 promoter hypermethylation in a colonic cancer provides 
good, although not unequivocal, evidence that the tumour is sporadic in origin, as occasional 
sporadic tumours do occur in LS and constitutional MLH1 promoter methylation can be 
found in a small proportion of patients with LS (Hitchins & Ward, 2009; Morak et al., 2018). 
Patients with digenic LS, who have inherited pathogenic variants in more than one MMR 
gene, are occasionally seen, but it is unclear if their risks are increased over those patients 
with a pathogenic variant in one MMR gene. It is often useful to have samples from more 
than one individual in the family, because case segregation studies may be required to 
determine pathogenicity or whether an individual is a phenocopy (InSiGHT, 2020e; 
Thompson et al., 2014). If the family shows evidence of hereditary transmission of LS but no 
point mutation is found, tests for large-scale mutations, such as deletion of a whole exon (or 
more), can be performed; 12–40% of pathogenic variants are of this type (InSiGHT, 2020b, 
2020a, 2020c, 2020d; Ligtenberg et al., 2009; Smith et al., 2016; Taylor et al., 2003; Wagner 
et al., 2002). LS-related tumour types that are rare in the general population and thus have 
a high predictive value for LS, such as small intestinal and  hepatobiliary cancer, upper urinary 
tract and bladder (under age 60) transitional cell carcinoma, or skin sebaceous 
adenoma/carcinomas, are therefore worth testing (Jessup et al., 2016). Synchronous or 
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metachronous bowel cancers are also significant, as is the development of any two LS-related 
tumours (e.g. CRC and endometrial cancer), and all such cases warrant testing for LS. 
 
 
1.1.6 Precursors of cancers in Lynch syndrome 
When LS was being defined in the early 1990s, the only known pathway to CRC was based 
on the work of Dukes, Bussey, and Morson on FAP. First was Dukes’ concept of ‘simple 
tumours and cancer’ described in 1925, as part of his system for the staging of rectal cancer 
in FAP, followed by the adenoma to carcinoma pathway published in 1958 (Dukes & Bussey, 
1958; Dukes, 1926; Dukes, 1932). Naturally, the reasonable assumption was that the same 
pathway applied in LS and colonoscopic surveillance to remove premalignant adenomas 
would thus be beneficial in LS. When early data on the efficacy of surveillance in LS showed 
a large number of interval cancers, and, moreover, these cancers occurred despite the 
interval between colonoscopies being steadily reduced to less than 3 years and sometimes 
even less than 1 year, it appeared that LS CRCs may develop much more rapidly than sporadic 
ones, assuming they all arose from adenomas (Vasen et al., 2010, 1995). In addition, because 
of the increased mutation rate observed in LS cancers, allied with the prevailing concept that 
genomic instability characterised all cancer, it was further assumed that this must be what 
was driving a faster adenoma-carcinoma progression (Poulogiannis et al., 2010; Tomlinson & 
Bodmer, 1999; Tomlinson et al., 1996). Furthermore, although dMMR adenomas could be 
found in LS patients, further doubts were raised when aspirin treatment failed to reduce the 
incidence of adenomas (although it later reduced that of CRCs), and results from the PLSD 
became available (Burn et al., 2011; Loukola et al., 1999; Møller et al., 2017; Seppälä et al., 
2017; Seppälä et al., 2019). LS patients on colonoscopic surveillance at various intervals could 
finally be compared (Seppälä et al., 2017). Remarkably, within the limits measurable, 
colonoscopy did not appear to reduce the rate at which CRCs were arising in LS patients, 
despite it being associated with a significant reduction in mortality and, in addition, stage 
was not related to the interval since last colonoscopy—completely the opposite of 
population screening programmes, which are based primarily on adenoma removal (Engel et 
al., 2018; Møller et al., 2017; Seppälä et al., 2017; Seppälä et al., 2019). 
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LS patient survival was shown to be improved by colonoscopic surveillance, enabling earlier 
diagnosis and a degree of downstaging, together this mass of evidence led to the conclusion 
that a pathway independent of adenomas must be occurring, and moreover, a pathway in 
which precursors were less obvious on colonoscopy (Snowsill et al., 2014). At about the same 
time, it was discovered that LS patients harbour an enormous number of dMMR crypts in the 
colorectum (~1/cm2 mucosa, so ~10 000 crypts/ patient), which are not dysplastic, and yet 
LS patients only go on to eventually develop between zero, one, two, or three cancers (Kloor 
et al., 2012; Staffa et al., 2015). It was suggested that these dMMR crypts might lead to 
cancers, perhaps by a route that was not readily visible on colonoscopy and this was 
supported by the finding of flat intramucosal cancers, in which the Wnt pathway was 
activated by mutations not in Adenomatous polyposis coli (APC) as in classical adenomas, but 
via mutations in repetitive coding sequences in the beta-catenin gene, as predicted from 
dMMR  (Ahadova et al., 2016). It is intriguing that subsequent work to sequence LS cancers 
has shown that some 61% of APC mutations are predicted to occur after MMR deficiency 
occurs, as they are found in repetitive sequences, exactly as would be expected in dMMR 
tumours. Hence, a proportion of these beta-catenin–mutant flat lesions acquire secondary 
APC mutations, thence to become polypoid adenomas and subsequently cancers (Ahadova 
et al., 2018; Binder et al., 2017). 
The current model describes at least three pathways to CRCs in LS, not including sporadic 
colonic cancer due to a right-sided sessile lesion, which are occasionally observed (Figure 
1.2). The first pathway is via sporadic adenomas that acquire secondary dMMR. The third 
pathway is via flat cancers within the mucosa that arise directly from dMMR crypts, and the 
second pathway is LS-specific polypoid adenomas that arise from flat dysplastic lesions due 
to secondary APC mutations (Ahadova et al., 2018). Hence, a proportion of LS CRCs arise 
from flat dysplastic / adenomatous lesions, which are inherently more difficult to detect 
endoscopically, let alone remove on colonoscopy, explaining at least in part the apparent 
high rate of interval cancers and the previous suggestion (now regarded as incorrect) of a 
faster progression rate in LS. Building on this, it has been shown that the cancers in patients 
with LS due to PMS2 mutations arise largely along pathway 1 (from sporadic adenomas), 
further explaining why patients with pathogenic PMS2 variants have only a small increased 
risk of CRC (Ten Broeke et al., 2018). It is interesting that very recently it has been found that 
pathway 3 (dMMR crypts evolving into flat cancers) predominates over pathway 2 (polypoid 
adenomas arising from flat dysplastic lesions) in patients with pathogenic MLH1 variants, but 
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pathway 2 predominates over pathway 3 in those with MSH2 pathogenic variants (Engel et 
al., 2020). These fascinating findings have clear implications for future surveillance 
strategies, which may soon also include modalities such as prophylactic aspirin and vaccines, 
to address the inherently limited efficacy of colonoscopy and increased risks of cancers in LS 
at sites other than the large bowel, which are becoming the predominant cause of mortality 
in LS patients under surveillance (Møller et al., 2017, 2018). Observers have recently found 
dMMR glands in morphologically normal endometrium from LS patients, which in turn has 

















Figure 1.2: Pathways to CRC in Lynch syndrome (adapted and modified from Ahadova et al., 2018, 
2016). There are three pathways to dMMR CRCs in LS. Pathway 1: Classic sporadic polypoid adenomas, 
initiated by Wnt pathway activation due to mutations in APC (APCm), acquire dMMR through somatic 
mutation of the remaining normal MMR allele (MLH1m, MSH2m, MSH6m, or PMS2m). This can occur at 
any stage of adenoma progression, from early adenoma through to adenoma-carcinoma transition. 
Pathway 3: Crypts that have acquired dMMR due to somatic mutation of the normal MMR allele are 
not dysplastic, but if they undergo somatic mutation of beta-catenin (CTNNB1m), which activates the 
Wnt pathway, they become flat adenomas/adenocarcinomas that later acquire mutations in TP53 
(TP53m), an otherwise rare event in dMMR CRCs. Pathway 2: A proportion of Pathway 3 lesions acquire 
secondary APC mutations and thus become polypoid adenomas. Because of this unique combination 
of somatic events, these Pathway 2 adenomas are, as far as is known, specific to LS (hence ‘Lynch-
specific dMMR adenomas’). Regarding pathways 2 and 3 in their original proposal, Ahadova and 
colleagues remark: ‘For better visibility, pre-malignant lesions that do not develop into cancer are not 
included in the diagram, because their number greatly exceeds the number of carcinomas’. Pathway 
1 predominates in patients with LS due to PMS2 pathogenic variants, whereas CTNNB1-mutant 
tumours are more likely in MLH1 patients and APC-mutant tumours are more likely in MSH2 and MSH6 
patients. Note that sporadic colonic cancers that arise from serrated lesions with MLH1 deficiency due 
to somatic biallelic hypermethylation of the MLH1 promoter may occur in LS, albeit perhaps less often 
due to the enhanced immunity in LS patients against dMMR cells because of chronic 





1.1.7 Immune escape by Lynch Syndrome neoplasms 
The early general observations of large local tumours and a lower rate of metastasis, 
together with a strong immune reaction to LS cancers, such as increased tumour infiltrating 
lymphocytes (TIL) and tertiary lymphoid structures (TLS; also termed Crohn-like peritumoural 
lymphoid aggregates or follicles), later backed up by gene expression signatures 
characteristic of immune cell activation, all indicate an important role for the immune system 
in LS (Aaltonen et al., 1994; Llosa et al., 2015; Smyrk et al., 2001). However, in the context of 
the normal immune architecture in the bowel, gut-associated lymphoid tissue (GALT) 
comprises both isolated and aggregated lymphoid follicles in both the small and large 
intestines. Humans have approximately 30,000 isolated lymphoid follicles (ILFs) scattered 
throughout the large and small intestines, but especially in the colon (Sipos & Muezes, 2011). 
ILFs vary in their distribution within the large and small intestines, may be mucosal or sub-
mucosal, and at their simplest may consist of a single follicle, with or without some T cells 
(Agace & McCoy, 2017; Mowat & Agace, 2014). They are considered to be the main source 
of immune priming in the colon and from where Crohn’s disease originates, and they have 
specialised follicle associated epithelium (FAE), which overlies a subepithelial dome 
containing numerous macrophages, dendritic cells, T and B lymphocytes, and special antigen 
sampling microfold/M cells (Colbeck et al., 2017; Stranford & Ruddle, 2012). The FAE has a 
crucial role in the initiation of the mucosal and systemic immune responses (Lorenz & 
Newberry, 2004). However, the relationship between Crohn-like follicles in LS and ILFs in 
normal colon is not completely clear. In LS, the follicles are generally peritumoural and not 
located inside cancers, and although they do not have FAE, they do have T cells, B cells, and 
germinal centres (Bento et al., 2015; Pfuderer et al., 2019). Whether they are induced de 
novo, as in chronic inflammation, or develop from submucosal ILFs remains to be determined 
(Drayton et al., 2006). Crohn-like follicles/TLS are found in CRCs apart from LS; however, the 
frequency/number is highest in LS cancers compared with sporadic dMMR and pMMR CRCs, 
which is not simply related to age (Pfuderer et al., 2019). 
In recent years, there has been a growing interest in TLSs in a variety of cancers including 
CRC, in particular as prognostic indicators of cancer progression and response predictors to 
immunotherapy (Colbeck et al., 2017; Sautès-Fridman et al., 2019). In hepatocellular 
carcinoma, intra-tumoural TLSs correlated with a lower risk of early relapse after surgery 
(Calderaro et al., 2019). In sarcoma, melanoma, and renal cell carcinoma, both intra-
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tumoural location and the presence of B cells (but not T cells), and particularly germinal 
centres, correlate with improved outcomes to checkpoint blockade immunotherapy (Cabrita 
et al., 2020; Helmink et al., 2020; Petitprez et al., 2020). Further studies of the location, 
cellular composition, and presence of germinal centres in TLS in hereditary dMMR may 
therefore shed light on their role in LS.  
In dMMR cells, predictable mutations can and do occur in repetitive protein coding 
sequences and result in frameshift peptides (FSPs) (Saeterdal et al., 2001; Schwitalle et al., 
2004; Woerner et al., 2001). Such FSPs are novel antigenic epitopes and elicit both humoral 
and cellular immune responses, which are seen as TILs around the dMMR crypts in LS 
patients as well as in dMMR cancers, both sporadic and due to LS (Kloor et al., 2012; 
Linnebacher et al., 2001; Reuschenbach et al., 2010; Schwitalle et al., 2004). In the face of 
such responses, how is it possible for tumours, let alone cancers, to develop in LS? The 
answer lies in the proposed three step process of elimination, equilibrium, and escape 
(Figure 1.3) (Dunn et al., 2004; Seth et al., 2018). Cells generating FSPs, present the FSPs on 
their surface by MHC-I, and are subjected to attack by cytotoxic T lymphocytes (CTLs), 
resulting in elimination. However, cells that acquire activating mutations in PDL1 before they 
are eliminated can hold the immune system to a local standstill (activating the PD-1 – PD-L1 
immune checkpoint)—the process of equilibrium. Subsequently, if before being eliminated 
these cells manage to acquire inactivating mutations in MHC-I or MHC-II (HLA classes I & II) 
and related genes, that abrogate presentation of FSPs on their surface, they are then able to 
escape the immune system, at least locally.  
Given the huge number of dMMR crypts in an LS patient, but that the average LS patient 
manifests between zero, one, two, or three CRCs, it is clear that the process of elimination 
must be highly efficient, giving a different perspective on cancer biology (Ahadova et al., 
2018; Møller et al., 2017). A number of different escape mechanisms have been observed. 
The most common, seen in approximately 30% of dMMR CRCs, is mutation of beta-2-
microglobulin (B2M), which prevents MHC-I presentation of FSPs. This was an early 
observation, the full significance of which is only now apparent (Bicknell et al., 1996; Bodmer 
et al., 1993; Clendenning et al., 2018; Kloor et al., 2007, 2010). The outgrowth of such B2M 
mutant clones is a prime example of cancer immunoediting, which has been further related 
to variation in host immune function, for example, mucosal density of FOXP3-positive 
regulatory T cells, indicating that such factors may be additional modifiers of LS (Echterdiek 
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et al., 2016). It is notable that B2M mutations in dMMR cancers are significantly associated 
with an almost zero rate of metastasis and thus indicate highly favourable prognosis (Koelzer 
et al., 2012; Tikidzhieva et al., 2012). In addition to mutations in B2M, mutations of CIITA or 
RFX5 are seen in approximately 20% of dMMR CRCs and prevent MHC-II antigen 
presentation, whereas approximately 10% of dMMR CRCs have mutations of TAP1 or TAP2, 
which are antigenic peptide transporters contributing to the process of antigen presentation, 
thus also preventing antigen presentation on the cell surface (Kasajima et al., 2010; Michel 
et al., 2010). 
In such ways, tumour cells escape the attention of the host’s immune system, both locally 
and in the circulation, but are in turn liable to attack with help from immunotherapy, such 
as anti-PD-1 or PD-L1 immune checkpoint blockade (Le et al., 2015; Steinert et al., 2014). The 
full variety of mechanisms by which tumours, and dMMR tumours in particular, manage to 
evade the immune system has yet to be determined. Undoubtedly, the colorectal 
microbiome plays an important part in the process of CRC development in LS as well as 
sporadically (Sears & Pardoll, 2018). Intriguingly, the immune response to dMMR CRCs in the 
form of the development of high endothelial venules (HEVs) responsible for trafficking 
lymphocytes into lymphoid follicles/TLS is stronger in LS patients than in sporadic dMMR 
colonic cancers, and especially high HEV densities in B2M mutant tumours support the 
concept of immunoediting during tumour evolution (Pfuderer et al., 2019). Such higher HEV 
densities in B2M-mutant tumours imply that under strong immunoselective pressure created 
by immune cells recruited via HEVs, tumour cells that have lost MHC class I antigens gain 
growth advantage due to immunoediting, thus revealing a major role of HEVs in enhancing 
the immunoselective pressure on highly immunogenic cancers. Taken together with the high 
numbers of dMMR crypts in LS and the low numbers of CRCs that actually manifest, these 
findings all point toward a longer process of immunoediting in LS CRCs, possibly due to the 
pre-existing dMMR crypts immunising LS patients against their own propensity to cancer, 
and explaining the higher proportion of B2M mutations in LS compared to sporadic CRCs 
(Kloor et al., 2012; Pfuderer et al., 2019; Staffa et al., 2015). However, HEVs generally recruit 
naïve lymphocytes from the blood into tissues and HEV-containing Crohn-like aggregates are 
generally seen in a peritumoural location in both pMMR and dMMR cancers, so our 
understanding of HEV and TLS in LS is as yet incomplete (Ager & May, 2015; Bento et al., 




Figure 1.3: Schematic diagram of the three-step process of elimination, equilibrium, and escape in 
MMR-deficient colorectal neoplasms (adapted and modified from Seth et al., 2018). CRCs in both LS 
and sporadic MSI CRCs elicit a strong immune response and undergo significant immunoediting. 
Cytotoxic T-lymphocytes (CTLs) are able to recognise immunogenic frameshift peptides (FSPs, red 
rectangle) that are synthesised in MMR-deficient cells as a result of unrepaired insertion/deletion 
loops in repetitive coding DNA sequences. CTLs can induce apoptosis of such dMMR cells (Elimination). 
However, tumour cells may evolve mechanisms to prevent immune destruction, including inhibition 
of CTLs by up-regulating expression of immune checkpoint proteins, such as PD-L1 (Equilibrium), or 
through various genetic mutations leading to loss of FSP antigen presentation (mutations to AIM2 or 
B2M for loss of MHC class I antigen presentation; mutations in CIITA or RFX5 for loss of MHC class II 




















1.1.8 Lynch Syndrome mouse models 
Mouse models have long been used as an essential tool to study and understand 
tumorigenesis and its mechanisms in a physiological system (Jahid & Lipkin, 2010). The use 
of tumour cell lines to modulate a gene's expression has the advantage of being a simple and 
easy way of performing experiments; however, cell culture does not model the complexity 
of the tumour microenvironment in vivo (McIntyre et al., 2015). The genetic composition of 
the mouse and human genomes has been mostly maintained through evolution, considering 
their developmental gap, and most cancer pathways are operative in both organisms. The 
genomic and transcriptomic landscapes and sequences of inbred laboratory mouse strains 
are well established and mice have been shown to be good models of a variety of diseases 
due to their ease of genetic manipulation, allowing experimental testing of genetic mutations 
in a cost-effective way (McIntyre et al., 2015). 
90% of all LS cases with cancer are caused by mutations in MLH1 and MSH2, whereas 
mutations in other MMR genes are less deleterious (de la Chapelle, 2005). The earliest 
murine models with potential to represent LS were Mlh1 knockout (Mlh1-/-) mice and Msh2 
knockout (Msh2-/-) mice; Msh2-/- mice showed complete loss of MMR pathway function in all 
cells resulting in high mutation rate (small insertions/deletions in mononucleotide and 
dinucleotide repeats) leading to high predisposition to cancer development with the MSI 
phenotype (de Wind et al., 1995; Jahid & Lipkin, 2010). Unfortunately, Msh2-/- mice had a 
short life span caused by the early development of lymphomas (mainly thymic T-cell 
lymphomas) with only a few mice surviving long enough to develop small numbers of 
intestinal adenomas (de Wind et al., 1995; McIntyre et al., 2015; Reitmair et al., 1995). 
Closely similar phenotypes were observed in Mlh1-/- deficient mice (Edelmann & Edelmann, 
2004; Edelmann et al., 1999; Jahid & Lipkin, 2010). Thus, the possible use of these 
constitutive knockout mouse models for the study of LS colorectal tumourigenesis and 
progression is very limited by their early development of lymphoma in around 80% of mice 
(Toft et al, 1999). 
LS mouse models deficient in other MMR genes have also been studied. Msh6-/- and Msh3-/- 
deficient mice showed a mild cancer predisposition characterized by late onset of cancer, 
with Msh6-/- mice developing mostly lymphomas with some epithelial tumours originating 
from the skin and uterus but only rarely from the intestines, whereas Msh3-/- mice either did 
not cause cancer predisposition or did so at a very late age, although combined Msh6-/- and 
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Msh3-/- did produce some late onset intestinal tumours similar to either Msh2-/- or Mlh1-/- 
mice (de Wind et al., 1999; Edelmann et al., 1997, 2000) . Pms2-/- deficient mice showed only 
late onset of lymphomas and sarcomas (Baker et al., 1995; Prolla et al., 1998).  
To restrict gene modifications to a specific tissue or organ of interest, tissue-specific Cre-
recombinase transgenic approaches can be used. Cre is a site-specific recombinase derived 
from the P1 bacteriophage that catalyses recombination between two loxP sites flanking the 
critical region of the gene of interest, resulting in excision of this region (flanking loxP sites 
are commonly termed flox sites) (Nagy, 2000). Tamoxifen-inducible forms of Cre 
recombinase (CreERT2) were developed that are only active in the presence of Tamoxifen, 
and expression of Cre or CreERT2 can be targeted to the intestinal epithelium by driving its 
expression by tissue-specific gene promoters such as either the Villin promoter or the Lgr5 
promoter (both are large and small intestinal specific genes) (Barker et al., 2007; Kucherlapati 
et al., 2010). A Villin-Cre;Msh2loxP/loxP mouse model was generated; these  Villin-
Cre;Msh2loxP/loxP mice showed intestinal tumorigenesis (adenomas and adenocarcinomas), 
but develop few lymphomas (Mcilhatton et al., 2016; McIntyre et al., 2015).  
Recently, Wojciechowicz et al (2014) generated a LS mouse model using the Lgr5 promoter 
to drive Tamoxifen-inducible Cre recombinase, in which loss of Msh2 expression is induced 
only in the murine small and large intestinal crypt base columnar stem cells (CBCs) 
(Wojciechowicz et al., 2014). Wojciechowicz et al generated the Lgr5CreERT2; Msh2flox/- mice 
by intercrossing the Lgr5CreERT2 mouse line (created by Barker et al. (2007) with the Msh2-
null (Msh2-) and Msh2-floxed (Msh2flox) lines (Barker et al., 2007; Claij & te Riele, 2004; de 
Wind et al., 1995). This mouse model is described in detail in Chapter 3. In Lgr5CreERT2; 
Msh2flox/- mice, tumorigenesis can be initiated by somatic loss of the second Msh2 allele in 
scattered foci along the intestines via Tamoxifen-induced activation of Cre expressed from 
the Lgr5CreERT2 transgene, mimicking the situation in LS patients. In Wojciechowicz et al. 
(2014), Lgr5CreERT2; Msh2flox/- mice developed intestinal tumours (adenomas and 
adenocarcinomas) after 19 months (Wojciechowicz et al., 2014). In this project, the 
Lgr5CreERT2; Msh2flox/- (Msh2-LS) mouse model was used to investigate intestinal tumour 





1.2 Colorectal cancer 
1.2.1 Epidemiology of sporadic colorectal cancer  
CRC is the third most commonly diagnosed cancer worldwide in males and the second in 
females, with more than 1.9 million new cases and approximately 935,000 deaths in 2020 
according to the World Health Organization (Global Cancer Observatory, 2020). In the UK, 
CRC is the 4th most common cancer, accounting for 11% of all new cancer cases in 2017, 
with around 42,300 new CRC cases in the UK every year (2015-2017), and approximately 
16,600 CRC deaths in the UK every year (2016-2018) (Cancer Research UK, 2016b). In the UK, 
44% of CRC cases are in females, and 56% are in males (Cancer Research UK, 2016a). Overall, 
left-sided (descending colon, sigmoid colon, and rectum) CRCs are more common than right-
sided (caecum, ascending colon, and transverse colon) cancers (Hsu et al., 2019). Incidence 
rates vary geographically, with the highest rates in developed countries, such as North 
America, Europe and Australia (Global Cancer Observatory, 2020), although CRC incidence 
rates are increasing in developing countries (Arnold et al., 2017).  
 
1.2.2 Pathogenesis and pathology of sporadic colorectal cancer  
CRCs are malignant neoplasms of the lining mucosal epithelium of the large intestine, 
anywhere from the ileocaecal valve to the rectum.  The large intestine can be divided into 
anatomic right and left sides. The right colon consists of the caecum, ascending colon, 
hepatic flexure and the transverse colon, whereas the left colon includes the descending 
colon, sigmoid colon, recto-sigmoid junction, and rectum (Figure 1.4). During embryogenesis, 
the right side derives from the midgut, whereas the left derives from the hindgut and the 
junction between the two is usually just proximal to the splenic flexure (Glebov et al., 2003).  
The colorectal wall is composed of four layers: serosa, muscularis propria, submucosa and 
mucosa that are very similar in mice and in humans (Treuting et al., 2017a, 2017b). The 
serosa is the outermost layer and has connective tissue and covering mesothelium for those 
parts of the bowel surface in contact with the peritoneal cavity. The muscularis propria is a 
double layer of smooth muscle (inner circular and outer longitudinal muscle fibres), which 
provide peristaltic movement that pushes the contents along the intestines. The connective 
tissue of the submucosa contains adipose cells, fibroblasts, nerves, blood vessels and 
lymphatic vessels. The mucosa is the innermost layer that can be further subdivided into 
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lining columnar epithelium, organised into test-tube shaped crypts, involved in water 
absorption and mucus secretion, lamina propria  (connective tissue supporting the crypts) 
and muscularis mucosae (thin strip of smooth muscle at the base of the mucosa) (Treuting 
et al., 2017b).  
The mucosal crypts contain a variety of specialized differentiated epithelial cells: colonic 
enterocytes that are involved in the absorption of water and some nutrients, 
enteroendocrine cells that produce hormones, goblet cells that secrete mucus and Paneth-
like cells that provide the stem cell niche at the base of the crypts to support the estimated 
2-4 stem cells in each crypt (although the number of stem cells per crypt may fluctuate) 
(Barker et al., 2008; Snippert et al., 2010). Barker et al (2007) identified leucine-rich-repeat-
containing G-protein-coupled receptor 5 (Lgr5), also known as Gpr49, as a characteristic 
epithelial stem cell marker in both the colon and the small intestine in mice and humans, 
although other stem cell markers have been  described (Barker et al., 2007; Barker & Clevers, 
2010).  These stem cells divide to produce one daughter stem cell that remains in the stem 
cell niche and one daughter cell that enters the transit-amplifying pathway to expand into 
more cells to help populate the crypt and eventually differentiate into the different 
specialized cells described above (Barker & Clevers, 2010). Stem cells play a key role in 
maintaining cellular homeostasis of the crypt and table surface epithelium of the large 
intestines which is replaced by new cells every 3 to 5 days (Copstead-Kirkhorn & Banasik, 
2014).  
There is evidence for mutated stem cells being able to replace other stem cells and fill the 
crypt with their daughter cells in a process known as monoclonal crypt conversion, and that 
the life cycle of crypts is linked to stem cell dynamics with crypts able to expand in number 
by the process of crypt fission (Loeffler et al., 1993, 1997; Reizel et al., 2011). Stem cells often 
exhibit the highest levels of Wnt signalling as demonstrated by nuclear B-catenin 
immunstaining; usually there is neutral competition between stem cells in crypts (Lopez-
Garcia et al., 2010; Snippert et al., 2010), however if a stem cell has a selective growth 
advantage, such as that conferred by mutated Apc or Kras, that stem cell can increase in 
number, more rapidly undergo monoclonal crypt conversion with crypt expansion by crypt 





Adenocarcinomas are the most common type of CRC (>90%) (Cancer Research UK, 2016b). 
They are epithelial neoplasms derived from glandular epithelial cells that invade through the 
muscularis mucosae into the submucosa (and into or though the muscularis propia in most 
cases).  Precursor lesions are thought to include dysplastic crypt foci that can develop into 
benign adenomas, some of which may subsequently evolve into malignant adenocarcinomas 
(Figure 1.5) (Cheng & Lai, 2003; Dukes, 1934; Dukes, 1956; Fearon & Vogelstein, 1990; 
Fleming et al., 2012).  This neoplastic process involves loss of the normal regulation of growth 
control with sustained proliferative signalling and cumulative acquisition of the hallmarks of 
cancer (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). Underlying these 
neoplastic hallmarks are genome instability, which generates the genetic diversity that 
expedites their acquisition (Hanahan & Weinberg, 2011). 
The stage of advancement of a CRC is most commonly described using the TNM system 
(tumour, node and metastasis) with tumours described according to their degree of 
penetration and spread. T1 cancers are confined to the submucosa, T2 cancers have invaded 
into (but not through) the muscularis propria, T3 cancers have penetrated the outer limit of 
the muscularis propria, whereas T4 cancers have infiltrated through the serosal surface 
and/or grow into other organs and tissues. N0 indicates no metastasis to lymph nodes. 
Cancers that have spread to lymph nodes are further classified as N1 or N2 according to the 
number of involved nodes. M0/M1 describes the absence or presence of metastatic spread 
to distant organs, most commonly the liver (Cancer Research UK, 2019; Loughrey et al., 
2020).  
The Dukes’ staging system is another commonly used system for describing CRC stage, in 
which Dukes’ A cancers have invaded into the submucosa or the muscularis propria, Dukes’ 
B cancers have penetrated through the outer edge of the muscularis propria and invade into 
the serosa, or beyond, but have not spread to lymph nodes or to other organs, and Dukes’ C 
cancers have involved lymph nodes (although a later addition was  Dukes’ stage D cancers 
that have metastasised to distant organs such as the liver) (Cancer Research UK, 2019; Dukes 
& Bussey, 1958). Histological grading of CRCs may provide further prognostically useful 





Figure 1.4: Comparison between human and mouse large intestinal tract (adapted and modified from Treuting et al., 2017). In the left panel, the anatomic divisions of 
the human colorectum are based on its configuration and location. The right colon is composed of the appendix, caecum, ascending colon, and transverse colon. The 
left colon includes the descending colon, sigmoid colon, and rectum. The outer longitudinal layer of the muscularis propria proximal to the rectum forms three distinct 
longitudinal bands called taenia coli. The colon becomes sacculated between the taenia, forming the haustra. In the right panel, the mouse large intestinal tract is 
shown. The cecum is a large J-shaped blind sac. The proximal colon exits near the ileocaecal junction. Faecal pellets are formed by consolidation and dehydration in 




Figure 1.5: Representation of large intestinal tumour progression (adapted and modified from Thrumurthy et al., 2016; Vogelstein et al., 2010, and others). The 
adenoma-carcinoma progression sequence has transitions from normal through the earliest stage of microadenoma formation (monocryptal adenoma or oligocryptal 
adenoma) followed by small early adenomas usually with low-grade (LG) dysplasia, then larger late adenomas often with high-grade (HG) dysplasia (yellow clone of 
cells), a proportion of which may progress to form a malignant clone that shows early invasion into the submucosa of the bowel wall, later becoming an established 
adenocarcinoma invading deeper into the muscularis propria and/or serosa. The murine sequence may show mucosal crypt hyperproliferation as a very early change 
before dysplasia is observed, but zones of hyperproliferation are infrequently or rarely seen in human colon. Progression over time is indicated by the horizontal black 




1.2.3 Genetic and epigenetic changes in sporadic colorectal cancer  
Molecular analysis of CRCs reveals underlying modifications related to three major 
mechanisms of genomic/genetic/epigenetic instability: chromosomal instability (CIN), 
microsatellite instability (MSI), and CpG island methylator phenotype (CIMP). CIN is observed 
in 65-85% of sporadic CRCs, resulting in high levels of DNA somatic copy number alterations 
(SCNAs), with DNA gains/amplifications and DNA losses/deletions that may affect small 
chromosome regions or whole chromosomes, causing aneuploidy and loss of heterozygosity 
that can affect tumour suppressor gene loci (Arends, 2013; Poulogiannis et al., 2010). MSI is 
detected in around 12-15% of sporadic CRC cases and is due to defective DNA mismatch 
repair, with a high mutation rate (hypermutant) affecting a large number of genes. CIMP is 
observed in around 20% of sporadic CRCs and it is characterised by hypermethylation of 
promoter CpG islands of susceptible genes, sometimes resulting in the inactivation of 
multiple tumour suppressor genes (Müller et al., 2016).  
One of the most frequent molecular genetic changes in sporadic CRCs is the disruption of the 
WNT signalling pathway, which occurs in over 90% of sporadic CRCs, (Cancer Genome Atlas, 
2012), mostly due to biallelic inactivation of the APC gene. APC mutations are found in around 
80-85% of both adenomas and carcinomas that occur very early in the pathogenetic 
sequence and appear to initiate adenomagenesis (Arends, 2013). APC is a WNT signalling 
pathway negative regulator and acts as part of the β-CATENIN degradation complex together 
with AXIN, Glycogen synthase kinase 3 (GSK3), and Casein kinase 1 (CK1). These APC 
mutations usually lead to truncation of the APC protein with reduced ability to degrade B-
CATENIN, leading to its accumulation and nuclear translocation, causing abnormal signalling 
through the WNT signalling pathway (Morin et al., 1997; Schatoff et al., 2017). Mutations in 
the β-CATENIN encoding gene CTNNB1, upregulation of the Wnt Frizzled (FZD) receptor, and 
inactivation of DKK-1 also contribute to deregulation of WNT signalling and are observed in 
sporadic CRCs (González-Sancho et al., 2005; Morin et al., 1997; Terasaki et al., 2002).  
Around 40-45% of sporadic CRCs show mutations in the RAS/MAPK pathway. The majority of 
the mutations involve KRAS, with a small proportion affecting NRAS or BRAF, resulting in the 
activation of this pathway. Mutation in any one of these genes, usually at specific sites (such 
as codons 12, 13 or 61 in the RAS gene or codon 600 for the BRAF proto-oncogene) cause the 
constitutive activation of the RAS-RAF-MEK-ERK (MAPkinase) proliferative signalling pathway 




Mutations in the TP53 tumour suppressor gene are found in around 60% of CRCs and this 
occurs late in sporadic colorectal tumorigenesis (around the transition of adenoma to 
adenocarcinoma) (Vogelstein et al., 2010). The p53 protein has been called the “guardian of 
the genome” as activation of the p53 pathway upon DNA damage detected by DNA damage 
response pathways (or other cellular stresses), leads to cell cycle arrest to allow opportunity 
for DNA repair, although in case of severe DNA damage it induces cell death via apoptosis 
(Kastenhuber & Lowe, 2017).  
Mutations in TGFBR1, ACVR2A, SMAD3 and SMAD4 are also common in sporadic CRCs. These 
genes encode for proteins involved in the transforming growth factor (TGF) β pathway that 
has growth suppressive roles in modulating proliferation, apoptosis, stem cell renewal, 
differentiation and adult tissue homeostasis (Weiss & Attisano, 2013). 
Some sporadic CRCs may evolve from serrated precursors such as hyperplastic polyps, sessile 
serrated lesions, and traditional serrated adenomas and these represent around 10-15% of 
all CRCs. These lesions follow an alternative neoplastic development pathway different to 
conventional adenomas. They are often characterized by more frequent activating mutations 
of BRAF and less frequent KRAS mutations, with greater involvement of the CIMP, in which a 
range of susceptible genes develop epigenetic promoter hypermethylation that silences their 
expression, frequently including MLH1 leading to dMMR and MSI (Kedrin & Gala, 2015; 
Yamane et al., 2014). Although most of the 12-15% dMMR sporadic CRC with 
hypermethylated MLH1 promoters appear to evolve from polypoid adenomas, and these are 














1.2.4 Lifestyle and other risk factors for sporadic colorectal cancer 
Several lifestyle factors, such as tobacco smoking, alcohol consumption, diet (with increased 
red and processed meat or insufficient fibre) and increased body mass index (BMI) 
(overweight and obesity) are associated with increased risk of sporadic CRC (Cancer Research 
UK, 2020; IARC, 2010). 
More than 40% of CRC cases are diagnosed in people aged 75 or over in the UK. CRC risk 
increases from 50 years of age reaching the highest incidence after 75 years of age, higher in 
men than in women (Bénard et al., 2018). 
7% of CRCs are linked to smoking in the UK, more for rectal cancer than colonic cancer (Brown 
et al., 2018). However, the relation of smoking with CRC is controversial, some, but not all 
studies include smoking as a risk factor (Lee et al., 2016). The risk of CRC is high in current 
and former smokers (17%-25%) with increasing risk in those who began smoking at a young 
age and the risk increases with the number of cigarettes smoked per day (Hannan et al., 2009; 
Liang et al., 2009).  
6% of CRCs are linked to alcohol consumption in the UK (Brown et al., 2018). In 2010, ethanol 
and its metabolite acetaldehyde were classified as group 1 carcinogens (carcinogenic to 
humans) by the International Agency for Research on Cancer for the locations: upper 
aerodigestive tract, liver, breast and colorectum (IARC, 2010). Moderate and heavy drinking 
(≥50g/day) has been associated with increased risk of CRC of 33% compared with light to 
non-drinkers, with a stronger association in men than in women (Bagnardi et al., 2015). 
13% of CRCs are linked to processed meat consumption in the UK (Brown et al., 2018). In 
2015, processed meat was classified as group 1 carcinogen and red meat was classified as 
group 2A carcinogen (probably carcinogenic to humans) by the World Health Organization 
(WHO) (Bouvard et al., 2015). Several meta-analyses studies, showed that 100g/day of red 
meat and 50g/day of processed meat increases CRC risk by 17-18% (Aune et al., 2013; Chan 
et al., 2011). This is mainly related to the genotoxic compounds generated during the meat 
metabolism that can cause DNA damage (H-nitroso-compounds, heterocyclic aromatic 
amines and polycyclic aromatic hydrocarbons) (Bouvard et al., 2015).  
11% of CRCs are linked to overweight and obesity in the UK (Brown et al., 2018). Meta-
analysis studies showed that a high BMI value can increase CRC risk. In overweight men 
(BMI=25-29), the risk of CRC is 18% higher, while obese men (BMI≥30) have 48% higher risk 




The relationship between CRC and increased BMI has been suggested to relate to endocrine 
abnormalities and metabolic changes linked to obesity, such as insulin resistance, chronic 
inflammation and altered adipokine secretion (Martinez-Useros & Garcia‑Foncillas, 2016; 
van Kruijsdijk et al., 2009). Meta-analysis studies have observed an increased CRC risk of 22-
30% in diabetes mellitus (DM) type 2 (Jiang et al., 2011; Luo et al., 2012). This is linked to the 
alteration of insulin levels and insulin-like growth factor (IGF) signalling pathway activity, 
which promotes cell growth and inhibits apoptosis (Schoen et al., 2005). 
Inflammatory bowel diseases (IBD) are an established risk factor for CRC, mainly ulcerative 
colitis (UC) and Crohn’s disease (CD) (Lutgens et al., 2008). The severity and duration of the 
inflammation is associated with the increase in CRC risk. The CRC risk is 70% higher in the IBD 
patients than in non-IBD patients, making IBD one of the highest non-hereditary risk factors 


















1.3.1 Ethanol metabolism 
Alcohol is one of the most used recreational drugs, with 2.3 billion current drinkers in 2018 
(World Health Organization (WHO), 2018). Alcohol consumption is responsible for around 1.8 
million deaths per year (3.2% of all death); worldwide, a total of approximately 389,000 
cancers representing 3.9% of all cancers derive from chronic alcohol consumption (5.2% in 
men and 1.7% in women) (World Health Organization (WHO), 2018)]. Chronic alcohol 
consumption has been associated with cancer development in the upper aerodigestive tract 
(including oesophageal, pharyngeal, head and neck cancers), liver, breast and colorectum 
(IARC, 2010).  
Carcinogenic effects of ethanol are related to its metabolism. Ingested ethanol is readily 
absorbed from the gastrointestinal tract, and about 90% is metabolized by oxidative 
pathways mainly in the liver (Brooks & Zakhari, 2014). Ethanol is oxidized mostly by the 
cytosolic class I alcohol dehydrogenase (ADH) isoenzymes (ADH1A, ADH1B and ADH1C), that 
use nicotinamide adenine dinucleotide (NAD+) to produce acetaldehyde and the reduced 
form of nicotinamide adenine dinucleotide (NADH). The cytochrome P450 (CYP2E1) is also 
involved in the oxidation of ethanol to acetaldehyde in the liver, mostly at elevated alcohol 
concentrations (Figure x), resulting also in the generation of reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) (Pöschl et al., 2004; Seitz & Stickel, 2007).  
Acetaldehyde is considered the important cancer-causing agent in the upper and lower 
gastrointestinal tract, as acetaldehyde concentrations in saliva and the large intestine are 
high enough to enable it to act as carcinogen. Acetaldehyde is a highly reactive small 
molecule able to induce a wide range of DNA damage resulting in tumour development (vide 
infra). Acetaldehyde is metabolized by a large family of mitochondrial aldehyde 
dehydrogenases (ALDHs), with different isoforms expressed in different cell types that use 
NAD+ to convert acetaldehyde to non-toxic acetate, water and NADH (Figure 1.6). 
Acetaldehyde is the major substrate for the mitochondrial ALDH2 (Km=3.2µM) and ALDH1B1 
enzymes (Km= 55µM) (Stagos et al., 2010). ALDH2 is the predominant isoform for 
acetaldehyde detoxification in the liver, whereas ALDH1B1 is highly expressed in the 
gastrointestinal epithelium, particularly in the epithelial stem cells and transit-amplifying 
cells, and studies have shown ALDH1B1 to be involved in acetaldehyde detoxification in the 




and/or oxidation of acetaldehyde to vary between individuals, leading to an increased cancer 
risk (vide infra) (Marchitti et al., 2008). In the mitochondria, the non-toxic acetate is ligated 
to coenzyme A (CoA) by acetyl-CoA synthetase and acyl-CoA synthetase 2, to form acetyl-
coenzyme A (acetyl-CoA).  Acetyl-CoA plays a key role in many metabolic reactions 








Figure 1.6: Schematic diagram of ethanol metabolism. Ethanol is oxidized to acetaldehyde in a 
reversible reaction catalyzed by the class I ADH isoenzymes and CYP2E1 in the liver. Ethanol oxidation 
is coupled to reduction of the cofactor NAD+.  ALDH enzymes (isozymes ALDH2, ALDH1B1) catalyse 
irreversible oxidation of the acetaldehyde carbonyl to its respective carboxylic acid, acetic 
acid/acetate. Oxidation of acetaldehyde to acetate by both ALDH2 and ALDH1B1 is coupled to 













1.3.2 ALDH1B1 function, genetics and polymorphisms 
ALDHs are involved in cell protection against the effects of a wide range of exogenous and 
endogenous aldehydes (Marchitti et al., 2008). The mitochondrial matrix protein ALDH2 is 
the main enzyme involved in acetaldehyde oxidization in the liver during ethanol metabolism, 
showing the lowest Michaelis-Menten constant (Km) for acetaldehyde (Km=3.2µM) of all the 
ALDH isoforms (Stagos et al., 2010). The key role of ALDH2 in acetaldehyde detoxification is 
exemplified by the study of human single nucleotide polymorphisms (SNPs) in the ALDH2 
gene. 40%-50% of Asians are ALDH2*2 carriers, an inactive variant of the normal allele 
ALDH2*1, due to a SNP (single base pair change G/CA/T) in the coding region of the ALDH2 
gene. People heterozygous for ALDH2*2 have reduced metabolism of acetaldehyde, showing 
a 6-fold increase of blood acetaldehyde levels compared with wild-type individuals, whereas 
individuals homozygous for ALDH2*2 have very poor metabolism of acetaldehyde, causing a 
20-fold increase of blood acetaldehyde levels compared with wild-type individuals. This 
results in the alcohol flushing syndrome (Seitz & Stickel, 2010; Yokoyama et al., 1998). This 
SNP has been associated with increased cancer risk for various cancers, including those of 
the upper aerodigestive tract and colorectum, and increased neoplasms have been observed 
in Aldh2-null mice that show markedly increased incidence of leukaemias and other cancers 
(Langevin et al., 2011; Yu et al., 2009).  
The mitochondrial ALDH1B1 (also known as ALDH5 and ALDHX) exhibits a Km= 55µM for 
acetaldehyde, representing the ALDH with the second lowest Michaelis-Menten constant 
involved in acetaldehyde oxidization. The human ALDH1B1 gene is located on chromosome 
9 (in a 5957-base pair region) and it is characterized by an intronless coding region. The 
expressed ALDH1B1 protein shares 75% homology in peptide sequence with ALDH2, it 
contains 517 amino acids with an N-terminal 19-residue mitochondrial lead signal and it 
functions as homotetrameric enzyme (Hsu & Chang, 1991; Stagos et al., 2010). 
Immunohistochemical analyses revealed that human ALDH1B1 is expressed at high levels in 
the small intestine, colon, liver, and pancreas, with the highest protein expression levels in 
colonic epithelial stem cells. This was also observed in mouse tissues (Stagos et al., 2010). 
High expression levels of ALDH1B1 are observed in human colonic adenocarcinomas, 
probably due to the ALDH1B1-positive normal colonic stem cells that act as progenitors for 
progression to malignancy during tumourigenesis, and become cancer stem cells. ALDH1B1 




The human ALDH enzymes share the same protein structure that contains three domains: a 
cofactor-binding domain, a linker domain and a catalytic domain. At the interface of the 
domains lies a hydrophobic tunnel at the base of which resides the enzyme active site, 
opposite the cofactor-binding site. The specificity of the ALDHs towards their substrate is 
determined by the residues from the three domains that line the hydrophobic tunnel of each 
ALDH subunit. NAD+ is the cofactor for ALDH1B1, not NADP+ (Marchitti et al., 2008; Steinmetz 
et al., 1997). The ability of ALDH1B1 (but also ALDH2) to catalyse oxidation is provided by the 
cysteine at position 302 (Cys302), a highly conserved residue in all catalytically active 
members of the ALDH family. The Cys302 is essential for the nucleophilic attack on 
acetaldehyde (Farres et al., 1995; Marchitti et al., 2008).  
ALDH1B1 major substrates are short-chain aldehydes, such as acetaldehyde and 
propionaldehyde. The increasing interest in ALDH1B1 and its role in acetaldehyde 
detoxification emerged following the identification of ALDH1B1 polymorphisms that are 
associated with drinking-behaviour (A69V) and alcohol hypersensitivity (A86V) in Caucasians 
(Husemoen et al., 2008; Linneberg et al., 2009). Jackson et al., 2015, confirmed that 
ALDH1B1*2 (A86V) variant/polymorphism is catalytically inactive due to inability to bind 
NAD+ (Jackson et al., 2015). In a recent study, our research group provided evidence for a 
role of Aldh1b1 in protection of the murine intestines from ethanol-induced DNA damage 
and intestinal tumour formation using Aldh1b1-depleted mice compared with wild-type mice 
under long-term ethanol treatment for up to 12 months (Müller et al., 2016). Ethanol-treated 
Aldh1b1-depleted mice showed increased plasma acetaldehyde levels and increased 
ethanol-induced large intestinal adenomas with occasional adenocarcinomas (Müller et al., 
2016). Our research group also described a role of Aldh1b1 in protection from ethanol-
induced hepatocellular hyperproliferation and liver tumour development in these Aldh1b1-
depleted mice (Müller et al., 2018). However, Aldh1b1 is still a relatively under-investigated 









1.3.3 Ethanol & Acetaldehyde induced DNA damage 
1.3.3.1 Ethanol, CYP2E1 induction and DNA damage 
Chronic alcohol consumption induces CYP2E1 expression by liver cells, resulting in decrease 
of retinol and retinoic acid tissue levels. Retinoic acid has a key role in cellular growth and 
differentiation, activating a signalling cascade through its nuclear retinoic acid receptors, 
resulting in the gene transcription of cell proliferation and migration regulators. The decrease 
in retinoic acid has consequences for cell proliferation, differentiation and malignant 
transformation (Liu et al., 2001). Chronic ethanol treatment in rats showed decreased 
retinoic acid in association with a decrease in mitogen-activated protein kinase (MAPK) and 
an increase phosphorylation of c-Jun N-terminal kinase (JNK), resulting in hepatic cell 
hyperproliferation and reduced apoptosis (Wang et al., 1998). Increased CYP2E1 activity 
results in the activation of the metabolism of certain pro-carcinogens, including 
nitrosamines, polycyclic hydrocarbons and aflatoxins, by alcohol-induced CYP2E1 (Seitz & 
Stickel, 2007). 
Most importantly, ethanol oxidation by CYP2E1 results in the generation of ROS, such as 
superoxide anion and hydrogen peroxide that causes oxidative damages contributing to 
various diseases such as cancer. The CYP2E1-produced ROS can cause the generation of lipid 
peroxidation products such as 4-hydroxynonenal (4-NHE) and malondialdehyde (MDA). 4-
NHE reacts with DNA to form highly mutagenic exocyclic DNA etheno-adducts 1,N6-
ethenodeoxyadenosine (εdA) and 3,N4-ethenodeoxycytidine (εdC) (Figure 1.7) (Vasiliou et 
al., 2015). These DNA adducts can cause mutations in TP53 at codon 249, resulting in 
proliferative advantage and reduced apoptosis (Hu et al., 2002). ROS are usually neutralized 
by the anti-oxidative defence system (AODS), endogenous mechanisms (glutathione 
peroxidase and superoxide dismutase) and exogenous mechanisms (antioxidant nutrients) 









1.3.3.2 Acetaldehyde and DNA damage 
Acetaldehyde can also indirectly induce ROS generation by injuring the mitochondria (Seitz 
& Stickel, 2007). Following increased alcohol intake, ethanol is oxidized in acetaldehyde 
generating large quantities of NADH that is reoxidized to NAD+ in the mitochondria. 
Furthermore, ROS can also be generated by increased electron leakage from the 
mitochondrial respiratory chain associated with the stimulation of NADH in the mitochondria 
(Bailey & Cunningham, 2002). The increased mitochondrial ROS production may also be 
caused by activation of N-acetylsphingosine by tumour necrosis factor-α (TNF-α) that 
increases the levels of ceramide, a mitochondrial electron-transport inhibitor (García‐Ruiz et 
al., 2000). The ROS generated indirectly by acetaldehyde may result in lipid peroxidation 
products that, as explained before, form highly mutagenic exocyclic DNA etheno-adducts 
(Figure 1.7).  
The electrophilic nature of acetaldehyde contributes to its high reactivity and it is provided 
by its carbonyl group (R-CHO) that reacts with nucleophilic sites in DNA and protein 
generating adducts. Acetaldehyde can induce DNA adducts by reacting directly with 
deoxyguanosine (dG) most frequently, followed by deoxyadenosine (dA) and then 
deoxycytosine (dC) (Vasiliou et al., 2015).   
One molecule of acetaldehyde can bind to DNA forming N2-ethylidene-2′-deoxyguanosine 
(N2-EtidG). N2-EtidG requires chemical reduction to become a stable adduct, N2-ethyl-2′-
deoxyguanosine (N2-EtdG). High levels of this DNA adduct were observed in Swedish drinkers 
compared with non-drinkers, and this was observed in ethanol-treated mice (with 10% 
ethanol in drinking water); these N2-EtdG adducts were abundant but not highly mutagenic 
(Brooks & Zakhari, 2014). Two molecules of acetaldehyde can react with DNA to form R- and 
S-α-CH3-γ-OH-1,N2-propano-2’-deoxyguanosine(PdG) adducts, called Cr-PdG because they 
were first observed in DNA treated with crotonaldehyde. The Cr-PdG adducts are less 
abundant compared with EtdG adducts, but more mutagenic. Choudhury et al. (2004) 
showed that nucleotide excision repair (NER) may possibly be involved in the repair of the 
PdG adducts (Choudhury et al., 2004). The Cr-PdG adducts can exist a ring-opened form when 
located in double-stranded DNA, in this way it can react with deoxyguanosine of the opposite 
strand of the DNA forming an interstrand crosslinks (ICLs), but it can also bind proteins 
forming DNA-protein crosslinks. DNA-protein crosslinks are precursor lesions to altered sister 
chromatid exchanges, DNA ICLs and DNA-protein crosslinks, that may lead to the generation 




Chronic alcohol consumption causes hyperproliferation of the upper aerodigestive tract 
mucosa and large intestinal mucosa, due to an acetaldehyde toxic effect. Acetaldehyde is 
highly concentrated in the saliva and colon, where the acetaldehyde generated by the 
mucosal ADHs combines with acetaldehyde generated by the oral or large intestinal 
microbiota. High concentrations of acetaldehyde can promote hyperproliferation and 
generation of Cr-PdG and other DNA adducts in these tissues (Seitz & Stickel, 2007, 2010). 
These reactions are possible thanks to the reactive aldehyde group exposed in the open-ring 
form. Cr-PdG can induce GT transversions, as well as base deletion and insertion 
mutations.  Furthermore, acetaldehyde can cause point mutations in the hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) locus in human lymphocytes, and induce sister 
chromatid exchanges and gross chromosomal aberrations (Seitz & Stickel, 2007). Langevin et 
al (2011) demonstrated that the Fanconi Anaemia (FA) DNA repair pathway plays a crucial 
role in counteracting acetaldehyde induced genotoxicity in mice (Langevin et al., 2011), as 
the FA DNA repair pathway is essential for the repair of DNA ICLs (Kim & D’Andrea, 2012). 
Chronic alcohol consumption can cause deficiencies of folate, vitamin B6 and certain 
lipotropes that are essential cofactors of methyl group transfer. Acetaldehyde seems to alter 
DNA methylation via inhibition of methyl adenosine transferase 1 (MAT 1) causing reduced 
production of S-adenosyl-L-methionine (SAMe, the universal methyl group donor and 
enzyme activator). Acetaldehyde also inhibits DNA methyltransferases (DNMTs) that are 
involved in the methylation of 1% of the DNA, replacing the hydrogen atom attached at the 
C5 of cytosine with a methyl group. So far, this has only been observed in rodent studies 
(Garro et al., 1991; Santamaría et al., 2006). The acetaldehyde hypomethylation effect may 
contribute to epigenetic alterations of genes involved in carcinogenesis (Seitz & Stickel, 2007; 
Vasiliou et al., 2015).   Acetaldehyde is also able to bind glutathione preventing glutathione-
S-transferase activity, a key component of the AODS, which is responsible for the 
detoxification of ROS and RNS (Vasiliou et al., 2015). In 1988, Espina et al. reported 
acetaldehyde as a possible inhibitor of O6-methylguanine methyltransferase (MGMT) activity 
in rat liver extracts (Espina et al., 1988). However, according to other studies, acetaldehyde 
is unable to react with MGMT (Brooks & Zakhari, 2014; Worrall & Thiele, 2001). Furthermore, 
acetaldehyde seems to inhibit DNA repair systems through inhibition of MGMT and 8-oxo-
guanine-DNA glycosylase (Seitz & Stickel, 2007). However, much remains to be investigated 





Figure 1.7: CYP2E1, acetaldehyde and DNA damage (adapted and modified from Seitz & Stickel, 2007). 
Active CYP2E1 decreases tissue levels of retinol and retinoic acid and increases activation of 
environmental pro-carcinogens. Chronic alcohol consumption induces CYP2E1 leading to reactive 
oxygen species (ROS) generation that mediate lipid peroxidation producing lipid peroxidation products 
such as 4-hydroxynonenal (4-HNE). Lipid peroxidation products can form etheno-DNA adducts, such 
as 1,N6-ethenodeoxyadenosine (εdA) and 3,N4-ethenodeoxycytidine (εdC). Acetaldehyde can also 
increase ROS formation indirectly by injuring mitochondria. Acetaldehyde reacts with DNA directly 
creating DNA-adducts, such as N2-ethyl-2′-deoxyguanosine (N2-EtdG) and R- and S-α-CH3-γ-OH-1,N2-
propano-2’-deoxyguanosine (Cr-PdG), leading to DNA-protein crosslinks and/or DNA interstrand 
crosslinks (ICLs) that are precursor lesions for DNA strand breaks, sister chromatid exchanges and 
chromosomal aberrations. Acetaldehyde can also cause point mutations in the hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) locus in human lymphocytes, and induce sister chromatid 
exchanges and gross chromosomal aberrations. Furthermore, acetaldehyde seems to play a role in 

















1.4 Aim and Objectives 
Lynch Syndrome patients carry an MMR pathogenic mutation that predisposes them to 
increased lifetime risks for several cancers that develop as a result of defective MMR 
following inactivation of the wild-type MMR allele during tumour formation. The variable 
expression of the cancer phenotypes amongst LS patients suggests important effects of allelic 
variation, genetic modifiers, environmental and/or lifestyle factors, together with complex 
genetic and environmental interactions. Therefore, it is important to investigate relevant 
environmental risk factors for developing cancer in LS patients, in order to provide 
appropriate cancer prevention advice, surveillance and care.  
Given the evidence for ethanol consumption being a risk factor for sporadic CRC 
development, it was decided to investigate whether ethanol is a key environmental/lifestyle 
risk factor for CRC in LS patients using a genetically altered animal model that can be exposed 
to ethanol consumption. The overall aim was to determine whether there is a 
gene/environment interaction between defective MMR and ethanol that accelerates 
colorectal tumour development and progression. To investigate this, an appropriate 
experimental mouse model was established, using a modified version of the LS-mouse model 
based around one inherited mutant allele and one inducible mutation of the murine Msh2 
gene that was recently created by Wojeciechowicz et al (2014) (Lgr5CreERT2; Msh2flox/-; 
mTmG). The specific objectives of this project included the following. 
1. To determine whether ethanol and / or its major metabolite acetaldehyde can cause 
acceleration of defective MMR-driven intestinal tumour formation. 
2. To elucidate whether ethanol and / or acetaldehyde can increase the number and size of 
intestinal precursor lesions and their progression to intestinal adenoma or invasive cancer. 
3. To investigate the role of the DNA mismatch repair system in protecting intestinal cells 








Chapter 2: Materials and Methods      
2.1 Animal work 
2.1.1 Introduction 
In this study, all murine experiments were performed under Professor Mark J Arends’ Home 
Office project licence issued under the United Kingdom Home Office Animals (Scientific 
Procedures) Act 1986, and my Home Office personal licence in accordance with the Animals 
(Scientific Procedures) Act 1986. All experiments received approval by the Named Veterinary 
Surgeons of the University of Edinburgh. Experiments were carried out at the Western 
General Hospital-BRF (University of Edinburgh) animal facility. 
In this study, mice were housed in individually ventilated cages (IVCs) with group sizes and 
enrichment according to Home Office regulations. Cages were one-time use and recyclable. 
Light was provided as 12 hours of light and 12 hours of dark every 24 hour period. The room 
air humidity was kept at 35% and temperature at 21-22°C. The unit had a pathogen health 
status rating of 4, however the mice were kept in IVCs in a clean room to limit the contact 
with animal gastrointestinal and other pathogens that could have altered significantly the 
results in the experiments. Mice were given the RM3 diet (Special Diets Services) in pellet 
form, a high nutrient diet containing fatty acids, with ad libitum access to food and water. 
Cages, bedding, cage enrichment, food and bottled water were autoclaved or irradiated 
before use. 
 
2.1.2 Mouse models 
Mouse models used in this project are shown in table 2.1. Mouse model generation is further 





Table2.1: Mouse models used in this study and how they were created by crossing the described strains, including the source of the strains and the relevant genotypes 




2.1.3 Tamoxifen, Temozolomide and ethanol treatments  
Experimental mice of 7-9 weeks age, received treatments with Tamoxifen, Temozolomide 
and/or ethanol.  Tamoxifen (Sigma-Aldrich, T5648) was dissolved in 10ml of molecular grade 
ethanol and 90ml of sterile corn oil (Sigma-Aldrich, C8267), at a concentration of 10mg/ml. 
Aliquots were prepared and stored at -20°C. Prior to injection, Tamoxifen was incubated for 
10min in a 40°C water bath. Mice were weighed and the correct Tamoxifen dose calculated 
at either 0.15mg/g body-weight (bw) or 0.1mg/g bw (according to the day of treatment). 
Tamoxifen was collected with a sterile syringe and intraperitoneal injections were performed 
with the assistance of an animal technician.  
Temozolomide (TMZ, Cayman, 14163) was dissolved in absolute ethanol and sterile water 
(ratio 1/9) at a concentration of 10mg/mL, sonicated (water bath sonicator; 5 minutes), 
centrifuged (4000g; 5 minutes; room temperature) and the supernatant was filtered through 
a 22um filter. Aliquots were prepared and stored at -80°C. Prior to administration, mice were 
weighed and the correct TMZ dose calculated at 0.1mg/g bw. TMZ was given to animals by 
oral gavage (o.g.) with the assistance of an animal technician. 
Ethanol molecular grade (Sigma Aldrich, E7023) at 20% concentration (v/v) was given in 
drinking water.  
 
 
2.1.4 Mouse models acronyms 
Specific acronyms were created for each mouse model and the relevant treatments they 









2.1.5 Collection of tissues and blood with subsequent processing 
At the end of each individual murine experiment, mice were sacrificed by CO2 asphyxiation 
and cervical dislocation. Blood was collected via cardiac puncture through the diaphragm 
under the rib cage, using a 25 gauge pre-heparinised needle (Sterican, 612-0153) and a 1ml 
syringe. Blood was dispensed in 1.3ml Lithium Heparin Paediatric tubes (Greiner Bio-One Inc, 
459084). Blood was fractionated by centrifugation at 3000 x g per 15 minutes at 4°C. Plasma 
was collected in a 2ml cryo-tube and immediately snap-frozen in liquid nitrogen and stored 
at -80°C.  
Necropsy was performed on the entire cadaver focusing on the gastrointestinal tract, from 
the oesophagus to the anal canal, and other abdominal organs. The small intestines (SI) and 
large intestines (LI) were prepared separately. Stomach, caecum, liver, spleen, thymus and 
any macroscopically abnormal tissues or organs were removed and rinsed with cold PBS prior 
to incubation in 10% neutral buffered formalin (NBF) (Sigma, HT501128) for 24h at RT. After 
NBF incubation, tissues were washed in PBS at RT and stored in 70% ethanol at 4°C.  
The small intestines (SI) and large intestines (LI) were removed and analysed for the presence 
of tumours, as whole mount specimens. The SI and LI were flushed twice in PBS and PBS 
containing Protease Inhibitor (PI, Calbiochem). All possible abnormalities were excised for 
histopathological analysis. The remaining small and large intestines were inverted using a 
30cm long and 3mm diameter bamboo skewer and pre-fixed in 10% NBF: the small intestines 
were fixed for 4 hours at RT and large intestines were fixed for 1 hour at RT.  
After this short-term fixation in NBF, both small and large intestines were opened 
longitudinally along the antimesenteric border and flattened out as whole mount specimens 
on a petri-dish (145x20mm, Greiner Bio-One, 639102) containing cold PBS on ice, to allow 
observation of mucosal surfaces and fluorescent microscopic analysis.  
After microscopic analysis, intestines were rolled-up as Swiss rolls around a toothpick for 
further fixation in 10% NBF over-night. The next day, intestines were washed in PBS at RT and 
stored in 70% ethanol at 4°C. All tissues collected were processed and paraffin-embedded to 
generate formalin-fixed paraffin-embedded (FFPE) blocks using standard histological 
methods by the Pathology laboratory technicians of IGMM, at the University of Edinburgh. 





2.2 Molecular Biology techniques 
2.2.1 Genotyping 
2.2.1.1 DNA extraction from murine tissue 
Ear-notches were taken from mice (for identification of individuals) at 14 days of age by 
animal technicians and stored at -20°C until DNA extraction for genotyping, using the 
GeneElute kit (Sigma, G1N70), following the kit instructions. DNA samples were stored at -
20°C. 
 
2.2.1.2 Genotyping PCR Assays 
Genotyping PCR assays were performed for Msh2-, Msh2flox, Cre, mTmG, Aldh1b1wt 
Aldh1b1flox and Aldh1b1- alleles. Genotyping primer sequences were taken from the relevant 
published manuscripts describing these alleles and are shown in Table 2.3 (Barker et al., 
2007; Claij & te Riele, 2004; de Wind et al., 1995; Muzumdar et al., 2007; Skarnes et al., 2011). 
Genotyping PCR reactions were performed using the GoTaq G2 Hot Start Taq Polymerase Mix 
kit (Promega, M7405) and PCR Nucleotide mix (Promega, C1141) for Msh2wt, Msh2-, Msh2flox, 
mTmG, Aldh1b1wt, Aldh1b1flox and Aldh1b1-. Whereas the REDExtract-N-Amp PCR Ready Mix 
(Sigma-Aldrich, R4775) was used for Cre genotyping, as shown in Table 2.4. DNA was 
















































2.2.1.3 Genotyping PCR products using gel electrophoresis 
Amplified PCR products were separated on gels prepared with agarose (Sigma-Aldrich, 
A9539) in 1XTris/Borate/EDTA (TBE) buffer. PCR products of genotyping assays for Msh2wt, 
Msh2flox, Msh2-, mTmG, Aldh1b1wt and Aldh1b1- alleles were separated on 2%(w/v) 
agarose gels (Sigma-Aldrich, A9539) and the PCR products of genotyping assays for Cre and 
Aldh1b1flox alleles were separated on 1.5% (w/v) agarose gels. The Sub-cell GT (Bio-Rad, 
1704404) buffer tank was filled with 1XTBE and the solidified agarose gel was placed inside 
this tank. Five microlitres of DNA ladder (100bp / 1 kb, New England Biolabs, N3231L) were 
loaded into flanking wells at the edges of the gel. Eight microliters for each genotyping PCR 
product were loaded directly into wells before electrophoretic separation at 140 V in 1XTBE 
buffer for 1 hour. After electrophoretic separation, the gel was washed with distilled water 
and incubated with GelRed Nucleic Acid Gel Stain (Biotium INC., 41003) for 30 min to enable 
DNA visualisation under Ultraviolet (UV) light. The DNA bands within the gel were visualised 
and photographed under UV light using the UVP GelDoc-It (Analytik Jena).  

















2.2.2 Microsatellite instability detection 
2.2.2.1 DNA extraction from FFPE 
DNA was extracted from FFPE sections using the DNAstormTM Kit, (Cambridge Biosciences, 
CD502), following the manufacturer’s instructions. Four or five FFPE sections of 8μm thick 
per sample (e.g. from a colonic adenoma), according to the size of the tissue. DNA quality 
and quantity were tested using the Nanodrop system (Thermo Fisher Scientific, 2000C). 
 
2.2.2.2 Microsatellite instability markers and PCR assays 
Microsatellite instability (MSI) detection PCR assays, using PCR primers on either side of 
selected repetitive microsatellite loci, were performed for a specific panel of 5 MSI markers 
(A27, A33, mBat26, mBat37 and mBat59), previously established for use in murine DNA 
(Bacher et al., 2005; Kabbarah et al., 2003), for which primer sequences are shown in Table 
2.6. MSI detection PCR reactions were performed using GoTaq G2 Hot Start Taq Polymerase 
Mix kit (Promega, M7405) and PCR Nucleotide mix (Promega, C1141), as shown in Table 2.7. 
DNA was amplified using the PCR thermocycler programmes detailed in Table 2.8.  
 
 































2.2.2.3 Microsatellite instability detection PCR assay products were analysed by 
polyacrylamide gel electrophoresis 
Amplified MSI detection PCR products were separated on 15% polyacrylamide gels. All of the 
solutions used for making the polyacrylamide gels (both stacking and separating components 
of the gels) and the various buffers used for this gel electrophoretic analysis are shown in 
Table 2.9.  Eight microlitres of DNA ladder (100bp /1 kb) were loaded into the first well of 
each gel. Twelve microliters of each PCR product were loaded directly into wells (the loading 
buffer is included in the PCR reagent kit) before electrophoretic separation at 80V for 30 min, 
then run 150V for 1.5hours at room temperature (RT). After electrophoretic separation, the 
gel was washed with distilled water (dH2O) and incubated with GelRed Nucleic Acid Gel Stain 
(Biotium INC., 41003) for 30 min to enable DNA visualisation under Ultraviolet (UV) light. Gels 
were visualised and photographed under UV light using the UVP GelDoc-It (Analytik Jena).  
 
 
Table 2.9: List of buffers used for the separation of MSI detection PCR products separated by 




2.2.3 Immunohistochemical and histochemical staining of FFPE tissue sections 
The details of the antibodies used for immunohistochemistry (IHC) are shown in Table 2.10 
and buffers used for IHC are shown in Table 2.11.  Slides were rehydrated by incubation in 
xylene for 15 minutes, followed by decreasing concentrations of ethanol (99%, 90%, 70%) for 
10 minutes each at RT. Slides were dipped in dH2O for 5min and blocked using 3% H2O2 ( 30% 
H2O2, Honeywell Fluka, 31642) solution for 20 minutes at RT. Slides were washed with 1XTBS-
Tween for 5 minutes at RT. 
Antigen retrieval was performed with either Tris-EDTA buffer or citrate buffer depending on 
the antibody (Table 2.10). A pressure cooker was filled with 1L of antigen retrieval buffer and 
heated to boiling point before slides were added. Slides were boiled in solution for 10, 12 or 
15 minutes depending on the antibody (Table 2.10). The pressure cooker containing the 
slides was filled with dH2O and the slides were cooled to RT for 1h. Slides were washed for 
10min in dH2O. Slides were permeabilised with 0.5% Triton-X100 (Sigma-Aldrich, X100-
500ML) in 1XTBS-Tween for 20 minutes at RT. Slides were washed  in 1XTBS-Tween  twice for 
5 minutes and  rinsed in 1XTBS. Slides were blocked with 5% goat serum in 1XTBS-Tween for 
1 hour at RT. Primary antibodies at the dilutions shown (Table 2.10) were added to slides in 
blocking buffer and incubated overnight at 4°C. The following day, slides were washed in 
1XTBS-Tween twice for 10 minutes at RT and rinsed in 1XTBS. N-Histofine simple stain mouse 
MAX PO (2B Scientific, 414341F) was used as secondary antibody, a single drop per slide was 
added and incubated for 30min at RT. Slides were washed in 1XTBS-Tween twice for 10 
minutes at RT and rinsed in 1XTBS. 
IHC signal was detected by incubation of the slide with 3,3’-diaminobenzine (DAB) (Liquid 
DAB+, K346811) for 1 or 2 minutes at RT. Slides were washed in dH2O for 10 minutes at RT 
and counterstained in Harris’ haematoxylin (Sigma-Aldrich, HHS32) for 30 seconds. Slides 
were washed under tap water for 5 minutes. Slides were dehydrated in increasing 
concentrations of ethanol (70%, 90% and 100%) for 10 minutes each, followed by xylene for 
15 minutes at RT. Coverslips were applied with mounting medium. The technical controls for 
the antibodies and immunohistochemical staining can be found in the Appendix 
(Supplementary Figure 2.5). 
Immunohistochemistry for infiltrating immune cells was performed by Dr Seth Coffelt’s 
research group from the Beatson Cancer Institute in Glasgow. The panel of immune cell 




Haematoxylin and eosin (H&E) staining was performed by the Pathology laboratory of IGMM, 
the University of Edinburgh. 
 
 
Table2.10: List of antibodies used for immunohistochemistry (vmt=various methods tried). 
 
 









2.2.4 Acetaldehyde assay 
Plasma acetaldehyde concentrations were determined using an acetaldehyde assay kit 
(Megazyme, K-ACHYD). Samples were assayed and analysed according to the manufacturer’s 
instructions. Plasma samples were analysed in experimental batches on the same day to 
ensure standardised recovery and measurement of acetaldehyde in all samples and to avoid 
unnecessary experimental variations. 50µl of plasma was used for each analysis and these 
were performed in triplicate. 
 
2.2.5 RNA extraction from small and large intestinal cells isolated and sorted from 
the Msh2-LS mouse model 
2.2.5.1 Small and large intestinal epithelial cell isolation from tissues  
Fresh (unfixed) SI and LI were flushed twice in cold PBS and inverted using the 30cm long and 
3mm diameter bamboo skewer to expose the inner mucosal lining. SI and LI were cut in 
segments of 5-10mm long and placed in separate 50ml Falcon tubes containing cold PBS. 
These tissue fragments were washed two times with cold PBS. Samples were incubated with 
25mM EDTA (in 25ml cold PBS) for 30 min on a tube roller at 4 ֯C. The cold PBS-EDTA buffer 
was discarded and the tissue fragments were washed with cold Advanced DMEM/F12 
medium (Thermofisher, 12634028). Cold PBS was added to the tubes containing the samples 
and each tube was strongly shaken to detach the intestinal epithelial cells. The supernatant 
was collected in a clean 50ml Falcon tube and kept on ice. This step was repeated until 30ml 
of supernatant was collected for each sample. Tubes were filled up to 50ml with Advanced 
DMEM/F12 medium and centrifuged at 500 x g for 5 minutes. The resulting pellets were re-
suspended with 1ml of TrypLE Express Enzyme (1X) (Thermofisher, 12604013) each and 
incubated in a waterbath for 15 minutes at 37 ֯C. Advanced DMEM/F12 medium was added 
and samples were filtered using a 70µm strainer (Corning, 15370801) into 50ml Falcon tubes 
and centrifuged at 500x g for 5 minutes. Supernatant was discarded and the pellet was re-
suspended in 5ml of 0.1% BSA in PBS and centrifuged at 500 x g for 5 minutes. Supernatant 
was discarded and the pellet was incubated with EpCAM antibody (or IgG2a isotype control) 
diluted to 1:200 (Table 2.13) in 200-500µl of 0.1% BSA in PBS for 30 minutes at 4֯C. Two 
millilitres of 0.1% BSA in PBS were added and transferred to the FACS tubes (Falcon, 352054). 
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Samples were centrifuged at 500 x g for 5 minutes and re-suspended in 500-1000µl of 0.1% 
BSA in PBS.  
 
 
Table2.13:  FACS antibodies. 
 
2.2.5.2 Fluorescent-Activated Cell Sorting (FACS) of small and large intestinal epithelial 
cells 
The FACS was performed by the flow cytometry facility of the IGMM, University of Edinburgh. 
Lasers were set up to identify EpCAM positive intestinal epithelial cells and FACS was used 
to divide them in 4 sub-populations according to their fluorescence signals (RFP+ only, GFP+ 
only, both RFP+ and GFP+, or no red or green fluorescence).  
 
2.2.5.3 RNA extraction 
Immediately after FACS, RNA was extracted from each of the sorted samples. 1ml TRIZOL 
Reagent (Thermo Fisher Scientific, 15596026) was added to each sample and it was 
repetitively pipetted and left for 5 minutes at RT. 0.2ml chloroform was added and samples 
shaken for 15 seconds and left at RT for 10 minutes. Samples were centrifuged at 12000g for 
15 minutes at RT. The samples showed a gradient separation in three phases. The colourless 
upper aqueous phase was removed and added to a new tube, the white solid and red lower 
aqueous phases were discarded. 0.5ml isopropanol was added and left for 10 minutes at RT. 
Samples were centrifuged at 12000g for 10 minutes at 4°C and the supernatant discarded. 
1ml 75% ethanol was added and samples were mixed by vortexing. Samples were 
centrifuged at 7500g for 5 minutes at 4°C, the supernatant discarded and the pellet air-dried. 
RNA was re-suspended in 30µl dH2O at 57°C, quantified using the Nanodrop system (Thermo 
Fischer Scientific, 2000C), and stored at -80°C. 
 
Antobody Source Manufacturer
EpCAM  Anti-mouse rat, monoclonal BioLegend, 118213
IgG2a Isotype control rat, monoclonal BioLegend, 400511
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2.3 Image analysis 
Histopathological examination was performed by Prof. Mark J Arends using a Leica DMR HC 
microscope (Leica DMR HC 0.7H.21.TL.-.E.16C, 213860) and images were taken from 
selected fields and acquired using a Leica DFC 450-C camera.  
Immunohistochemically stained and histochemically stained FFPE tissue sections were 
scanned using a Nanozoomer (Hamamatsu) slidescanner and analysed with the Hamamatsu 
NDP Viewer software (NDP.view2) at the Pathology laboratory of IGMM, the University of 
Edinburgh. Image analysis software QuPATH v0.2.0 was used to analyse 
immunohistochemically detected Msh2, Ki67, y-H2AX and p53 protein expression.  
Expression of the red and green fluorescent proteins encoded by the mTmG transgene were 
evaluated in whole mount specimens of the small and large intestines using a Leica MZFLIII 
fluorescence stereo microscope with 1x objective and a Nikon A1R point scanning confocal 
microscope (IGMM imaging facility, University of Edinburgh). The obtained images were 
analysed using Fiji (ImageJ)-Trainable WEKA Segmentation software, through which the 
proportion of green areas divided by the total green + red areas (termed the % green area) 
were measured. 
 
2.4 Statistical analysis 
Data were analysed using GraphPad Prism version v7.0 software, which was used for all 
statistical analyses and these are mostly shown as mean with standard deviation (SD) error 
bars. Group data were compared using unpaired, two-tailed Student’s t-test (for normally 
distributed data) or Mann–Whitney U test (for non-parametric data) as appropriate, or two-
way ANOVA with Bonferroni’s multiple comparisons correction test. Association between 
two categories was assessed by two-sided Fisher’s test. Percentage of survival was analysed 
by the Log-rank (Mantel-Cox) test. Differences between groups were considered statistically 






Chapter 3: Establishment of an Msh2-Lynch Syndrome mouse 
model colony and its characterization 
3.1 Introduction 
In the past, Lynch syndrome mouse models have been important for the study and 
understanding of the disease mechanisms and the roles of the MMR genes. However, none 
of these models fully represented human LS, as described in Chapter 1.1.8. Recently, 
Wojciechowicz et al (2014) generated a novel Msh2-Lynch Syndrome (Msh2-LS) mouse 
model that closely mimics key components of the large intestinal disease characteristics in 
LS patients.  
The Msh2-LS mouse model has one constitutive knockout Msh2 allele (Msh2-) and one 
(floxed) conditional knockout Msh2 allele (Msh2flox). The Msh2- allele was generated by the 
incorporation of a hygromycin (hyg) resistance gene between codons 588 and 589 in exon 
12 of Msh2 (Claij & te Riele, 2004), completely preventing Msh2 protein expression (de Wind 
et al., 1995). The Msh2flox allele was constructed by insertion of a loxP site 53 bp downstream 
of exon 13 and another loxP site 2 kb upstream of exon 12 in the opposite orientation (Figure 
3.1). Cre-mediated recombination between these two loxP sites results in inversion of exons 
12 and 13 (Figure 3.1), abrogating gene activity (Claij & te Riele, 2004). 
To target Msh2 loss of activity to only a limited number of self-renewing intestinal epithelial 
stem cells, the Lgr5CreERT2 transgene was used. The Cre recombinase protein is fused to the 
modified oestrogen receptor ERT2. Only in the presence of tamoxifen metabolites, does the 
CreERT2 protein translocate to the nucleus and become active, where it can execute 
recombination between the loxP sites leading to inactivation of the conditional Msh2 allele. 
As CreERT2 is expressed from the Lgr5 locus, this occurs in Lgr5-expressing intestinal 
epithelial stem cells (Barker et al., 2007) (Figure 3.2). In this Msh2-LS mouse model, scattered 
dMMR stem cells are induced among surrounding MMR-proficient cells in the large and small 
intestinal epithelium (as observed in LS patients). Wojciechowicz et al (2014) demonstrated 
an increased risk of intestinal tumour development in the Msh2-LS model mice.  
In order to visualize those cells that underwent Cre activation, and thus Msh2 inactivation, 
the mTmG transgene was crossed into the mouse model.  The mTmG transgene was 
originally generated by Dr. Lou, Stanford University (Muzumdar et al., 2007). This Cre 
reporter construct confers a red fluorescence to cells of all tissues without Cre activation, 
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due to whole body expression of membrane-targeted modified Tomato red fluorescent 
protein (mT). Upon Cre activation, Cre recombines the two LoxP sites surrounding the floxed 
mT allele and the adjacent polyadenylation site, thus excising this section of DNA, allowing 
expression of a membrane-targeted modified Green Fluorescent Protein or GFP (mG) (Figure 
3.3). 
In this chapter, the aim is to establish an Msh2-LS mouse model colony, provided by Dr Hein 
te Riele (Wojciechowicz et al., 2014), and upgrade it by introducing the mTmG transgene. In 







Figure 3.1: Schematic diagram of the Msh2fl/- alleles before and after Cre activation. Constitutive 
(Msh2-) and conditional (Msh2flox ON) knockout alleles of Msh2 are shown (adapted and modified from 
Wojciechowicz et al., 2014). Cre activation results in inversion of exons 12 and 13 of the conditional 






Figure 3.2: Schematic diagram of Tamoxifen metabolite-mediated Cre activation in Lgr5 expressing 
intestinal epithelial stem cells. The Lgr5CreERT2 transgene was inserted into the murine Lgr5 locus, 
ensuring that the CreERT2 protein is only expressed in Lgr5+ intestinal stem cells (green cells at the 
base of the crypt shown on the left). Tamoxifen is converted by cytochrome p450 enzymes into the 
active metabolite 4-Hydroxy-Tamoxifen (4-OHT) that binds to the ERT2 ligand-binding domain of the 
CreERT2 protein, allowing its translocation from the cytoplasm into the nucleus, where the active Cre 
enzymatic function leads to recombination of loxP sites flanking Msh2 exons 12 and 13 (Msh2floxON), 
resulting in the inversion of exons 12 and 13 sequences, thus inducing inactivation of the second Msh2 
allele (Msh2floxOFF) (the first Msh2 allele has been inactivated by insertion of a hygromycin-resistance 
gene (hyg) into exon 12). This abrogates DNA mismatch repair function in that stem cell and in any 
daughter cells formed by that stem cell. (Image created with BioRender.com). 
 
 
Figure 3.3. Schematic diagram of the mTmG coloured fluorescent protein reporter construct before 
(cell expresses mT and appears red) and after (cell expresses mG and appears green). Cre-mediated 
recombination of loxP sites (black triangles) flanking the mT and pA sequences (adapted and modified 




3.2 Mouse Model Colony Breeding, Maintenance and Husbandry 
3.2.1 Methods 
Mice were housed in IVCs with group sizes and enrichment according to Home Office 
regulations. Further details on the mice housing conditions and maintenance can be found 
in Chapter 2 (2.1.1). 
 
3.2.2 Results 
3.2.2.1 Establishment of the colony of Msh2-LS mice and cross-breeding with mTmG 
transgene bearing mice  
Msh2-LS mouse model founder mice were received from Professor Hein te Riele’s research 
group at the Netherlands Cancer Institute (Wojciechowicz et al., 2014). 2 male and 2 female 
Msh2flox/flox mice were received, along with 1 male and 2 female Msh2+/-; Lgr5CreERT2+/- mice 
(Lgr5CreERT2- indicates a normal wild-type Lgr5 allele, whereas Lgr5CreERT2+ indicates 
insertion of the CreERT2 transgene into a modified Lgr5 locus).  All animals were of breeding 
age. The Msh2 flox/flox mice were bred with the Msh2+/-; Lgr5CreERT2 +/- mice to obtain the 
Msh2-LS mouse model experimental subjects (Msh2flox/-; Lgr5CreERT2+/-). Homozygous 
Lgr5CreERT2+/+ mice are not viable (due to loss of normal Lgr5 alleles that are required for 
normal development), so only heterozygous Lgr5CreERT2+/- mice were used for breeding 
with Lgr5 wild-type mice (Lgr5CreERT2+/- X Lgr5CreERT2-/-), to generate viable and fertile 
progeny. The genotype frequencies that resulted from this breeding almost perfectly 
reflected the expected Mendelian ratios with around 25% of the progeny having the correct 
genotype for Msh2-LS experimental subject mice (Msh2flox/-; Lgr5CreERT2+/-) (Figure 3.4A). 
Mice with the genotype Msh2flox/-; Lgr5CreERT2+/- were also bred with Msh2flox/-; 
Lgr5CreERT2-/- mice, in order to obtain a higher number of Msh2-LS experimental subject 
mice from each litter. The mice resulting from these matings showed 25% progeny with 
Msh2flox/-; Lgr5CreERT2+/- genotypes and 12.5% progeny with Msh2flox/flox; Lgr5CreERT2+/- 
genotypes (Figure 3.4B). Mice with these genotypes were used as experimental subject mice 
or breeders. Tabular representation of the inter-cross to generate the Msh2-LS mouse model 
experimental subjects is shown in the Appendix (Supplementary Table 3.1). Another 25% 
(12.5% of Msh2-/-; Lgr5CreERT2-/-and 12.5% of Msh2-/-; Lgr5CreERT2+/-) of the mice resulting 
from this breeding showed complete Msh2 deletion (Msh2-/-). Msh2-/- mice have been 
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reported to develop tumours (mostly early thymic and other lymphomas, with some 
intestinal adenomas in a few surviving mice) that required termination of most of these mice 
starting from around 10 weeks of age (de Wind et al., 1995). Therefore, Msh2-/- pups were 
culled immediately after genotyping.  
In the stage prior to the administration of Tamoxifen, Msh2-LS experimental mice did not 
present altered or harmful phenotypes. Nor did they show increased tumour predisposition 
(without Cre activation) compared with wild-type mice (see data below in Chapters 4.3). 
To introduce the mTmG transgene (Muzumdar et al., 2007), the Msh2flox/-; Lgr5CreERT2+/- 
mice were cross-bred with mTmG+/+ mice, generating Msh2+/-; Lgr5CreERT2+/-; mTmG+/- and 
Msh2flox/+; Lgr5CreERT2+/-; mTmG+/- mice (mTmG-/- indicates a normal wildtype genotype 
without the mTmG construct, whereas mTmG+/+ or mTmG+/- indicates presence of two copies 
or one copy, respectively, of the mTmG construct) (Figure 3.5A). These mice were interbred 
to generate Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice and after further breeding Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/+ mice, which were used as experimental subject mice or breeders 
(Figure 3.5B). Tabular representation of the inter-cross to introduce the mTmG transgene 













Figure 3.4: A) Percentage of resulting genotypes from the breeding between Msh2 flox/flox and the 
Msh2+/-; Lgr5CreERT2 +/- mice. B) Percentage of resulting genotypes from the breeding between 
Msh2flox/-; Lgr5CreERT2+/- and Msh2flox/-; Lgr5CreERT2-/- mice. 
 
 
Figure 3.5: A) Percentage of resulting genotypes from the cross-breeding between Msh2flox/-; 
Lgr5CreERT2+/- and mTmG+/+ mice. B) Percentage of resulting genotypes from the cross-breeding 
between Msh2+/-; Lgr5CreERT2+/-; mTmG+/- and Msh2flox/+; Lgr5CreERT2+/-; mTmG+/- mice. 
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3.2.2.2 Comparison of Tamoxifen treatments for Cre recombinase activation  
To verify the efficacy of the mTmG transgene and identify the optimal concentration and 
dosage regime of Tamoxifen for the most appropriate level and pattern of Cre induction 
using the LgrCreERT2 construct, different Tamoxifen treatments were tested using 
Lgr5CreERT2+/-; mTmG+/- mice. The most commonly published Tamoxifen treatment 
regimens for Cre induction were compared in this strain. Mice were treated with either one 
i.p. injection of 3 mg Tamoxifen (0.15mg/g bw) on one single day (Group-A) (Barker et al., 
2007; Zhang et al., 2014), or one i.p. injection of 3 mg Tamoxifen (0.15 mg/g bw) on day 1 
and 2mg Tamoxifen (0.1mg/g bw) on days 2, 3 and 4 (Group-B) (Nandan et al., 2016; 
Veniaminova et al., 2012). Furthermore, a control group (Group-C) received one i.p. injection 
of corn oil (the vehicle for dissolved Tamoxifen) without Tamoxifen per day for 4 consecutive 
days (without i.p. Tamoxifen treatment, Cre recombinase is not activated) (Figure 3.6). Two 
animals were used for each condition. Mice were culled and the small and large intestines 
collected on day 8 (after the start of Tamoxifen or corn oil treatment), allowing time for the 
activated Cre to recombine loxP sites in the stem cells at the bases of the crypts, converting 
mT expression to mG expression. These mG+ intestinal stem cells form daughter cells that 
move up the crypts and on to the villi in the small intestine, or up the crypts in the colonic 
mucosa, thus appearing as green foci surrounded by red background epithelium (when 
viewed by fluorescence stereomicroscopy). The efficiency of the different Tamoxifen 
treatments was evaluated through the detection and quantification of these green foci (mG 
expression), analysing whole mount intestinal tissues (as described in Materials and 
Methods).   
In Group-C, the whole mount intestinal specimens showed only mT protein expression 
conferring red fluorescence to the tissues with no mG expression, as expected. In Group-A 
(only one i.p injection of Tamoxifen), mice showed ~25% foci of positive mG crypts/villi in 
the small intestine and ~10% mG+ crypt foci in the large intestine (Figure 3.7-3.8). In Group-
B (4 i.p. Tamoxifen injections over 4 days), mice showed ~35% foci of positive mG crypts/villi 
in the small intestine and ~15% mG+ crypt foci in the large intestine (Figure 3.7-3.8). No 
major differences were observed between Group-A and Group-B. However, the Group-B 
Tamoxifen protocol appeared to be mildly more efficient, showing a more widely scattered 
distribution of the mG positive crypt foci along both of the small and large intestines, similar 
to the pattern seen in human LS patients with widely scattered dMMR crypt foci in the colon 
(Kloor et al., 2012). Hence, the 4 day Tamoxifen treatment protocol was adopted for all 
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Figure 3.6: Comparison of experimental Tamoxifen treatment protocols for Group-A (one i.p. injection 
of 3 mg Tamoxifen (0.15mg/g) on one single day), Group-B (one i.p. injection of 3 mg Tamoxifen per 
mouse (0.15 mg/g) on day 1 and 2mg Tamoxifen (0.1mg/g) on days 2, 3 and 4); and Group–C (one i.p. 









Figure 3.7: Representative fluorescent images of the mT & mG/GFP detection in the colon using the fluorescence stereomicroscope. Pictures acquired from Group-A 
(1 i.p. Tamoxifen injection) (top row), Group-B (4 i.p. Tamoxifen injections) (middle row), and Group-C (4 i.p. corn oil injections, control cohort) (bottom row) mice, 




Figure 3.8: Representative fluorescent images of the mT & mG/GFP detection in the distal small intestine using the fluorescence stereomicroscope. Pictures acquired 
from Group-A (1 i.p. Tamoxifen injection) (top row), Group-B (4 i.p. Tamoxifen injections) (middle row) and Group-C (4 i.p. corn oil injections, control cohort) (bottom 




3.2.2.3 Immunohistochemical characterization of positive mG-expressing 
intestinal crypt foci 
To test whether the expression of mG/GFP observed by fluorescence microscopic detection, 
following Cre activation, correlated with the loss of Msh2 expression, immunohistochemical 
(IHC) analyses were performed using anti-Msh2 antibody and anti-GFP antibody on intestinal 
tissue serial sections. Small intestine, caecum and colon serial sections were cut from 
Tamoxifen-induced Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- (Msh2-LS) mice and stained for both 
mG/GFP and Msh2 proteins.  
We used small intestinal tissue samples of Msh2-/- mice as Msh2-null controls and GFP-
negative expression controls; and small intestinal (SI) tissue samples of Tamoxifen-induced 
mTmG+/+ mice as Msh2-positive and GFP-positive expression controls (Figure 3.9). The lack 
of DAB-brown staining for both anti-Msh2 and anti-GFP IHC in the Msh2-/- SI tissues 
confirmed complete loss of Msh2 expression and lack of GFP expression (Figure 3.9 A-B) in 
the Msh2-null negative control tissues. The presence of DAB-brown staining in the mTmG+/+ 
SI tissues confirmed presence of Msh2 expression in all tissue and GFP expression in some 
Cre-activated crypts (Figure 3.9 C-D) in the mTmG+/+ positive control tissues.  
The immunohistochemical analysis of Msh2 in Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mouse 
intestinal tissue showed lack of DAB-brown staining in some crypts scattered along the 
length of both small intestinal mucosa and large intestinal mucosa (Figure 3.10 A-C). The 
exact same crypts appeared DAB-brown stained after immunohistochemical analysis of GFP 
on the adjacent serial section of the same Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mouse 
intestinal tissue (Figure 3.10 B-D), confirming that the same small and large intestinal crypts 





Figure 3.9: Immunohistochemical analysis of Msh2 and GFP protein expression in small intestinal mucosal epithelium from a negative-control Msh2-/- mouse (upper 
row), in which the lack of brown staining confirms the absence of Msh2 (A) and GFP (B) expression in the intestinal mucosal epithelium; and from a positive-control 
mTmG+/+ mouse (lower row), in which the brown staining indicates positive Msh2 expression in all crypts (C) and positive GFP expression in some scattered Cre-
activated crypts (D). Images taken using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 5X magnification (bar at lower left 




Figure 3.10: Representative comparison between Msh2 and mG/GFP immunostaining of adjacent serial sections of caecum of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-
mice treated with Tamoxifen to activate Cre in scattered crypts. The same dMMR crypt foci (A and C) are negative for Msh2 and positive for mG/GFP (B and D) (red 





In this chapter, the mouse breeding programme was described to illustrate the generation 
of the appropriate murine progeny to be used in experiments and for further breeding. The 
mice obtained from Professor Hein te Riele’s research group were acquired to start the 
Msh2-Ls mouse model colony. The matings between the starting mice produced: 25% 
Msh2flox/+; Lgr5CreERT2+/- mice, 25% Msh2flox/+; Lgr5CreERT2-/- mice, 25% Msh2flox/-; 
Lgr5CreERT2-/- mice and 25% of the desired Msh2flox/-; Lgr5CreERT2+/- mice (for use as 
experimental subjects). To establish a bigger Msh2-LS mouse model colony we bred the 
Msh2flox/-; Lgr5CreERT2+/- with Msh2flox/-; Lgr5CreERT2-/-. As explained previously, 
heterozygous Lgr5CreERT2+/- mice can only be bred with Lgr5 wild-type mice (Lgr5CreERT2+/- 
X Lgr5CreERT2-/-) because homozygous Lgr5CreERT2+/+ mice are not viable (due to loss of 
wildtype Lgr5 alleles that are required for normal development), influencing the percentage 
of mice with the correct genotype per litter (only 25% of the progeny).  
The introduction of the mTmG transgene into the Msh2-LS mouse model further decreased 
the percentage of mice with the desired genotype for experimental subjects per litter.     
The introduction of the mTmG transgene was performed through cross-breeding between 
Msh2-LS mice and homozygous mTmG mice (mTmG+/+). The progeny obtained from the first 
breeding showed the following genotypes: 25% Msh2fl/+; Lgr5CreERT2+/-; mTmG+/-, 25% 
Msh2fl/+; Lgr5CreERT2-/-; mTmG+/-, 25% Msh2-/+; Lgr5CreERT2+/-; mTmG+/- and 25% Msh2-/+; 
Lgr5CreERT2-/-; mTmG+/-. To obtain mice with the correct genotypes for use as experimental 
subjects, we used these mice as breeders. The resulting progeny showed only 6.25% of 
Msh2fl/-; Lgr5CreERT2+/-mice; mTmG+/- and 3.13% of Msh2fl/-; Lgr5CreERT2+/-; mTmG+/+ mice.  
We cross-bred the progeny to obtain an appropriate number of Msh2fl/-; Lgr5CreERT2+/-; 
mTmG+/- to use as experimental subjects, which required a high number of breeding rounds 
and time. 
Once the Msh2-LS mouse colony was established, we proceeded with the characterisation 
of the mouse model and identification of the optimal concentration and dosage regime of 
Tamoxifen for the most appropriate level and pattern of Cre induction using the LgrCreERT2 
construct. We divided the mice into three groups which received either 1 i.p Tamoxifen 
injection, or 4 i.p. Tamoxifen injections, or 4 i.p. corn oil injections. The introduction of the 
mTmG transgene was used to identify the best treatment by analysing the numbers and 
patterns of crypts expressing mG/GFP in both the small and large intestines, viewed as 
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whole-mount specimens using a fluorescent stereomicroscope and counting the numbers of 
mG-expressing foci. This fluorescent reporter transgene enabled visual monitoring of the 
effects of Tamoxifen-induced activation of Cre recombinase to convert expression of red 
fluorescent mT to expression of green fluorescent mG protein in intestinal epithelial Lgr5-
expressing stem cells and the crypts that they form.  
The whole mount intestinal specimens of corn oil-treated control mice appeared completely 
red under the microscope, and no mG expression was observed. This confirmed the lack of 
Cre activation due to the absence of Tamoxifen treatment. By contrast, in both Tamoxifen-
treated groups, positive mG/GFP expressing foci were observed scattered along the whole 
small and large intestines. Mice treated with 1 i.p Tamoxifen injection showed ~25% foci of 
mG+ crypt/villi in the small intestine and ~10% mG+ crypt foci in the large intestine, whereas 
mice treated with 4 i.p. Tamoxifen injections showed ~35% foci of mG+ crypt/villi in the small 
intestine and ~15% mG+ crypt foci in the large intestine. These groups of mice did not show 
major differences in mG+ expression, however we decided to adopt the 4 day Tamoxifen 
treatment protocol for Cre induction on LgrCreERT2 construct. The mice treated with 4 i.p. 
Tamoxifen injections showed a more widely scattered distribution of the mG+ crypt foci 
along both the small and large intestine, similar to the pattern seen in human LS patients’ 
colons with widely scattered dMMR crypt foci.  Hence, in this experiment, we identified the 
correct Tamoxifen protocol and we validated the efficacy of the mTmG transgene.  
In the modified version of the Msh2-LS mouse model, explained in this chapter (Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mouse model), the activation of Cre recombinase by Tamoxifen-
treatment induced recombination between two inverted loxP sites flanking Msh2 exons 12 
and 13 and the loxP sites flanking the mT allele, generating a Msh2 knockout allele 
(Msh2flox/OFF) and converting the same intestinal stem cells to mG expression, generating 
dMMR intestinal stem cells that subsequently form dMMR crypts, which are marked by 
green fluorescent mG expression.  We confirmed this by performing IHC for both Msh2 and 
GFP expression on adjacent serial sections of small intestine, caecum and colon. The results 
showed the colocalization in the same crypts of mG expression and the loss of Msh2 
expression. The detection and quantification of mG+ crypt foci allow evaluation of any 
subsequent changes of dMMR crypts marked in this way, such as changes in crypt focus size 




In conclusion, we generated a modified version of the Msh2-LS mouse model and established 
a colony of this Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mouse model. The mTmG Cre reporter 
system was validated and the most appropriate Tamoxifen treatment protocol (daily i.p. 
injection over 4 days) was identified and shown to be sufficient to activate Cre recombinase. 
We verified that Cre induced loss of Msh2 and expression of mG/GFP were observed in the 























Chapter 4: Investigation of long-term ethanol consumption 
effects on the Msh2-LS mouse model 
4.1 Introduction 
LS is caused by a constitutional (often germline) pathogenic mutation in one of the MMR 
genes (MSH2, MLH1, MSH6, and PMS2). LS patients have a higher lifetime risk for several 
cancer types, mainly in the large bowel and the endometrium, but also in small intestine, 
stomach, and several other organs (Bellizzi & Frankel, 2009; Poulogiannis et al., 2010), as 
previously described in the main introduction, Chapter 1.1. 
Several lifestyle-related factors are associated with an increased risk of certain sporadic 
cancers; these may have similar or enhanced effects in LS patients. Several systematic 
reviews and cohort studies showed evidence that smoking is linked with an increased risk of 
CRC (Hannan et al., 2009; Leufkens et al., 2011). In 2011, the World Cancer Research Fund 
(WCRF)/American Institute for Cancer Research (AICR) published a review providing 
evidence that body fatness or obesity (expressed as BMI of greater than 30 kg/m2), 
abdominal fatness (waist circumference and waist-hip ratio), nutrition and physical activity 
can influence the risk of CRC (Dai, 2007; Ning et al., 2010; van Duijnhoven et al., 2013).  
Worldwide, a total of approximately 389,000 cancers representing 3.9% of all cancers have 
been calculated to derive from chronic alcohol consumption (Rehm et al., 2003). However, 
there are limited studies investigating the effects of alcohol consumption on increased risk 
of CRC in LS patients. Carcinogenic effects of ethanol are related to its metabolism and mainly 
to its metabolite acetaldehyde. Acetaldehyde is a highly reactive molecule able to induce a 
wide range of DNA damage, as described in Chapter 1.3. However, the DNA repair pathways 
responsible for repairing many of these lesions remain unknown.  
The MMR pathway plays an important role in maintaining genomic stability and cellular 
homeostasis. In addition to its post-replicative DNA error repair, MMR is involved in cellular 
responses to DNA damage induced by endogenous chemical carcinogens (Stojic et al., 2004). 
Furthermore, MMR plays a role in the cell’s response to DNA damage through cell cycle 
arrest and/or apoptosis.  
In this chapter, the aim is to test the hypothesis that the DNA MMR system plays a role in 
protecting cells from some types of ethanol/acetaldehyde-induced DNA damage and that 
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there is a gene-environment interaction between ethanol/acetaldehyde and dMMR pathway 
that accelerates colorectal tumour development and progression. Here, using the Msh2-LS 
mouse model, the effects of long-term ethanol treatment on intestinal tumour formation 
and progression are investigated. 
 
 
4.2 Long-term ethanol effects on intestinal tumourigenesis in the 
Msh2-LS mouse model 
4.2.1 Methods 
Groups of 7-9 weeks old Msh2flox/-; Lgr5CreERT2+/- and Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- 
(Msh2-LS) experimental mice were divided into two groups. Group-A mice received 
intraperitoneal (i.p.) injections of 0.15mg Tamoxifen/g bw on day 1 and 0.1mg Tamoxifen/g 
bw on day 2, 3 and 4; on day 5 mice were provided with normal drinking water. By contrast, 
Group-B received i.p. injections of 0.15mg Tamoxifen/g bw on day 1 and 0.1mg Tamoxifen/g 
bw on day 2, 3 and 4; but on day 5 the Group-B mice were provided with 20% ethanol in 
drinking water (as previously validated by our group; (Müller et al., 2016)) (Figure 4.1). 
Animals were culled and tissues collected when either clinical signs of distress were visible 
or they displayed >20% body weight loss compared with the initial weight. The small and 
large intestines, caecum, stomach, liver, spleen, thymus, lymph nodes (if visible) and any 
other organ or tissue showing abnormalities, were collected following schedule 1 culling and 
necropsy dissection. Tissues were fixed in 10% NBF, processed using standard tissue 
processing protocols and were paraffin embedded in preparation for section cutting and 
staining. The acronyms used for the Msh2-LS model mice and their relevant treatments are 










Figure 4.1: Experimental treatment protocols and timelines for Group-A (water-treated) and -B 
(ethanol-treated) mice, showing 4 days of i.p. injections of Tamoxifen, followed by either 
standard/normal drinking water (Group-A) or drinking or water containing 20% ethanol (Group-B). 





















4.2.2.1 Experimental group organization and observations 
Previous work using Aldh1b1 depleted mice and control mice treated with 20% ethanol 
showed intestinal tumour formation within 1 year in both groups (Müller et al., 2016).  Long-
term ethanol-treatment of Msh2-LS mice followed two different approaches.  First, in this 
tumour watch experiment, the murine subjects included 20 mice in total (12 females and 8 
males) were divided into two groups: Group-A (10 mice: 8 females and 2 males; water-
treated control group) and Group-B (10 mice: 4 females and 6 males; ethanol-treated test 
group). Animals from both groups were culled when either clinical signs of distress indicative 
of intestinal tumour formation were visible or they displayed >20% body weight loss 
compared with the initial weight.  
Second, in this matched control and test subject experiment, 26 mice (10 females and 16 
males) in total were divided into two groups of 13 mice, with 5 females and 8 males in each 
group, and they underwent treatments in drinking water as control Group-A (water) and test 
Group-B (ethanol). In this experiment, a matching control mouse was culled at the same time 
point that an ethanol-treated mouse had to be culled for signs of distress due to intestinal 
tumour formation or >20% loss of body weight.  
During Tamoxifen treatment (daily Tamoxifen i.p injections for 4 consecutive days), body 
weights and health status were recorded. Body weights of the female and male mice didn’t 
significantly differ during the Tamoxifen treatment (Figure 4.2), showing successful drug 
administration and acceptance of the experimental procedures by the mice. Body weights of 
Msh2-LS males (~28.34g) were significantly higher than body weights of Msh2-LS females 
(~21.38g) both before and during the Tamoxifen treatments. After Tamoxifen treatment 
mice received either 20% ethanol in drinking water or normal drinking water regimes and 
the body weights and health status of the mice were recorded twice a week (Figure 4.3). 
Female and male ethanol-treated Msh2-LS mice did not show abnormal behaviour or 
reduced weight indicating good acceptance of the ethanol regime. EtOH_Msh2fl KO mice 
weighed on average 34.3g for the males and 31g for the females, whereas H2O_Msh2fl KO 
weighed on average 36.5g for the males and 29.6g for the females. Significant differences 
were not observed between the body weights of EtOH_Msh2fl KO versus H2O_Msh2fl KO males 
or females.  
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Drinking bottles were changed and bottle weights were recorded once a week. Liquid 
consumption per mouse was estimated by analysing the weights of the drinking bottles (per 
cage) and calculating the average weight of consumed liquid per mouse per day (Figure 4.4). 
An average H2O_Msh2fl KO male mouse consumed around 13.85ml of drinking water per day, 
whereas an average EtOH_Msh2fl KO male mouse consumed around 11.65ml of 20% ethanol 
in drinking water. An average H2O_Msh2fl KO female mouse consumed around 10.33ml of 
water per day, whereas an average EtOH_Msh2fl KO female mouse consumed around 9.65ml 
of 20% ethanol in drinking water per day. No significant differences were observed between 






Figure 4.2: Body weights during Tamoxifen treatment. Body weights of Msh2-LS males were 
significantly higher than body weights of Msh2-LS females, before and during Tamoxifen treatments. 
2-way-ANOVA test with Bonferroni post-test correction, p<0.0001 on day 1-4 (data shown as mean ± 







Figure 4.3: Body weights for males and females during 20% ethanol or standard/normal drinking water 
regimes. There were no significant differences between the body weights of ethanol-treated Msh2-LS 
(EtOH_Msh2fl KO) versus water-treated Msh2-LS (H2O_Msh2fl KO) males or females. 2-way-ANOVA with 
Bonferroni post-test correction analysis (data shown as mean±SD).  
 
 
Figure 4.4: Liquid consumption of either 20% ethanol containing drinking water or standard/normal 
water per mouse per day. 2-way-ANOVA with Bonferroni post-test correction analysis (data shown as 
mean±SD). No significant differences were observed for any of the comparisons of ethanol versus 
water treatment or males versus females. 
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4.2.2.2 Tumour development in Msh2-LS mice under long-term ethanol treatment 
The results from both approaches were collected and are presented together. The two 
cohorts of Msh2-LS model mice, Group-A (water-treated, H2O_Msh2fl KO) and Group-B 
(ethanol-treated, EtOH_Msh2fl KO), were monitored for signs of intestinal tumour 
development or other pathological abnormalities, using a clinical scoring system that 
included known clinical signs of distress seen in mice that develop intestinal neoplasms (Foltz 
& Ullman-Cullere, 1999; Burkholder et al., 2012), to determine when the mice should be 
culled for necropsy dissection and tumour analysis (Table 4.1). Most of the mice in Group-B 
(ethanol experimental group) displayed either anal prolapse or >20% reduction in body 
weight as common clinical signs of distress, at varying lengths of time from the start of the 
experimental protocol and were then culled for necropsy dissection. During necropsy 
dissection, naked eye inspection revealed that the majority of the EtOH_Msh2fl KO mice 
showed a thicker colonic wall compared with the colons of the H2O_Msh2fl KO mice, but no 
gross differences were observed in the small intestines. The lengths of the small intestines 
and colons were measured and recorded, but no significant differences in length were 
observed (Figure 4.5). The histopathological analyses of Msh2-LS large intestines and small 
intestines confirmed the macroscopic observations of no significant morphological 
differences between the two groups in the small intestines, but increased colonic wall 
thickness in EtOH_Msh2fl KO mice, due to a widespread increase in the colon crypt length as 
a result of extended zones of crypt epithelial hyperproliferation that were not observed in 
H2O_Msh2fl KO murine colons (Figure 4.6). These extended zones of colonic crypt 
hyperproliferation were seen to affect 50% – 90% of the whole colonic length, usually 
involving parts of the proximal colon and mid colon, in most of the EtOH_Msh2fl KO mice (65%) 
who survived more than 1 month of the ethanol treatment protocol. By contrast, 
histopathological analyses of the small intestines did not show any significant morphological 
differences between the two groups of animals using H&E-stained Swiss rolls of the 
intestines (Figure 4.7).  
In total, 15 out of 23 (65%) EtOH_Msh2fl KO mice demonstrated zones of large intestinal crypt 
epithelial hyperproliferation, with adenoma formation and, in 5 cases, invasive 
adenocarcinoma was present, all within an average of 6 months (minimum 4 weeks and 
maximum 48 weeks) of the start of the experimental protocol compared with only 1 case of 




All 15 EtOH_Msh2fl KO tumour-bearing mice showed both colonic crypt hyperproliferative 
changes (Figure 4.9) with the adenoma formation mainly in either the proximal colon or the 
mid colon (Figure 4.10). No Msh2-LS mouse showed only colonic hyperproliferation without 
tumour formation, all mice with colonic hyperproliferation also showed adenoma formation. 
Two out of 15 were diagnosed with invasive adenocarcinoma in the proximal colon and 3 out 
of 15 had invasive adenocarcinoma in the mid colon (Figure 4.11-4.12). Colonic invasive 
adenocarcinoma was observed in 21.7% of EtOH_Msh2fl KO mice. In addition, in 6 out of 15 
mice, we found caecal adenomas and in one case there was a caecal invasive 
adenocarcinoma (Figure 4.13). Among these 15 mice only 2 were diagnosed with distal 
colonic adenoma or rectal adenoma respectively. In total, we observed 36 neoplasms 
distributed between both the caecum (19.5%), colon (77.8) and the rectum (2.7%) (Figure 
4.14). Additionally, 2 out of these 15 mice developed cutaneous sebaceous adenoma (a type 
of skin tumour that occurs in LS patients) (Figure 4.15).  
Eight out of 23 EtOH_Msh2fl KO mice did not show any intestinal adenoma formation, but in 
one of these cases there was a uterine endometrial adenocarcinoma (after 12 months of 
ethanol treatment). The Msh2-LS mouse models have one deleted Msh2 allele and one 
functioning Msh2 allele, the same as in human LS patients who have inherited one mutant 
MSH2 allele and one normal MSH2 allele, and thus are susceptible to LS-associated cancers 
due to inactivation of the normal or functioning MSH2 allele, including endometrial 
adenocarcinoma, which is a common cancer in women with LS. 
In Group-A (water-treated control cohort, H2O_Msh2fl KO), only 1 out of 23 mice showed 
intestinal tumour formation in the proximal colon (one adenoma with evolution to an 
invasive adenocarcinoma) and in the caecum (one adenoma) after 15 months. We didn’t find 
any other intestinal abnormality in any of the other 22 H2O_Msh2fl KO mice, however we 
observed uterine endometrial invasive adenocarcinomas in 2 mice (after 12 and 15 months 
of treatment, respectively; Figure 4.16). 
No morphological abnormalities or tumours were observed following necropsy and 
histopathological analysis of the H&E-stained sections of the small intestines, stomach, liver, 









A no signs of ill health                                                                                      
B
moderate dehydration, scruff test indicates dehydration (when 
picking up the skin over the shoulders, it does not return to its 
original shape quickly)             
C
severe dehydration, symptoms include: mice are weak or appear 
paralysed in their hind legs, eyes appear recessed in the head, facial 
fur appears fuzzier (piloerection), mice might have difficulties 
gripping the cage bars with their forefeet                                      
D Blood in cage or on faecal pellets.                                                                 
E Prolapse of rectum visible at perianal area                                                    
F Visible tumours at perianal area or elsewhere                                                
G Pale paw pads (significant anaemia)           
H
Clear signs of pain or distress or other signs of ill health. Lost >20% 




Figure 4.5: Representative macroscopic photographs of the Small Intestine and Large Intestine from an ethanol-treated Msh2-LS mouse (EtOH_Msh2fl KO) (with 
caecum) (A), and a water-treated Msh2-LS mouse (H2O_Msh2fl KO) (without caecum) (B). (C) Photograph of two specimens of colons, one from an EtOH_Msh2 fl KO 
mouse (upper colon specimen) compared with one from an H2O_Msh2fl KO mouse (lower colon specimen, and showing that the upper ethanol-treated colon has a 
thicker wall. (D) Quantification of the Small Intestinal lengths and Large Intestinal lengths. Data shown as mean ± SD, Student’s t-test analysis. No significant 




Figure 4.6: Representative H&E stained images of colon Swiss rolls. A) Images of H&E stained LI Swiss rolls from water-treated Msh2-LS (H2O_Msh2fl KO) mice, 
further magnified in image (C). Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer software at 0.8X and 2.5X objective 
magnification respectively (bar at lower left indicates 2.5mm and 1mm). B) Images of H&E stained LI Swiss rolls from ethanol-treated Msh2-LS (EtOH_Msh2fl KO) 
mice, further magnified in image (D). Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer software at 0.5X, and 2.5X objective 
magnification respectively (bar at lower left indicates 2.5mm and 1mm). E) Quantification of the colon crypt lengths (in μm) comparing colons from EtOH_Msh2fl 




Figure 4.7: Representative H&E stained images of SI Swiss rolls. A) Image of H&E stained SI Swiss roll 
from a water-treated Msh2-LS (H2O_Msh2fl KO) mouse, further magnified in image (C). Images taken 
from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer software at 0.5X and 2.5X 
magnification respectively (bar at lower left indicates 5mm and 1mm). B) Image of H&E stained SI 
Swiss roll from an ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mouse, further magnified in image (D). 
Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer software at 0.5X 




Figure 4.8: A) Bar chart of the number of Msh2-LS mice that developed intestinal tumours (both 
adenomas and adenocarcinomas) after receiving either 20% ethanol in drinking water or regular 
drinking water. 15/23 (65%) ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mice developed large 
intestinal tumours compared with 1/23 (4%) water-treated Msh2-LS (H2O_Msh2fl KO) mice. Fisher’s 
exact test, **** p<0.0001. B) Tumour incidence in Msh2-LS mice treated with either 20% ethanol or 
water. The survival plot shows the significantly earlier development of tumours (both adenomas and 
adenocarcinomas) in the ethanol-treated Msh2-LS (EtOH_Msh2fl KO) group (red) compared with the 













Figure 4.9: A and B show representative images of colonic crypt epithelial hyperproliferative changes 
in ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mice, demonstrating the increase in length of the 
affected crypts. Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer 






Figure 4.10: Representative images of a proximal colon adenoma in ethanol-treated Msh2-LS 
(EtOH_Msh2fl KO) mice. Images taken at 25X (A), 50X (B) and 100X (C and D) magnification taken with 




Figure 4.11: Representative images of colon invasive adenocarcinoma in ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mice. Images taken at 100X (A), 200X (B), 400X 
(C) and 50X (D) magnification taken with a Leica DMR HC microscope and Leica DFC 450-C camera Further magnified areas are indicated by the red rectangles 




Figure 4.12: Representative images of 2 colon invasive adenocarcinomas in ethanol-treated Msh2-LS 
(EtOH_Msh2fl KO) mice. Images taken at 50X (left column A and C) and 100X (right column B and D) 











Figure 4.13: Representative images of caecal invasive adenocarcinoma in ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mice. Images taken at 25X (A), 50X (B) and 100X 





Figure 4.14: Tumour distribution in ethanol-treated Msh2-LS (EtOH_Msh2fl KO) tumour-bearing mice. 
A) Numbers of adenomas and adenocarcinomas found and their locations. In total, 36 neoplasms were 
observed, 7 in the caecum (1/7 was an invasive adenocarcinoma), 12 in the proximal colon (2/12 were 
invasive adenocarcinomas), 15 in the mid-colon (3/15 were invasive adenocarcinomas), 1 adenoma in 
the distal colon and 1 adenoma in the rectum. B) Tumour distribution and number per EtOH_Msh2fl 
KO tumour-bearing mouse. 3/15 tumour-bearing mice showed one caecal adenoma and 2/15 mice 
showed two adenomas in the caecum. 10/15 tumour-bearing mice showed one proximal colonic 
adenoma and 1/15 showed two adenomas in the proximal colon. 7/15 tumour-bearing mice showed 
one mid-colonic adenoma and 4/15 showed 2 adenomas in the mid colon. The remaining two tumour-





Figure 4.15: A and B show images of the two skin sebaceous adenomas in ethanol-treated Msh2-LS 
(EtOH_Msh2fl KO) mice (a partially cystic skin sebaceous adenoma on the left in A). Images taken at 






Figure 4.16: Representative images of uterine endometrial invasive adenocarcinoma. Images taken at 




4.3 Long-term ethanol effects in Msh2-LS model control mice and wild-
type mice 
4.3.1 Methods 
Groups of 7-9 weeks old Msh2-LS control mice (Msh2flox/-; Lgr5CreERT2+/- and Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-) were divided into two groups (A and B) prior to corn oil (without 
Tamoxifen) treatment.  
Both Group-A and Group-B mice received i.p. injections of corn oil on days 1, 2, 3, and 4 
(equivalent volume of corn oil as previously used). On day 5 Group-A mice were provided 
with normal drinking water and Group-B mice with 20% ethanol in drinking water (Figure 
4.17). 
These control animals were monitored and culled when they reached the same end-time 
point as the matched experimental Tamoxifen-induced mice (following tumour development 
or clinical distress in these experimental subjects), or when the control mice showed either 
clinical signs of distress or they displayed >20% body weight loss compared with the initial 
weight. The small and large intestines, caecum, stomach, liver, spleen, thymus, lymph nodes 
(if visible) and any other organ or tissue showing abnormalities, were collected following 
schedule 1 culling and necropsy dissection. Following standard tissue processing protocols, 
the tissue blocks were paraffin-embedded in preparation for section cutting and staining.  
In previous work, Aldh1b1 depleted mice were used as experimental subjects, along with 
wild-type control mice, under long-term (>1 year) treatment with 20% ethanol in drinking 
water or normal/standard drinking water (Müller et al., 2016). Data related to wild-type mice 
have been collected by Mike Müeller. The data on the ethanol/acetaldehyde effects in 
intestinal tumourigenesis were compared for Tamoxifen-induced Msh2-LS mice, non-
induced Msh2-LS mice and wild-type mice. The acronyms used for the mouse models and 








Figure 4.17: Experimental treatment protocols and timelines for Group-A (water-treated) and Group-
B (ethanol-treated) mice, showing 4 days of intraperitoneal (i.p.) injections of corn oil, followed by 
either standard/normal drinking water (Group-A) or drinking water containing 20% ethanol (Group-





















4.3.2.1 Control group organization and observations 
In previous work, 14 WT mice (7 females and 7 males) were provided with 20% ethanol in 
drinking water and 15 WT mice (8 females and 7 males, control group) with standard/normal 
drinking water ad libitum for 1 year (Müller et al., 2016).  
Twenty-four non-induced Msh2-LS control mice were divided into two groups: 12 mice in 
Group-A (6 females and 6 males, water-treated control group) and 12 mice in Group-B (6 
females and 6 males, ethanol-treated group). Non-induced Msh2-LS animals were culled, 
necropsy dissected and tissues were collected when they reached the same end-time point 
as the experimental EtOH_Msh2fl KO mice (Chapter 4.2.2)  
During corn oil administration (daily corn oil i.p injections for 4 consecutive days), body 
weights and health status were recorded. Body weights of the female and male mice did not 
significantly differ during the corn oil treatment (Figure 4.18). The average non-induced 
Msh2-LS male body weight (approx. 33.57g) was significantly higher than the non-induced 
Msh2-LS female average body weight (approx. 24.2g) both before and during the corn oil 
treatment.  
After corn oil treatment, mice received either 20% ethanol in drinking water regime or 
standard/normal drinking water regime and the body weights and health status of the mice 
were monitored and recorded twice a week (Figure 4.19B). The average weight of 
EtOH_Msh2fl mice was 43g for males and 31g for females, and the average weight of 
H2O_Msh2fl mice was 44.3g for males and 37.3g for females. Significant differences were not 
observed between the body weights of EtOH_Msh2fl versus H2O_Msh2fl mice, regardless of 
the sex. The body weights of Tamoxifen-induced Msh2-LS mice, non-induced Msh2-LS mice, 
and WT mice were compared, during either 20% ethanol treatment or normal drinking water 
treatment (Figure 4.19A, B, C). In every study group, both female and male ethanol-treated 
Msh2-LS mice did not show significant differences in body weight, or abnormal behaviour, 
indicating good acceptance of the 20% ethanol treatment regime.  
Drinking bottles were changed and bottle weights were recorded once a week. Liquid 
consumption per mouse was estimated by analysing the weights of the drinking bottles (per 
cage) and calculating the average weight of consumed liquid per mouse per day (Figure 4.20). 
H2O_Msh2fl male mice consumed on average 12.17ml of drinking water per day, compared 
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with 7.2ml of 20% ethanol in drinking water consumed by EtOH_Msh2fl male mice. The 
difference in liquid consumption between EtOH_Msh2fl and H2O_Msh2fl males is statically 
significant (p= 0.0053). Note that, this difference was not observed in the EtOH_Msh2fl and 
H2O_Msh2fl female mice, with both groups consuming (on average) 9.2ml of water per day, 











Figure 4.18: Body weights during corn oil treatment. Body weights of non-induced (no Tamoxifen) 
Msh2-LS males were significantly higher than body weights of non-induced Msh2-LS females, before 
and during corn oil treatments. 2-way-ANOVA test with Bonferroni post-test correction, p<0.0001 on 
day 1, p=0.0002 on day 2, p=0.0001 on day 3 and p=0.0015 on day 4 (data shown as mean ± SD, n=10 












Figure 4.19: Body weights for males and females during 20% ethanol or standard/normal drinking water regimes. Body weight graphs of non-induced Msh2-LS control 
mice (A), Tamoxifen-induced Msh2-LS experimental subject mice (B), and WT mice (C) during 20% ethanol or standard/normal drinking water regimes. In each group, 
there were no significant differences between the body weights of ethanol-treated versus water-treated groups of mice for either males or females. 2-way-ANOVA 
test with Bonferroni post-test correction analysis (data shown as mean±SD, n= 26, n=14, n=14, SD too small to show as bars in some experiments, particularly towards 




Figure 4.20: Liquid consumption of either 20% ethanol containing drinking water or standard/normal 
water per mouse per day. 2-way-ANOVA with Bonferroni post-test correction analysis, **p=0.0053 



















4.3.2.2 Tumour development in control mice exposed to long-term ethanol 
treatment 
The intestines of these mice were analysed and compared to age- and sex-matched induced 
mice in Chapter 4 (4.2). These control mice underwent necropsy dissection and organ/tissue 
collection in the same way as the experimental mice. The histopathological analyses of the 
LI and SI of non-induced Msh2-LS control mice were performed using H&E-stained Swiss rolls. 
In Group-B (ethanol-treated cohort, EtOH_Msh2fl), 3 out of 12 (25%) EtOH_Msh2fl mice 
showed zones of crypt epithelial hyperproliferation involving only the mid colon (after 8, 10 
and 22 weeks of 20% ethanol in drinking water regime, respectively) and 1 (8.4%) showed a 
proximal colon invasive adenocarcinoma (after 28 weeks). Eight out of 12 (66.6%) 
EtOH_Msh2fl mice did not show any abnormality or intestinal adenoma formation. In Group-
A (water-treated cohort, H2O_Msh2fl), only 1 out of 12 (8.4%) H2O_Msh2fl mice showed 
intestinal adenoma formation in the proximal colon (after 22 weeks of treatment). Msh2 
expression by this adenoma was tested by IHC, but no loss of Msh2 expression was observed. 
This tumour was regarded as a sporadic adenoma, with no further tests being performed on 
it. No intestinal abnormality was observed in any of the other 11 (91.6%) H2O_Msh2fl control 
mice (Figure 4.21). The tumour incidence was then compared between Tamoxifen-induced 
Msh2-LS experimental cohort mice and non-induced Msh2-LS control mice (Figure 4.22). 
No morphological abnormalities or tumours were observed following necropsy dissection 
and histopathological analysis of the H&E-stained sections of the caecum, small intestines, 
stomach, anal canal, liver, spleen, lymph nodes and thymus, of any of the 12 EtOH_Msh2fl 
control mice or the 12 H2O_Msh2fl control mice. 
In previous work, 4 out of 14 (28.6%) ethanol-treated WT mice showed proximal colon 
adenoma formation and in one case also formation of one small intestinal adenoma after 
over a year of exposure to the 20% ethanol in drinking water regime. No other intestinal 
abnormality or tumour formation were observed in any of the other 10 out of 14 (71.4%) 
ethanol-treated WT mice. In this current investigation, no abnormalities or tumours were 
observed in either LI or SI in the 15 water-treated WT control mice during the same time 
period. No morphological abnormalities or tumours were observed following necropsy 
dissection and histopathological analysis of the H&E-stained sections of the caecum, 
stomach, liver, spleen, lymph nodes and thymus, of any of the 14 WT ethanol-treated or 15 
WT water-treated mice.  
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We next compared the intestinal tumour formation in the 6 groups of Tamoxifen-induced 
Msh2-LS experimental mice, non-induced Msh2-LS control mice and WT control mice, 





















Figure 4.21: A) Bar chart of the number of non-induced Msh2-LS control mice that developed intestinal 
tumours after receiving either 20% ethanol in drinking water or normal/standard drinking water. In 
both groups (water-treated cohort and ethanol-treated cohort) 1/12 (8.4%) non-induced Msh2-LS 
control mice developed large intestinal adenomas (no adenocarcinomas were observed). Fisher’s 
exact test, no significant differences observed. B) Tumour (adenoma) incidence shown as a survival 
plot in non-induced Msh2-LS control mice treated with either 20% ethanol (red) or water (blue). Log-
rank (Mantel-Cox) test, no significant differences observed. 
 
 
Figure 4.22: Tumour incidence, shown as survival plots, in non-induced Msh2-LS control mice both 
water-treated (H2O_Msh2fl) (green) and ethanol-treated (EtOH_Msh2fl) (violet), compared with 
Tamoxifen-induced Msh2-LS experimental mice, both water-treated (H2O_Msh2fl KO) (blue) and 20% 
ethanol-treated (EtOH_Msh2fl KO) (red). Log-rank (Mantel-Cox) test, **p = 0.0060 indicating significant 






Figure 4.23: Bar chart of the numbers of WT control mice, non-induced Msh2-LS control mice, and 
Tamoxifen-induced Msh2-LS experimental mice that developed intestinal tumours after receiving 
either 20% ethanol in drinking water or normal/standard drinking water. Fisher’s exact test was 
carried out to compare the effects of ethanol in the three different pairs of cohorts:  4/14 (28.6%) 
ethanol-treated WT control mice developed large intestinal tumours compared with 0/14 (0%) in 
water-treated WT control mice (*p≤0.05); 1/12 (8.4%) ethanol-treated non-induced Msh2-LS 
(EtOH_Msh2fl) control mice and 1/12 (8.4%) water-treated non-induced Msh2-LS (H2O_Msh2fl) control 
mice each developed a single large intestinal adenoma (no significant differences observed between 
these two groups); and 15/23 (65%) ethanol-treated Msh2-LS (EtOH_Msh2fl KO) experimental mice 
developed large intestinal tumours compared with 1/23 (4%) water-treated Msh2-LS (H2O_Msh2fl KO) 
experimental mice that developed large intestinal tumours, ****p<0.0001. Fisher’s exact test was 
carried out to compare the tumour incidence between ethanol-treated WT control mice and ethanol-
treated non-induced Msh2-LS (EtOH_Msh2fl) control mice (no significant differences observed 
between these two groups); ethanol-treated WT control mice and ethanol treated Msh2-LS 
(EtOH_Msh2fl KO) experimental mice (p≤0.0448) and ethanol-treated Msh2-LS experimental mice and 





















4.4 Immunohistochemical characterization of tumours and tissues from 
the Msh2-LS mouse model with and without ethanol treatment 
 
4.4.1 Methods 
We performed IHC analyses in FFPE colonic and small intestinal tissues from induced 
Lgr5CreERT2; Msh2flox/-; mTmG mice and non-induced control Lgr5CreERT2; Msh2flox/-; mTmG 
mice to verify the expression of various proteins of interest. We performed the same analysis 
on the colonic and SI tissues comparing ethanol-treated mice with water-treated mice. Small 
and large intestinal tissues were harvested, prepared as Swiss-rolls and fixed in 10% NBF (as 
described in Materials and Methods). They were processed using standard tissue processing 
protocols for paraffin wax embedding and microtome sectioning. 
IHC was performed to confirm changes to Msh2 expression (target protein) and other MMR 
proteins (Msh6, Mlh1 and Pms2), the proliferation marker Ki-67, the Wnt pathway marker 
β-Catenin, the DNA damage marker γ-H2AX and DNA damage / tumour suppressor marker 
p53, and cCas-3 a critical executioner of apoptosis. IHC for infiltrating immune cells was 
performed by Dr Seth Coffelt’s research group from the Beatson Cancer Institute in Glasgow 
(the panel of immune cell antibodies is displayed in Materials and Methods, Table 2.12) 
Immunohistochemical staining was performed using the protocols described in Materials 
and Methods (2.2.3). Staining and quantification was performed either by manually scoring 













4.4.2.1 Mismatch Repair proteins immunostaining of Msh2-LS murine small 
intestinal and colonic tissues 
Normally, Msh2 is highly expressed in crypt stem cells and transit amplifying cells in the small 
intestinal crypts, but fades in the non-dividing differentiated SI villus cells, and similarly fades 
in the differentiated cells of the upper third of the colonic crypts (Tomé et al., 2013). 
Tamoxifen treatment induced the loss of Msh2 expression in Lgr5+ expressing crypt 
epithelial stem cells scattered along the entire small and large intestines. The Lgr5+ 
expressing stem cells, located at the bottom of the crypts, generate daughter cells that can 
expand to fill the entire crypt-villus epithelium in SI or entire crypt in the colon (Barker et al., 
2007; Wojciechowicz et al., 2014). We used colonic tissue samples of Msh2-/- and WT mice 
as Msh2-negative and -positive expression controls respectively (Figure 4.24). The lack of IHC 
DAB-brown staining in all of the SI crypts and villi and in all of the colonic crypts of the Msh2-
/- mice confirmed complete loss of Msh2 expression in the Msh2-null control tissues. In 
contrast, scattered crypts, in both SI and colon, showed Msh2 expression loss in the Msh2-
LS model mice.  
The number of Msh2-negative crypts was higher in the SI than in the colon in Msh2-LS model 
mice, however no tumours were observed in the small intestine. The number of Msh2-
negative crypts in the SI was statistically significantly higher in the EtOH_Msh2fl KO mice 
compared with the H2O_Msh2fl KO mice (Figure 4.25). In EtOH_Msh2fl KO mice, 43% Msh2-
negative small intestinal crypts were observed compared with 25.8% Msh2-negative small 
intestinal crypts found in H2O_Msh2fl KO mice (Figure 4.26).  
IHC analysis of Msh2 expression in the intestinal tissue samples from EtOH_Msh2fl mice and 
H2O_Msh2fl mice showed no Msh2-negative crypts in either small or large intestinal mucosal 
epithelium (Figure 4.27-4.28), consistent with lack of induction of Cre activity with continued 
expression of protein from the floxed Msh2 allele.  
In the colon, the number of Msh2-negative crypts was statistically significantly higher in the 
EtOH_Msh2fl KO mice compared with the H2O_Msh2fl KO mice (Figure 4.29). In EtOH_Msh2fl KO 
mice 11.2% Msh2-negative colonic crypts were observed compared with 5% Msh2-negative 
colonic crypts found in H2O_Msh2fl KO controls (Figure 4.30). EtOH_Msh2fl KO mice formed 
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some large intestinal adenomas that were characterized by Msh2-negative dysplastic glands 
often surrounded by or admixed with Msh2-positive crypts showing reactive or 
hyperproliferative changes (Figure 4.31).  
Furthermore, we performed IHC for Msh6, Mlh1 and Pms2 to investigate expression changes 
in other MMR proteins in the Msh2-LS mouse model.  
In the MMR repair pathway, a base mismatch or single nucleotide insertion/deletion (InDel) 
error is recognised by the MutSα complex, which is composed of Msh2 and Msh6 
heterodimeric proteins. In the absence of Msh2, the heterodimeric MutSα complex cannot 
be formed and Msh6 is rapidly degraded (Poulogiannis et al., 2010). We used colonic tissue 
samples of Msh2-/- and WT mice as Msh6-negative and -positive normal expression controls 
respectively (Figure 4.32). As previously observed for Msh2 IHC results (Figure 4.24), the lack 
of IHC DAB-brown staining in all of the colonic crypts of the Msh2-/- mice confirmed complete 
loss of Msh6 expression, whereas wild-type murine colonic epithelium showed DAB-brown 
staining in all of the colonic crypts, with the typical MMR protein expression gradient of 
staining, with strong MMR staining at the crypt base, with decreased staining towards the 
lumen of the intestine. IHC analysis of Msh6 was performed on large and small intestinal 
tissue from both Tamoxifen-induced Msh2-LS mice and non-induced (no Tamoxifen 
treatment) Msh2-LS mice. These samples showed Msh6-negative crypts scattered along both 
SI and colon of Tamoxifen-induced Msh2-LS mice (Figure 4.33). IHC analysis of Msh6 
expression in the intestinal tissue samples from non-induced Msh2-LS mice showed no 
Msh6-negative crypts in either small or large intestinal mucosal epithelium (Figure 4.33).  
The MutLα complex, composed of Mlh1 and Pms2, is recruited by the binding of MutSα 
(composed by Msh2 and Msh6) to the mismatched or InDel DNA lesion. The absence of Msh2 
does not inhibit or modify the expression of Mlh1 or Pms2 (Poulogiannis et al., 2010). Colonic 
tissue samples of Msh2-/- and WT mice were used as expression controls for Mlh1 (Figure 
4.34). The DAB-brown staining was observed in the typical MMR protein expression pattern 
in all of the colonic crypts of both Msh2-/- and WT murine colonic tissue. We verified Mlh1 
expression in large and small intestinal tissue from both Tamoxifen-induced Msh2-LS mice 
and non-induced Msh2-LS mice. These samples showed normal Mlh1 expression in both 
colonic and small intestinal crypts of Tamoxifen-induced Msh2-LS mice and non-induced 
Msh2-LS mice (Figure 4.35). The immunostaining for Pms2 proved to be technically 
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problematic due to antibody failure and it was not possible to determine the staining pattern 







Figure 4.24: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal 
epithelium from a positive-control WT mouse (A), in which the brown staining indicates positive Msh2 
expression in all crypts (further magnified in the upper right inset red rectangle); and from a negative-
control Msh2-/- mouse (B), in which the lack of brown staining confirms the absence of Msh2 
expression in large intestinal mucosal epithelium (further magnified in the upper right inset red 
rectangle). Images taken from anti-Msh2 IHC stained sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification 






Figure 4.25: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% 
ethanol in drinking water (A) or normal / standard drinking water (B). Msh2-negative crypts (indicated by the red arrows) were manually counted along the entire small intestine 
of treated Msh2-LS mice (C). Paired Students t Test, **p= 0.0044 vs. water (data shown as mean±SD, n=6 mice in each group). Images taken from sections scanned using the 




Figure 4.26: Percentage of Msh2 protein-non-expressing crypts in small intestinal mucosa of Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal water. Paired 
Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 300 crypts counted were analysed, n=6 
mice from each group).  
 
 
Figure 4.27: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal 
epithelium of non-induced Msh2-LS control mice treated with either 20% of ethanol in drinking water (A) 
or normal / standard water (B). No Msh2-negative crypts were observed along the entire colon of non-
induced Msh2-LS mice (n=6 mice in each group). Images taken from sections scanned using the 
Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X 




Figure 4.28: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal 
epithelium of non-induced Msh2-LS control mice treated with either 20% ethanol in drinking water (A) or 
normal / standard drinking water (B). No Msh2-negative crypts were observed along the entire small 
intestine of non-induced Msh2-LS mice (n=6 mice in each group). Images taken from sections scanned 
using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X 




Figure 4.29: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% 
ethanol in drinking water (A) or normal/standard water (B). Msh2-negative crypts (indicated by the red square and further magnified in the upper right inset red rectangle in 
Figure panels A and B) were manually counted along the entire colon of treated Msh2-LS mice (C). Mann-Whitney U Test, **p=0.0097 vs. water (data shown as mean±SD, n=6 
mice each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification 




Figure 4.30: Percentage of Msh2 protein-non-expressing crypts in large intestinal mucosa of Msh2flox/-
; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal/standard 
water. Paired Students t Test, **p=0.0029 vs. water (data shown as mean±SD, 300 crypts counted in 




Figure 4.31: Representative images of Msh2 immunohistochemical staining in two large intestinal 
adenomas from 2 ethanol-treated Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- (EtOH_Msh2fl KO) mice (A & B). 
In both examples, there are Msh2-negative dysplastic or adenomatous glands, either surrounded by 
or admixed with reactive crypts or hyperproliferative crypts that are staining positively for Msh2. 
Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the 





Figure 4.32: Immunohistochemical analysis of Msh6 protein expression in large intestinal mucosal 
epithelium from a positive-control WT mouse (A), in which the brown staining indicates positive Msh6 
expression in all crypts (further magnified in the upper right inset red rectangle); and from a negative-
control Msh2-/- mouse (B), in which the lack of brown staining confirms the absence of Msh6 
expression in large intestinal mucosal epithelium (further magnified in the upper right inset red 
rectangle). Images taken from anti-Msh6 IHC stained sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification 





Figure 4.33: Immunohistochemical analysis of Msh6 protein expression in large and small intestinal 
mucosal epithelium of Tamoxifen-induced Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice (A and C) and non-
induced Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- (B and D). Tamoxifen-induced Msh2-LS mice showed 
Msh6-negative crypts in colonic intestinal  mucosal epithelium (indicated by the red square and 
further magnified in the upper right inset red rectangle in figure panel A) and small intestinal mucosal 
epithelium (indicated by the red arrows in figure panel C). No Msh6-negative crypts were observed in 
both large and small intestinal mucosal epithelium (B and D respectively) of non-induced Msh2-LS 
mice. Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the 
Hamamatsu NDP Viewer software at 10X and 20X magnification (bar at lower left indicates 250μm, 





Figure 4.34: Immunohistochemical analysis of Mlh1 protein expression in large intestinal mucosal 
epithelium from WT mouse (A) and from Msh2-/- mouse (B), in which the brown staining indicates 
positive Mlh1 expression in all crypts (further magnified in the upper right inset red rectangle in figure 
panels A and B). Images taken sections scanned using the Hamamatsu Nanozoomer and analysed with 
the Hamamatsu NDP Viewer software at 10X and 20X magnification (bar at lower left indicates 250μm, 






Figure 4.35: Immunohistochemical analysis of Mlh1 protein expression in large and small intestinal 
mucosal epithelium of Tamoxifen-induced Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice (A and C) and non-
induced Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- (B and D). Normal Mh1 expression was observed in both 
colonic mucosal epithelium (indicated by the red square and further magnified in the upper right inset 
red rectangle in figure panels A and B) and small intestinal mucosal epithelium (C and D) of both 
Tamoxifen-induced Msh2-LS mice and non-induced Msh2-LS mice. Images taken from sections 
scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software 








4.4.2.2 Ki-67 immunostaining of Msh2-LS murine small intestinal and colonic 
tissues 
The Ki-67 protein is a cellular marker for proliferation. During active phases of the cell 
cycle (part of G1, S, and G2 phases), the Ki-67 antigen can be detected within the cell 
nucleus, whereas in mitosis (M phase) most of the protein is relocated to the surface of 
the condensed chromosomes (and the nuclear membrane disappears during most of M 
phase). Previous studies have shown that Ki-67 is present in proliferating cells, but it is absent 
in quiescent cells (Gerdes et al., 1984). Detection of Ki-67 by IHC may be performed to 
determine proliferative activity that may be predictive of some tumour behaviour. In normal 
large and small intestinal tissue, Ki-67 is expressed only in the proliferating cells at the base 
of crypts (Johnston et al., 1989). 
IHC analysis of Ki-67 showed large and significant differences in the number of intestinal 
Ki67-positive cells between the EtOH_Msh2fl KO murine colon and the H2O_Msh2fl KO murine 
colon (Figure 4.36). The percentage of Ki-67-positive cells per crypt was significantly higher 
in EtOH_Msh2fl KO mice (75.76%) compared with H2O_Msh2fl KO mice (19.64%) (Figure 4.37). 
This is due to the large regions of mucosal crypt hyperproliferation found in ethanol-treated 
murine colons (Figure 4.6).   
The comparative analysis of SI Ki-67 expression between EtOH_Msh2fl KO and H2O_Msh2fl KO 
mice didn’t show the same large differences. EtOH_Msh2fl KO murine SI showed similar 
numbers of Ki-67-positive cells per crypt when compared with H2O_Msh2fl KO mice SI, with 
no significant differences observed between the two groups (Figure 4.38). The percentage 
of Ki-67-positive cells per crypt was significantly higher in SI of EtOH_Msh2fl KO mice (12.21%) 
compared with H2O_Msh2fl KO mice (8.7%), but with only a small difference between the two 





Figure 4.36: Immunohistochemical analysis of Ki-67 protein expression in large intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% 
of ethanol in drinking water (A) or normal/standard water (B). Numbers of Ki-67-positive cells per colonic crypt (further magnified in the upper right inset red rectangle in figure 
panels A and B) were counted using QuPath (C). Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 30 crypts per mouse were analysed, n=6 mice in each 
group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification (bar at 




Figure 4.37: Percentage of Ki-67 protein expressing cells in large intestinal mucosal crypts of Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal / standard 
water. Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 30 crypts per mouse 





Figure 4.38: Immunohistochemical analysis of Ki-67 protein expression in small intestinal mucosa of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in 
drinking water (A) or normal / standard drinking water (B). Ki-67-positive cells per colonic crypt/villus were counted using QuPath (C). Paired Students t Test, (data shown as 
mean±SD, 30 crypts/villi per mouse were analysed, n=6 mice in each group).No statistical differences were observed. Images taken from sections scanned using the Hamamatsu 





Figure 4.39: Percentage of Ki-67 protein expressing cells in small intestinal mucosa of Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal / standard 
water. Paired Students t Test, *p=0.0172 vs. water (data shown as mean±SD, 30 crypts per mouse 



















4.4.2.3 Beta-Catenin immunostaining of Msh2-LS murine small intestinal and 
colonic tissues 
β-catenin is the key effector in the intracellular signal transduction of the Wnt signalling 
pathway (Cong et al., 2003). Normal colorectal tissue exhibits membranous and cytoplasmic 
localisation of β-catenin, whereas colorectal adenoma/adenocarcinoma shows nuclear β-
catenin localization and thus β-catenin is regarded as a useful CRC biomarker (Lugli et al., 
2007). 
β-catenin IHC was performed with assistance from Marion Bacou using large intestinal 
samples from Apc Min mice that contained large intestinal adenomas (provided by Vidya 
Rajasekaran), and WT mice as β-catenin-positive and β-catenin-normal expression controls 
respectively (Figure 4.40). Whereas wildtype murine colonic epithelium showed 
membranous and cytoplasmic β-catenin light immunostaining, indicating absent activation 
of the Wnt signalling pathway, the Apc-Min murine adenomas showed increased brown 
nuclear β-catenin immunostaining in variable numbers of adenoma cells in a heterogeneous 
pattern, confirming dysregulation of Wnt signalling in this neoplastic intestinal epithelium. 
The IHC analysis of β-catenin was performed on large intestinal adenomas and caecal 
adenomas from Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice. Analysed samples showed a 
heterogeneous pattern with variable numbers of adenoma cells showing positive β-catenin 
nuclear immunostaining due to accumulation and translocation of β-catenin in the nuclei 






Figure 4.40: Immunohistochemical analysis of β-catenin protein expression and localisation in large 
intestinal mucosal adenoma and adjacent normal epithelium from a positive-control Apc Min mouse 
(A), in which the increased brown nuclear β-catenin staining in variable numbers of adenoma cells in 
a heterogeneous pattern confirms dysregulation of Wnt signalling in this neoplastic intestinal 
epithelium (further magnified in the red rectangle); and from a  normal control WT mouse (B), in which 
the membranous and cytoplasmic β-catenin light staining indicates normal large intestinal mucosal 
epithelium without activation of the Wnt signalling pathway (further magnified in the red rectangle). 
Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the 
Hamamatsu NDP Viewer software at 10X and 20X magnification (bar at lower left indicates 250μm, 




Figure 4.41: Representative images of immunohistochemical analysis of β-catenin protein expression and localisation in intestinal adenomas of Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with 20% ethanol in drinking water. Variable areas of positive β-catenin nuclear immunostaining in adenomatous cells were 
observed in both caecal adenomas (A) and colonic adenomas (B and C), indicated by the red ovals. Selected areas (red ovals) within images in panels A-C are further 
magnified in panels D-F, and clusters of positive β-catenin nuclei are indicated by the red arrows. Images taken from sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 40X magnification (bar at lower left indicates 250μm and 50 μm). 
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4.4.2.4 DNA damage response evaluation by immunohistochemistry of Msh2-LS 
murine small intestinal and colonic tissues 
4.4.2.4.1 DNA damage response evaluation by Gamma-H2AX immunostaining of Msh2-LS 
murine small intestinal and colonic tissues 
In order to evaluate the presence and extent of DNA damage, y-H2AX immunostaining was 
used. Y-H2AX is the key player in signalling and activating DNA damage repair pathways and 
for this it is considered a specific molecular marker for monitoring DNA damage (Mah et al., 
2010).  
We used colonic tissue samples from WT mice and TMZ-treated Msh2-LS mice as negative 
and positive y-H2AX expression controls respectively (Figure 4.42). The lack of IHC DAB-
brown staining in all of the colonic crypts of the WT mice confirmed the lack of y-H2AX 
expression. In contrast, the widespread presence of IHC DAB-brown staining in colonic crypts 
of the TMZ-treated Msh2-LS murine colon confirmed positive y-H2AX immunostaining 
technique. 
IHC analysis of y-H2AX showed large and significant differences in the number of intestinal 
y-H2AX-positive cells between the EtOH_Msh2fl KO murine colon and the H2O_Msh2fl KO 
murine colon (Figure 4.43). The percentage of y-H2AX-positive cells per crypt was 
significantly higher in EtOH_Msh2fl KO mice (35%) compared with H2O_Msh2fl KO mice (0.4%) 
(Figure 4.43C), consistent with ethanol/acetaldehyde induced DNA damage. The 
comparative analysis of SI y-H2AX expression between EtOH_Msh2fl KO and H2O_Msh2fl KO 
mice didn’t show any differences, as EtOH_Msh2fl KO and H2O_Msh2fl KO murine SI showed no 
y-H2AX-positive cells (Figure 4.44). EtOH_Msh2fl KO murine large intestinal adenomas showed 






Figure 4.42: Immunohistochemical analysis of y-H2AX protein expression in large intestinal mucosal 
epithelium from a negative-control WT mouse (A), in which the lack of DAB brown staining indicates 
negative y-H2AX expression in all crypts (further magnified in the upper right inset red rectangle); and 
from a positive-control TMZ-treated Msh2-LS mouse (B), in which the brown staining confirms the 
presence of y-H2AX expression in large intestinal mucosal epithelium consistent with TMZ-induced 
widespread DNA damage (further magnified in the upper right inset red rectangle). Images taken from 
sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 
software at 10X and 20X magnification (bar at lower left indicates 250μm, bar in red rectangle 






Figure 4.43: Immunohistochemical analysis of y-H2AX protein expression in large intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with 
either 20% ethanol in drinking water (A) or normal/standard water (B). Gamma-H2AX-positive cells in colonic crypts (further magnified in the upper right inset red 
rectangle in figure panel A) were observed in ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mice but not in water-treated Msh2-LS (H2O_Msh2fl KO) mice (further magnified 
in the upper right inset red rectangle in figure panel B). Numbers of y-H2AX-positive cells per colonic crypt were counted using QuPath (C) showing a large and 
statistically significant difference. Paired Students t-Test, ***p<0.0009 vs. water (data shown as mean±SD, 40 crypts per mouse were analysed, n=4 mice in each group). 
Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification (bar 




Figure 4.44: Immunohistochemical analysis of y-H2AX protein expression in small intestinal mucosa of 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water (A) or 
normal / standard drinking water (B). No y-H2AX-positive cells were observed in either sample. Images 
taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu 
NDP Viewer software at 10X magnification (bar at lower left indicates 250μm).  
 
 
Figure 4.45: Representative images of y-H2AX immunohistochemical staining in a caecal adenoma (A) 
and a large intestinal adenoma (B) from 2 ethanol-treated Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice. In 
both examples, there are numerous y-H2AX-positive cells within the regions of dysplastic cells in the 
adenomas. Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with 







4.4.2.4.2 DNA damage response evaluation by p53 immunostaining of Msh2-LS murine 
small intestinal and colonic tissues 
The presence of DNA damage induces p53 pathway activation, and this is involved in 
maintaining genomic stability following DNA damage (and other stimuli) via transcriptional 
activation of a variety of response pathways, such as apoptosis, cell cycle arrest and DNA 
repair (Levine, 1997; Williams & Schumacher, 2016).  Upon DNA damage, increased p53 
levels are detected in the cell which can be demonstrated immunohistochemically as a 
greater proportion of cells containing moderate to high (but variable) nuclear staining of p53 
in individual cells (referred as p53 “wildtype pattern”) (Köbel et al., 2016; Lakin & Jackson, 
1999). 
We used colonic tissue samples from WT mice and TMZ-treated Msh2-LS mice as p53-normal 
and p53-positive expression (resulting from TMZ-induced DNA damage) controls respectively 
(Figure 4.46). Whereas wildtype murine colonic epithelium showed membranous and 
cytoplasmic p53 light immunostaining, indicating low-level non-induced expression of p53, 
the TMZ-treated Msh2-LS murine colonic epithelium showed moderately to highly increase 
brown nuclear p53 immunostaining in variable numbers of cells, confirming p53-DNA 
damage response activation.   
IHC analysis of p53 showed large and significant differences in the number of intestinal p53-
positive cells between the EtOH_Msh2fl KO murine colon and the H2O_Msh2fl KO murine colon 
(Figure 4.7). The percentage of cells with either moderate or high levels of p53-positive 
nuclear staining per crypt was significantly higher in EtOH_Msh2fl KO mice (41.3%) compared 
with H2O_Msh2fl KO mice (10.8%) (Figure 4.47C), consistent with ethanol/acetaldehyde 
induced DNA damage. 
The percentage of small intestinal p53-positive cells per crypt was higher in EtOH_Msh2fl KO 
mice (15%) compared with H2O_Msh2fl KO mice (5.2%) (Figure 4.48). EtOH_Msh2fl KO murine 
large intestinal adenomas, both colonic and caecal, showed high percentages of p53-positive 
cells, with variably moderate to high nuclear p53 positivity and some negative nuclei in a 
“p53 wildtype” pattern indicative of widespread response to DNA damage, rather than a 





Figure 4.46: Immunohistochemical analysis of p53 protein expression and localisation in large 
intestinal mucosal normal epithelium from a  normal control WT mouse (A), in which the membranous 
and cytoplasmic p53 light staining indicates normal low-level non-induced p53 expression  (further 
magnified in the red rectangle); and from  a positive-control TMZ-treated Msh2-LS mouse (B), in which 
the increased brown nuclear p53 staining in variable numbers of colonic epithelial cells confirms the 
presence of DNA damage (further magnified in the red rectangle). Images taken from sections scanned 
using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X 




Figure 4.47: Representative images of immunohistochemical analysis of p53 protein expression in large intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/-mice treated with either 20% ethanol in drinking water (A) or normal/standard water (B). The percentage of positive p53-positive nuclei in colonic crypts in 
ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel A) was higher compared with water-treated 
Msh2-LS (H2O_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel B). Numbers of cells with positive p53 nuclear staining per colonic 
crypt were counted using QuPath (C), showing a statistically significant difference. Paired Students t-Test, **p<0.0011 vs. water (data shown as mean±SD, 40 crypts 
per mouse were analysed, n=4 mice in each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP 







Figure 4.48: Representative images of immunohistochemical analysis of p53 protein expression in small intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/-mice treated with either 20% ethanol in drinking water (A) or normal/standard water (B). The percentage of positive p53-nuclear stained cells in small intestinal 
crypts was higher in ethanol-treated Msh2-LS (EtOH_Msh2fl KO) mice compared with water-treated Msh2-LS (H2O_Msh2fl KO) mice. Numbers of cells with positive p53 
nuclear staining per small intestinal crypt were counted using QuPath (C), showing a statistically significant difference. Paired Students t-Test, ***p<0.0008 vs. water 
(data shown as mean±SD, 40 crypts per mouse were analysed, n=4 mice in each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and 




Figure 4.49: Representative images of p53 immunohistochemical staining in a colonic adenoma (A) 
and a caecal adenoma (B), from ethanol-treated 2 Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice. In both 
examples, there are numerous p53-positive nuclei (variably moderate to high p53 nuclear staining 
with some p53-negative nuclei) within the regions of dysplastic cells in the adenomas. Images are 
further magnified in panels C and D. Images taken from sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 40X magnification 












4.4.2.5 Cleaved Caspase-3 immunostaining of Msh2-LS murine small intestinal and 
colonic tissues 
Caspase-3 (Cas3) is a key executive member of the caspase cascade, with cysteine-aspartic 
acid protease activity, that acts as one of the key effectors of cell death by apoptosis. IHC for 
cCas3 was performed to detect the incidence of apoptotic events in tumour and normal 
tissue samples from EtOH_Msh2fl KO mice and H2O_Msh2fl KO mice. Colonic mucosal tissue 
samples from WT mice and TMZ-treated Msh2-LS mice were used as negative and positive 
controls respectively (Figure 4.50). In WT murine colonic mucosal epithelium, almost no 
apoptotic bodies were detected, apart from rare occurrences, indicating rare apoptotic 
events detectable in normal colonic mucosal epithelium. In contrast, the TMZ-treated Msh2-
LS murine colonic mucosal epithelium showed increased easily detectable apoptotic bodies, 
mostly at or around the bases of colonic crypts, confirming that apoptotic events occurred 
in association with TMZ-exposure of the colonic mucosal epithelium. 
IHC analysis of cCas3 with quantification of cCas3-positive apoptotic bodies, showed 
significant differences in the numbers of cCas3-positive apoptotic bodies per 30 colonic 
crypts per mouse between the EtOH_Msh2fl KO murine colonic epithelium and the 
H2O_Msh2fl KO murine colonic epithelium, with significantly higher number of cCas3+ 
apoptotic bodies in EtOH_Msh2fl KO mice compared with no detectable cCas3+ apoptotic 
bodies in H2O_Msh2fl KO mice (Figure 4.51), consistent with increased apoptosis associated 
with colonic epithelial exposure to ethanol/acetaldehyde. EtOH_Msh2fl KO murine large 
intestinal adenomas showed no detectable cCas3+ apoptotic bodies, indicating rare to no 
apoptotic events in dMMR colonic tumours (Figure 4.52). 
IHC analysis of cCas3 of EtOH_Msh2fl KO murine small intestinal epithelium and the 





Figure 4.50: Immunohistochemical analysis of cCas3. In a representative WT negative control mouse 
(A), the lack of brown staining indicates absence of cCas3 positivity, reflecting the absence of apoptotic 
bodies in the colonic crypt epithelium analysed here (further magnified in the upper right inset red 
rectangle). In a representative TMZ-treated Msh2-LS positive control mouse (B), in the large intestinal 
mucosal crypt epithelium (mostly in the lower third of the crypt), there are scattered strongly brown 
staining apoptotic bodies with small round condensed chromatin nuclear particles typical of 
apoptosis, that are strongly positive for cCas3, on a background of pale brown non-specific staining of 
cellular cytoplasm (further magnified in the upper right inset red rectangle). Images taken from 
sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 





Figure 4.51: Representative images of immunohistochemical analysis of cCas3 in large intestinal mucosal epithelium of induced Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice 
treated with either 20% ethanol in drinking water (A), or normal/standard water (B). The number of apoptotic bodies positive for cCas3 in the colonic crypts of ethanol-
treated Msh2-LS (EtOH_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel A) was significantly higher compared with that for 
water-treated Msh2-LS (H2O_Msh2fl KO) mice, in which no apoptotic bodies were detected (further magnified in the upper right inset red rectangle in figure panel B). 
Numbers of cCas3-positive apoptotic bodies per colonic crypt were counted manually (C), showing a statistically significant difference. Paired Students t-Test, 
**p=0.0026 vs. water (data shown as mean±SD, 30 crypts per mouse were analysed, n=3 mice in each group). Images taken from sections scanned using the Hamamatsu 





Figure 4.52: Representative images of immunohistochemical analysis of cCas3 in 2 large intestinal 
adenomas (A and B), from 2 ethanol-treated Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice. In both 
examples, there are almost no apoptotic bodies within the regions of dysplastic cells in the adenomas, 
indicating rare apoptotic events detectable in dMMR colonic adenoma. Images are further magnified 
in panels C and D. Images taken from sections scanned using the Hamamatsu Nanozoomer and 
analysed with the Hamamatsu NDP Viewer software at 10X and 40X magnification (bar at lower left 











4.4.2.6 Immune cells infiltrating caecal adenomas from the Msh2-LS murine model 
The immune system has an important role in tumour incidence, prognosis and response to 
immunotherapy (Gonzalez et al., 2018). In dMMR cells, predictable mutations can and do 
occur in repetitive protein coding sequences and result in frameshift peptides (FSPs) 
(Sæterdal et al., 2001). Such FSPs are novel antigens and elicit both humoral and cellular 
immune responses, which are seen as tumour-infiltrating lymphocytes (TILs) around the 
dMMR crypts in LS patients as well as in dMMR cancers, both sporadic and due to LS 
(Linnebacher et al., 2001; Reuschenbach et al., 2010; Seth et al., 2018). 
To characterize the immune system response to Msh2-LS murine intestinal dMMR tumours, 
these were studied immunohistochemistry for a range of infiltrating immune cells, in 
collaboration with Dr. Seth Coffelt from the Beatson Cancer Institute, Glasgow. A panel of 
antibodies to B-cell markers, T-cell markers and macrophage markers (listed in Materials and 
Methods, Table 2.12) was selected and used to immunohistochemically investigate well-
fixed caecal adenomas from the Msh2-LS model.  
Pilot immunohistochemistry experiments were performed on EtOH_Msh2fl KO caecal 
adenomas. Positive immunostaining was observed for CD4 (murine T-helper cells), B220 
(murine-specific B cells), CD8 (T-cytotoxic cells), F480 (murine macrophages) and Ly6G 
(murine myeloid cells including monocytes, macrophages, granulocytes, neutrophils) in the 
stroma surrounding the dysplastic crypts in EtOH_Msh2fl KO caecal adenomas. By contrast, 
we detected very few cells or no positive cells by immunostaining for any of the above 
immune cell markers in Msh2-LS murine morphologically normal caecal mucosa or 
surrounding stroma (Figure 4.53). These observations are consistent with an active immune 
response to dMMR adenomatous epithelial glands in this model. These pilot experiments 














Figure 4.53: Representative images of immunohistochemical analysis of infiltrating immune cells in 
caecal adenomas and normal caecal mucosa, from ethanol-treated Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- 
mice. The images show DAB-brown staining for CD4, B220, CD8, F4/80 and Ly6G in Msh2-LS caecal 
neoplastic tissue (left column) compared with very few or no positive cells in Msh2-LS caecal normal 
tissue (right column). Images taken from sections scanned using the Hamamatsu Nanozoomer and 
analysed with the Hamamatsu NDP Viewer software at 10X and 40X magnification (bar at lower left 













4.5 Plasma acetaldehyde concentrations from the Msh2-LS mouse 
model with and without ethanol treatment. 
 
4.5.1 Methods 
During the dissection procedure, blood was harvested from the Msh2-LS mice by post-
mortem cardiac puncture. Blood was collected in a heparinized tube and centrifuged at 3000 
X g for 15 min at 4֯C to allow blood fractionation. Acetaldehyde is a highly volatile compound, 
classified as a volatile organic compound (VOC) (Missia et al., 2010; Sarigiannis et al., 2011). 
To preserve the acetaldehyde concentration, plasma was collected in cryo-tubes and 
immediately snap-frozen in liquid nitrogen and stored at −80 ֯C until analysis. Plasma samples 
were analysed in a single batch and plasma acetaldehyde concentrations were determined 
using an enzymatic acetaldehyde assay kit (K-ACHYD; Megazyme), as described in Materials 
and Methods.  
 
4.5.2 Results 
Plasma acetaldehyde levels were analysed comparing samples from EtOH_Msh2fl KO mice and 
H2O_Msh2fl KO mice as well as comparing these with EtOH_Msh2fl mice and H2O_Msh2fl mice 
after long term ethanol treatment (experimental mice were treated with ethanol for 
between 8 and 48 weeks prior to sacrifice). 
Plasma acetaldehyde levels were significantly higher in EtOH_Msh2fl KO mice compared with 
H2O_Msh2fl KO mice (p=0.0019) (Figure 4.54). The difference in plasma acetaldehyde levels 
between EtOH_Msh2fl mice and H2O_Msh2fl mice did not show any statistically significant 
difference. This is probably due to the small number of samples (n=4) used in the plasma 
acetaldehyde assay of non-induced Msh2-LS mice. Plasma acetaldehyde levels in 
EtOH_Msh2fl KO mice were slightly higher compared with EtOH_Msh2fl mice, but this 





Figure 4.54: Plasma acetaldehyde concentrations in ethanol-treated Tamoxifen-induced Msh2-LS 
(EtOH_Msh2fl KO) and water-treated Tamoxifen-induced Msh2-LS (H2O_Msh2fl KO) mice and ethanol-
treated non-induced Msh2-LS (EtOH_Msh2fl) and water-treated non-induced Msh2-LS (H2O_Msh2fl) 
mice, after long-term ethanol or water treatment. Mann-Whitney U-test was carried out to compare 
EtOH_Msh2fl KO and H2O_Msh2fl KO mice (**p=0.0019) (data shown as mean±SD, n=4-6 plasma samples 
















4.6 Detection of Microsatellite instability in Msh2-LS mouse model  
4.6.1 Methods 
Deficiency of MMR leads to hypermutability, resulting in an increase in the mutation rate by 
100- to 1000-fold due to uncorrected base mismatches and to MSI detected as variation in 
the lengths of repetitive sequences (e.g. AAAAAAA… or CACACACA…. or similar, known as 
microsatellites) due to uncorrected insertion/deletion loops that are prone to occur as DNA 
replication errors in repetitive sequences (Poulogiannis et al., 2010). Detection of MSI in 
tumours from the Msh2-LS mouse model was performed.  
We selected from the literature a panel of mononucleotide repeat murine microsatellite 
markers (A27, A33, mBat26, mBat37 and mBat59, primers sequences in Materials and 
Methods, Table 2.6) (Bacher et al., 2005; Kabbarah et al., 2003; Zou et al., 2012). In MMR-
deficient mice, mononucleotide repeats showed high sensitivity for detection of MSI and 
MMR-deficient neoplasms exhibit more frequent instability in mononucleotide repeats than 
dinucleotide repeats (Kabbarah et al., 2003).  
Large intestinal adenomas from Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice and Msh2-/- mice 
were selected along with normal control tissue from wild-type mice. DNA was extracted from 
FFPE samples. PCR-based amplification of the 5 mononucleotide repeat markers was 
performed and PCR products were separated on 15% polyacrylamide native gels by 
electrophoresis and stained with GelRed (as described in Materials and Methods). 
 
4.6.2 Results 
A large intestinal adenoma from a constitutive Msh2-/- mouse (Msh2 constitutive-knockout, 
Msh2 KO) and normal colonic tissue from a WT mouse were used as MSI-positive and MSI-
negative controls respectively, for testing the 5 mononucleotide repeats markers for MSI 
detection (Figure 4.55). The PCR products analysed by gel electrophoresis showed no 
difference in banding patterns for A27 and mBat37 microsatellite markers between the Msh2-
/- adenoma and WT colonic tissue, indicating that MSI was not detectable at all microsatellite 
markers. However, the PCR products analysed showed differences in banding patterns with 
some extra bands or differences in sizes of bands, indicating the presence of microsatellite 
instability, detected for A33, mBat26 and mBat59 microsatellite markers, between the Msh2-
/- adenoma and WT colonic tissue. Subsequently, in order to detect MSI in adenomas from 
the MSh2-LS mouse model, tumour DNA was extracted from FFPE samples of 4 large 
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intestinal adenomas / adenocarcinomas from EtOH_Msh2fl KO mice tested for MSI using the 
same panel of microsatellite markers (Figure 4.56). No MSI was detected at A27 and mBat37 
in any of the large intestinal adenomas from EtOH_Msh2fl KO mice, and only one tumour 
sample showed MSI at mBat59. MSI was detected at A33 and mBat26 in all tumour samples 
from Msh2-LS mice. However, the quality of the DNA extracted from FFPE samples was not 
high enough to guarantee accurate results. Furthermore, Msh2-LS large intestinal tumours 
included a mixed cell population of MMR-proficient surrounding and intermingling reactive 
epithelial cells and stromal cells as well as MMR-deficient adenoma cells, complicating the 




Figure 4.55: Detection of MSI using mononucleotide repeat murine microsatellite markers. A large intestinal adenoma from a constitutive Msh2-/- mouse (Msh2 KO) 
and compared this with normal colonic tissue from a WT mouse. The Msh2 KO adenoma showed MSI at A33, mBat26 and mBat59 confirmed by the differences in 
banding patterns with extra bands, between the Msh2 KO adenoma and the WT colonic tissue. The lack of differences in banding pattern at A27 and mBat37 between 








Figure 4.56: Detection of MSI using mononucleotide repeat murine 
microsatellite markers on colonic adenomas from the Msh2-LS mouse 
model. DNA was extracted from 4 large intestinal adenomas/ 
adenocarcinomas from EtOH_Msh2fl KO mice (labelled T1, T2, T3 and T4, 
respectively) and these were compared with normal colonic tissue from 
a WT mouse for MSI detection. All 4 tumours from EtOH_Msh2fl KO 
mouse showed MSI at A33 and mBat26 markers, whereas only one 
adenoma (T2) showed MSI at mBat59. No MSI was observed at A27 and 





In this chapter, the aim was to test the hypothesis that the DNA MMR system plays a role in 
protecting cells from some types of ethanol/acetaldehyde-induced DNA damage and that 
there is a gene-environment interaction between dMMR pathway and ethanol/acetaldehyde 
exposure that accelerates colorectal tumour development and progression.  
In Müller at al., (2016), we examined intestinal tumorigenesis in WT and Aldh1b1 depleted 
mice after long-term ethanol treatment for one year. Ethanol was shown to initiate intestinal 
tumourigenesis without any additional carcinogen treatment or prior tumour suppressor 
gene inactivation and there was evidence for ethanol/acetaldehyde showing both 
carcinogenic and tumour promoting functions, in the form of increased proliferative activity 
of colonic mucosal epithelium. This was consistent with increased progression of ethanol-
induced adenomas and adenocarcinomas. Moreover, a significant increase in DNA damage 
in the small and large intestinal epithelium of ethanol-treated mice was observed (Müller et 
al., 2016).  
Wojciechowicz et al., (2014), successfully created the Msh2-LS mouse model (without the 
mTmG transgene) and characterized it for the first time. After Tamoxifen injections, Msh2flox/-
; Lgr5CreERT2+/- developed more adenomas and adenocarcinomas than control mice (non-
induced Msh2flox/-; Lgr5CreERT2+/-). Eight out of 20 (40%) Msh2flox/-; Lgr5CreERT2+/- mice 
showed intestinal tumour formation within an average of 19 months. All the tumours were 
located in the small intestine, no tumours were observed in the colon.  
In the current investigation, long-term ethanol in drinking water treatment (compared with 
control water-treatment) was used to study whether ethanol causes acceleration of dMMR 
driven intestinal tumour formation with increased numbers of adenomas and/or 
adenocarcinomas.  
Mice received Tamoxifen treatment by daily i.p. injection for 4 consecutive days, to activate 
Cre-recombinase in a low proportion of Lgr5-expressing intestinal stem cells, as described in 
Chapter 3. Both male and female Msh2-LS mice showed good acceptance of Tamoxifen 
treatment, showing no major alterations in body weights during the treatment duration.  
Msh2-LS male mice showed statistically higher mean body weight compared with Msh2-LS 
female murine mean body weight at the same age (p<0.0001) (as expected due to normal 
sexual dimorphism for body weight observed in rodents). On the fifth day after the last 
Tamoxifen i.p. injection, Msh2-LS mice received 20% ethanol in drinking water or normal 
drinking water. We administrated ethanol in drinking water to mimic human consumption 
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of ethanol intake. In addition, in order to simulate the levels of toxicity and pathological 
effects of high ethanol consumption in humans we used a concentration of 20% ethanol in 
drinking water in mice, previously tested and validated by Müller et al., (2016), because it 
has been shown that ethanol clearance in mice is five times faster than in humans (Dole & 
Gentry, 1984; Holmes et al., 1986). EtOH_Msh2fl KO female and male mice did not show any 
abnormal behaviour or reduction in body weight demonstrating good acceptance of the 
ethanol regime.  
Most of the EtOH_Msh2fl KO mice displayed either anal prolapse or >20% reduction in body 
weight as common clinical sign of distress and were culled for necropsy dissection. Long-
term ethanol treatment of the Msh2-LS mice showed evidence of large intestinal 
hyperproliferation and adenoma formation (with 5 adenocarcinomas) in 65% (15/23 mice) 
of the EtOH_Msh2fl KO mice, for an average of 6 months of ethanol treatment. This is in stark 
contrast to the H2O_Msh2fl KO control mice, none of which developed intestinal tumours over 
the same time period, with only 1 colonic adenoma observed at 15 months (4%, 1/23).  
The EtOH_Msh2fl KO mice showed a pattern of tumour distribution of one or more large 
intestinal tumours mainly in the proximal colon and mid colon. A similar pattern is observed 
in human LS patients, in which colonic tumour formation occurs more in the caecum, 
ascending colon and transverse colon regions (proximal colon), than in the descending colon, 
sigmoid colon and rectum (distal colon), compared with sporadic colorectal tumours that are 
predominantly distal in location. No small intestinal adenomas were seen in the H2O_Msh2fl 
KO or EtOH_Msh2fl KO mice. 
Rijcken et al. (2008), described 50% of colonic adenomas in human LS cases were found in 
the proximal colon, compared with 26% of sporadic adenomas. In addition, proximal LS 
adenomas progressed to high-grade dysplasia more frequently than distal LS adenomas, and 
were also more often highly dysplastic than larger distal adenomas (Rijcken et al., 2008).  
Hence, the Msh2-LS mouse model may be viewed as a good model of human LS in terms of 
the location of both the scattered dMMR crypt foci precursor lesions in the whole of the 
large (and small) intestines, but with colonic only tumour formation (adenomas and 
adenocarcinomas).  
Long-term ethanol-treatment (compared with water-treatment) of the Tamoxifen-induced 
Msh2-LS mice provided evidence of ethanol-induced colonic adenomas that occurred at 
much higher numbers and at an earlier time, consistent with acceleration of dMMR-driven 
large intestinal tumour formation. A range of relevant control animal cohorts were also 
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tested for comparison with tumour formation in this test cohort. Some control animal 
cohorts were subjected to long-term ethanol treatment and some to water-treatment. The 
data on the effects of ethanol on intestinal tumourigenesis were compared for Tamoxifen-
induced Msh2-LS mice, non-induced Msh2-LS mice (no Tamoxifen-treatment, hence no Cre 
activation and no loss of Msh2 protein expression), and WT mice (using data collected during 
previous work by Mike Müller and not repeated here in order to reduce animal numbers 
used for experiments, in line with the 3Rs principle in animal experimentation).  
Non-induced Msh2-LS mice were treated with ethanol as a control group to test whether any 
unknown variables might affect tumour formation in the absence of induction of loss of 
Msh2. Furthermore, this control non-induced cohort would also test whether sporadic 
recombination (in the absence of Tamoxifen) of the Msh2flox/OFF allele occurred to any 
significant extent. 
The EtOH_Msh2fl mice and the ethanol-treated WT mice (Müller et al., 2016) responded well 
to the 20% ethanol in drinking water regime with no abnormal behaviour and no significant 
reduction in body weight. Large intestinal tumour formation was observed in 8.4% (1/12) of 
the EtOH_Msh2fl mice after 28 weeks. In 25% (3/12) EtOH_Msh2fl mice hyperproliferation of 
the colonic crypt epithelium was observed in the mid colon. Large intestinal crypt epithelial 
hyperproliferation had previously been seen and described by our research group after long-
term ethanol-treatment of wild-type mice and Aldh1b1-depleted mice (Müller et al., 2016). 
66.6% (9/12) of the EtOH_Msh2fl control mice did not show any intestinal or other 
abnormality, or formation of intestinal adenomas or adenocarcinomas. In Group-A, 91.6% of 
H2O_Msh2fl control mice showed no intestinal abnormality.  
Long-term ethanol treatment of the cohort of WT mice (Müller et al., 2016) showed large 
intestinal tumour formation (and in one case a small intestinal adenoma formation) in 28.6% 
(4/14 mice) of after 1 year of ethanol-treatment, and 71.4% of the ethanol-treated control 
mice did not show any intestinal abnormality over the same time period. No intestinal 
abnormality was observed in the water-treated WT control mice. Hence, the non-induced 
Msh2-LS mice showed similar levels of colonic tumour formation to the wild-type controls 
with ethanol treatment and this was significantly lower than in the EtOH_Msh2fl mice. 
The tumours and normal tissue samples from Msh2-LS model mice were characterised by 
IHC comparing ethanol-treated and water-treated mice. IHC was used to investigate the 
expression of Msh2 and other MMR proteins in tumours and tissue samples from Tamoxifen-
induced Msh2-LS mice and non-induced Msh2-LS control mice. Tamoxifen treatment 
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induced the loss of Msh2 expression in Lgr5+ expressing crypt epithelial stem cells scattered 
along the entire SI and LI. The Lgr5+ expressing stem cells, located at the bottom of the 
crypts, generate daughter cells that can expand to fill the entire crypt-villus epithelium in SI 
or entire crypt in the colon (Barker et al., 2007; Wojciechowicz et al., 2014). 
EtOH_Msh2fl KO mice showed 43% Msh2-negative small intestinal crypts and 11.2% Msh2-
negative colonic crypts compared with H2O_Msh2fl KO mice that showed 25.8% Msh2-
negative small intestinal crypts and 5% Msh2-negative colonic crypts. The number of Msh2-
negative or dMMR crypts was statistically significantly higher in both SI and colon of 
EtOH_Msh2fl KO mice compared with H2O_Msh2fl KO mice, consistent with ethanol-mediated 
selection for survival of dMMR cells. The number of Msh2-negative crypts was higher in SI 
than in the colon in Msh2-LS mice, however although tumours were observed in the colon, 
no tumours formed in the small intestine. All large intestinal adenomas tested from 
EtOH_Msh2fl KO mice showed Msh2-negative dysplastic glands, often surrounded by or 
admixed with Msh2-positive crypts showing reactive or hyperproliferative changes. This 
confirmed colonic adenomas arose from dMMR (Msh2-negative) crypts. This is consistent 
with observations from human LS patients that the risk of colonic tumour formation 
correlates with the size of the MMR-deficient crypt clusters that grow over time in affected 
patients, in line with what was observed by Wojciechowicz et al, (2014) (Kloor et al., 2012; 
Shia et al., 2015). 
No Msh2-negative crypts were observed in either small or large intestinal mucosal 
epithelium of non-induced Msh2-LS mice, consistent with lack of induction of Cre activity 
resulting in continued expression of protein from the floxed Msh2 allele. In the MMR repair 
pathway, a base mismatch or single nucleotide InDel error is recognised by the MutSα 
complex, which is composed of Msh2 and Msh6 heterodimeric proteins. The MutLα complex, 
composed of Mlh1 and Pms2, is recruited by the binding of MutSα to the mismatched or 
InDel DNA lesion. The loss of either Msh2 or Mlh1 lead to the abrogation of all MMR activity 
(Poulogiannis et al., 2010). In the absence of Msh2, the heterodimeric MutSα complex 
cannot be formed and Msh6 is rapidly degraded. This was confirmed by the presence of 
Msh6-negative crypts (by IHC) scattered along both SI and colon of Tamoxifen-induced 
Msh2-LS mice in a very similar frequency and pattern as Msh2-negative crypts. IHC was used 
to explore whether the absence of Msh2 protein inhibits or modifies the expression of Mlh1 
or Pms2. The IHC analysis of Mlh1 showed normal/positive expression of Mlh1 at the base 
of both colonic and small intestinal crypts of induced Msh2-LS mice, confirming the Msh2 
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absence does not inhibit Mlh1. However, the immunostaining for Pms2 proved to be 
technically problematic due to antibody failure and it was not possible to determine the 
staining pattern for Pms2.  
IHC was performed to investigate Ki-67 expression in intestinal tissue samples from 
Tamoxifen-induced Msh2-LS mice to determine proliferative activity. The percentage of Ki-
67-positive cells per crypt was significantly higher in colon in EtOH_Msh2fl KO mice compared 
with H2O_Msh2fl KO mice, confirming the presence of large regions of mucosal crypt epithelial 
hyperproliferation observed in histological sections EtOH_Msh2fl KO murine colons. The 
percentage of Ki-67-positive cells per crypt in SI of EtOH_Msh2fl KO mice was slightly higher 
than in the SI of H2O_Msh2fl KO mice. These observations confirm the previously reported 
association of long-term ethanol treatment of mice and colonic mucosal epithelial 
hyperproliferation (Müller et al., 2016). 
We investigated the expression of β-catenin protein, an intracellular signal transducer in the 
Wnt signalling pathway (Cong et al., 2003a), on tumours and tissue samples from Tamoxifen-
induced Msh2-LS mice. In the absence of the Wnt signalling, β-catenin is located mostly at 
the inner cell membrane bound to E-Cadherin at adherens junctions, or at very low levels in 
the cytoplasm, where its level is kept low through constant degradation by the β-catenin-
degradation complex that includes Apc and Axin2 proteins. In the presence of Wnt signalling, 
the β-catenin-degradation complex is disrupted and β-catenin accumulates in the cytoplasm 
and translocates into the nucleus, where it binds with transcriptional co-factors and induces 
transcription of Wnt-responsive genes (Chen et al., 2013). Normal colorectal mucosal crypt 
epithelium exhibited moderate membranous and weak cytoplasmic staining for β-catenin, 
but absent nuclear localisation. In contrast, both colorectal adenomas and adenocarcinomas 
from induced Msh2-LS mice showed variably moderately to strongly positive nuclear β-
catenin localisation and thus the immunostaining pattern of β-catenin is consistent with Wnt 
pathway activation, which is why nuclear β-catenin is regarded as a useful CRC biomarker 
(Lugli et al., 2007). In colonic tumours in the EtOH_Msh2fl KO mice, the IHC analysis of β-
catenin showed a heterogeneous pattern with variable numbers of adenoma cells showing 
moderately to strongly positive β-catenin nuclear immunostaining due to accumulation and 
translocation of β-catenin in to the nuclei. This pattern has been observed in human MMR-
deficient CRC (Lugli et al., 2007). 
Ethanol is rapidly absorbed from the gastrointestinal tract (Brooks & Zakhari, 2014). Ethanol 
is metabolized to highly reactive acetaldehyde by ADHs and this is further oxidized to acetate 
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by ALDHs. Aldehydes are very reactive molecules and they can cause a range of DNA 
modifications: DNA adducts, single and double strand breaks, point mutations, increased 
sister chromatid exchanges, DNA-protein crosslinks or DNA ICLs (Seitz & Stickel, 2007). 
Langevin et al (2011) demonstrated that the Fanconi Anaemia (FA) DNA repair pathway has 
a crucial role in counteracting acetaldehyde-induced genotoxicity in mice, as the FA DNA 
repair pathway is essential for the repair of DNA ICLs (Kim & D’Andrea, 2012; Langevin et al., 
2011). Recently, our research group has proposed the hypothesis that the DNA MMR repair 
system plays a role in protecting the cell from some types of ethanol/acetaldehyde induced 
DNA damage. The MMR pathway is involved in the removal of base mismatches and 
insertion/deletion loops caused by oxidative stress, lipid peroxidation, base deamination, 
methylation, certain alkylation changes and replication associated errors. Loss of MMR 
pathway function results in dMMR with hypermutability (increased mutation rate by 100x – 
1000x due to uncorrected mismatches) and MSI (the variation in length of repetitive 
microsatellite sequences due to uncorrected insertion/deletion loops), but more importantly 
dMMR results in reduced susceptibility to either cell cycle arrest or apoptosis induced by 
those types of DNA damage recognised by the MMR pathway (Poulogiannis et al., 2010; Seth 
et al., 2018; Toft et al., 1999). 
MMR is involved in a signalling cascade that leads to cell cycle arrest and/or apoptosis, if 
severe DNA damage has previously occurred. It has been observed that MMR-deficient cells 
fail to recruit ATM and ATR proteins, preventing p53 phosphorylation in response to DNA 
damage. MMR-deficient cells show predisposition to malignancy by failing to repair DNA 
damage (of MMR-recognised type) and failing to engage apoptosis to remove DNA-damaged 
cells (Cerretelli et al., 2020; Toft et al., 1999).  
IHC analysis of y-H2AX and p53 was performed to investigate the DNA damage response in 
tumour and normal tissue samples from EtOH_Msh2fl KO and H2O_Msh2fl KO mice. Upon DNA 
damage, an early response is the phosphorylation of the C-terminal part of the core histone 
protein H2AX (termed gamma-H2AX when phosphorylated) by a complex including ATM, 
ATR and DNA protein kinase catalytic subunit (DNA-PKcs) (Siddiqui, 2015). Y-H2AX is a key 
co-ordinator of signalling and activating DNA damage repair pathways and for this it is 
considered a specific molecular marker for monitoring DNA damage (Mah et al., 2010). At 
the completion of DNA repair, y-H2AX is typically de-activated (Cook et al., 2009). The 
immunohistochemical analysis of y-H2AX showed a higher percentage of y-H2AX positive 
cells in EtOH_Msh2fl KO murine colonic mucosal epithelium (35%) compared with H2O_Msh2fl 
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KO murine colonic epithelium (0.4%). EtOH_Msh2fl KO murine large intestinal adenomas (both 
colonic and caecal) showed high y-H2AX expression. By contrast, very few or no y-H2AX 
positive cells were observed in H2O_Msh2fl KO murine small intestinal mucosa. The high 
expression of y-H2AX in EtOH_Msh2fl KO murine colonic mucosal epithelium is consistent with 
DNA damage induced by ethanol/acetaldehyde suggesting that ethanol exposure has a 
significant mutagenic effect mainly on dMMR colonic mucosal epithelium rather than on 
dMMR small intestinal mucosa. This suggests that Msh2 has a key role in protecting the 
MMR-proficient colonic epithelial cells against this type of DNA damage, but Msh2 may not 
be the sole protective mechanism for small intestinal epithelium cells from 
ethanol/acetaldehyde-induced DNA damage.  
The presence of DNA damage induces p53 pathway activation, and this is involved in 
maintaining genomic stability following DNA damage (and other stimuli) via transcriptional 
activation of a variety of response pathways, such as apoptosis, cell cycle arrest and DNA 
repair (Levine, 1997; Williams & Schumacher, 2016).  Under normal conditions, p53 protein 
levels are kept low by its rapid degradation (maintaining a 20-30 minute short half-life for 
p53 polypeptide) and p53 is in a largely inactive state. DNA damage-mediated activation of 
the p53 pathway involves decreased Mdm2-mediated degradation of the p53 protein and 
thus stabilisation of p53 with increased p53 levels in the cell, which can be demonstrated 
immunohistochemically as a greater proportion of cells containing moderate to high (but 
variable) nuclear staining of p53 in individual cells (“wildtype pattern”, distinguishable from 
mutated p53-associated “overexpression” or “complete absence” patterns seen in some 
neoplasms) (Köbel et al., 2016; Lakin & Jackson, 1999).  
In the IHC analysis of p53, a higher percentage of p53 positive cells with high to moderate 
nuclear staining were observed in EtOH_Msh2fl KO murine colon (41.3%) compared with 
H2O_Msh2fl KO murine colon (10.8%). The percentage of p53-positive cells in small intestinal 
mucosal epithelium was higher in EtOH_Msh2fl KO mice (15%) compared with H2O_Msh2fl KO 
mice (5.2%). In EtOH_Msh2fl KO murine large intestinal adenomas (colonic and caecal) showed 
widespread variably high p53 expression. The variable pattern of p53 nuclear staining 
reflected the “wild-type pattern” in response to ethanol/acetaldehyde-induced genotoxic 
damage and there were no tumours showing either the “overexpression” or “null” patterns 
associated with Tp53 mutation.  
IHC analysis of cCas3 was performed to detect the incidence of apoptotic events in tumour 
and normal tissue samples from in EtOH_Msh2fl KO and H2O_Msh2fl KO mice. Caspase-3 (Cas3) 
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is a key executive member of the caspase cascade, with cysteine-aspartic acid protease 
activity, that acts as one of the key effectors of cell death by apoptosis. It requires proteolytic 
cleavage into 2 subunits that dimerize to create the active form, cCas3 (Talmon et al., 2010, 
Holubec et al., 2005). Once activated, cCas3 is responsible for the cleavage of key target 
proteins essential in cell proliferation and survival, inducing DNA fragmentation, cell 
shrinkage, chromatin and cytoplasmic condensation and formation of apoptotic cells and 
bodies. Apoptotic bodies express ligands for phagocytic cell receptors for recognition by 
phagocytic cells or neighbouring cells (Elmore, 2007).  
Immunohistochemical analysis of cCas3 showed significantly higher number of cCas3+ 
apoptotic bodies in in EtOH_Msh2fl KO mice compared with no detectable cCas3+ apoptotic 
bodies in H2O_Msh2fl KO mice, consistent with increased apoptosis associated with colonic 
epithelial exposure to ethanol/acetaldehyde. EtOH_Msh2fl KO murine large intestinal 
adenomas showed no detectable cCas3+ apoptotic bodies, indicating rare to no apoptotic 
events in dMMR colonic tumours. IHC analysis of cCas3 of EtOH_Msh2fl KO murine small 
intestinal epithelium and the H2O_Msh2fl KO murine small intestinal epithelium failed on 
technical grounds.  
The increased DNA damage observed in EtOH_Msh2fl KO murine large intestinal mucosal 
epithelium is consistent with the high levels of circulating acetaldehyde detected by plasma 
acetaldehyde assay. We found statistically higher plasma acetaldehyde levels in EtOH_Msh2fl 
KO mice compared with H2O_Msh2fl KO mice (p=0.0019).  
Finally, we performed MSI detection using a panel of 5 mononucleotide murine 
microsatellite markers, validated by other studies (Bacher et al., 2005; Kabbarah et al., 2003; 
Zuo et al., 2012). We detected some variations in the banding patterns for three of the 
markers, indicating the presence of MSI in 4 colonic adenomas from EtOH_Msh2fl KO mice, 
although the MSI assay was suboptimal. However, the quality of the DNA extracted from 
FFPE samples was variable and often insufficiently high enough to guarantee reproducible 
results. Furthermore, Msh2-LS large intestinal tumours include a mixed cell population of 
variable ratios of surrounding and intermingling MMR-proficient reactive epithelial cells and 
stromal cells as well as MMR-deficient adenoma cells, complicating the interpretation of the 
MSI detection results and thus this experimental approach was discontinued.  
In conclusion, we further characterised the Msh2-LS mouse model, demonstrating that it 
closely mimics the situation in human LS patients for both precursor dMMR crypt foci and 
tumour development in terms of colonic adenoma and (in a few cases) progression to 
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adenocarcinoma formation. Ethanol-treatment was shown to cause DNA damage and induce 
colonic crypt epithelial hyperproliferation in this Msh2-LS model, confirming similar 
observations made by others and our own research group (Brooks & Zakhari, 2014; Müller 
et al., 2016). We provided evidence that ethanol-treatment can induce regions of 
hyperproliferation of the large intestinal mucosal epithelium (but not the small intestinal 
mucosal epithelium) and this appears to contribute to intestinal adenoma formation by 
acting as a tumour promoter, which occurs mostly in the parts of the colon (proximal and 
mid colon) affected by hyperproliferation in this Msh2-LS mouse model (Msh2flox/-; 
Lgr5CreERT2+/-) following ethanol-treatment, but not water-treatment. EtOH_Msh2fl KO mice 
showed accelerated formation of large intestinal tumours within ~6 months of starting 
ethanol exposure, compared with the control cohorts of H2O_Msh2fl KO mice, EtOH_Msh2fl 
mice and ethanol-treated WT mice, with these control cohorts developing significantly fewer 
large intestinal tumours after 12 months of the ethanol-treatment or water-treatment 
regimes.  
The data shown here are consistent with the hypothesis that in normal pMMR intestinal 
epithelial stem cells, ethanol/acetaldehyde-induced DNA damage results in activation of the 
DNA mismatch repair pathway, inducing either cell cycle arrest in the case of mild DNA 
damage to allow DNA repair, or cell death by apoptosis in the case of more severe DNA 
damage. In this way, tissue homeostasis is maintained. We propose that in dMMR cells, 
modelled in this Msh2-LS mouse model, ethanol/acetaldehyde caused DNA damage that was 
not recognised or repaired by the dMMR intestinal epithelial stem cells (and their daughter 
cells) as they are unable to activate the MMR signalling pathway. Hence, dMMR cells showed 
inappropriate survival of these ethanol-damaged cells, compared with proficient MMR cells. 
These aberrantly surviving DNA-damaged dMMR colonic epithelial cells were stimulated to 
hyperproliferate by ethanol, leading to an increased probability of acquisition and fixation of 
DNA mutations explaining the accelerated colonic adenoma formation.  Hence, there is 
evidence for a selective advantage of the dMMR/ethanol/acetaldehyde interaction, as a 
gene/environment interaction, that explains the acceleration of colonic adenoma 
development and further progression to adenocarcinoma (in some cases) in ethanol-treated 
Msh2-LS (EtOH_Msh2fl OK) mice (Figure 4.57). This process is observed mostly in the proximal 
colon and mid colon, but not in the small intestine, very similar to the anatomical tumour 






Figure 4.57: Schematic diagram of the proposed model of the MMR/ethanol/acetaldehyde 
gene/environment interactions in both MMR-proficient (pMMR) and MMR-deficient (dMMR) 
intestinal epithelial cells. Upon ethanol/acetaldehyde exposure, in some intestinal epithelial stem cells 
there is some DNA base damage that normally would be recognised and repaired by the MMR system, 
or if unrepaired this base damage may induce replication errors, such as base mismatches or InDels, 
during S-phase of the cell cycle. Here, the pMMR cell (red cell membrane) is able to activate DNA 
mismatch repair of the (MMR-recognised) base damage bringing about either cell cycle arrest in the 
case of mild DNA damage to allow DNA repair, or cell death by apoptosis in the case of more severe 
DNA damage. By contrast, the dMMR cell (green cell membrane) is unable to activate the MMR 
signalling pathway and so there is neither cell cycle arrest nor apoptosis, resulting in aberrant survival 
of DNA-damaged cells and their subsequent proliferation. These proliferating dMMR stem cells 
populate the crypt and expand further (by crypt fission) to form dMMR crypt foci. Stimulated by 
ethanol to undergo increased proliferation, these cells form hyperproliferative crypts whilst remaining 
subject to ongoing DNA damage from continued exposure to ethanol/acetaldehyde. Thus, these 
dMMR cells can accumulate mutations reflecting a form of dMMR genomic instability, and are 
consequently at increased risk of tumour formation, thus explaining the acceleration of colonic 








Chapter 5: Effects of Temozolomide Treatment on the Msh2-
LS Mouse Model  
5.1 Introduction 
The carcinogenic and tumour promoting/hyperproliferative effects of ethanol on the murine 
colon were previously studied by comparing Aldh1b1-depleted mice and WT mice treated 
with 20% ethanol in drinking water (Müller et al., 2016). 27% of ethanol-treated Aldh1b1-
depleted mice showed large intestinal adenomas (with a few adenocarcinomas) after 1 year 
of treatment, compared with 29% of ethanol-treated WT mice that showed large intestinal 
adenomas after 1 year. Ethanol was shown to initiate intestinal tumorigenesis without any 
additional chemical carcinogen treatment or prior tumour suppressor gene inactivation or 
oncogene activation, and there was evidence for both carcinogenic and tumour promoting 
functions of ethanol and its main metabolite acetaldehyde, including increased progression 
of ethanol-induced adenomas to early adenocarcinomas in some cases (Müller et al., 2016).  
In LS patients, dMMR tumours arise from somatic cells that acquire inactivation of the MMR 
gene’s wild-type allele (on the background of inheritance of a mutation in that MMR gene’s 
other allele). It has been observed that the number and size of dMMR crypt foci that 
accumulate in LS patients’ colons over time influences their risk of tumour development 
(Kloor et al., 2012).  
A Msh2-LS mouse model (Msh2flox/-; Lgr5CreERT2+/-) was generated, in which it was observed 
that loss of Msh2 expression occurs in approximately 10% of intestinal crypts after Tamoxifen 
treatment to induce inactivation of the second conditional knockout Msh2 allele in scattered 
intestinal stem cells, leading to intestinal tumour formation in 40% of the mice after 1.5 years 
(Wojciechowicz et al., 2014). To increase the number of dMMR crypts and accelerate the 
tumourigenesis process, a methylating chemotherapy agent, Temozolomide, was used 
because MMR-deficient cells are known to be resistant to killing by methylating agents 
(Karran, 2001). Temozolomide (TMZ) treatments were applied to Msh2-LS mice after 
Tamoxifen treatment, resulting in gastrointestinal intraepithelial neoplasms developing 3 
weeks or more after the last TMZ administration. Intestinal adenomas and/or 
adenocarcinomas were observed between 13 and 19 weeks after TMZ administration. In the 
TMZ-treated tumour-bearing mice, loss of Msh2 expression was observed in approximately 
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32% of intestinal crypts compared with 10% in non-TMZ-treated control mice 
(Wojciechowicz et al., 2014). Data provided were interpreted as showing evidence that TMZ 
confers upon dMMR cells a proliferative advantage over WT cells, resulting in an expansion 
of the pool of dMMR cells, with TMZ inducing increases in both dMMR crypt foci and DNA 
mutation load causing the acceleration of tumourigenesis. 
TMZ is converted (by non-enzymatic chemical conversion) to the active metabolite 5-(3-
methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) which can cause several base 
methylation events, such as at the O6 position of guanine (O6-MeG) (Zhang et al., 2012). In 
normal cells, O6-MeG is directly repaired by the enzyme MGMT that removes the methyl 
adduct. When MGMT fails, the O6-MeG lesions are replicated during DNA synthesis 
generating an aberrant base pair. This stimulates activation of the DNA MMR pathway and 
is processed into a double-stranded DNA break, eventually resulting in apoptosis. MMR-
deficient cells do not detect such alkylation adducts and hence are resistant to TMZ (Thomas 
et al., 2017).   
In this chapter, the aim was to accelerate the process of intestinal tumourigenesis in the 
Msh2-LS mice used in this research work, by combining the effects of TMZ, as described by 
Wojciechowicz et al. (2014), with the effects of long-term 20% ethanol in drinking water, as 
described by Mueller et al., (2016). A new protocol was designed to apply to the Msh2-LS 
mouse model in order to try to accelerate intestinal tumour formation to around 2-4 months, 
in contrast to the 1 year of ethanol treatment required for intestinal adenoma formation in 
WT and Aldh1b1-depeleted mice (Müller et al., 2016) and the 1.5 years for intestinal 
adenoma development in induced conditional Msh2 knockout Msh2-LS model mice without 








5.2 Potential Acceleration of the Msh2-LS Mouse Model Using 
Temozolomide treatment 
5.2.1 Methods 
 Experiments were designed firstly to establish the most appropriate TMZ dose and 
treatment regime, and secondly, to observe the effects of TMZ on tumour development in 
the Msh2-LS mice.   
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- 7-9 weeks old mice were divided into 6 Groups A-F (Figure 
5.1). During the first week of treatment, Group-A mice received an i.p injection of 0.15mg 
Tamoxifen/g bw on day 1 and 0.1mg Tamoxifen/g bw on day 2, from the second week to the 
fourth week these mice were treated with 10 daily doses of 0.1mg TMZ/g bw by oral gavage 
(o.g.), followed by the 20% ethanol in drinking water regime from the 5th week onwards. 
Group-B mice received 2 i.p injections of tamoxifen in the first week (the same as for Group-
A mice), from the second week to the third week these mice were given 5 daily doses of 
0.1mg TMZ/g bw by o.g., followed by the 20% ethanol in drinking water regime from the 3rd 
week onwards (Figure 5.1). The Group-A and -B mice were sacrificed after 4 weeks of the 
ethanol regime to investigate the presence of any intestinal abnormalities or early signs of 
intestinal tumour formation.  
To observe the combined effects of TMZ and long-term ethanol treatment (compared with 
water-treated controls) on the Msh2-LS mice, a further 4 groups were included in the study. 
Group-C to Group-F mice followed the same Tamoxifen treatment protocol as Group-A and 
-B, receiving an i.p injection of 0.15mg Tamoxifen/g bw on day 1 and 0.1mg Tamoxifen/g bw 
on day 2. Group-C and -E mice were treated with 10 daily doses of 0.1mg TMZ/g bw by o.g. 
over 3 weeks (from the second week to the fourth week), followed by either 20% ethanol in 
drinking water regime for Group-C mice or normal / standard drinking water for Group-E 
mice until signs of tumour formation were observed. Group-D and -F mice were given 5 daily 
doses of TMZ by o.g. over 2 weeks from the second week to the third week, followed by 
either 20% ethanol in drinking water regime for Group-D mice or normal / standard drinking 
water for Group-F mice, until signs of tumour formation were observed (Figure 5.1).  
Animals in Group-C to -F were culled and tissues collected when either clinical signs of 
distress were visible or they displayed >20% body weight loss compared with the initial body 
weight. The small and large intestines, caecum, stomach, liver, spleen, thymus, lymph nodes 
(if visible) and any other organ or tissue showing abnormalities, were collected following 
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schedule 1 culling and necropsy dissection (as described in Materials and Methods). Tissues 
were fixed in 10% NBF, processed using standard tissue processing protocols and paraffin 
embedded in preparation for section cutting and staining. The acronyms used for Msh2-LS 

















Figure 5.1: Experimental treatment protocols and timelines for Group-A to -F using Msh2-LS mice. 
Animals in all groups received i.p Tamoxifen injections over two days (0.15mg Tamoxifen/g bw on day 
1 and 0.1mg Tamoxifen/g bw on day 2). Animals in Group-A (10 TMZ doses over 3 weeks, 0.1mg TMZ/g 
bw by o.g) and Group-B (5 TMZ doses over 2 weeks, 0.1mg TMZ/g bw by o.g) were culled after 4 weeks 
of 20% ethanol in drinking water regime. Animals in Group-C and -D followed the same Tamoxifen and 
TMZ treatment protocol as Group-A and -B respectively, but they were kept alive until sign until signs 
of tumour formation were observed. Group-E and -F mice received the same Tamoxifen and TMZ 
treatment protocol as Group-C and -D respectively, but were water-treated controls for Group-C and 




5.2.2.1 Experimental Group Organization and Comparisons of Body Weight 
Changes. 
The first experiment was designed to determine the most appropriate TMZ dose and 
treatment regime, starting with the protocols set out by Wojciechowicz et al (2014). Six 
experimental subjects (3 females and 3 males) were divided into two groups: Group-A (3 
mice: 2 females and 1 male, receiving 10 TMZ doses over 3 weeks) and Group-B (3 mice: 1 
female and 2 males, receiving 5 TMZ doses over 2 weeks). Animals from Group-A and -B were 
culled 4 weeks after the last TMZ administration. The second experiment was designed to 
include 4 groups to study the combined effects of TMZ and ethanol treatment on the Msh2-
LS mice. Animals were divided into ethanol-treated groups, Group-C (7 mice: 3 females and 
4 males, receiving 10 TMZ doses over 3 weeks), and Group-D (7 mice: 2 females and 5 males, 
receiving 5 TMZ doses over 2 weeks); and water-treated groups, Group-E (4 mice: 3 females 
and 1 male, receiving 10 TMZ doses over 3 weeks) and Group-F (7 mice: 3 females and 4 
males, receiving 5 TMZ doses over 2 weeks).  
During the first week, Msh2-LS mice (Group-A to -F) started the Tamoxifen treatment (daily 
Tamoxifen i.p injections for 2 consecutive days), and body weight and health status were 
recorded. Body weights of the female and male mice didn’t significantly differ during the 
Tamoxifen treatment (Figure 5.2), showing successful drug administration and acceptance of 
the experimental procedures by the mice. Body weights of Msh2-LS males (~28g) were 
significantly higher than body weights of Msh2-LS females (~21g) both before and during the 
Tamoxifen treatments (Figure 5.2), in line with data shown in Chapter 4 (4.2.2.1).  
In the second week, mice started the TMZ treatment with either 5 daily doses of 0.1mg 
TMZ/g bw by o.g. over 2 weeks or 10 daily doses of 0.1mg TMZ/g bw by o.g. over 3 weeks. 
Body weights and health status of the mice were recorded (Figure 5.3). Body weights of the 
female and male mice receiving both treatments (5 or 10 TMZ doses) didn’t significantly 
differ during the TMZ treatment (Figure 5.3). However, 4 mice died (1 female from Group-C, 
one male from Group-D, 1 female from Group-E and 1 female from Group-F ) due to 
gastrointestinal paralysis after the administration of TMZ via oral gavage and these mice 
were excluded from the study. Body weights of Msh2-LS males were significantly higher than 




After TMZ treatment, animals received either 20% ethanol in drinking water or normal / 
standard drinking water regimes, with continued monitoring of body weights and health 
status twice a week (Figure 5.4). Ethanol-treated Msh2-LS female mice did not show 
abnormal behaviour or reduced body weight compared with the water-treated female mice, 
indicating good acceptance of the ethanol regime. Ethanol-treated Msh2-LS female mice 
weighed on average 23.14g compared with 23.28g of the water-treated Msh2-LS female 
mice (Figure 5.4B).  
By contrast, ethanol-treated and water-treated Msh2-LS male mice, showed statistically 
significant differences between the two groups. Ethanol-treated Msh2-LS male murine body 
weights changed from ~30g to ~25g over 13 weeks of the ethanol treatment regime, whereas 
water-treated Msh2-LS male mice showed a general increase in body weight (to ~34g) over 
the same time with some fluctuation between weeks 15 and 21 of the water treatment 
regime (Figure 5.4A).  
Drinking bottles were changed and bottle weights were recorded once a week to allow 
measurement of liquid consumption. Liquid consumption per mouse was estimated by 
analysing the weights of the drinking bottles (per cage) and calculating the average weight 
of consumed liquid per mouse per day (Figure 5.5). Water-treated and ethanol-treated 
Msh2-LS male mice consumed around the same amount of liquid per day, 13.5 and 13.8 ml 
respectively. On average water-treated Msh2-LS female mice consumed around 8.9ml of 
water per day, whereas on average ethanol-treated Msh2-LS female mice consumed around 
11.2ml of 20% ethanol in drinking water per day. No significant differences were observed 









Figure5.2: Murine body weights during Tamoxifen treatment. Body weights of Msh2-LS males (circles) 
were significantly higher than body weights of Msh2-LS females (squares), before and during 
Tamoxifen treatments, although both showed no significant change over the two days of Tamoxifen 
treatment. 2-way-ANOVA test with Bonferroni post-test correction showed statistically significant 
differences between the two sex cohorts, p<0.0001 on day 1 and day 2 (data shown as mean ± SD, 















Figure 5.3: Murine body weights during Temozolomide (TMZ) treatment. Body weights of Msh2-LS 
males (circles) and females (squares) that received either 5 TMZ doses (A) or 10 TMZ doses (B). Body 
weights of Msh2-LS males were significantly higher than body weights of Msh2-LS females, although 
all 4 groups of mice showed no significant change over the period of TMZ treatment. 2-way-ANOVA 
test with Bonferroni post-test correction showed statistically significant differences between these 
two sex cohorts, p<0.0001 on days 1 -5 in graph A and on day 1 in graph B, p=0.0004 on days 2-9 in 








Figure 5.4: Murine body weights for males and females during 20% ethanol or standard/normal 
drinking water regimes. A statistically significant difference was observed between the ethanol-
treated Msh2-LS males (red circles) body weights curve and the water-treated Msh2-LS males (blue 
squares) body weights curve, p<0.0001. There were no significant differences between the body 
weights curves of ethanol-treated Msh2-LS females versus water-treated Msh2-LS females. 2-way-







Figure 5.5: Liquid consumption of either 20% ethanol containing drinking water (black bars) or 
standard/normal water (white bars) per mouse per day for Msh2-LS males and females. No significant 
differences were observed for any of the comparisons of ethanol versus water treatment or males 


















5.2.2.2 Tumour Development in the Msh2-LS Mouse Model after Temozolomide 
and Ethanol Treatment 
The ethanol-treated Msh2-LS mice in Group-A (10 TMZ doses over 3 weeks) and in Group-B 
(5 TMZ doses over 2 weeks), were culled after 4-5 weeks of 20% ethanol in drinking water 
regime to investigate the presence of any intestinal abnormalities or early signs of intestinal 
tumour formation. In both Group-A and Group-B mice, no gastrointestinal abnormalities or 
tumours were observed after 4 weeks from the last TMZ administration.  
The other 4 cohorts (C-F) of Msh2-LS mice were monitored every day for signs of intestinal 
tumour development or other pathological abnormalities, using the clinical scoring system 
described in Chapter 4 (Table 4.1). Most of the mice in Group-C to -F displayed irregular 
breathing or >20% reduction in body weight as common clinical signs of distress, at varying 
lengths of time from the start of the experimental protocol and these mice were then culled 
for necropsy dissection.  
During necropsy dissection, the majority of the Msh2-LS mice treated with either 5 TMZ 
doses or 10 TMZ doses, and either water or ethanol, showed an expansion of the thymus 
covering the heart and lungs in the thorax (Figure 5.6). Histopathological analyses revealed 
the presence of thymic lymphomas in these cases, with many showing evidence of 
lymphoma infiltrating into other tissues (mostly liver, spleen and in few cases into the small 
intestinal mucosa and submucosa). The H&E analyses revealed some cases of small and large 
intestinal adenoma formation (Figure 5.7).  
Group-C (10 TMZ doses, ethanol-treated cohort; 10TMZ_EtOH_Msh2fl KO) mice were 
sacrificed after 8-10 weeks of starting the 20% ethanol regime. Four out of 6 
10TMZ_EtOH_Msh2fl KO mice showed primary thymic lymphoma, with lymphoma infiltration 
in liver and spleen, 2 out of 6 showed monocryptal adenomas in the small intestine and in 
one case a caecal adenoma (Figure 5.7). In the corresponding water-treated control group 
(Group-E: 10 TMZ doses, water-treated cohort; 10TMZ_H2O_Msh2fl KO), 2 mice were culled 8 
weeks after the last TMZ dose, in one of which a thymic lymphoma was observed together 
with a few small adenomas in the small intestine, and the other case showed lymphoma 
formation with infiltration into the lamina propria of the mucosa and into the submucosa of 
the small intestine. The remaining mice were sacrificed after 17 weeks from the last TMZ 
dose because of discomfort due to axillary squamous carcinoma. In both 
10TMZ_EtOH_Msh2fl KO mice and 10TMZ_H2O_Msh2fl KO mice, the incidence of lymphomas 
(in the thymus with some showing infiltration into the small intestine) was 66% and the 
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incidence of intestinal tumour formation was 30% (Figure 5.8). In total, there were 3 
intestinal neoplasms and 4 thymic lymphomas in 10TMZ_EtOH_Msh2fl KO mice compared 
with 4 intestinal neoplasms and 1 thymic lymphoma in 10TMZ_H2O_Msh2fl KO mice (Figure 
5.9). 
In Group-D (5 TMZ doses, ethanol-treated cohort; 5TMZ_EtOH_Msh2fl KO), Msh2-LS mice 
were culled between 8 and 12 weeks of the start of the 20% ethanol in drinking water regime. 
Four out of 6 5TMZ_EtOH_Msh2fl KO mice showed primary thymic lymphoma with infiltration 
of lymphoma into liver and spleen, one showed a colonic adenoma, and one showed an 
adenoma in the duodenum and an adenoma in the caecum. In the remaining 2 animals, 
extended colonic mucosal hyperproliferative areas and small adenomas were observed in 
the proximal colon and mid colon. In the corresponding water-treated control group (Group-
F, 5 TMZ doses, water-treated cohort; 5TMZ_H2O_Msh2fl KO), 4 out of 6 mice were culled 
between 10 and 14 weeks after the last TMZ administration because of discomfort or distress 
due to thymic lymphoma with lymphoma infiltration into liver and spleen. In addition, 1 of 
the mice showed a small intestinal adenoma and another one of the mice developed small 
adenomas in the proximal colon and mid colon (with no evidence of colonic mucosal 
hyperproliferation). The remaining 2 5TMZ_H2O_Msh2fl KO mice showed small adenomas in 
the small intestine, colon and caecum after 18 and 15 weeks following the last TMZ dose, 
respectively. In both 5TMZ_EtOH_Msh2fl KO and 5TMZ_H2O_Msh2fl KO mice, the incidence of 
thymic lymphomas was 66%, and the incidence of intestinal tumour formation was 66% 
(Figure 5.10). In total, 4 thymic lymphomas and 10 intestinal neoplasms were observed in 








Figure 5.6: Representative necropsy images of normal thymus (A, highlighted in the yellow circle) from 
a wildtype mouse and thymus expanded by lymphoma (B, highlighted in the yellow circle) from a TMZ- 




Figure 5.7: Representative images of histopathological sections of tumours observed in TMZ- and ethanol-treated Msh2-LS mice. In the first row, images are shown 
of H&E stained sections of thymic lymphoma (A), lymphoma infiltrating liver (B), and lymphoma infiltrating spleen (C). In the second row, images are shown of H&E 
stained sections of caecal adenoma (D), small intestinal monocryptal adenoma (red oval) (E), and colonic adenoma (red oval) with surrounding infiltration by 
lymphoma in mucosal and submucosal regions (F). Images taken from stained sections that were subsequently scanned using the Hamamatsu Nanozoomer and 




Figure 5.8: A) Bar chart of the number of Msh2-LS mice in Group-C (ethanol-treated, 
10TMZ_EtOH_Msh2fl KO) and Group-E (water-treated, 10TMZ_H2O_Msh2fl KO) that developed any 
tumours (lymphomas and intestinal adenomas) after receiving 10 TMZ doses and either 20% ethanol 
in drinking water or regular drinking water: 5/6 (83%) 10TMZ_EtOH_Msh2fl KO mice developed 
tumours compared with 3/3 (100%) 10TMZ_H2O_Msh2fl KO mice that developed tumours. Fisher’s 
exact test, no significant differences observed. B) Bar chart of the number of Msh2-LS mice in Group-
C (10TMZ_EtOH_Msh2fl KO) and Group-E (10TMZ_H2O_Msh2fl KO) that developed intestinal tumours 
after receiving 10 TMZ doses and either 20% ethanol in drinking water or regular drinking water: 2/6 
(33%) 10TMZ_EtOH_Msh2fl KO mice developed intestinal tumours compared with 1/3 (33%) 
10TMZ_H2O_Msh2fl KO mice that developed intestinal tumours. Fisher’s exact test, no significant 
differences observed. C) Tumour incidence in Msh2-LS mice in Group-C (10TMZ_EtOH_Msh2fl KO) and 
Group-E (10TMZ_H2O_Msh2fl KO) following 10 TMZ doses and either 20% ethanol or normal drinking 
water. The survival plot shows development of tumours (both lymphomas and intestinal adenomas) 
in the ethanol-treated group (red) compared with the water-treated group (blue), Log-rank (Mantel-







Figure 5.9: Tumour distribution in Msh2-LS mice in Group-C (ethanol-treated, 10TMZ_EtOH_ Msh2fl KO 
mice, black bars) and Group-E (water-treated, 10TMZ_H2O_ Msh2fl KO mice, white bars) after 10 doses 
of TMZ treatment. In 10TMZ_EtOH_ Msh2fl KO mice (Group-C), 4 thymus lymphomas, 2 small intestinal 
adenomas and 1 caecal adenoma were observed. In 10TMZ_H2O_ Msh2fl KO mice (Group-E), 1 thymus 




Figure 5.10: A) Bar chart of the number of Msh2-LS mice in Group-D (ethanol-treated, 5TMZ_EtOH_ 
Msh2fl KO) and Group-F (water-treated, 5TMZ_H2O_ Msh2fl KO) that developed tumours (lymphomas 
and intestinal adenomas) after receiving 5 TMZ doses and either 20% ethanol in drinking water or 
regular drinking water: 6/6 (100%) 5TMZ_EtOH_ Msh2fl KO mice and 6/6 (100%) 5TMZ_H2O_ Msh2fl KO 
mice developed tumours. Fisher’s exact test, no significant differences observed. B) Bar chart of the 
number of Msh2-LS mice in Group-D (5TMZ_EtOH_ Msh2fl KO) and Group-F (5TMZ_H2O_ Msh2fl KO) that 
developed intestinal tumours after receiving 5 TMZ doses and either 20% ethanol in drinking water or 
regular drinking water: 4/6 (66%) 5TMZ_EtOH_ Msh2fl KO and 4/6 (66%) 5TMZ_H2O_ Msh2fl KO mice 
developed intestinal tumours. Fisher’s exact test, no significant differences observed. C) Tumour 
incidence in Msh2-LS mice in Group-D (5TMZ_EtOH_ Msh2fl KO) and Group-F (5TMZ_H2O_ Msh2fl KO) 
following 5 TMZ doses and either 20% ethanol or normal drinking water. The survival plot shows 
development of tumours (both lymphomas and intestinal adenomas) in the ethanol-treated group 
(red) compared with the water-treated group (blue). Log-rank (Mantel-Cox) test showed a statistically 





Figure 5.11: Tumour distribution in Msh2-LS mice in Group-D (ethanol-treated, 5TMZ_EtOH_ Msh2fl 
KO mice, black bars) and Group-F (water-treated, 5TMZ_H2O_ Msh2fl KO mice, white bars) after 5 doses 
of TMZ treatment. In 5TMZ_EtOH_ Msh2fl KO mice (Group-D), 4 thymic lymphomas, 1 small intestinal 
adenoma, 8 colonic adenomas and 1 caecal adenoma were observed. In 5TMZ_H2O_ Msh2fl KO mice 
(Group-F), 4 thymic lymphomas, 3 small intestinal adenomas, 5 colonic adenomas and 2 caecal 
















5.2.2.3 Immunohistochemical characterization of tumours and tissues from the 
Msh2-LS mouse model after Temozolomide and ethanol treatment  
5.2.2.3.1 Msh2 immunostaining of Msh2-LS murine small intestinal and colonic 
tissues 
Msh2 expression was analysed in murine tumour and normal intestinal tissues and other 
tissues in Msh2flox/+; Lgr5CreERT2+/-; mTmG+/-mice following Cre activation by Tamoxifen 
treatment, either 5 or 10 daily TMZ doses, and either ethanol or water treatments. Small and 
large intestinal tissues were harvested, prepared as Swiss-rolls and fixed in 10% NBF (as 
described in Materials and Methods). They were processed using standard tissue processing 
protocols for paraffin wax embedding and microtome sectioning. Immunohistochemical 
staining for Msh2 was performed using protocols described in Materials and Methods (2.2.3) 
followed by manual counting of Msh2-positive and negative crypts. Tamoxifen treatment 
induced the loss of Msh2 expression in Lgr5+ expressing crypt epithelial stem cells scattered 
along the entire intestines, as previously shown in Chapter 4 (4.4.2.1). We used small 
intestinal tissue samples of Msh2-/- and WT mice as Msh2-negative and -positive expression 
controls respectively (Figure 5.12). The lack of IHC DAB-brown staining in the Msh2-/- tissues 
confirmed complete loss of Msh2 expression in the Msh2-null control tissues and similar 
patterns of Msh2 expression loss were observed in the intestinal epithelium in scattered 
crypts of the Msh2-LS mice.  
In the colon, the number of Msh2-negative crypts was slightly higher (but not significantly 
so) in the ethanol-treated mice compared with the water-treated mice in both Msh2-LS mice 
treated with 5 and 10 TMZ doses (Figure 5.13). In 5TMZ_EtOH_Msh2fl KO mice, 23% Msh2-
negative colonic crypts were observed compared with 20% Msh2-negative colonic crypts 
found in 5TMZ_H2O_Msh2fl KO controls. In 10TMZ_EtOH_Msh2fl KO mice, 32% Msh2-negative 
colonic crypts were observed compared with 27% Msh2-negative colonic crypts found in 
10TMZ_H2O_Msh2fl KO controls (Figure 5.14). The number of Msh2-negative crypts was 
higher in the SI than in the colon; the number of Msh2-negative crypts in the SI was slightly 
higher (but not significantly so) in the ethanol-treated mice compared with the water-treated 
mice, in both Msh2-LS mice treated with 5 and 10 TMZ doses (Figure 5.15). In 
5TMZ_EtOH_Msh2fl KO mice, 48% Msh2-negative colonic crypts were observed compared 
with 40% Msh2-negative colonic crypts found in 5TMZ_H2O_Msh2fl KO mice. In 
10TMZ_EtOH_Msh2fl KO, 48% Msh2-negative colonic crypts were observed compared with 
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41% Msh2-negative colonic crypts found in 10TMZ_H2O_Msh2fl KO mice (Figure 5.16). No 
significant differences were observed in any of these comparisons.  
Due to the small size of large intestinal adenomas that were found in these Msh2-LS mice, 
there was insufficient adenoma tissue remaining in the tissue blocks for anti-Msh2 IHC 
analysis. However, some small intestinal adenomas showed Msh2-negative dysplastic glands 
often surrounded by or admixed with Msh2-positive crypts showing reactive or 
hyperproliferative changes (Figure 5.17).  
Msh2 protein expression was examined by IHC in both normal thymus tissue and thymic 
lymphomas in order to investigate whether TMZ treatment can induce loss of the second 
Msh2 allele (Msh2flox/OFF) leading to MMR abrogation in Lgr5- thymus cells in the Msh2-LS 
mouse model, contributing to tumour formation outside of the intestinal Lgr5+ stem cells. 
Thymic lymphoma and normal thymus tissue samples from Msh2-LS model mice were 
investigated and no evidence of loss of Msh2 expression (no lack of brown IHC DAB staining) 
was found in either thymic lymphomas or normal thymus samples from Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with Tamoxifen and either 5 or 10 TMZ doses, including 










Figure 5.12: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal 
epithelium from a positive-control WT mouse (A), in which the brown staining indicates positive Msh2 
expression in all crypts (further magnified in the red rectangle); and from a negative-control Msh2-/- 
mouse (B), in which the lack of brown staining confirms the absence of Msh2 expression in intestinal 
mucosal epithelium (further magnified in the red rectangle). Images taken from anti-Msh2 IHC stained 
sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 






Figure 5.13: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal epithelium of 5TMZ_EtOH_Msh2fl KO mice (A), compared with 5TMZ_H2O_Msh2fl 
KO mice (B) and 10TMZ_EtOH_Msh2fl KO mice (D), compared with 10TMZ_H2O_Msh2fl KO mice (E). Msh2-negative crypts (indicated by the red arrows and further magnified in the 
red rectangle in figure A) were manually counted along the entire colon for all four of these groups of treated Msh2-LS mice (shown in C and F, respectively). No significant 
differences were observed between ethanol-treated versus water-treated mice following either 5 or 10 doses of TMZ. Mann-Whitney U Test (data shown as mean±SD, n=3 mice 
each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification (bar 





Figure 5.14: Percentage of Msh2 protein-non-expressing crypts in large intestinal mucosal epithelium of 
5TMZ_EtOH_Msh2fl KO mice compared with 5TMZ_H2O_Msh2fl KO mice (A), and 10TMZ_EtOH_Msh2fl KO 
compared with 10TMZ_H2O_Msh2fl KO mice (B). No significant differences were observed between 
ethanol-treated versus water-treated mice following either 5 or 10 doses of TMZ. Mann-Whitney U Test 





Figure 5.15: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal epithelium of 5TMZ_EtOH_Msh2fl KO mice (A), compared with 
5TMZ_H2O_Msh2fl KO mice (B), and 10TMZ_EtOH_Msh2fl KO mice (D), compared with 10TMZ_EtOH_Msh2fl KO mice (E). Msh2-negative crypts were manually counted along the 
entire small intestine for both of these groups of treated Msh2-LS mice (C and F, respectively). No significant differences were observed between ethanol-treated versus water-
treated mice following either 5 or 10 doses of TMZ. Mann-Whitney U Test (data shown as mean±SD, n=3 mice each group). Images taken from sections scanned using the 




Figure 5.16: Percentage of Msh2 protein-non-expressing crypts in small intestinal mucosal epithelium of 
5TMZ_EtOH_Msh2fl KO mice compared with 5TMZ_H2O_Msh2fl KO mice (A), and 10TMZ_EtOH_Msh2fl KO 
mice compared with 10TMZ_H2O_Msh2fl KO mice (B). No significant differences were observed between 
ethanol-treated versus water-treated mice following either 5 or 10 doses of TMZ. Mann-Whitney U Test 









Figure 5.17: Representative images of Msh2 immunohistochemical staining for Msh2 in small intestinal 
adenomas from 5TMZ_EtOH_Msh2fl KO mice (A) and from 5TMZ_H2O_Msh2fl KO mice (B). In both examples, 
there are Msh2-negative dysplastic or adenomatous glands, either surrounded by or admixed with 
reactive crypts or hyperproliferative crypts that are staining positively for Msh2. Images taken from 
sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 




Figure 5.18: Immunohistochemical analysis of Msh2 protein expression in thymic lymphoma (A), and 
in normal thymus tissue (B), from Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice, showing no evidence of 




















5.2.2.3.2 Ki-67 and Beta-Catenin immunostaining of Msh2-LS murine small 
intestinal and colonic tissues 
Immunohistochemical staining for Ki-67 was performed using protocols described in 
Materials and Methods (2.2.3). This was used to investigate Ki-67 expression in Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with TMZ and either 20% ethanol in drinking water or 
normal water. This was observed in normal large and small intestinal tissues of Msh2-LS 
mice, indicating absence of aberrant cell proliferation taking place outside the stem cell at 
the base of crypts (Figure 5.19B and C). By contrast, large regions of colonic mucosal crypt 
hyperproliferation and small intestinal adenomas of Msh2-LS mice showed Ki-67-positive 
crypts all along the extended crypts, confirming the presence of neoplastic tissue (Figure 
5.19A and B).  
Immunohistochemical staining for β-catenin was performed using protocols described in 
Materials and Methods (2.2.3). β-catenin is the key signalling intermediate of the Wnt 
pathway and is sometimes used as a CRC biomarker (Lugli et al., 2007), as described in 
Chapter 4 (4.4.2.3). This was used to investigate β-catenin and expression in tumour tissue 
of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice treated with TMZ and either 20% ethanol in 
drinking water or normal water. β-catenin IHC was performed with assistance from Marion 
Bacou using large intestinal samples from Apc Min mice that contained large intestinal 
adenomas (provided by Vidya Rajasekaran), and WT mice as β-catenin-positive and β-
catenin-normal expression controls respectively (Figure 4.41). The immunohistochemical 
analysis of β-catenin was performed on small and large intestinal adenomas from Msh2-LS 
mice. Analysed samples showed a heterogeneous pattern with variable numbers of adenoma 
cells showing positive β-catenin nuclear immunostaining due to accumulation and 






Figure 5.19: Immunohistochemical analysis of Ki-67 protein expression in normal large and small 
intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with TMZ (B and D) 
and neoplastic large and small intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-
mice treated with TMZ (A and C). Images taken from sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification 




Figure 5.20: Representative images of immunohistochemical analysis of β-catenin protein expression 
and localisation in intestinal adenomas of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with TMZ. 
Variable areas of positive β-catenin nuclear immunostaining in adenomatous cells were observed in 
both small intestinal adenomas (A) and colonic adenomas (B), indicated by the red ovals. Images are 
further magnified in panel figures C and D. Images taken from sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 40X magnification 











In this work, the aim was to potentially accelerate dMMR-driven intestinal tumour formation 
in the Msh2-LS mouse model by applying TMZ treatment, as used by Wojciechowicz et al. 
(2014).  
Wojciechowicz et al. (2014) generated the Msh2-LS mouse model in which Tamoxifen-
induced loss of Msh2 expression in approximately 10% of intestinal crypts, without any 
additional carcinogen treatment, and this led to intestinal tumours in 40% of the mice after 
1.5 years. Wojciechowicz et al. (2014) showed that Msh2-LS (Msh2flox/-; Lgr5CreERT2+/- ) mice 
of 6–7 weeks age received either 5 or 10 daily doses of TMZ over three weeks (100mg/kg of 
TMZ) after Tamoxifen treatment, resulting in early gastrointestinal intra-epithelial 
neoplasms and later intestinal adenomas and/or adenocarcinomas, with some thymic 
lymphomas (no quantitative data on lymphomas were provided). It is known that the 
number of dMMR crypt foci influences the risk of tumour development in LS patients. The 
size and growth rate of the dMMR cell pool appears to vary with time (as consequence of an 
increased mutation rate) and with exposure to some environmental factors (Kloor et al., 
2012). TMZ is a methylating agent and MMR-deficient cells are known to be resistant to 
killing by methylating agents. TMZ exposure caused an expansion of pre-existing Msh2-
deficient colonic crypt foci increasing the number of fully Msh2-deficient crypts in a 
statistically significant way (Wojciechowicz et al., 2014). 
In this chapter, a modification of the standard protocol was designed by introducing an 
additional treatment with TMZ with the aim of potentially accelerating intestinal tumour 
formation to around 2-4 months, when combined with ethanol. 
In these preliminary experiments, Tamoxifen treatment was halved from that used in the 
Chapter 4 procedure, to a daily i.p injection for 2 consecutive days, in line with Wojciechowicz 
et al (2014). This change in Tamoxifen treatment was made to reduce the probability of very 
large numbers of tumours arising from widespread dMMR foci induced by Tamoxifen-
mediated Cre activation followed by TMZ treatment. This change also reduced the number 
of procedures applied to the experimental subjects in line with 3Rs. However, it had already 
been demonstrated in Chapter 3 that 2 i.p. Tamoxifen injections were sufficient to activate 
Cre-recombinase in an acceptable number of Lgr5-expressing intestinal stem cells. Both male 
and female Msh2-LS mice showed good acceptance of Tamoxifen treatment, showing stable 
body weights during the treatment duration. Msh2-LS male mice showed statistically higher 
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mean body weight compared with Msh2-LS female mice mean body weight at the same age 
(p<0.0001).  Subsequently, in order to identify the most appropriate TMZ dose and treatment 
regime to induce tumorigenesis in around 2-4 months, animals were divided into groups that 
received either 5 or 10 daily doses of TMZ (100mg/kg) by o.g. over 2 or 3 weeks respectively, 
as described by Wojciechowicz et al. (2014).  
TMZ treatment was commenced the following week to allow time for the activated Cre to 
inactivate the second conditional knockout Msh2 allele. In this way, the dMMR stem cells at 
the crypt bases had time to expand into many dMMR daughter cells passing through the 
transit-amplifying compartment into the differentiation compartment, moving up the crypts 
and on to the table surface of the colonic mucosa or onto the small intestinal villi. Most of 
the mice accepted the TMZ administrations well. During TMZ treatment with either 5 or 10 
TMZ doses treatment, body-weights of Msh2-LS female and male mice did not significantly 
change. Body weights of Msh2-LS males were significantly higher than body weights of Msh2-
LS females (as expected due to normal sexual dimorphism observed in rodents), but no major 
fluctuations in body weights were observed during the treatments. However, a few mice died 
during the treatments likely due to presumed hypersensitivity to the methylating agent, 
which has been reported by others.  
After TMZ, Msh2-LS mice received either 20% ethanol in drinking water or normal drinking 
water. Msh2-LS female and male mice did not show any reduction in body weight during the 
first weeks showing good acceptance of the ethanol regime. Ethanol-treated and water-
treated Msh2-LS female mice showed similar mean body weights (23.14g and 23.28g 
respectively) and no significant differences were observed between these two cohorts. By 
contrast, Msh2-LS ethanol-treated mice showed a decrease of an average of 5g over 13 
weeks (from ~30g to ~25g), whereas the water-treated mice showed a general increase in 
body weight over the same time period. The trend over time of the body weights curves 
between these two cohorts showed a statistically significant difference of p<0.0001. The 
female Msh2-LS mice survived only 13-14 weeks under either liquid regime. Similarly, the 
ethanol-treated male Msh2-LS mice survived 13-14 weeks, whereas water-treated male 
Msh2-LS mice survived until 21-22 weeks. However, the average ml of liquid consumption 
per mouse (13.5ml for water-treated Msh2-LS males, 13.8ml for ethanol-treated Msh2-LS 
males, 8.9ml for water-treated Msh2-LS females, and 11.2ml for ethanol-treated Msh2-LS 
females) did not significantly differ from the data obtained in the previous experiments 
(13.85ml for water-treated Msh2-LS males, 11.65ml for ethanol-treated Msh2-LS males, 
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10.33ml for water-treated Msh2-LS females, and 9.65ml for ethanol-treated Msh2-LS 
females; see Chapter 4; Figure 4.4). 
Msh2-LS mice in this experiment did not survive as long as the mice in the previous 
experiment due to the carcinogenic effects of TMZ treatment. The main reason for early 
death of the mice was that in most cases Msh2-LS mice receiving either 5 or 10 daily TMZ 
doses, and either ethanol or water treatments, needed to be culled because of clinical signs 
relating to thymic lymphoma. Wojciechowicz et al. (2014) treated Msh2-LS mice with TMZ 
and they survived only 19 weeks from the last TMZ administration: 11 out of 13 Msh2-LS 
TMZ-treated mice displayed extended extra-intestinal lymphoid formations or lymphomas 
that were the main cause of death. Only two mice were culled for clinical signs of large 
intestinal neoplasms. In most cases, gastrointestinal abnormalities and neoplasms were only 
discovered during histopathological analysis suggesting secondary relevance.  
In all cohorts, we observed thymic lymphomas in 66% of the cases in each group. By contrast, 
10TMZ_EtOH_Msh2fl KO and 10TMZ_H2O_Msh2fl KO mice showed only 33% intestinal tumour 
incidence, while in 5TMZ_EtOH_Msh2fl KO and 5TMZ_H2O_Msh2fl KO mice showed 66% 
intestinal tumour incidence. When tested for presence or absence of Msh2 protein 
expression by IHC, the thymic lymphomas showed positive expression of Msh2, indicating 
that these tumours had arisen from MMR-proficient cells, most likely as a result of the 
carcinogenic effects of TMZ rather than by selection of dMMR cells for neoplastic growth. 
The results obtained from these experiments were similar to those described by 
Wojciechowicz et al. (2014), suggesting that both the lymphomas and the intestinal tumours 
observed were most likely a consequence of TMZ carcinogenic effects and not related to any 
ethanol effects. The TMZ carcinogenic properties appear to be too potent and mask any 
ethanol tumour-inducing effects. In 5TMZ_EtOH_Msh2fl KO and 5TMZ_H2O_Msh2fl KO mice, 
the intestinal tumour incidence was higher than that in 10TMZ_EtOH_Msh2fl KO and 
10TMZ_H2O_Msh2fl KO mice, demonstrating that the TMZ carcinogenic and toxic properties 
appeared to vary amongst these four groups to an extent that this prevented experimental 
revelation of any tumour-initiating or tumour-promoting ethanol effects on the Msh2-LS 
mice. In 5TMZ_EtOH_Msh2fl KO mice and 5TMZ_H2O_Msh2fl KO mice, the lower dose TMZ 
treatment slightly extended the survival allowing time for the Tamoxifen-induced Msh2-LS 
mice to express in part their intestinal tumour prone phenotype. By contrast, in 
10TMZ_EtOH_Msh2fl KO mice and 10TMZ_H2O_Msh2fl KO mice, we observed a lower number 
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of intestinal tumours largely because these mice died earlier from extra-intestinal tumours 
(thymic lymphomas) induced by the higher dose of carcinogenic TMZ. 
Some environmental factors (such as methylating compounds either naturally produced by 
the intestinal flora or absorbed with food) can promote survival of dMMR intestinal cells and 
their expansion (Stojic et al., 2004). Wojciechowicz et al. (2014) performed anti-Msh2 IHC on 
tumour and normal tissue samples comparing Msh2-LS mice treated with Tamoxifen 
followed by TMZ treatment with Msh2-LS mice treated only with Tamoxifen. They observed 
a higher number of crypts lacking Msh2 staining in the TMZ-treated Msh2-LS mice than in 
the non-TMZ treated Msh2-LS mice. Furthermore, the gastrointestinal intra-epithelial 
neoplasms showed lack of Msh2 expression IHC staining in crypts, thus forming dMMR crypts 
in around 68% around the tumour area. They demonstrated that TMZ treatment conferred 
a proliferative advantage upon dMMR cells over wild-type intestinal epithelial cells, leading 
to expansion of the dMMR crypt compartment.  
We performed anti-Msh2-LS IHC on tumour and tissue samples from the Msh2-LS mice 
treated with TMZ and ethanol. We analysed Msh2 expression in murine small and large 
intestinal samples in Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice after either 5 or 10 daily TMZ 
doses, and either ethanol or water treatments. In both colon and SI, we did not observe any 
statistically significant differences in the numbers of Msh2-negative crypts between ethanol-
treated and water-treated mice in Msh2-LS mice treated with either 5 or 10 daily TMZ doses. 
The number of dMMR crypts was higher in the SI than in the colon, as expected from previous 
experiments (see Chapter 4; 4.4.2.1). However, Msh2-LS mice treated with TMZ showed 
higher numbers of Msh2-negative crypt foci compared with those observed in the absence 
of TMZ-treatment in the Msh2-LS mice in the previous experiments (see Chapter 4; Figure 
4.26 and Figure 4.30), suggesting a dominant effect due to selection for survival and 
expansion of dMMR crypt foci by the methylating agent TMZ. 
TMZ is a strongly carcinogenic tumour-inducer and for this reason, the mice died 
prematurely from extra-intestinal tumours, predominantly thymic lymphomas, before 
intestinal tumours had time to develop. Due to the small size of large intestinal adenomas 
that were found in these Msh2-LS mice, there was insufficient adenoma tissue remaining in 
the tissue blocks for anti-Msh2 IHC analysis. However, some small intestinal adenomas 
showed Msh2-negative dysplastic glands often surrounded by or admixed with Msh2-
positive crypts showing reactive or hyperproliferative changes. 
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Msh2 protein expression was examined by IHC in both normal thymus tissue and thymic 
lymphomas in order to investigate whether TMZ treatment can induce loss of the second 
Msh2 allele (Msh2flox/OFF) leading to MMR abrogation in Lgr5- thymus cells in the Msh2-LS 
mouse model, potentially contributing to tumour formation from other sources outside of 
the intestinal Lgr5+ stem cells. The immunostaining for Msh2 proved to be technically 
difficult on thymus tissue, therefore we relied on the samples that showed a reliable result.  
No evidence of loss of Msh2 expression (no lack of brown IHC DAB staining) was found in 
either thymic lymphomas or normal thymus control samples from Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/-mice treated with either 5 or 10 TMZ doses, including both ethanol-treated and 
water-treated mice, indicating that inactivation of mismatch repair was not involved in this 
pathway of thymic lymphoma formation. 
Immunohistochemistry was performed to investigate Ki-67 expression in intestinal tissue 
samples from Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with TMZ and either 20% 
ethanol in drinking water or normal water to determine proliferative activity. In normal large 
and small intestinal tissue, Ki-67 is expressed only in the proliferating cells at the base of 
crypts as previously reported (Johnston et al., 1989). Large regions of colonic mucosal crypt 
hyperproliferation and small intestinal adenomas of Msh2-LS mice showed Ki-67-positive 
crypts all along the extended crypts, confirming the presence of neoplastic tissue.  
We investigated the expression of β-catenin protein, an intracellular signal transducer in the 
Wnt signalling pathway (Cong et al., 2003a), on tumours and tissue samples from Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with TMZ and either 20% ethanol in drinking water or 
normal water. Normal colorectal tissue exhibits membranous localisation of β catenin 
whereas colorectal adenoma/adenocarcinoma shows nuclear β catenin localization, 
nuclear β-catenin is regarded as a useful CRC biomarker (Lugli et al., 2007). Small intestinal 
and colon adenomas showed a heterogeneous pattern with variable numbers of adenoma 
cells showing positive β-catenin nuclear immunostaining due to accumulation and 
translocation of β-catenin in the nuclei. 
In conclusion, TMZ is a powerful methylating agent and carcinogen that can confer a 
proliferative advantage upon established dMMR crypt foci leading to selection for survival 
and expansion in the Msh2-LS murine intestines that could, potentially, lead to an 
acceleration of intestinal tumorigenesis. However, the carcinogenic properties of TMZ 
appear to be too potent in these experiments, inducing a variety of extra-intestinal tumours 
(independent from dMMR), predominantly thymic lymphomas, that mask any carcinogenic 
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ethanol effects. The data obtained were inconclusive and the use of TMZ was misleading for 
the purpose of exploring the carcinogenic and tumour-promoting effects of ethanol and its 
major metabolite acetaldehyde, particularly in combination with deficient MMR. For this 
reason, it was decided to discontinue the experimental investigation of TMZ in combination 


















Chapter 6:  Investigation of long-term ethanol consumption 
effects on  Aldh1b1 conditional-knockout Msh2-LS mice and 
Aldh1b1 constitutive-knockout Msh2-LS mice  
6.1 Introduction 
The mechanisms of how ethanol induces intestinal carcinogenesis include involvement of its 
metabolite acetaldehyde. Acetaldehyde is a highly reactive molecule able to induce a wide 
range of DNA damage, as described in Chapter 1, 1.3.3.  Evidence of acetaldehyde 
involvement in ethanol-related cancers emerged from the study of human polymorphisms 
in ADH and ALDH enzymes. A polymorphism of ALDH1B1 causes reduced enzyme activity and 
has been associated with altered drinking habits and alcohol sensitivity in Caucasians. 
ALDH1B1 plays a key role in acetaldehyde detoxification in the gastrointestinal epithelium 
(Stagos et al., 2010), as we previously explained in Chapter 1, 1.3.2.  
As already mentioned in Chapter 4, our group demonstrated an important role of murine 
Aldh1b1 in acetaldehyde detoxification in vivo during intestinal tumorigenesis in wildtype 
and Aldh1b1-depleted mice after long-term ethanol treatment for one year (Müller et al., 
2016).  
Aldh1b1-depleted mice were generated using the ‘knockout-first’ Aldh1b1 allele (tm1a) 
(Figure 6.1) (Skarnes et al., 2011). This contains an IRES:lacZ trapping cassette and a floxed 
promoter-driven neo cassette inserted into the intron of Aldh1b1, disrupting gene function. 
Aldh1b1 tm1a was shown previously to be a hypomorph (Müller et al., 2016). The knockout-
first allele can be easily modified in ES cells or in adult murine crosses with transgenic Flp 
and/or Cre transgenic mice. Conditional alleles (Aldh1b1flox/flox) are generated by removal of 
the gene-trap cassette by Flp recombinase, which reverts the mutation to wild type, leaving 
loxP sites on either side of a critical exon creating a conditional allele (tm1c). Subsequent 
exposure to Cre deletes the critical exon to induce an exon deletion knockout mutation 
(tm1d) and this triggers nonsense-mediated decay of the mutant transcript, with production 
of no functional Aldh1b1 protein (Figure 6.1). If whole mouse Cre activation is used, this 





In this chapter, the first aim is to introduce the conditional Aldh1b1 allele (Aldh1b1flox/flox) and 
the constitutive Aldh1b1 knockout allele (Aldh1b1-/-), by cross-breeding of the Msh2-LS 
mouse model in order to establish an Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox 
colony and an Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/- colony. In this chapter, the 
generation and characterization of these mouse models are described.  
 
The second aim is to study the combined effects of inactivation of Msh2 and Aldh1b1 in mice 
with long-term ethanol treatment. We hypothesised that loss of Aldh1b1 function increases 
the levels of acetaldehyde in the intestinal epithelial cells, causing more acetaldehyde-
mediated DNA damage that may interact with defective mismatch repair to influence 
intestinal tumour formation in these Msh2-LS mouse models.  
In Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox mice, the conditional loss of Aldh1b1 
expression is dependent on Tamoxifen-induced Cre recombinase activation and this only 
occurs in Lgr5-expressing small intestinal and large intestinal stem cells along with loss of 
Msh2 expression. We predicted that Lgr5-expressing intestinal cells and their daughter cells 
would acquire a high number of DNA mutations due to the combined lack of MMR pathway 
activity and increased levels of acetaldehyde.  
In contrast, Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/- constitutive knockout mice are 
characterized by complete loss of Aldh1b1 expression in all cells of the organism (Tamoxifen 
independent). We hypothesised that this would cause a further increase in acetaldehyde 
levels (above that in the conditional model), resulting in more acetaldehyde-mediated DNA 
damage in all cells of the organism, including a higher level of acetaldehyde-induced DNA 
mutations in the MMR-deficient intestinal cells, (loss of Msh2 expression in scattered 
induced-Lgr5-expressing intestinal stem cells) manifested by accelerated or increased 







Figure 6.1: Schematic representation of the ‘knockout-first’ allele (tm1a) and its modifications. The 
tm1a allele contains an IRES:lacZ trapping cassette and a floxed promoter-driven neo cassette 
inserted into the intron of the target gene, disrupting gene function (in this case, the gene is Aldh1b1). 
Following breeding with an Flp expressing mouse, Flp recombines the two FRT sites and converts the 
‘knockout-first’ allele to a conditional allele (tm1c, Aldh1b1flox/flox), restoring normal gene activity. After 
subsequently breeding with a Cre expressing mouse, Cre recombines the two loxP sites and deletes 
the floxed exon of the tm1c allele to inactivate the gene (tm1d, Aldh1b1-/-), triggering nonsense 
mediated decay of the exon-deleted transcript with complete loss of gene function (adapted and 













6.2 Establishment of the colony of combined Aldh1b1-knockout and 
Msh2-LS model mice 
6.2.1 Methods 
Mice were housed in IVCs with group sizes and enrichment according to Home Office 
regulations. Further details on the mice housing conditions and maintenance can be found 
in Chapter 2, 2.1.1. 
 
6.2.2 Results 
To generate the Aldh1b1 conditional-knockout (Aldh1b1flox/flox) mice, (Zhu & Sadowski, 1995) 
the Aldh1b1 tm1a mice were cross-bred with Flpe mice obtained from Professor Ian Jackson 
(University of Edinburgh, Institute of Genetics & Molecular Medicine) (Zhu & Sadowski, 
1995). Subsequently, the Msh2+/+; Lgr5CreERT2-/-; mTmG-/-; Aldh1b1flox/flox mice were cross-
bred with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/+; Aldh1b1+/+ mice (Figure 6.2). The genotype 
frequencies that resulted from this breeding almost perfectly reflected the expected 
Mendelian ratios (Figure 6.2). Subsequently, the resulting progeny were used as breeders for 
the creation of the correct genotype for Aldh1b1 conditional-knockout Msh2-LS 
experimental subject mice: Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox. The mice 
resulting from these matings showed 1.5% progeny with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-
; Aldh1b1flox/flox genotypes and 0.8% progeny with Msh2flox/flox; Lgr5CreERT2+/-; mTmG-/-; 
Aldh1b1flox/flox genotypes (Figure 6.3). Tabular representation of the inter-cross to generate 
the Aldh1b1 conditional-knockout Msh2-LS mouse model experimental subjects is shown in 
the Appendix (Supplementary Table 6.1-6.2). Mice with these genotypes were used as 
experimental subject mice or breeders. Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox 
mice only show loss of Aldh1b1 activity following Cre recombinase activation and this only 
occurs in the scattered Lgr5-expressing intestinal epithelial stem cells (that go on to form 
crypt foci) along with inactivation of the second allele of Msh2 and conversion to mG 
expression by Cre following Tamoxifen treatment (Figure 6.4). 
To generate the Aldh1b1 constitutive-knockout (Aldh1b1-/-) mice, embryos from the Aldh1b1 
conditional-knockout (Aldh1b1flox/flox) mice were treated with TAT-Cre in vitro and implanted 
into surrogate mothers using standard techniques (performed by Matt Sharp, Ailsa Travers 
and Julie Thomson, Bioresearch & Veterinary Services, Central Transgenic Core, University of 
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Edinburgh) (Ryder et al., 2014). The resulting Aldh1b1-/- mice (with genotype Msh2+/+; 
Lgr5CreERT2-/-; mTmG-/-; Aldh1b1-/-) obtained from the surrogate mothers were cross-bred 
with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/+; Aldh1b1+/+ mice. The genotype frequencies that 
resulted from this breeding almost perfectly reflected the expected Mendelian ratios (Figure 
6.5). Subsequently, the resulting progeny were used as breeders for the generation of the 
correct genotype for Aldh1b1 constitutive-knockout Msh2-LS experimental subject mice with 
the genotype Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/-. The mice resulting from these 
matings showed 1.5% progeny with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/- genotypes 
and 0.8% progeny with Msh2flox/flox; Lgr5CreERT2+/-; mTmG-/-; Aldh1b1-/- genotypes (Figure 
6.6). Tabular representation of the inter-cross to generate the Aldh1b1 constitutive-
knockout Msh2-LS mouse model experimental subjects is shown in the Appendix 
(Supplementary Table 6.3-6.4). Mice with these genotypes were used as experimental 
subject mice or breeders. Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/- mice have complete 






Figure 6.2: Percentage of resulting genotypes from the breeding between the Msh2+/+; Lgr5CreERT2-/-
; mTmG-/-; Aldh1b1flox/flox with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/+; Aldh1b1+/+ mice 
 
  
Figure 6.3: Percentage of resulting genotypes from the breeding between the Msh2+/-; Lgr5CreERT2-/-





Figure 6.4: Schematic diagram of the Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox genotype before and after Cre activation. On the left, the schematic diagram of 
the Msh2fl/- alleles before and after Cre activation, showing constitutive inactivation (Msh2-) and conditional knockout (before: Msh2 flox ON and after: Msh2 flox OFF) 
alleles of Msh2 (adapted and modified from Wojciechowicz et al., 2014). In the middle, the schematic diagram of the mTmG coloured fluorescent protein reporter 
construct shows the status before (cell expresses mT and appears red) and after (cell expresses mG and appears green) Cre-mediated recombination (adapted and 
modified from Muzumdar et al., 2007). On the right, the schematic diagram of the Aldh1b1flox/flox alleles before and after Cre activation: Cre-mediated recombination 
of the loxP sites flanking the critical exon induces loss of Aldh1b1 expression only in Lgr5-driven Cre-expressing intestinal epithelial stem cells (adapted and modified 




Figure 6.5: Percentage of resulting genotypes from the breeding between the Msh2+/+; Lgr5CreERT2-/-
; mTmG-/-; Aldh1b1-/- with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/+; Aldh1b1+/+ mice.  
 
 
Figure 6.6: Percentage of resulting genotypes from the breeding between the Msh2+/-; Lgr5CreERT2-/-





Figure 6.7: Schematic diagram of the Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/- genotype before and after Cre activation. On the left, the schematic diagram of the 
Msh2fl/- alleles before and after Cre activation: constitutive-knockout (Msh2-) and conditional-knockout (before: Msh2 flox ON; and after: Msh2 flox OFF) alleles of Msh2 
(adapted and modified from Wojciechowicz et al., 2014). In the middle, the schematic diagram of the mTmG coloured fluorescent protein reporter construct before 
(cell expresses mT and appears red) and after (cell expresses mG and appears green) Cre-mediated recombination (adapted and modified from Muzumdar et al., 2007). 
On the right, the schematic diagram of the Aldh1b1-/- alleles. In Aldh1b1 constitutive-knockout mice, all cells have complete loss of Aldh1b1.
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6.3 Long-term ethanol effects on intestinal tumourigenesis in the 
combined Aldh1b1-knockout and Msh2-LS mouse model 
6.3.1 Methods 
Groups of 7-9 weeks old mice with either Aldh1b1 conditional-knockout or Aldh1b1 
constitutive-knockout alleles were used in combination with the Msh2-LS mice. The 
combined Aldh1b1 conditional-knockout and Msh2-LS experimental mice had the genotypes 
Msh2flox/-; Lgr5CreERT2+/-; Aldh1b1flox/flox or Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox. 
Whereas, the combined Aldh1b1 constitutive-knockout and Msh2-LS experimental mice had 
the genotypes Msh2flox/-; Lgr5CreERT2+/-; Aldh1b1-/- or Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; 
Aldh1b1-/-. All experiments involved these mice being divided into two groups for treatment 
with either standard / conventional drinking water (Group-A) or 20% ethanol in drinking 
water (Group-B). Group-A mice received i.p. injections of 0.15mg Tamoxifen/g bw on day 1 
and 0.1mg Tamoxifen/g bw on days 2, 3 and 4; on day 5 mice were provided with 
standard/normal drinking water. By contrast, Group-B received i.p. injections of 0.15mg 
Tamoxifen/g bw on day 1 and 0.1mg Tamoxifen/g bw on days 2, 3 and 4; but on day 5 the 
Group-B mice were provided with 20% ethanol in drinking water (as previously validated by 
our group; (Müller et al., 2016)) (Figure 6.8). Animals were culled and tissues collected when 
either clinical signs of distress were visible or they displayed >20% body weight loss 
compared with the initial weight. The small and large intestines, caecum, stomach, liver, 
spleen, thymus, lymph nodes (if visible) and any other organ or tissue showing abnormalities, 
were collected following schedule 1 culling and necropsy dissection. Tissues were fixed in 
10% NBF, processed using standard tissue processing protocols and paraffin embedded in 
preparation for section cutting and staining. The acronyms used for the Msh2-LS model mice 







Figure 6.8: Experimental treatment protocols and timelines for Group-A (water-treated) and -B 
(ethanol-treated) mice, showing 4 days of i.p. injections of Tamoxifen, followed by either standard / 






















6.3.2.1 Experimental group organization and observations 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox experimental subjects (18 females and 6 
males) were divided into two groups: Group-A (12 mice: 9 females and 3 males; water-
treated control group) and Group-B (12 mice: 9 females and 3 males; ethanol-treated test 
group).  
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/- experimental subjects (8 females and 16 
males) were divided into in two groups: Group-A (12 mice: 4 females and 8 males; water-
treated control group) and Group-B (12 mice: 4 females and 8 males; ethanol-treated test 
group).  
Ethanol-treated animals from both groups were culled when either clinical signs of distress 
were visible or they displayed >20% body weight loss compared with the initial weight, 
whereas water-treated mice (pair matched for age and sex) were culled at the same 
timepoints as ethanol-treated mice. During Tamoxifen treatment (daily Tamoxifen i.p 
injections for 4 consecutive days), body weights and health status were recorded. In both 
Aldh1b1 conditional-knockout Msh2-LS mice and Aldh1b1 constitutive-knockout Msh2-LS 
mice, body weights of the female and male mice didn’t significantly differ during the 
Tamoxifen treatment (Figure 6.9), showing successful drug administration and acceptance of 
the experimental procedures by the mice.  
In Aldh1b1flox/flox Msh2-LS mice, body weights of males (~25g) were significantly higher than 
body weights of females (~21g) both before and during the Tamoxifen treatments (Figure 
6.9A). In Aldh1b1-/- Msh2-LS mice, body weights of males (~26.4g) were significantly higher 
than body weights of females (~22g), both before and during the Tamoxifen treatments 
(Figure 6.9B).  
After Tamoxifen treatment mice received either 20% ethanol in drinking water or normal 
drinking water regimes and the body weights and health status of the mice were recorded 
twice a week (Figure 6.10-6.11).  
EtOH_Aldh1b1fl/fl_Msh2fl KO female mice did not show abnormal behaviour or reduced weight 
compared with H2O_Aldh1b1fl/fl_Msh2fl KO female mice, indicating good acceptance of the 
ethanol regime (Figure 6.10A). In EtOH_Aldh1b1fl/fl_Msh2fl KO and H2O_Aldh1b1fl/fl_Msh2fl KO 
male mice showed some variation in body weight most likely reflecting the low number of 
male experimental mice in this experiment (Figure 6.10B). EtOH_Aldh1b1fl/fl_Msh2fl KO mice 
weighed on average 31g for the males and 31g for the females, whereas 
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H2O_Aldh1b1fl/fl_Msh2fl KO mice weighed on average 34g for the males and 33g for the 
females (Figure 6.10). 
EtOH_Aldh1b1-/-_Msh2fl KO female and male mice did not show abnormal behaviour or 
reduced body weight compared with H2O_Aldh1b1-/-_Msh2fl KO female and male mice, 
indicating good acceptance of the ethanol regime (Figure 6.11). EtOH_Aldh1b1-/-_ Msh2fl KO 
mice weighed on average 36g for the males and 27g for the females, whereas H2O_Aldh1b1-
/-_Msh2fl KO mice weighed on average 39g for the males and 30g for the females (Figure 6.11).  
Drinking bottles were changed and bottle weights were recorded once a week. Liquid 
consumption per mouse was estimated by analysing the weights of the drinking bottles (per 
cage) and calculating the average weight of consumed liquid per mouse per day (Figure 6.12-
6.13). In Aldh1b1flox/flox Msh2-LS mice, an average H2O_Aldh1b1fl/fl_Msh2fl KO male mouse 
consumed around 12.83ml of drinking water per day, whereas an average 
EtOH_Aldh1b1fl/fl_Msh2fl KO male mouse consumed around 13.4ml of 20% ethanol in drinking 
water. In Aldh1b1flox/flox Msh2-LS mice, an average H2O_Aldh1b1fl/fl_Msh2fl KO female mouse 
consumed around 12.87ml of water per day, whereas an average EtOH_Aldh1b1fl/fl_Msh2fl 
KO female mouse consumed around 9ml of 20% ethanol in drinking water per day (Figure 
6.12). In Aldh1b1-/- Msh2-LS mice, an average H2O_Aldh1b1-/-_Msh2fl KO male mouse 
consumed around 10.4ml of drinking water per day, whereas an average EtOH_Aldh1b1-/-
_Msh2fl KO male mouse consumed around 10.5ml of 20% ethanol in drinking water. In 
Aldh1b1-/- Msh2-LS mice, an average H2O_Aldh1b1-/-_Msh2fl KO female mouse consumed 
around 10.2ml of water per day, whereas an average EtOH_Aldh1b1-/-_Msh2fl KO female 
mouse consumed around 11.5ml of 20% ethanol in drinking water per day (Figure 6.13). In 
both experiments, no significant differences were observed between any of the comparisons 








Figure 6.9: Body weights during Tamoxifen treatment. A) Body weights of Aldh1b1flox/flox Msh2-LS 
males were significantly higher than body weights of females, before and during Tamoxifen 
treatments. 2-way-ANOVA test with Bonferroni post-test correction, p=0.0005 on days 1 and 2, 
p<0.0001 on days 3 and 4 (data shown as mean ± SD, n=6 mice in each group). B) Body weights of 
Aldh1b1-/- Msh2-LS males were significantly higher than body weights of females, before and during 
Tamoxifen treatments. 2-way-ANOVA test with Bonferroni post-test correction, p=0.0014 on day 1, 









Figure 6.10: Body weights for Aldh1b1flox/flox Msh2-LS males and females during 20% ethanol or 
standard/normal drinking water regimes. The data distribution for the body weight curves for the 
Aldh1b1flox/flox Msh2-LS male mice were influenced by the low number of male animals used in the 
experiment. There were no significant differences between the body weights of Aldh1b1flox/flox Msh2-
LS ethanol-treated (EtOH_Aldh1b1fl/fl_Msh2fl KO) males (or females) versus Aldh1b1flox/flox Msh2-LS 
water-treated (H2O_Aldh1b1fl/fl_Msh2fl KO) males (or females). 2-way-ANOVA with Bonferroni post-





Figure 6.11: Body weights for Aldh1b1-/- Msh2-LS males and females during 20% ethanol or standard 
/ normal drinking water regimes. There were no significant differences between the body weights of 
Aldh1b1-/- Msh2-LS ethanol-treated (EtOH_Aldh1b1-/-_Msh2fl KO) males (or females) versus Aldh1b1-/- 
Msh2-LS water-treated (H2O_Aldh1b1-/-_Msh2fl KO) males (or females). 2-way-ANOVA with Bonferroni 







Figure 6.12: Liquid consumption of Aldh1b1flox/flox Msh2-LS males and females treated with either 20% 
ethanol in drinking water or standard / normal water per mouse per day. 2-way-ANOVA with 
Bonferroni post-test correction analysis (data shown as mean±SD, n=6 mice in each group). No 
significant differences were observed for any of the comparisons of ethanol versus water treatment, 
or males versus females. 
 
 
Figure 6.13: Liquid consumption of Aldh1b1-/- Msh2-LS males and females treated with either 20% 
ethanol in drinking water or standard / normal water per mouse per day. 2-way-ANOVA with 
Bonferroni post-test correction analysis (data shown as mean±SD, n=6 mice in each group). No 
significant differences were observed for any of the comparisons of ethanol versus water treatment, 
or males versus females. 
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6.3.2.2 Tumour development in Aldh1b1 conditional-knockout Msh2-LS mice 
under long-term ethanol treatment 
The two cohorts of Aldh1b1flox/flox Msh2-LS model mice, Group-A (water-treated, 
H2O_Aldh1b1fl.fl_Msh2fl KO) and Group-B (ethanol-treated, EtOH_Aldh1b1fl.fl_Msh2fl KO), were 
monitored for up to 12 months for signs of intestinal tumour development or other 
pathological abnormalities, using a clinical scoring system that included known clinical signs 
of distress seen in mice that develop intestinal neoplasms, to determine when the mice 
should be culled for necropsy dissection and tumour analysis (Table 4.1). Most of the mice 
in Group-B (ethanol experimental group) displayed either anal prolapse or >20% reduction 
in body weight as common clinical signs of distress, at varying lengths of time from the start 
of the experimental protocol and were then culled for necropsy dissection. During necropsy 
dissection, naked eye inspection revealed that the majority of the EtOH_Aldh1b1fl.fl_Msh2fl 
KO mice showed a thicker colonic wall compared with the colonic walls of the 
H2O_Aldh1b1fl.fl_Msh2fl KO mice, but no gross morphological differences were observed in the 
small intestines. The lengths of the small intestines and colons were measured and recorded, 
but no significant differences in length were observed between the ethanol-treated and the 
water-treated groups. 
 
The histopathological analyses of Aldh1b1flox/flox Msh2-LS large intestines and small intestines 
confirmed the macroscopic observations of no significant morphological differences 
between the two groups in the small intestines, but increased colonic wall thickness in 
EtOH_Aldh1b1fl.fl_Msh2fl KO mice, due to a widespread increase in the colon crypt length as a 
result of extended zones of crypt epithelial hyperproliferation that were not observed in 
H2O_Aldh1b1fl.fl_Msh2fl KO murine colons (Figure 6.14). These extended zones of colonic crypt 
hyperproliferation were seen to affect 50% – 90% of the whole colonic length, usually 
involving proximal colon and mid colon more than distal colon and rectum, in most of the 
EtOH_Aldh1b1fl.fl_Msh2fl KO mice who survived more than 3 months of the ethanol treatment 
protocol. By contrast, histopathological analyses of the small intestines did not show any 
significant morphological differences between the two groups of animals using H&E-stained 
Swiss rolls of the intestines (Figure 6.15).  
 
In total, 5 out of 12 EtOH_Aldh1b1fl.fl_Msh2fl KO mice demonstrated zones of large intestinal 
crypt epithelial hyperproliferation, with adenoma formation and, in 1 case, invasive 
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adenocarcinoma was present, forming within an average of 4.5 months (minimum 13 weeks 
and maximum 39 weeks) of the start of the experimental protocol, compared with no cases 
of large intestinal adenoma formation in the 12 H2O_Aldh1b1fl.fl_Msh2fl KO control mice, in 
the same time-period (Figure 6.16). 
Almost all 5 EtOH_Aldh1b1fl.fl_Msh2fl KO adenoma-bearing mice showed colonic crypt 
hyperproliferative changes along the whole colon. Only one Aldh1b1flox/flox Msh2-LS mouse 
showed only colonic hyperproliferation without tumour formation (after 35 weeks of ethanol 
treatment). One out of these 5 EtOH_Aldh1b1fl.fl_Msh2fl KO adenoma-bearing mice was 
diagnosed with invasive adenocarcinoma in the proximal colon. In addition, in 2 out of these 
5 mice, caecal adenomas were found. Among these 5 EtOH_Aldh1b1fl.fl_Msh2fl KO mice, 2 
were diagnosed with rectal adenoma. In total, we observed 21 neoplasms distributed across 
the caecum, colon and rectum (Figure 6.17). Additionally, 1 out of these 5 mice developed a 
cutaneous sebaceous adenoma (a type of skin tumour that occurs in LS patients).  
Seven out of 12 EtOH_Aldh1b1fl.fl_Msh2fl KO mice did not show any intestinal adenoma 
formation, but in one of these cases there was a uterine endometrial adenocarcinoma (after 
13 weeks of ethanol treatment). Endometrial adenocarcinoma was also observed in 
EtOH_Msh2fl and H2O_Msh2fl mice, after 12 and 15 months, under 20% ethanol in drinking 
water and normal water treatment respectively (Chapter 4, 4.2.2.2).   
In Group-A (water-treated control cohort, H2O_Aldh1b1fl.fl_Msh2fl KO), no abnormalities or 
tumours were found in the large intestines in any of the 12 H2O_Aldh1b1fl.fl_Msh2fl KO mice. 
No morphological abnormalities or tumours were observed following necropsy and 
histopathological analysis of the H&E-stained sections of the small intestines, stomach, liver, 
spleen, lymph nodes and thymus, of any of the 12 EtOH_Aldh1b1fl.fl_Msh2fl KO mice or 12 








Figure 6.14: Representative images of H&E stained colon Swiss rolls. A) Images of H&E stained LI Swiss 
rolls from water-treated Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl.fl_Msh2fl KO) mice, further magnified in 
image (C) showing normal large intestinal mucosal appearances. Images taken from scanned slide files 
with the Hamamatsu Nanozoomer NDP Viewer software at 0.7X and 2.5X magnification respectively (bar 
at lower left indicates 2.5mm and 1mm). B) Images of H&E stained LI Swiss rolls from ethanol-treated 
Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl.fl_Msh2fl KO) mice, further magnified in image (D) showing 
widespread hyperproliferation of the elongated colonic crypts. Images taken from scanned slide files with 
the Hamamatsu Nanozoomer NDP Viewer software at 0.6X and 2.5X magnification respectively (bar at 





Figure 6.15: Representative images of H&E stained SI Swiss rolls. A) Image of H&E stained SI Swiss roll 
from a water-treated Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl.fl_Msh2fl KO) mouse, further magnified in 
image (C). Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer 
software at 0.7X and 2.5X magnification respectively. B) Image of H&E stained small intestine Swiss 
roll from an ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl.fl_Msh2fl KO) mouse, further 
magnified in image (D). Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP 
Viewer software at 0.7X and 2.5X magnification respectively (bar at lower left indicates 2.5mm and 





Figure 6.16: A) Bar chart of the number of Aldh1b1flox/flox Msh2-LS mice that developed intestinal 
tumours (both adenomas and adenocarcinomas) after receiving either 20% ethanol in drinking water 
or normal/regular drinking water. 5/12 (41.7%) Aldh1b1flox/flox Msh2-LS ethanol-treated 
(EtOH_Aldh1b1fl.fl_Msh2fl KO) mice developed large intestinal tumours compared with 0/12 (0%) 
Aldh1b1flox/flox Msh2-LS water-treated (H2O_Aldh1b1fl.fl_Msh2fl KO) mice that developed large intestinal 
tumours. Fisher’s exact test, *p=0.0373. B) Survival chart showing tumour incidence in Aldh1b1flox/flox 
Msh2-LS mice treated with either 20% ethanol or water. The survival plot shows the development of 
tumours (both adenomas and adenocarcinomas) in the Aldh1b1flox/flox Msh2-LS ethanol-treated 
(EtOH_Aldh1b1fl.fl_Msh2fl KO) group (red) compared with the lack of intestinal tumours over the same 
time period in the Aldh1b1flox/flox Msh2-LS water-treated (H2O_Aldh1b1fl.fl_Msh2fl KO) group (blue). Log-















Figure 6.17: Tumour distribution in ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl.fl_Msh2fl 
KO) tumour-bearing mice. A) Numbers of adenomas and adenocarcinomas found and their locations. 
In total, 21 neoplasms were observed: 3 adenomas in the caecum; 8 adenomas in the proximal colon 
(1/8 was an invasive adenocarcinomas); 5 adenomas in the mid-colon; 3 adenomas in the distal colon; 
and 2 adenomas in the rectum. B) Tumour distribution and number per EtOH_Aldh1b1fl.fl_Msh2fl KO 
tumour-bearing mouse: 1/5 tumour-bearing mice showed one caecal adenoma and 1/5 mice showed 
two adenomas in the caecum; 1/5 tumour-bearing mice showed one proximal colonic adenoma; 2/5 
showed two adenomas and 1/5 showed three adenomas in the proximal colon; 5/5 tumour-bearing 
mice showed one mid-colonic adenoma; 1/5 tumour-bearing mice showed 2 distal colonic adenomas 










6.3.2.3 Tumour development in Aldh1b1 constitutive-knockout Msh2-LS mice 
under long-term ethanol treatment 
The two cohorts of Aldh1b1-/- Msh2-LS model mice, Group-A (water-treated, H2O_Aldh1b1-/-
_Msh2fl KO) and Group-B (ethanol-treated, EtOH_Aldh1b1-/-_Msh2fl KO), were monitored for 
up to 12 months for signs of intestinal tumour development or other pathological 
abnormalities, using a clinical scoring system that included known clinical signs of distress 
seen in mice that develop intestinal neoplasms, to determine when the mice should be culled 
for necropsy dissection and tumour analysis (Table 4.1). Most of the mice in Group-B 
(ethanol-treated experimental group) displayed either anal prolapse or >20% reduction in 
body weight as common clinical signs of distress, at varying lengths of time from the start of 
the experimental protocol and were then culled for necropsy dissection. During necropsy 
dissection, naked eye inspection revealed that the majority of the EtOH_Aldh1b1-/-_Msh2fl KO 
mice showed a thicker colonic wall compared with the normal colonic walls of the 
H2O_Aldh1b1-/-_Msh2fl KO mice, but no gross morphological differences were observed in the 
small intestines. The lengths of the small intestines and colons were measured and recorded, 
but no significant differences in length were observed between the ethanol-treated mice and 
the water-treated mice. 
 
The histopathological analyses of Aldh1b1-/- Msh2-LS large intestines and small intestines 
confirmed the macroscopic observations of no significant morphological differences 
between the two groups in the small intestines, but increased colonic wall thickness in 
EtOH_Aldh1b1-/-_Msh2fl KO mice, due to a widespread increase in the colonic crypt length as 
a result of extended zones of crypt epithelial hyperproliferation that were not observed in 
H2O_Aldh1b1-/-_Msh2fl KO murine colons (Figure 6.18). These extended zones of colonic crypt 
hyperproliferation were seen to affect 50% – 90% of the whole colonic length, usually 
involving proximal colon and mid colon, more than distal colon and rectum, in most of the 
EtOH_Aldh1b1-/-_Msh2fl KO mice who survived more than 2 months of the ethanol treatment 
protocol. By contrast, histopathological analyses of the small intestines showed normal 
mucosal appearances with no significant morphological differences between the two groups 
of animals using H&E-stained Swiss rolls of the small intestines (Figure 6.19).  
 
In total, 8 out of 12 EtOH_Aldh1b1-/-_Msh2fl KO mice demonstrated zones of large intestinal 
crypt elongation with epithelial hyperproliferation, and with adenoma formation, all within 
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an average of 6 months (minimum 9 weeks and maximum 42 weeks) of the start of the 
experimental protocol, compared with no cases of either colonic crypt hyperproliferation or 
large intestinal adenoma formation in the 12 H2O_Aldh1b1-/-_Msh2fl KO control mice, over the 
same time-period (Figure 6.20). 
Almost all of the 8 EtOH_Aldh1b1-/-_Msh2fl KO tumour-bearing mice showed colonic crypt 
hyperproliferative changes along the whole colon. No Aldh1b1-/- Msh2-LS mice showed only 
colonic hyperproliferation without tumour formation. In addition, in 4 out of 8 
EtOH_Aldh1b1-/-_Msh2fl KO mice, caecal adenomas were found. Among these 8 
EtOH_Aldh1b1-/-_Msh2fl KO mice, 5 were diagnosed with rectal adenoma. In total, 35 
neoplasms were observed, distributed between both the caecum and the colon (Figure 6.21).  
Four out of 12 EtOH_Aldh1b1-/-_Msh2fl KO mice did not show any intestinal adenoma 
formation or extra-intestinal abnormality or tumour.  
In Group-A (water-treated control cohort), no abnormalities or tumours in the large 
intestines were found in any of the 12 H2O_Aldh1b1-/-_Msh2fl KO mice. 
No morphological abnormalities or tumours were observed following necropsy and 
histopathological analysis of the H&E-stained sections of the small intestines, stomach, liver, 
spleen, lymph nodes and thymus, in any of the 12 EtOH_Aldh1b1-/-_Msh2fl KO mice or in any 



















Figure 6.18: Representative images of H&E stained colon Swiss rolls. A) Images of H&E stained LI Swiss 
rolls from water-treated Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl KO) mice, further magnified in 
image (C) showing normal large intestinal mucosal appearances. Images taken from scanned slide files 
with the Hamamatsu Nanozoomer NDP Viewer software at 0.7X and 2.5X magnification respectively. 
B) Images of H&E stained LI Swiss rolls from ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-
_Msh2fl KO) mice, further magnified in image (D) showing widespread hyperproliferative changes with 
colonic crypt elongation. Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP 






Figure 6.19: Representative images of H&E stained SI Swiss rolls. A) Image of H&E stained SI Swiss roll 
from a water-treated Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl KO) mouse, further magnified in 
image (C). Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer 
software at 0.7X and 2.5X magnification respectively. B) Image of H&E stained small intestine Swiss 
roll from an ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mouse, further magnified 
in image (D). Images taken from scanned slide files with the Hamamatsu Nanozoomer NDP Viewer 
software at 0.5X and 2.5X magnification respectively magnification (bar at lower left indicates 5mm 






Figure 6.20: A) Bar chart of the number of Aldh1b1-/- Msh2-LS mice that developed intestinal tumours 
after receiving either 20% ethanol in drinking water or normal/regular drinking water. 8/12 (66.7%) 
ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice developed large intestinal 
tumours compared with 0/12 (0%) water-treated Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl KO) mice. 
Fisher’s exact test, **p=0.0013. 
B) Survival chart showing tumour incidence in Aldh1b1-/- Msh2-LS mice treated with either 20% 
ethanol or water. The survival plot shows the development of tumours (both adenomas and 
adenocarcinomas) in the ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) group (red) 
compared with the lack of intestinal tumours over the same time period in the water-treated Aldh1b1-




Figure 6.21: Tumour distribution in ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) 
tumour-bearing mice. A) Numbers of adenomas (no adenocarcinomas observed in this group) found 
and their locations. In total, 35 neoplasms were observed: 8 adenomas in the caecum; 14 adenomas 
in the proximal colon; 8 adenomas in the mid-colon; 0 adenomas in the distal colon; and 5 adenomas 
in the rectum. B) Tumour distribution and number per EtOH_Aldh1b1-/-_Msh2fl KO tumour-bearing 
mouse: 2/8 tumour-bearing mice showed one caecal adenoma, 1/8 mice showed two caecal 
adenomas and 1/8 showed 4 adenomas in the caecum; 1/8 tumour-bearing mice showed one 
proximal colonic adenoma, 2/8 showed two adenomas and 3/8 showed three adenomas in the 
proximal colon; 2/8 tumour-bearing mice showed one mid-colonic adenoma and 3/8 showed 2 
adenomas in the mid-colon. No EtOH_Aldh1b1-/-_Msh2fl KO mice showed adenoma formation in the 







6.3.2.4 Comparative analysis of tumour development between in Aldh1b1 
conditional-knockout Msh2-LS mice, Aldh1b1 constitutive-knockout Msh2-LS mice 
and Aldh1b1 wild-type Msh2-LS mice under long-term ethanol treatment 
In Aldh1b1flox/flox Msh2-LS subjects, 41.7% (5/12 mice) of  EtOH_Aldh1b1fl/fl_Msh2fl KO mice 
demonstrated adenoma formation (with 1 case of invasive adenocarcinoma), forming within 
an average of 4.5 months (minimum 13 weeks and maximum 39 weeks), compared with 
Aldh1b1 wild-type (Aldh1b1wt) Msh2-LS in which 65% (15/23) of EtOH_Msh2fl KO mice showed 
adenoma formation (5 cases of  invasive adenocarcinoma), all within an average of 6 months 
(minimum 4 weeks and maximum 48 weeks) (Figure 6.22). EtOH_Aldh1b1fl/fl_Msh2fl KOmice 
showed tumour formation slightly earlier than EtOH_Msh2fl KO mice, but no statistically 
significant difference was observed. However, tumour-bearing EtOH_Aldh1b1fl/fl_Msh2fl KO 
mice showed statistically significantly higher numbers of tumour per mouse (21 neoplasms 
were observed in 5 tumour-bearing mice) compared with tumour-bearing e EtOH_Msh2fl KO 
mice (36 neoplasms were observed in 15 tumour-bearing mice) (Figure 6.23).  
 
In Aldh1b1-/- Msh2-LS subjects, 66.7% (8/12 mice) of  EtOH_Aldh1b1-/-_Msh2fl KO mice 
demonstrated adenoma formation (no adenocarcinomas observed in this group), forming 
within an average of 6 months (minimum 9 weeks and maximum 42 weeks), compared with 
Aldh1b1wt Msh2-LS in which 65% (15/23) of EtOH_Msh2fl KO mice showed adenoma formation 
(5 cases of  invasive adenocarcinoma), all within an average of 6 months (minimum 4 weeks 
and maximum 48 weeks) (Figure 6.24). Tumour-bearing EtOH_Aldh1b1-/-_Msh2fl KO mice 
showed statistically higher numbers of tumours per mouse (35 neoplasms were observed in 
8 tumour-bearing mice) compared with tumour-bearing EtOH_Msh2fl KO mice (36 neoplasms 
were observed in 15 tumour-bearing mice) (Figure 6.25).  
We performed the same comparative analyses of tumour development between 
EtOH_Aldh1b1fl/fl_Msh2fl KO and EtOH_Aldh1b1-/-_Msh2fl KO mice, but no statistically 




Figure 6.22: A) Bar chart of the number of ethanol-treated Aldh1b1wt Msh2-LS (EtOH_Msh2fl KO) 
tumour-bearing mice (15/23, 65%) compared with ethanol-treated Aldh1b1flox/flox Msh2-LS 
(EtOH_Aldh1b1fl/fl_Msh2fl KO) tumour-bearing mice (5/12, 41.7%). No significant differences were 
observed between these groups. B) Survival chart showing tumour incidence in ethanol-treated 
Aldh1b1wt Msh2-LS (EtOH_Msh2fl KO) mice compared with ethanol-treated Aldh1b1flox/flox Msh2-LS 
(EtOH_Aldh1b1fl/fl_Msh2fl KO) mice. The survival plot shows the development of tumours (both 
adenomas and adenocarcinomas) in both EtOH_Msh2fl KO mice (blue) and EtOH_Aldh1b1fl/fl_Msh2fl KO 







Figure 6.23: Number of tumours per mouse in ethanol-treated Aldh1b1wt Msh2-LS (EtOH_Msh2fl KO) 
tumour-bearing mice compared with ethanol-treated Aldh1b1flox/flox Msh2-LS 
(EtOH_Aldh1b1fl/fl_Msh2fl KO) tumour-bearing mice. EtOH_Msh2fl KO tumour-bearing mice showed an 
average of 2.4 tumours per mouse compared with EtOH_Aldh1b1fl/fl_Msh2fl KO tumour-bearing mice 









Figure 6.24: A) Bar chart of the number of ethanol-treated Aldh1b1wt Msh2-LS (EtOH_Msh2fl KO) 
tumour-bearing mice (15/23, 65%) compared with ethanol-treated Aldh1b1-/- Msh2-LS 
(EtOH_Aldh1b1-/-_Msh2fl KO) tumour-bearing mice (8/12, 66.7%). No statistically significant differences 
were observed between these groups. B) Survival chart showing tumour incidence in ethanol-treated 
Aldh1b1wt Msh2-LS (EtOH_Msh2fl KO) mice compared with ethanol-treated Aldh1b1-/- Msh2-LS 
(EtOH_Aldh1b1-/-_Msh2fl KO) mice. The survival plot shows the development of tumours (both 
adenomas and adenocarcinomas) in both EtOH_Msh2fl KO mice (blue) and EtOH_Aldh1b1-/-_Msh2fl KO 





Figure 6.25: Number of tumours per mouse in ethanol-treated Aldh1b1wt Msh2-LS (EtOH_Msh2fl KO) 
tumour-bearing mice compared with ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) 
tumour-bearing mice. EtOH_Msh2fl KO tumour-bearing mice showed on average 2.4 tumours per 
mouse compared with EtOH_Aldh1b1-/-_Msh2fl KO tumour-bearing mice with an average of 4.8 
















Figure 6.26: A) Bar chart of the number of ethanol-treated Aldh1b1flo/flox Msh2-LS 
(EtOH_Aldh1b1fl/fl_Msh2fl KO) tumour-bearing mice (5/12, 41.7%) compared with ethanol-treated 
Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) tumour-bearing mice (8/12, 66.7%). No statistically 
significant differences were observed between these groups. B) Survival chart showing tumour 
incidence in ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl KO) mice compared with 
ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice. The survival plot shows the 
development of tumours (both adenomas and adenocarcinomas) in both EtOH_Aldh1b1fl/fl_Msh2fl KO 
mice (blue) and EtOH_Aldh1b1-/-_Msh2fl KO (red). No statistically significant differences were observed 





Figure 6.27: Number of tumours per mouse in ethanol-treated Aldh1b1flox/flox Msh2-LS 
(EtOH_Aldh1b1fl/fl_Msh2fl KO) tumour-bearing mice compared with ethanol-treated Aldh1b1-/- Msh2-
LS (EtOH_Aldh1b1-/-_Msh2fl KO) tumour-bearing mice. EtOH_Aldh1b1fl/fl_Msh2fl KO tumour-bearing 
mice showed an average of 4.2 tumours per mouse compared with EtOH_Aldh1b1-/-_Msh2fl KO tumour-
bearing mice with an average of 4.8 tumours. No statistically significant difference was observed 















6.4 Long-term ethanol effects in Aldh1b1-knockout Msh2-LS mouse 
model control mice. 
6.4.1 Methods 
We introduced negative control experimental groups to study the ethanol effect in Msh2-LS 
mice without treating them with Tamoxifen.  
Groups of 7-9 weeks old Aldh1b1flox/flox Msh2-LS control mice (Msh2flox/-; Lgr5CreERT2+/-; 
Aldh1b1flox/flox or Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox) and Aldh1b1-/- Msh2-LS 
control mice (Msh2flox/-; Lgr5CreERT2+/-; Aldh1b1-/- or Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; 
Aldh1b1-/) were divided into two groups (A and B) prior to treatment with corn oil (without 
Tamoxifen).  
Both Group-A and Group-B mice received i.p. injections of corn oil on days 1, 2, 3, and 4 
(using the same volume of corn oil as used in treatments of the experimental subjects). On 
day 5 Group-A mice were provided with normal drinking water and Group-B mice with 20% 
ethanol in drinking water (Figure 6.28). 
These control animals were culled when they reached the same end-timepoint as the age- 
and sex-matched experimental Tamoxifen-induced mice (following tumour development or 
clinical distress in these experimental subjects), or when the control mice showed either 
clinical signs of distress or they displayed >20% body weight loss compared with the initial 
weight. Following schedule 1 culling and necropsy dissection of the control mice, tissues 
were collected and fixed in 10% NBF (as described in Materials and Methods). Following 
standard tissue processing protocols, the tissue blocks were paraffin-embedded in 
preparation for section cutting and staining. 
In previous work, Aldh1b1-depleted mice were used as experimental subjects, along with 
wild-type control mice, under long-term (>1 year) treatment with 20% ethanol in drinking 
water or normal/standard drinking water (Müller et al., 2016). The data related to wild-type 
control mice have already been discussed in Chapter 4 (4.3.2.1). Here, the data are shown 
for the ethanol/acetaldehyde effects on intestinal tumourigenesis, comparing both Aldh1b1 
conditional-knockout Tamoxifen-induced Msh2-LS mice and Aldh1b1 constitutive-knockout 
Tamoxifen-induced Msh2-LS mice with Aldh1b1 conditional-knockout non-induced Msh2-LS 
mice and Aldh1b1 constitutive-knockout non-induced Msh2-LS mice. The acronyms used for 





Figure 6.28: Experimental treatment protocols and timelines for Group-A (water-treated) and -B 
ethanol-treated) mice, showing 4 days of i.p. injections of corn oil (without Tamoxifen), followed by 
either standard/normal drinking water (Group-A) or drinking water containing 20% ethanol (Group-




















6.4.2.1 Control group organization and observations. 
We studied the effects of ethanol/acetaldehyde (compared with water-treatment) on 
intestinal tumour formation in Aldh1b1 conditional-knockout non-induced Msh2-LS mice 
and Aldh1b1 constitutive-knockout non-induced Msh2-LS mice.  
Fourteen non-induced Aldh1b1flox/flox Msh2-LS control mice were divided into two groups: 7 
mice in Group-A (4 females and 3 males, water-treated control group) and 7 mice in Group-
B (4 females and 3 males, ethanol-treated group).  
Twelve non-induced Aldh1b1-/- Msh2-LS control mice were divided into two groups: 6 mice 
in Group-A (2 females and 4 males, water-treated control group) and 6 mice in Group-B (2 
females and 4 males, ethanol-treated group).  
Animals were culled, necropsy dissected and tissues were collected when they reached the 
same end-timepoint as the age- and sex-matched experimental Tamoxifen-induced ethanol-
treated Aldh1b1 conditional- or constitutive-knockout Msh2-LS mice.  
During corn oil administration (daily corn oil i.p injections for 4 consecutive days), body 
weights and health status were recorded. In both Aldh1b1 conditional-knockout Msh2-LS 
mice and Aldh1b1 constitutive-knockout Msh2-LS mice, body weights of the female and male 
mice didn’t significantly differ during the corn oil treatment (Figure 6.29), showing successful 
drug administration and acceptance of the experimental procedures by the mice. In non-
induced Aldh1b1flox/flox Msh2-LS mice, body weights of males (~22.5g) were significantly 
higher than body weights of females (~18.9g) both before and during the corn oil treatments 
(Figure 6.29A). In non-induced Aldh1b1-/- Msh2-LS mice, body weights of males (~22.2g) were 
slightly lower than body weights of females (~22.8g), both before and during the corn oil 
treatments (Figure 6.29B).  
After corn oil treatment, mice received either 20% ethanol in drinking water regime or 
standard/normal drinking water regime and the body weights and health status of the mice 
were monitored and recorded twice per week. 
EtOH_Aldh1b1fl/fl_Msh2fl female and male mice did not show abnormal behaviour or reduced 
weight compared with H2O_Aldh1b1fl/fl_Msh2fl female and male mice, indicating good 
acceptance of the ethanol regime (Figure 6.30A). The EtOH_Aldh1b1fl/fl_Msh2fl and 
H2O_Aldh1b1fl/fl_Msh2fl male mice showed some variation in body weight within the groups, 
most likely reflecting the use of small numbers of mice from different litters starting at 
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different times (Figure 6.31B). EtOH_Aldh1b1fl/fl_Msh2fl mice weighed on average 32.4g for 
the males and 27g for the females, whereas H2O_Aldh1b1fl/fl_Msh2fl mice weighed on 
average 29.5g for the males and 23g for the females (Figure 6.30). 
EtOH_Aldh1b1-/-_Msh2fl female and male mice did not show abnormal behaviour or reduced 
body weight compared with H2O_Aldh1b1-/-_Msh2fl female and male mice, indicating good 
acceptance of the ethanol regime (Figure 6.31). The EtOH_Aldh1b1-/-_Msh2fl and 
H2O_Aldh1b1-/-_Msh2fl female and male mice showed some variation in body weight within 
the groups, most likely reflecting the use of small numbers of mice from different litters 
starting at different times. EtOH_Aldh1b1-/-_Msh2fl mice weighed on average 30g for the 
males and 31g for the females, whereas H2O_Aldh1b1-/-_Msh2fl mice weighed on average 
30.3g for the males and 26.3g for the females (Figure 6.31).  
The body weights of both Tamoxifen-induced Aldh1b1 conditional-knockout and Aldh1b1 
constitutive-knockout Msh2-LS mice, were compared with both non-induced Aldh1b1 
conditional-knockout and Aldh1b1 constitutive-knockout Msh2-LS mice, during either 20% 
ethanol treatment or normal drinking water treatment (Figure 6.32-6.33). In every study 
group, ethanol-treated Msh2-LS female and male mice did not show significant differences 
in body weight, or abnormal behaviour, indicating good acceptance of the 20% ethanol 
treatment regime.  
Drinking bottles were changed and bottle weights were recorded once a week. Liquid 
consumption per mouse was estimated by analysing the weights of the drinking bottles (per 
cage) and calculating the average weight of consumed liquid per mouse per day (Figure 6.34). 
H2O_Aldh1b1fl/fl_Msh2fl female mice consumed on average 12ml of drinking water per day, 
compared with 7.7ml of 20% ethanol in drinking water consumed by 
EtOH_Aldh1b1fl/fl_Msh2fl female mice. The difference in liquid consumption between 
EtOH_Aldh1b1fl/fl_Msh2fl and H2O_Aldh1b1fl/fl_Msh2fl females is statistically significant (p = 
0.0018). H2O_Aldh1b1fl/fl_Msh2fl male mice consumed on average 12.7ml of drinking water 
per day, compared with 11.2ml of 20% ethanol in drinking water consumed by 
EtOH_Aldh1b1fl/fl_Msh2fl male mice, with no significant differences observed (Figure 6.34A). 
In non-induced Aldh1b1-/- Msh2-LS mice, an average H2O_Aldh1b1-/-_Msh2fl male mouse 
consumed around 11.3ml of drinking water per day, whereas an average EtOH_Aldh1b1-/-
_Msh2fl male mouse consumed around 13ml of 20% ethanol in drinking water. In Aldh1b1-/- 
Msh2-LS mice, an average H2O_Aldh1b1-/-_Msh2fl female mouse consumed around 11.5ml of 
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water per day, whereas an average EtOH_Aldh1b1-/-_Msh2fl female mouse consumed around 
7ml of 20% ethanol in drinking water per day (Figure 6.34B). No significant differences were 
observed between any of the comparisons of EtOH_Aldh1b1-/-_Msh2fl versus H2O_Aldh1b1-






Figure 6.29: Body weights during corn oil treatment. A) Body weights of non-induced (no Tamoxifen) 
Aldh1b1flox/flox Msh2-LS males were significantly higher than body weights of non-induced 
Aldh1b1flox/flox Msh2-LS females, before and during corn oil treatments. 2-way-ANOVA test with 
Bonferroni post-test correction, p=0.0145 on day 1 and p<0.0001 on days 2-4 (data shown as mean ± 
SD, n=6 mice in each group).  B) Body weights of non-induced Aldh1b1-/- Msh2-LS males were similar 
to body weights of females, before and during corn oil treatments. 2-way-ANOVA test with Bonferroni 









Figure 6.30: Body weights for non-induced Aldh1b1flox/flox Msh2-LS males and females during 20% 
ethanol or standard/normal drinking water regimes. The data distribution for the body weight curves 
of the Aldh1b1flox/flox Msh2-LS mice were influenced by the small numbers of mice coming from 
different litters and starting at different time points. There were no significant differences between 
the body weights of non-induced ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl) 
males (or females) versus non-induced water-treated Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl/fl_Msh2fl) 
males (or females). 2-way-ANOVA with Bonferroni post-test correction analysis (data shown as 






Figure 6.31: Body weights for non-induced Aldh1b1-/- Msh2-LS males and females during 20% ethanol 
or standard/normal drinking water regimes. The data distribution for the body weight curves for the 
Aldh1b1-/- Msh2-LS mice were influenced by the small numbers of mice coming from different litters 
and starting at different time points. There were no significant differences between the body weights 
of non-induced ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl) males (or females) 
versus non-induced water-treated Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl) males (or females). 2-
way-ANOVA with Bonferroni post-test correction analysis (data shown as mean±SD, n=2 mice each 





Figure 6.32: Body weights for males and females during 20% ethanol or standard/normal drinking water regimes. Body weight graphs of Tamoxifen-induced 
Aldh1b1flox/flox Msh2-LS experimental subject mice (A), non-induced Aldh1b1flox/flox Msh2-LS control mice (B), during 20% ethanol or standard/normal drinking water 
regimes. In each group, there were no significant differences between the body weights of ethanol-treated versus water-treated groups of mice for either males or 





Figure 6.33: Body weights for males and females during 20% ethanol or standard/normal drinking water regimes. Body weight graphs of Tamoxifen-induced Aldh1b1-
/- Msh2-LS experimental subject mice (A), non-induced Aldh1b1-/- Msh2-LS control mice (B), during 20% ethanol or standard/normal drinking water regimes. In each 
group, there were no significant differences between the body weights of ethanol-treated versus water-treated groups of mice for either males or females. 2-way-






Figure 6.34: Liquid consumption of either 20% ethanol containing drinking water or standard/normal 
water per mouse per day of non-induced Aldh1b1flox/flox Msh2-LS control mice (A), and non-induced 
Aldh1b1-/- Msh2-LS control mice (B). 2-way-ANOVA with Bonferroni post-test correction analysis, 
**p=0.0018 (data shown as mean±SD).
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6.4.2.2 Tumour development in control mice exposed to long-term ethanol 
treatment 
Both non-induced Aldh1b1 conditional-knockout and Aldh1b1 constitutive-knockout Msh2-
LS control mice treated with either ethanol or water, were culled when they reached the 
same end-timepoint as age- and sex-matched Tamoxifen-induced ethanol-treated Aldh1b1 
conditional-knockout and Aldh1b1 constitutive-knockout Msh2-LS experimental mice.  
These control mice underwent necropsy dissection and organ/tissue collection in the same 
way as the experimental mice.  
In non-induced Aldh1b1flox/flox Msh2-LS control mice, Group-B (ethanol-treated cohort, 
EtOH_Aldh1b1fl/fl_Msh2fl), 3 out of 7 (43%) mice showed zones of colonic crypt epithelial 
hyperproliferation involving mainly the proximal and mid colon (after 13, 15 and 39 weeks 
of 20% ethanol in drinking water regime, respectively). None of the EtOH_Aldh1b1fl/fl_Msh2fl 
control mice showed intestinal adenoma formation. In Group-A (water-treated control 
cohort, H2O_Aldh1b1fl/fl_Msh2fl), no intestinal hyperproliferation, adenoma or other 
abnormality was observed in any of the 7 H2O_Aldh1b1fl/fl_Msh2fl control mice (Figure 6.35). 
The tumour incidence was compared between Tamoxifen-induced Aldh1b1flox/flox Msh2-LS 
experimental cohort mice and non-induced Aldh1b1flox/flox Msh2-LS control mice (Figure 
6.36). 
In non-induced Aldh1b1-/- Msh2-LS control mice, Group-B (ethanol-treated cohort, 
EtOH_Aldh1b1-/-_Msh2fl), 2 out of 6 (33.4%) mice showed zones of colonic crypt epithelial 
hyperproliferation involving mainly the mid colon (after 14 and 22 weeks of 20% ethanol in 
drinking water regime, respectively). None of the EtOH_Aldh1b1-/-_Msh2fl control mice 
showed intestinal adenoma formation. In Group-A (water-treated control cohort, 
H2O_Aldh1b1-/-_Msh2fl), no intestinal hyperproliferation, adenoma or other abnormality was 
observed in any of the 6 H2O_Aldh1b1-/-_Msh2fl control mice (Figure 6.36). The tumour 
incidence was compared between Tamoxifen-induced Aldh1b1-/- Msh2-LS experimental 
cohort mice and non-induced Aldh1b1-/- Msh2-LS control mice (Figure 6.37). 
No morphological abnormalities or tumours were observed following necropsy dissection 
and histopathological analysis of the H&E-stained sections of the caecum, small intestines, 
stomach, anal canal, liver, spleen, lymph nodes and thymus, of any of the 14 
EtOH_Aldh1b1fl/fl_Msh2fl or H2O_Aldh1b1fl/fl_Msh2fl mice, and of any of the 12 
EtOH_Aldh1b1-/-_Msh2fl or H2O_Aldh1b1fl/fl_Msh2fl mice. The intestinal tumour formation in 
the Tamoxifen-induced Aldh1b1flox/flox MSh2-LS experimental mice was compared with that 
243 
 
for non-induced Aldh1b1flox/flox Msh2-LS control mice, treated with either 20% ethanol in 
drinking water or normal/standard drinking water (Figure 6.38). The intestinal tumour 
formation in the Tamoxifen-induced Aldh1b1-/- MSh2-LS experimental mice was compared 




Figure 6.35: A) Bar chart of the number of non-induced Aldh1b1flox/flox Msh2-LS control mice that 
developed intestinal tumours (adenomas or adenocarcinomas) after receiving either 20% ethanol in 
drinking water or normal/standard drinking water. In both groups (water-treated cohort and ethanol-
treated cohort) 0/7 non-induced Aldh1b1flox/flox Msh2-LS control mice developed large intestinal 
adenomas. Fisher’s exact test showed no significant differences were observed. B) Tumour incidence 
shown as a survival plot in non-induced Aldh1b1flox/flox Msh2-LS control mice treated with either 20% 
ethanol (red) or water (blue). The blue curve (water-treated control mice) completely overlaps the 
red curve (ethanol-treated control mice) such that it can’t be seen in the graph.  Log-rank (Mantel-








Figure 6.36: Tumour incidence, shown as survival plots, in non-induced Aldh1b1flox/flox Msh2-LS control 
mice both water-treated (H2O_Aldh1b1fl/fl_Msh2fl) (green) and ethanol-treated 
(EtOH_Aldh1b1fl/fl_Msh2fl) (violet), compared with Tamoxifen-induced Aldh1b1flox/flox Msh2-LS 
experimental mice, both water-treated (H2O_Aldh1b1fl/fl_Msh2fl KO) (blue) and 20% ethanol-treated 
(EtOH_Aldh1b1fl/fl_Msh2fl KO) (red). The green curve completely overlaps both violet and blue curves, 
such that these curves can’t be seen in the graph. Log-rank (Mantel-Cox) test, p = 0.0018 indicating 
significant differences observed between the ethanol-treated Tamoxifen-induced Aldh1b1flox/flox 









Figure 6.37: A) Bar chart of the number of non-induced Aldh1b1-/- Msh2-LS control mice that 
developed intestinal tumours (adenomas or adenocarcinomas) after receiving either 20% ethanol in 
drinking water or normal/standard drinking water. In both groups (water-treated cohort and ethanol-
treated cohort) 0/6 non-induced Aldh1b1-/- Msh2-LS control mice developed large intestinal 
adenomas. Fisher’s exact test, no significant differences observed. B) Tumour incidence shown as a 
survival plot in non-induced Aldh1b1-/- Msh2-LS control mice treated with either 20% ethanol (red) or 
water (blue). The blue curve (water-treated control mice) completely overlaps the red curve (ethanol-










Figure 6.38: Tumour incidence, shown as survival plots, in non-induced Aldh1b1-/- Msh2-LS control 
mice both water-treated (H2O_Aldh1b1-/-_Msh2fl) (green) and ethanol-treated (EtOH_Aldh1b1-/-
_Msh2fl) (violet), compared with Tamoxifen-induced Aldh1b1-/- Msh2-LS experimental mice, both 
water-treated (H2O_Aldh1b1-/-_Msh2fl KO) (blue) and 20% ethanol-treated (EtOH_Aldh1b1-/-_Msh2fl KO) 
(red). The green curve completely overlaps both violet and blue curves, such that these curves can’t 
be seen in the graph. Log-rank (Mantel-Cox) test, p = 0.0039 indicating significant differences observed 
between the ethanol-treated Tamoxifen-induced Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) 





Figure 6.39: Bar chart of the numbers of non-induced Aldh1b1flox/flox Msh2-LS control mice, and 
Tamoxifen-induced Aldh1b1flox/flox Msh2-LS experimental mice that developed intestinal tumours after 
receiving either 20% ethanol in drinking water or normal/standard drinking water. Fisher’s exact test 
was carried out to compare the effects of ethanol in the three different pairs of cohorts: 5/12 (41.7%) 
ethanol-treated Tamoxifen-induced Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl KO) mice 
developed large intestinal tumours compared with 0/12 (0%) water-treated Aldh1b1flox/flox Msh2-LS 
(H2O_Aldh1b1fl/fl_Msh2fl KO) mice (Fisher’s exact test, *p=0.0373), 0/7 (0%) ethanol-treated non-
induced Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl) mice, and 0/7 (0%) water-treated non-
induced Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl/fl_Msh2fl) mice. Fisher’s exact test was carried out to 
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compare the tumour incidence between EtOH_Aldh1b1fl/fl_Msh2fl KO and EtOH_Aldh1b1fl/fl_Msh2fl 




Figure 3.40: Bar chart of the numbers of non-induced Aldh1b1-/- Msh2-LS control mice, and Tamoxifen-
induced Aldh1b1-/- Msh2-LS experimental mice that developed intestinal tumours after receiving 
either 20% ethanol in drinking water or normal/standard drinking water. Fisher’s exact test was 
carried out to compare the effects of ethanol in the three different pairs of cohorts: 8/12 (66.7%) 
ethanol-treated Tamoxifen-induced Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice developed 
large intestinal tumours compared with 0/12 (0%) water-treated induced Aldh1b1-/- Msh2-LS 
(H2O_Aldh1b1-/-_Msh2fl KO) mice (Fisher’s exact test,**p=0.0013), 0/6 (0%) ethanol-treated non-
induced Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl) mice, and 0/6 (0%) water-treated non-induced 
Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl) mice. Fisher’s exact test was carried out to compare the 
















6.5 Immunohistochemical characterization of tumours and tissues from 
the Aldh1b1 conditional-knockout Msh2-LS and Aldh1b1 constitutive-
knockout Msh2-LS model mice with and without ethanol treatment 
6.5.1 Methods 
We performed IHC analyses in FFPE colonic and small intestinal tissues from induced Aldh1b1 
conditional-knockout Msh2-LS mice, Aldh1b1 constitutive-knockout Msh2-LS mice, non-
induced Aldh1b1 conditional-knockout Msh2-LS control mice and non-induced Aldh1b1 
constitutive-knockout Msh2-LS control mice to verify or investigate the expression of various 
proteins of interest. We performed the same analysis on the colonic and SI tissues comparing 
ethanol-treated mice with water-treated mice. Small and large intestinal tissues were 
harvested, prepared as Swiss-rolls and fixed in 10% NBF (as described in Materials and 
Methods). They were processed using standard tissue processing protocols for paraffin wax 
embedding and microtome sectioning. 
IHC was performed to confirm changes to the expression of Msh2 and Aldh1b1 (target 
proteins), the proliferation marker Ki-67, the Wnt pathway marker β-Catenin, the DNA 
damage marker γ-H2AX, the DNA damage / tumour suppressor marker p53, and cCas-3 a 
critical executioner of apoptosis.  DAB was used to visualise positive staining by these 
antibodies. IHC staining for these antibodies was performed using protocols described in 
Materials and Methods (Chapter 2, 2.2.3). Staining and quantification was performed either 














6.5.2.1 Msh2 immunohistochemical analyses of intestinal samples from Aldh1b1 
conditional-knockout Msh2-LS and Aldh1b1 constitutive-knockout Msh2-LS mouse 
models  
6.5.2.1.1 Msh2 immunostaining of Aldh1b1 conditional-knockout Msh2-LS murine small 
intestinal and colonic tissues 
We investigated Msh2 expression in Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice. 
We used small intestinal samples of Msh2-/- and WT mice as Msh2-negative and -positive 
expression controls respectively (Figure 6.41). The lack of IHC DAB-brown staining in all of 
the SI crypts and villi and in all of the colonic crypts of the Msh2-/- mice confirmed complete 
loss of Msh2 expression in the Msh2-null control tissues. In contrast, scattered crypts, in both 
SI and colon, showed Msh2 expression loss in the Msh2-LS model mice.  
The number of Msh2-negative crypts was higher in the SI than in the colon in 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice, however no tumours were observed in the small intestine. 
The number of Msh2-negative crypts in the SI was statistically significantly higher in the 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice compared with the H2O_Aldh1b1fl/fl_Msh2fl KO mice (Figure 
6.42). In EtOH_Aldh1b1fl/fl_Msh2fl KO mice, 43% Msh2-negative small intestinal crypts were 
observed compared with 24% Msh2-negative small intestinal crypts found in 
H2O_Aldh1b1fl/fl_Msh2fl KO mice (Figure 6.43).  
IHC analysis of Msh2 expression in the intestinal tissue samples from 
EtOH_Aldh1b1fl/fl_Msh2fl mice and H2O_Aldh1b1fl/fl_Msh2fl mice showed no Msh2-negative 
crypts in either small or large intestinal mucosal epithelium (Figures 6.44-6.45), consistent 
with lack of induction of Cre activity with continued expression of protein from the floxed 
Msh2 allele.  
In the colon, the number of Msh2-negative crypts was statistically significantly higher in the 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice compared with the H2O_Aldh1b1fl/fl_Msh2fl KO control mice 
(Figure 6.46). In EtOH_Aldh1b1fl/fl_Msh2fl KO mice 17% Msh2-negative colonic crypts were 
observed compared with 7% Msh2-negative colonic crypts found in H2O_Aldh1b1fl/fl_Msh2fl 
KO control mice (Figure 6.47). EtOH_Aldh1b1fl/fl_Msh2fl KO mice formed some caecal and some 
colonic adenomas that were characterized by Msh2-negative dysplastic glands often 
surrounded by or admixed with Msh2-positive crypts showing reactive or hyperproliferative 




Figure 6.41: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal 
epithelium from a positive-control WT mouse (A), in which the brown staining indicates positive Msh2 
expression in all crypts (further magnified in the red rectangle); and from a negative-control Msh2-/- 
mouse (B), in which the lack of brown staining confirms the absence of Msh2 expression in small 
intestinal mucosal epithelium (further magnified in the red rectangle). Images taken from anti-Msh2 
IHC stained sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu 
NDP Viewer software at 10X and 20X magnification (bar at lower left indicates 250μm, bar in red 






Figure 6.42: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal epithelium of Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated 
with either 20% ethanol in drinking water (A) or normal / standard drinking water (B). Msh2-negative crypts (indicated by the red arrows) were manually counted along the entire 
small intestine of treated Aldh1b1flox/flox; Msh2-LS mice (C). Paired Students t Test, *p= 0.0169 vs. water (data shown as mean±SD, n=3 mice in each group). Images taken from 




Figure 6.43: Percentage of Msh2 protein-non-expressing crypts in small intestinal mucosa of 
Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water 
or normal / standard water. Paired Students t Test, **p=0.0056 vs. water (data shown as mean±SD, 200 
crypts counted in 3 mice from each group).  
 
 
Figure 6.44: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal 
epithelium of non-induced Aldh1b1 conditional-knockout Msh2-LS control mice treated with either 20% 
of ethanol in drinking water (A) or normal / standard water (B). No Msh2-negative crypts were observed 
along the entire colon of non-induced Aldh1b1 conditional-knockout Msh2-LS mice in either the ethanol- 
or water-treated groups (n=3 mice in each group). Images taken from sections scanned using the 
Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X 




Figure 6.45: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal 
epithelium of non-induced Aldh1b1 conditional-knockout Msh2-LS control mice treated with either 20% 
ethanol in drinking water (A) or normal / standard drinking water (B). No Msh2-negative crypts were 
observed along the entire small intestine of non-induced Aldh1b1 conditional-knockout Msh2-LS mice in 
either the ethanol- or water-treated groups (n=3 mice in each group). Images taken from sections scanned 
using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X 





Figure 6.46: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal epithelium of of  Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated 
with either 20% ethanol in drinking water (A) or normal/standard water (B). Msh2-negative crypts (indicated by the red rectangle and further magnified in the upper right inset 
red rectangle in Figures A and B) were manually counted along the entire colon of treated Aldh1b1flox/flox Msh2-LS mice (C). Mann-Whitney U Test, *p=0.0210 vs. water (data 
shown as mean±SD, n=5 mice each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 




Figure 6.47: Percentage of Msh2 protein-non-expressing crypts in large intestinal mucosa of 
Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking 
water or normal/standard water. Paired Students t Test, ***p=0.0006 vs. water (data shown as 
mean±SD, 200 crypts counted in 5 mice from each group).  
 
 
Figure 6.48: Representative images of immunohistochemical staining for Msh2 in adenomas from 2 
ethanol-treated Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice. In both examples, a caecal 
adenoma (A) and a colonic adenoma (B), there are Msh2-negative dysplastic or adenomatous glands, 
either surrounded by or admixed with reactive crypts or hyperproliferative crypts that are staining 
positively for Msh2. Images taken from sections scanned using the Hamamatsu Nanozoomer and 




6.5.2.1.2 Msh2 immunostaining of Aldh1b1 constitutive-knockout Msh2-LS murine small 
intestinal and colonic tissues 
Msh2 IHC analyses were performed to verify or investigate Msh2 expression in Aldh1b1-/-; 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice. Details of the positive and negative controls are 
reported in the previous section (6.5.2.1.1, Figure 6.41). The number of Msh2-negative crypts 
was higher in the SI than in the colon in EtOH_Aldh1b1-/-_Msh2fl KO mice, however no tumours 
were observed in the small intestine. The number of Msh2-negative crypts in the SI was 
statistically significantly higher in the EtOH_Aldh1b1-/-_Msh2fl KO mice compared with the 
H2O_Aldh1b1-/-_Msh2fl KO mice (Figure 6.49). In EtOH_Aldh1b1-/-_Msh2fl KO mice, 55.7% Msh2-
negative small intestinal crypts were observed compared with 28% Msh2-negative small 
intestinal crypts found in H2O_Aldh1b1-/-_Msh2fl KO mice (Figure 4.50).  
IHC analysis of Msh2 expression in the intestinal tissue samples from EtOH_Aldh1b1-/-_Msh2fl 
mice and H2O_Aldh1b1-/-_Msh2fl mice showed no Msh2-negative crypts in either small or 
large intestinal mucosal epithelium (Figure 6.51-6.52), consistent with lack of induction of 
Cre activity with continued expression of protein from the floxed Msh2 allele.  
In the colon, the number of Msh2-negative crypts was statistically significantly higher in the 
EtOH_Aldh1b1-/-_Msh2fl KO mice compared with the H2O_Aldh1b1-/-_Msh2fl KO (Figure 6.53). 
In EtOH_Aldh1b1-/-_Msh2fl KO mice 29% Msh2-negative colonic crypts were observed 
compared with 10% Msh2-negative colonic crypts found in H2O_Aldh1b1-/-_Msh2fl KO control 
mice (Figure 6.54). EtOH_Aldh1b1-/-_Msh2fl KO mice formed some caecal and some colonic 
adenomas that were characterized by Msh2-negative dysplastic glands often surrounded by 





Figure 6.49 Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal epithelium of Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with 
either 20% ethanol in drinking water (A) or normal / standard drinking water (B). Msh2-negative crypts (indicated by the red arrows) were manually counted along the entire 
small intestine of treated Aldh1b1-/- Msh2-LS mice (C). Paired Students t Test, *p= 0.0246 vs. water (data shown as mean±SD, n=3 mice in each group). Images taken from sections 




Figure 6.50: Percentage of Msh2 protein-non-expressing crypts in small intestinal mucosa of Aldh1b1-/-; 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal / 
standard water. Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 200 crypts 
counted in 3 mice from each group).  
 
 
Figure 6.51: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal 
epithelium of non-induced Aldh1b1 constitutive-knockout Msh2-LS control mice treated with either 20% 
of ethanol in drinking water (A) or normal / standard water (B). No Msh2-negative crypts were observed 
along the entire colon of non-induced Aldh1b1-/- Msh2-LS mice (n=3 mice in each group). Images taken 
from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 
software at 10X and 20X magnification (bar at lower left indicates 250μm, bar in red rectangle indicates 




Figure 6.52: Immunohistochemical analysis of Msh2 protein expression in small intestinal mucosal 
epithelium of non-induced Aldh1b1 constitutive-knockout Msh2-LS control mice treated with either 20% 
ethanol in drinking water (A) or normal / standard drinking water (B). No Msh2-negative crypts were 
observed along the entire small intestine of non-induced Aldh1b1-/- Msh2-LS mice (n=3 mice in each 
group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the 





Figure 6.53: Immunohistochemical analysis of Msh2 protein expression in large intestinal mucosal epithelium of Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with 
either 20% ethanol in drinking water (A) or normal/standard water (B). Msh2-negative crypts (indicated by the red square/rectangle and further magnified in the upper right 
inset red rectangle in figures A and B) were manually counted along the entire colon of treated Aldh1b1-/- Msh2-LS mice (C). Mann-Whitney U Test, **p=0.0085 vs. water (data 
shown as mean±SD, n=5 mice each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 




Figure 6.54: Percentage of Msh2 protein-non-expressing crypts in large intestinal mucosa of Aldh1b1-
/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or 
normal/standard water. Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 200 
crypts counted in 5 mice from each group).  
 
 
Figure 6.55: Representative images of immunohistochemical staining for Msh2 in adenomas from 2 
Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- ethanol-treated mice. In both examples, a caecal 
adenoma (A) and a colonic adenoma (B), there are Msh2-negative dysplastic or adenomatous glands, 
either surrounded by or admixed with reactive crypts or hyperproliferative crypts that are staining 
positively for Msh2. Images taken from sections scanned using the Hamamatsu Nanozoomer and 




6.5.2.2 Aldh1b1 immunostaining of Aldh1b1 conditional-knockout Msh2-LS and 
Aldh1b1 constitutive-knockout Msh2-LS murine small intestinal and colonic tissues 
Aldh1b1 protein is highly expressed in the intestinal epithelial cells. In normal small 
intestines, there is strong Aldh1b1 cytoplasmic immunostaining in the crypt epithelial cells, 
but this fades in the non-dividing differentiated SI villus cells. In contrast in normal colon, 
Aldh1b1 cytoplasmic immunostaining appears homogeneous along the crypt axis (Müller et 
al., 2016). We used colonic tissue samples of WT and Aldh1b1tm2a(EUCOMM)Wtsi mice (mice with 
depletion of Aldh1b1, used by Müller at al., 2016) as Aldh1b1-positive and Aldh1b1-negative 
expression controls respectively (Figure 6.56).  
In Aldh1b1flox/flox conditional-knockout Msh2-LS mice, Tamoxifen treatment induced the loss 
of Aldh1b1 expression, together with the loss of Msh2, in Lgr5+ expressing crypt epithelial 
stem cells scattered along the entire small and large intestines (Figure 6.57). Aldh1b1-
negative crypts were observed in the intestinal samples of EtOH_Aldh1b1fl/fl_Msh2fl KO and 
H2O_Aldh1b1fl/fl_Msh2fl KO mice (Figure 6.58). IHC analysis of Aldh1b1 expression in the 
intestinal tissue samples from EtOH_Aldh1b1fl/fl_Msh2fl mice and H2O_Aldh1b1fl/fl_Msh2fl 
mice showed no Aldh1b1-negative crypts in either small or large intestinal mucosal 
epithelium (Figure 6.59), consistent with lack of induction of Cre activity with continued 
expression of protein from the floxed Aldh1b1 allele.  
In Aldh1b1-/- constitutive-knockout Msh2-LS mice, Aldh1b1 is permanently inactivated in all 
tissues and cells (Tamoxifen treatment is not required to induce the loss of Aldh1b1 
expression).  Immunohistochemical analysis of Aldh1b1 expression in the intestinal tissue 
samples from both Tamoxifen induced and non-induced (no Tamoxifen treatment) Aldh1b1-
/- Msh2-LS model mice treated with either 20% ethanol in drinking water or normal water 
showed only Aldh1b1-negative crypts in both small intestinal and large intestinal mucosal 





Figure 6.56: Immunohistochemical analysis of Aldh1b1 protein expression in colonic mucosal 
epithelium from a positive-control WT mouse (A), in which the brown staining indicates positive 
Aldh1b1 expression in all crypts (further magnified in the red rectangle); and from a negative-control 
Aldh1b1tm2a (EUCOMM)Wtsi mouse (B), in which the lack of brown staining confirms the absence of Aldh1b1 
expression in colonic mucosal epithelium (further magnified in the red rectangle). The Aldh1b1 protein 
is predominantly located in the cytoplasm of epithelial cells. Images taken from anti-Aldh1b1 IHC 
stained sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP 




Figure 6.57: Representative comparison between Msh2 and Aldh1b1 immunostaining of adjacent 
serial sections of caecum of Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice treated with 
Tamoxifen to activate Cre in scattered crypts. The same dMMR crypt foci (A) are negative for Msh2 
and negative for Aldh1b1 (B) (red ovals). Images taken using the Hamamatsu Nanozoomer and 
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Figure 6.58: Immunohistochemical analysis of Aldh1b1 protein expression in large intestinal (A&B) and 
small intestinal (C and D) mucosal epithelium of Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- 
mice treated with either 20% ethanol in drinking water (A and C) or normal/standard water (B and D). 
Colonic Aldh1b1-negative crypts are indicated by the red rectangle and further magnified in the upper 
right inset red rectangle in figure panels A and B and small intestinal Aldh1b1-negative crypts are 
indicated by the red arrows in figure panels C and D. Images taken from sections scanned using the 
Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X 




Figure 6.59: Immunohistochemical analysis of Aldh1b1 protein expression in intestinal mucosal 
epithelium of non-induced (no Tamoxifen treatment) Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/- mice treated with either 20% ethanol in drinking water (A and C) or normal/standard water 
(B and D). Normal Aldh1b1 expression is observed in colonic mucosal epithelium (Aldh1b1-positive 
crypts indicated by the red rectangle and further magnified in the upper right inset red rectangle in 
figure panels A and B) and in small intestinal mucosal epithelium (C and D). Images taken from sections 
scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software 





Figure 6.60: Immunohistochemical analysis of Aldh1b1 protein expression in intestinal mucosal 
epithelium of Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice treated with either 20% ethanol in 
drinking water (A and C) or normal/standard water (B and D). Complete loss of Aldh1b1 expression is 
observed in colonic mucosal epithelium (Aldh1b1-negative crypts are indicated by the red rectangle 
and further magnified in the upper right inset red rectangle in figure panels A and B) and in small 
intestinal mucosal epithelium (C and D). Images taken from sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification 




Figure 6.61: Immunohistochemical analysis of Aldh1b1 protein expression in intestinal mucosal 
epithelium of non-induced (no Tamoxifen treatment) Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- 
mice treated with either 20% ethanol in drinking water (A and C) or normal/standard water (B and D). 
Complete loss of Aldh1b1 expression is observed in colonic mucosal epithelium (Aldh1b1-negative 
crypts are indicated by the red rectangle and further magnified in the upper right inset red rectangle 
in  A and B) and in small intestinal mucosal epithelium (C and D). Images taken from sections scanned 
using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X 






6.5.2.2 Ki-67 immunohistochemical analyses of intestinal samples from Aldh1b1 
conditional-knockout Msh2-LS and Aldh1b1 constitutive-knockout Msh2-LS mouse 
models  
6.5.2.2.1 Ki-67 immunostaining of Aldh1b1 conditional-knockout Msh2-LS murine small 
intestinal and colonic tissues 
Immunohistochemical analysis of Ki-67 showed large and significant differences in the 
number of intestinal Ki-67-positive cells between EtOH_Aldh1b1fl/fl_Msh2fl KO murine colon 
and H2O_Aldh1b1fl/fl_Msh2fl KO murine colon (Figure 6.62). The percentage of Ki-67-positive 
cells per crypt was significantly higher in EtOH_Aldh1b1fl/fl_Msh2fl KO mice (80.6%) compared 
with H2O_Aldh1b1fl/fl_Msh2fl KO mice (27.3%) (Figure 6.63), consistent with the large regions 
of mucosal crypt hyperproliferation, that show extended crypt lengths, observed in H&E 
stained sections of EtOH_Aldh1b1fl/fl_Msh2fl KO murine colons (Figure 6.64).   
The comparative analysis of SI Ki-67 expression between EtOH_Aldh1b1fl/fl_Msh2fl KO and 
H2O_Aldh1b1fl/fl_Msh2fl KO mice didn’t show the same large differences. 
EtOH_Aldh1b1fl/fl_Msh2fl KO murine SI showed similar numbers of Ki-67-positive cells per 
crypt when compared with H2O_Aldh1b1fl/fl_Msh2fl KO mice SI, with no significant differences 
observed between the two groups (Figure 6.65). However, the percentage of Ki-67-positive 
cells per crypt was significantly higher in SI of EtOH_Aldh1b1fl/fl_Msh2fl KO mice (13.5%) 





Figure 6.62: Immunohistochemical analysis of Ki-67 protein expression in large intestinal mucosal epithelium of Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated 
with either 20% of ethanol in drinking water (A) or normal/standard water (B) (magnified in the upper right inset red rectangles in figure panels A and B). Numbers of Ki-67-
positive cells per colonic crypt were manually counted (C). Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 30 crypts per mouse were analysed, n=4 
mice in each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X 




Figure 6.63: Percentage of Ki-67 protein expressing cells in large intestinal mucosal crypts of 
Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water 
or normal / standard water. Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 30 
crypts per mouse counted, n=4 mice from each group).  
 
 
Figure 6.64: Quantification of the colonic crypt lengths (in μm) comparing colons from ethanol-treated 
versus water-treated Aldh1b1flox/flox Msh2-LS mice. Mann-Whitney U test analysis, ****p<0.0001 vs. water 




Figure 6.65: Immunohistochemical analysis of Ki-67 protein expression in small intestinal mucosa of Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 
20% ethanol in drinking water (A) or normal / standard drinking water (B). Ki-67-positive cells per colonic crypt/villus were counted using QuPath (C). Paired Students t Test, (data 
shown as mean±SD, 30 crypts/villi per mouse were analysed, n=3 mice in each group) showed no statistical differences were observed between these 2 groups. Images taken 





Figure 6.66: Percentage of Ki-67 protein expressing cells in small intestinal mucosa of Aldh1b1flox/flox; 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal 
/ standard water. Paired Students t Test, ***p=0.0005 vs. water (data shown as mean±SD, 30 crypts 


















6.5.2.2.2 Ki-67 immunostaining of Aldh1b1 constitutive-knockout Msh2-LS murine small 
intestinal and colonic tissues 
Immunohistochemical analysis of Ki-67 showed large and significant differences in the 
number of intestinal Ki-67-positive cells between the EtOH_Aldh1b1-/-_Msh2fl KO murine 
colon and the H2O_Aldh1b1-/-_Msh2fl KO murine colon (Figure 6.67). The percentage of Ki-67-
positive cells per crypt was significantly higher in EtOH_Aldh1b1-/-_Msh2fl KO mice (87%) 
compared with H2O_Aldh1b1-/-_Msh2fl KO mice (25.3%) (Figure 6.68), consistent with the large 
regions of crypt hyperproliferation, that show extended crypt lengths, observed in H&E 
stained sections of EtOH_Aldh1b1-/-_Msh2fl KO murine colons (Figure 6.69). 
The comparative analysis of SI Ki-67 expression between EtOH_Aldh1b1-/-_Msh2fl KO and 
H2O_Aldh1b1-/-_Msh2fl KO mice didn’t show the same large differences. EtOH_Aldh1b1-/-
_Msh2fl KO murine SI showed similar numbers of Ki-67-positive cells per crypt compared with 
H2O_Aldh1b1-/-_Msh2fl KO mice SI, with no significant differences observed between the two 
groups (Figure 6.70). The percentage of Ki-67-positive cells per crypt was significantly higher 
in SI of EtOH_Aldh1b1-/-_Msh2fl KO mice (17.8%) compared with H2O_Aldh1b1-/-_Msh2fl KO 




Figure 6.67: Immunohistochemical analysis of Ki-67 protein expression in large intestinal mucosal epithelium of Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with 
either 20% of ethanol in drinking water (A) or normal/standard water (B). Numbers of Ki-67-positive cells per colonic crypt (magnified in the upper right inset red rectangles in 
figure panels A and B) were manually counted (C). Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 30 crypts per mouse were analysed, n=4 mice in 
each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification (bar 




Figure 6.68: Percentage of Ki-67 protein expressing cells in large intestinal mucosal crypts of Aldh1b1-/-; 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal / 
standard water. Paired Students t Test, ****p<0.0001 vs. water (data shown as mean±SD, 30 crypts per 
mouse counted, n=4 mice from each group).  
 
 
Figure 6.69: Quantification of the colonic crypt lengths (in μm) comparing colons from ethanol-treated 
versus water-treated Aldh1b1-/- Msh2-LS mice. Paired Students t Test, ****p<0.0001 vs. water (data 




Figure 6.70: Immunohistochemical analysis of Ki-67 protein expression in small intestinal mucosa of Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with 
either 20% ethanol in drinking water (A) or normal / standard drinking water (B). Ki-67-positive cells per colonic crypt/villus were counted using QuPath (C). Paired 
Students t test, (data shown as mean±SD, 30 crypts/villi per mouse were analysed, n=3 mice in each group) showed no statistical differences were observed between 
the 2 groups. Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X magnification 




Figure 6.71: Percentage of Ki-67 protein expressing cells in small intestinal mucosa of Aldh1b1-/-; 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water or normal 
/ standard water. Paired Students t test, *p=0.0127 vs. water (data shown as mean±SD, 30 crypts per 
















6.5.2.3 Beta-Catenin immunostaining of Aldh1b1 conditional-knockout Msh2-LS 
and Aldh1b1 constitutive-knockout Msh2-LS murine small intestinal and colonic 
tissues 
We investigated β-catenin expression in Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-
mice and Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-. β-catenin IHC was performed with 
assistance from Marion Bacou using large intestinal samples from Apc Min mice that 
contained large intestinal adenomas (provided by Vidya Rajasekaran), and WT mice as β-
catenin-positive and β-catenin-normal expression controls respectively (Figure 4.41). Details 
of the IHC positive and normal β-catenin expression controls were reported in Chapter 4 
(4.4.2.3). The IHC analysis of β-catenin was performed on large intestinal adenomas and 
caecal adenomas from Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice (Figure 6.72) 
and Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- (Figure 6.73). Analysed samples showed a 
heterogeneous pattern with variable numbers of adenoma cells showing positive β-catenin 




Figure 6.72: Representative images of immunohistochemical analysis of β-catenin protein expression and localisation in large intestinal adenomas of Aldh1b1-/-; 
Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with 20% ethanol in drinking water. Variable areas of positive β-catenin nuclear immunostaining in adenomatous cells 
were observed in colonic adenomas (A-C), indicated by the red ovals. Selected areas (red ovals) within images in panels A-C are further magnified in panels D-F, and 
clusters of cells with nuclei positive for β-catenin are indicated by the red arrows. Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed 




Figure 6.73: Representative images of immunohistochemical analysis of β-catenin protein expression and localisation in intestinal adenomas of Aldh1b1-/-; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with 20% ethanol in drinking water. Variable areas of positive β-catenin nuclear immunostaining in adenomatous cells were 
observed in both caecal adenomas (A) and colonic adenomas (B&C), indicated by the red ovals. Selected areas (red ovals) within images in panels A-C are further 
magnified in panels D-F, and clusters of cells with nuclei positive for β-catenin are indicated by the red arrows. Images taken from sections scanned using the 
Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 40X magnification (bar at lower left indicates 250μm and 50μm).  
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6.5.2.4 DNA damage response evaluation by immunohistochemistry of Aldh1b1 
conditional-knockout Msh2-LS and Aldh1b1 constitutive-knockout Msh2-LS murine 
small intestinal and colonic tissues 
6.5.2.4.1 DNA damage response evaluation by Gamma-H2AX immunostaining of Aldh1b1 
conditional-knockout Msh2-LS murine small intestinal and colonic tissues 
In order to evaluate the presence and extent of DNA damage, y-H2AX immunostaining was 
used. We used colonic tissue samples from WT mice and TMZ-treated Msh2-LS mice as 
negative and positive y-H2AX expression controls, respectively. Details of the negative and 
positive y-H2AX expression controls can be found in Chapter 4 (4.4.2.4.1; Figure 4.43). IHC 
analysis of y-H2AX showed large and significant differences in the number of intestinal y-
H2AX-positive cells between the EtOH_Aldh1b1fl/fl_Msh2fl KO murine colon and the 
H2O_Aldh1b1fl/fl_Msh2fl KO murine colon (Figure 6.74). The percentage of y-H2AX-positive 
cells per crypt was significantly higher in EtOH_Aldh1b1fl/fl_Msh2fl KO mice (38.7%) compared 
with H2O_Aldh1b1fl/fl_Msh2fl KO mice (0.5%) (Figure 6.74), consistent with 
ethanol/acetaldehyde induced DNA damage.  The comparative analysis of SI y-H2AX 
expression between EtOH_Aldh1b1fl/fl_Msh2fl KO and H2O_Aldh1b1fl/fl_Msh2fl KO mice didn’t 
show any differences, as EtOH_Aldh1b1fl/fl_Msh2fl KO and H2O_Aldh1b1fl/fl_Msh2fl KO murine SI 
showed no y-H2AX-positive cells (Figure 6.75). EtOH_Aldh1b1fl/fl_Msh2fl KO Msh2-LS murine 





Figure 6.74: Immunohistochemical analysis of y-H2AX protein expression in large intestinal mucosal epithelium of Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-
mice treated with either 20% ethanol in drinking water (A) or normal/standard water (B). Gamma-H2AX-positive cells in colonic crypts (further magnified in the upper 
right inset red rectangle in figure panel A) were observed in ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl KO) mice but not in water-treated 
Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl/fl_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel B). Numbers of y-H2AX-positive cells 
per colonic crypt were counted using QuPath to calculate the percentage of y-H2AX-positive cells (C) and these showed a large and statistically significant difference. 
Paired Students t-Test, ****p<0.0001 vs. water (data shown as mean±SD, 40 crypts per mouse were analysed, n=4 mice in each group). Images taken from sections 
scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification (bar at lower left indicates 250μm, 





Figure 6.75: Immunohistochemical analysis of y-H2AX protein expression in small intestinal mucosa of 
Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking 
water (A) or normal / standard drinking water (B). No y-H2AX-positive cells were observed in either 
sample. Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with 





Figure 6.76: Representative images of y-H2AX immunohistochemical staining in a large intestinal 
adenoma (A) and a caecal adenoma (B) from 2 ethanol-treated Aldh1b1flox/flox; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mice. In both examples, there are numerous y-H2AX-positive cells within the 
regions of dysplastic cells in the adenomas. Images are further magnified in panels C and D. Images 
taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu 










6.5.2.4.2 DNA damage response evaluation by Gamma-H2AX immunostaining of Aldh1b1 
constitutive-knockout Msh2-LS murine small intestinal and colonic tissues 
Details of the negative and positive y-H2AX IHC expression controls can be found in Chapter 
4 (4.4.2.4.1; Figure 4.43). IHC analysis of y-H2AX showed large and significant differences in 
the number of intestinal y-H2AX-positive cells between the EtOH_Aldh1b1-/-_Msh2fl KO 
murine colon and the H2O_Aldh1b1-/-_Msh2fl KO murine colon (Figure 6.77). The percentage 
of y-H2AX-positive cells per crypt was significantly higher in EtOH_Aldh1b1-/-_Msh2fl KO mice 
(46%) compared with H2O_Aldh1b1-/-_Msh2fl KO mice (0.5%) (Figure 6.77), consistent with 
ethanol/acetaldehyde induced DNA damage.  The percentage of SI y-H2AX-positive cells was 
higher in EtOH_Aldh1b1-/-_Msh2fl KO mice (3.4%) compared with H2O_Aldh1b1-/-_Msh2fl KO 
mice (0.1%) (Figure 6.78). EtOH_Aldh1b1-/-_Msh2fl KO murine large intestinal adenomas, both 




Figure 6.77: Immunohistochemical analysis of y-H2AX protein expression in large intestinal mucosal epithelium of Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice 
treated with either 20% ethanol in drinking water (A) or normal/standard water (B). Gamma-H2AX-positive cells in colonic crypts (further magnified in the upper right 
inset red rectangle in figure panel A) were observed in ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice but not in water-treated Aldh1b1-/- Msh2-
LS (H2O_Aldh1b1-/-_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel B). Numbers of y-H2AX-positive cells per colonic crypt were 
counted using QuPath to calculate the percentage of y-H2AX-positive cells (C) and these showed a large and statistically significant difference. Paired Students t-Test, 
****p<0.0001 vs. water (data shown as mean±SD, 40 crypts per mouse were analysed, n=4 mice in each group). Images taken from sections scanned using the 








Figure 6.78: Immunohistochemical analysis of y-H2AX protein expression in small intestinal mucosal epithelium of Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice 
treated with either 20% ethanol in drinking water (A) or normal/standard water (B). Gamma-H2AX-positive cells in small intestinal crypts (further magnified in the 
upper right inset red rectangle in figure panel A) were observed in ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice but not in water-treated 
Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel B). Numbers of y-H2AX-positive cells per 
small intetsinal crypt were counted using QuPath to calculate the percentage of y-H2AX-positive cells (C) and these showed a large and statistically significant 
difference. Paired Students t-Test, **p<0.0012 vs. water (data shown as mean±SD, 40 crypts per mouse were analysed, n=4 mice in each group). Images taken from 
sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification (bar at lower left indicates 




Figure 6.79: Representative images of y-H2AX immunohistochemical staining in a caecal adenoma (A) 
and a large intestinal adenoma (B) from 2 ethanol-treated Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/- mice. In both examples, there are numerous y-H2AX-positive cells within the regions of 
dysplastic cells in the adenomas. Images are further magnified in panels C and D. Images taken from 
sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 











6.5.2.4.3 DNA damage response evaluation by p53 immunostaining of Aldh1b1 
conditional-knockout Msh2-LS murine small intestinal and colonic tissues 
As reported in Chapter 4 (4.4.2.4.2), p53 IHC was performed to detect activation of DNA 
damage response mechanisms (referred as p53 “wildtype pattern”) (Köbel et al., 2016; Lakin 
& Jackson, 1999). We used colonic tissue samples from WT mice and TMZ-treated Msh2-LS 
mice as p53-wildtype and p53-positive expression (resulting from TMZ-induced DNA 
damage) controls, respectively. Details of the wildtype and positive p53 expression controls 
can be found in Chapter 4 (4.4.2.4.2, Figure 4.47).  
In Aldh1b1flox/flox Msh2-LS mice, IHC analysis of p53 showed large and significant differences 
in the number of intestinal p53-positive cells between the EtOH_Aldh1b1fl/fl_Msh2fl KO murine 
colon and the H2O_Aldh1b1fl/fl_Msh2fl KO murine colon (Figure 6.80). The percentage of cells 
with either moderate or high levels of p53-positive nuclear staining per crypt was 
significantly higher in EtOH_Aldh1b1fl/fl_Msh2fl KO mice (52.7%) compared with 
H2O_Aldh1b1fl/fl_Msh2fl KO mice (6.3%) (Figure 6.80), consistent with an 
ethanol/acetaldehyde induced DNA damage response.   
The percentage of small intestinal p53-positive cells per crypt was higher in 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice (21.7%) compared with H2O_Aldh1b1fl/fl_Msh2fl KO mice 
(3.3%) (Figure 6.81). EtOH_Aldh1b1fl/fl_Msh2fl KO murine large intestinal adenomas, both 
colonic and caecal, showed high percentages of p53-positive cells, with variably moderate to 
marked nuclear p53 positivity with some surrounding or mixed cells showing p53-negative 
nuclei in a “p53 wildtype” pattern, indicative of a widespread response to DNA damage, 






Figure 6.80: Representative images of immunohistochemical analysis of p53 protein expression in large intestinal mucosal epithelium of Aldh1b1flox/flox; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water (A) or normal/standard water (B). The percentage of positive p53-positive nuclei in 
colonic crypts in ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel A) 
was higher compared with water-treated Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl/fl_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure 
panel B). Numbers of cells with positive p53 nuclear staining per colonic crypt were counted using QuPath to calculate the percentage of p53-positive cells (C) and 
these showed a statistically significant difference. Paired Students t-Test, ***p<0.0002 vs. water (data shown as mean±SD, 40 crypts per mouse were analysed, n=4 
mice in each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X 








Figure 6.81: Representative images of immunohistochemical analysis of p53 protein expression in small intestinal mucosal epithelium of Aldh1b1flox/flox; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water (A) or normal/standard water (B). The percentage of positive p53-nuclear stained cells 
in small intestinal crypts was higher in ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl KO) mice compared with water-treated Aldh1b1flox/flox Msh2-LS 
(H2O_Aldh1b1fl/fl_Msh2fl KO) mice. Numbers of cells with positive p53 nuclear staining per small intestinal crypt were counted using QuPath to calculate the percentage 
of p53-positive cells (C) and these showed a statistically significant difference. Paired Students t-Test, ***p<0.0001 vs. water (data shown as mean±SD, 40 crypts per 
mouse were analysed, n=4 mice in each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP 




Figure 6.82: Representative images of p53 immunohistochemical staining in a colonic adenoma (A and 
C) and a caecal adenoma (B and D), from 2 ethanol-treated Aldh1b1flox/flox; Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/- mice. In both examples, there are numerous p53-positive nuclei (variably moderate to high 
p53 nuclear staining with some p53-negative nuclei) within the regions of dysplastic cells in the 
adenomas. Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with 
the Hamamatsu NDP Viewer software at 10X (A and B) and 40X (C and D) magnification (bar at lower 












6.5.2.4.4 DNA damage response evaluation by p53 immunostaining of Aldhd1b1 
constitutive-knockout Msh2-LS murine small intestinal and colonic tissues 
Details of the normal and positive p53 expression controls can be found in Chapter 4 
(4.4.2.4.2, Figure 4.47).  
In Aldh1b1-/- Msh2-LS mice, IHC analysis of p53 showed large and significant differences in 
the number of intestinal p53-positive cells between the EtOH_Aldh1b1-/-_Msh2fl KO murine 
colon and the H2O_Aldh1b1-/-_Msh2fl KO murine colon (Figure 6.83). The percentage of cells 
with either moderate or high levels of p53-positive nuclear staining per crypt was 
significantly higher in EtOH_Aldh1b1-/-_Msh2fl KO mice (47.5%) compared with H2O_Aldh1b1-
/-_Msh2fl KO mice (3.3%) (Figure 6.83), consistent with ethanol/acetaldehyde induced DNA 
damage.   
The percentage of small intestinal p53-positive cells per crypt was higher in EtOH_Aldh1b1-/-
_Msh2fl KO mice (20%) compared with H2O_Aldh1b1-/-_Msh2fl KO mice (4%) (Figure 6.84). 
EtOH_Aldh1b1-/-_Msh2fl KO murine large intestinal adenomas, both colonic and caecal, 
showed high percentages of p53-positive cells, with variably moderate to marked nuclear 
p53 positivity and some negative nuclei in a “p53 wildtype” pattern, as observed previously 




Figure 6.83: Representative images of immunohistochemical analysis of p53 protein expression in large intestinal mucosal epithelium of Aldh1b1-/-; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mice treated with either 20% ethanol in drinking water (A) or normal/standard water (B). The percentage of p53-positive nuclei in colonic 
crypts in ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel A) was higher 
compared with water-treated Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel B). Numbers 
of cells with positive p53 nuclear staining per colonic crypt were counted using QuPath to calculate the percentage of p53-positive cells (C) and these showed a 
statistically significant difference. Paired Students t-Test, ****p<0.0001 vs. water (data shown as mean±SD, 40 crypts per mouse were analysed, n=4 mice in each 
group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification 








Figure 6.84: Representative images of immunohistochemical analysis of p53 protein expression in small intestinal mucosal epithelium of Aldh1b1-/-; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-mice treated with either 20% ethanol in drinking water (A) or normal/standard water (B). The percentage of positive p53-nuclear stained cells 
in small intestinal crypts was higher in ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice compared with water-treated Aldh1b1-/- Msh2-LS 
(H2O_Aldh1b1-/-_Msh2fl KO) mice. Numbers of cells with positive p53 nuclear staining per small intestinal crypt were counted using QuPath to calculate the percentage 
of p53-positive cells (C) and these showed a statistically significant difference. Paired Students t-Test, *p<0.0105 vs. water (data shown as mean±SD, 40 crypts per 
mouse were analysed, n=4 mice in each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP 




Figure 6.85: Representative images of p53 immunohistochemical staining in a colonic adenoma (A and 
C) and a caecal adenoma (B and D), from 2 ethanol-treated Aldh1b1-/-; Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/- mice. In both examples, there are numerous p53-positive nuclei (variably moderate to high 
p53 nuclear staining with some p53-negative nuclei) within the regions of dysplastic cells in the 
adenomas. Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with 
the Hamamatsu NDP Viewer software at 10X (A and B) and 40X (C and D) magnification (bar at lower 





6.5.2.5 Cleaved Caspase-3 immunostaining of Aldh1b1 conditional-knockout Msh2-
LS and Aldh1b1 constitutive-knockout Msh2-LS murine small intestinal and colonic 
tissues 
Caspase-3 (Cas3) IHC was performed to identify cCas3-positive apoptotic bodies, as 
explained in Chapter 4 (4.4.2.5). Colonic mucosal tissue samples from WT mice and TMZ-
treated Msh2-LS mice were used as negative and positive controls, respectively. Details of 
the positive and negative controls can be found in Chapter 4 (4.4.2.5; Figure 4.51).  
In Aldh1b1flox/flox Msh2-LS mice, IHC analysis of cCas3 with quantification of cCas3-positive 
apoptotic bodies, showed significant differences in the numbers of cCas3-positive apoptotic 
bodies per 30 colonic crypts per mouse between the EtOH_Aldh1b1fl/fl_Msh2fl KO murine 
colonic epithelium and the H2O_Aldh1b1fl/fl_Msh2fl KO murine colonic epithelium. There were 
significantly higher numbers of cCas3+ apoptotic bodies in EtOH_Aldh1b1fl/fl_Msh2fl KO mice 
compared with no detectable cCas3+ apoptotic bodies in H2O_Aldh1b1fl/fl_Msh2fl KO mice 
(Figure 6.86), consistent with increased apoptosis associated with colonic epithelial exposure 
to ethanol/acetaldehyde. EtOH_Aldh1b1fl/fl_Msh2fl KO murine large intestinal adenomas 
showed no detectable cCas3+ apoptotic bodies, indicating rare to no apoptotic events in 
dMMR colonic tumours (Figure 6.87).  
In Aldh1b1-/- Msh2-LS mice, IHC analysis of cCas3 with quantification of cCas3-positive 
apoptotic bodies, showed significantly higher number of cCas3+ apoptotic bodies in 
EtOH_Aldh1b1-/-_Msh2fl KO mice compared with no detectable cCas3+ apoptotic bodies in 
H2O_Aldh1b1-/-_Msh2fl KO mice (Figure 6.89), consistent with increased apoptosis associated 
with colonic epithelial exposure to ethanol/acetaldehyde. EtOH_Aldh1b1-/-_Msh2fl KO murine 
large intestinal adenomas showed no detectable cCas3+ apoptotic bodies, indicating rare to 
no apoptotic events in dMMR colonic tumours (Figure 6.90). In both Aldh1b1flox/flox Msh2-LS 
mice and Aldh1b1-/- Msh2-LS mice, IHC analysis of cCas3 of small intestinal epithelium failed 




Figure 6.86: Representative images of immunohistochemical analysis of cCas3 in large intestinal mucosal epithelium of induced Aldh1b1flox/flox;  Msh2flox/-; Lgr5CreERT2+/-
; mTmG+/- mice treated with either 20% ethanol in drinking water (A), or normal/standard water (B). The number of apoptotic bodies positive for cCas3 in the colonic 
crypts of ethanol-treated Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in figure panel A) was 
significantly higher compared with that for water-treated Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl/fl_Msh2fl KO) mice, in which no apoptotic bodies were detected (further 
magnified in the upper right inset red rectangle in figure panel B). Numbers of cCas3-positive apoptotic bodies per colonic crypt were counted manually (C), showing 
a statistically significant difference. Paired Students t-Test, **p=0.0024 vs. water (data shown as mean±SD, 30 crypts per mouse were analysed, n=3 mice in each 
group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification 




Figure 6.87: Representative images of immunohistochemical analysis of cCas3 in a large intestinal 
adenoma (A and C) and a caecal adenoma (B and D), from 2 ethanol-treated Aldh1b1flox/flox; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mice. In both examples, there are almost no apoptotic bodies within the 
regions of dysplastic cells in the adenomas, indicating rare apoptotic events detectable in dMMR 
colonic adenomas. Images taken from sections scanned using the Hamamatsu Nanozoomer and 
analysed with the Hamamatsu NDP Viewer software at 10X (A and B) and 40X (C and D) magnification 




Figure 6.88: Representative images of immunohistochemical analysis of cCas3 in large intestinal mucosal epithelium of induced Aldh1b1-/-;  Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/-mice treated with either 20% ethanol in drinking water (A), or normal/standard water (B). The number of apoptotic bodies positive for cCas3 in the 
hyperproliferative colonic crypts of ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) mice (further magnified in the upper right inset red rectangle in 
figure panel A) was significantly higher compared with the colonic epithelium of water-treated Aldh1b1-/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl KO) mice, in which no 
apoptotic bodies were detected (further magnified in the upper right inset red rectangle in figure panel B). Numbers of cCas3-positive apoptotic bodies per colonic 
crypt were counted manually (C), showing a statistically significant difference. Paired Students t-Test, ***p=0.0001 vs. water (data shown as mean±SD, 30 crypts per 
mouse were analysed, n=3 mice in each group). Images taken from sections scanned using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP 




Figure 6.89: Representative images of immunohistochemical analysis of cCas3 in a large intestinal 
adenoma (A and C) and a caecal adenoma (B and D), from 2 ethanol-treated Aldh1b1-/-; Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mice. In both examples, there are almost no apoptotic bodies within the 
regions of dysplastic cells in the adenomas, indicating rare apoptotic events detectable in dMMR 
colonic adenomas. Images taken from sections scanned using the Hamamatsu Nanozoomer and 
analysed with the Hamamatsu NDP Viewer software at 10X (A and B) and 40X (C and D) magnification 
(bar at lower left indicates 250μm and 50 μm). 
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6.6 Plasma acetaldehyde concentrations from the Aldh1b1 conditional-
knockout Msh2-LS and Aldh1b1 constitutive-knockout Msh2-LS mouse 
models with and without ethanol treatment 
 
6.6.1 Methods 
During the necropsy dissection procedure, blood was taken from the Aldh1b1 conditional-
knockout Msh2-LS and Aldh1b1 constitutive-knockout Msh2-LS mice by post-mortem 
cardiac puncture. Blood was collected in heparinized tubes, which were centrifuged at 3000 
X g for 15 min at 4∘C to allow blood fractionation. Acetaldehyde is a highly volatile compound, 
classified as a VOC (Missia et al., 2010; Sarigiannis et al., 2011). To preserve the acetaldehyde 
concentration, plasma was collected in cryo-tubes and immediately snap-frozen in liquid 
nitrogen and stored at −80∘C until analysis. Plasma samples were analysed in a single batch 
and plasma acetaldehyde concentrations were determined using an enzymatic acetaldehyde 
assay kit (K-ACHYD; Megazyme), as described in Materials and Methods.  
 
6.6.2 Results 
In Aldh1b1flox/flox Msh2-LS mice, plasma acetaldehyde levels were analysed comparing 
samples from EtOH_Aldh1b1fl/fl_Msh2fl KO mice and H2O_Aldh1b1fl/fl_Msh2fl KO mice, as well 
as comparing these with EtOH_Aldh1b1fl/fl_Msh2fl mice and H2O_Aldh1b1fl/fl_Msh2fl mice, 
after long-term ethanol or water treatment (experimental mice were treated with ethanol 
for between 10 and 52 weeks prior to sacrifice). 
Plasma acetaldehyde levels were statistically significantly higher in EtOH_Aldh1b1fl/fl_Msh2fl 
KO mice compared with H2O_Aldh1b1fl/fl_Msh2fl KO mice (p=0.0019, Mann-Whitney U-test) 
(Figure 6.90). The difference in plasma acetaldehyde levels between H2O_Aldh1b1fl/fl_Msh2fl 
mice and EtOH_Aldh1b1fl/fl_Msh2fl mice did not show any statistically significant differences.  
Plasma acetaldehyde levels in the EtOH_Aldh1b1fl/fl_Msh2fl KO mice were slightly higher 
compared with the EtOH_Aldh1b1fl/fl_Msh2fl mice, but this difference was not statistically 
significant.  
In Aldh1b1-/- Msh2-LS mice, plasma acetaldehyde levels were analysed comparing samples 
from EtOH_Aldh1b1-/-_Msh2fl KO mice and H2O_Aldh1b1-/-_Msh2fl KO mice, as well as 
comparing these with EtOH_Aldh1b1-/-_Msh2fl mice and H2O_Aldh1b1-/-_Msh2fl mice after 
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long-term ethanol or water treatment (experimental mice were treated with ethanol for 
between 10 and 52 weeks prior to sacrifice). 
Plasma acetaldehyde levels were significantly higher in EtOH_Aldh1b1-/-_Msh2fl KO mice 
compared with H2O_Aldh1b1-/-_Msh2fl KO mice (p<0.0001) (Figure 6.91). Plasma acetaldehyde 
levels in EtOH_Aldh1b1-/-_Msh2fl mice were higher than those in H2O_Aldh1b1-/-_Msh2fl mice 
(p<0.0362).  Plasma acetaldehyde levels in EtOH_Aldh1b1-/-_Msh2fl KO mice were significantly 








Figure 6.90: Plasma acetaldehyde concentrations in ethanol- and water-treated Tamoxifen-induced 
Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl KO and H2O_ Aldh1b1fl/fl_Msh2fl KO respectively) mice 
and ethanol- and water-treated non-induced Aldh1b1flox/flox Msh2-LS (EtOH_Aldh1b1fl/fl_Msh2fl and 
H2O_Aldh1b1fl/fl_Msh2fl respectively) mice, after long-term ethanol or water treatment. Mann-
Whitney U-test was carried out to compare plasma acetaldehyde levels (*p=0.0159) (data shown as 





Figure 6.91: Plasma acetaldehyde concentrations in ethanol- and water-treated Tamoxifen-induced 
Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO and H2O_ Aldh1b1-/-_Msh2fl KO respectively) mice and 
ethanol- and water-treated non-induced Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl and H2O_ 
Aldh1b1-/-_Msh2fl respectively) mice, after long-term ethanol or water treatment. Mann-Whitney U-
test was carried out to compare plasma acetaldehyde concentrations in EtOH_Aldh1b1-/-_Msh2fl KO 
and H2O_ Aldh1b1-/-_Msh2fl KO mice (****p<0.0001), and it was carried out to compare plasma 
acetaldehyde concentrations in EtOH_Aldh1b1-/-_Msh2fl KO mice and EtOH_Aldh1b1-/-_Msh2fl mice 
(∆∆∆∆p<0.0001). Mann-Whitney U-test was carried out to compare plasma acetaldehyde 
concentrations in EtOH_Aldh1b1-/-_Msh2fl and H2O_ Aldh1b1-/-_Msh2fl mice (p=0.0362) (data shown 














In this chapter, the first aim was to introduce the conditional Aldh1b1 allele (Aldh1b1flox/flox) 
and the constitutive Aldh1b1 knockout allele (Aldh1b1-/-) by cross-breeding into the Msh2-LS 
mouse model, in order to establish an Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox 
colony and an Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1-/- colony.  To generate the 
Aldh1b1 conditional-knockout (Aldh1b1flox/flox) mice, the Aldh1b1 tm1a mice were cross-bred 
with Flpe mice and subsequently, the generated Msh2+/+; Lgr5CreERT2-/-; mTmG-/-; 
Aldh1b1flox/flox mice were cross-bred with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/+; Aldh1b1+/+ mice 
(Msh2-LS model mice) producing: 25% Msh2flox/+; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1fl/+ mice, 
25% Msh2flox/+; Lgr5CreERT2-/-; mTmG+/-; Aldh1b1fl/+ mice, 25% Msh2-/+; Lgr5CreERT2+/-; 
mTmG+/-; Aldh1b1fl/+ mice, and 25% Msh2-/+; Lgr5CreERT2-/-; mTmG+/-; Aldh1b1fl/+ mice. The 
resulting progeny were used as breeders for the creation of the Aldh1b1 conditional-
knockout Msh2-LS experimental subject mice. The mice derived from these matings were 
predicted to show 1.5% progeny with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox 
genotypes and 0.8% progeny with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/+; Aldh1b1flox/flox 
genotypes, and the actual progeny proportions were similar. In Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/-; Aldh1b1flox/flox, loss of Aldh1b1 activity following Cre recombinase activation only 
occurs in the scattered Lgr5-expressing intestinal epithelial stem cells (that go on to form 
crypt daughter cells) along with inactivation of the second allele of Msh2 and conversion to 
mG expression, by Cre recombinase activity induced following Tamoxifen treatment.  
To generate the Aldh1b1 constitutive-knockout (Aldh1b1-/-) mice, embryos from the Aldh1b1 
conditional-knockout (Aldh1b1flox/flox) mice were treated with TAT-Cre in vitro and implanted 
into surrogate mothers using standard techniques. Subsequently, the generated Msh2+/+; 
Lgr5CreERT2-/-; mTmG-/-; Aldh1b1-/- mice were cross-bred with Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/+; Aldh1b1+/+ mice (Msh2-LS model mice) producing: 25% Msh2flox/+; Lgr5CreERT2+/-; 
mTmG+/-; Aldh1b1+/- mice, 25% Msh2flox/+; Lgr5CreERT2-/-; mTmG+/-; Aldh1b1+/-mice, 25% 
Msh2-/+; Lgr5CreERT2+/-; mTmG+/-; Aldh1b1+/- mice, and 25% Msh2-/+; Lgr5CreERT2-/-; mTmG+/-
; Aldh1b1+/- mice. The resulting progeny were used as breeders for the creation of the 
Aldh1b1 constitutive-knockout Msh2-LS experimental subject mice. The mice resulting from 
these matings were predicted to show 1.5% progeny with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-
; Aldh1b1-/- genotypes and 0.8% progeny with Msh2flox/-; Lgr5CreERT2+/-; mTmG+/+; Aldh1b1-/- 
genotypes, and the actual progeny proportions were similar. Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/-; Aldh1b1-/- mice were shown by immunohistochemistry to have complete loss of 
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Aldh1b1 in all cells, but only showed loss of Msh2 expression in scattered Lgr5-expressing 
intestinal stem cells (and crypts populated by their daughter cells) due to Cre recombinase 
activity induced following Tamoxifen treatment. 
 
The second aim was to study the interaction of defective MMR with either low/moderate or 
high levels of intestinal acetaldehyde in the model mice when placed on long-term ethanol 
treatment. In this chapter we investigated whether conditional-knockout and/or 
constitutive-knockout of Aldh1b1 resulted in increased plasma levels of acetaldehyde, as a 
surrogate indicator of increased intraepithelial acetaldehyde in the intestines, previously 
shown to mediate increased DNA damage (Garaycoechea et al., 2012; Langevin et al., 2011; 
Müller et al., 2016), that together with defective MMR could influence intestinal tumour 
formation. Once the Aldh1b1 conditional-knockout Msh2-LS mouse colony and the Aldh1b1 
constitutive-knockout Msh2-LS mouse colony were established, the long-term ethanol 
treatment protocol was applied to these two groups of mice for up to one year. It was 
hypothesised that the conditional-knockout Aldh1b1flox/flox mice would result in only 
scattered stem cells, and subsequently scattered crypts or crypt foci, having inactivated 
Aldh1b1 enzyme activity, generating mildly to moderately increased plasma levels of 
acetaldehyde overall, reflecting intestinal intraepithelial levels. In contrast, it was 
hypothesised that the constitutive-knockout Aldh1b1-/- mice would have widespread 
inactivation of the Aldh1b1 enzyme activity in all cells of the murine body, having the most 
biologically significant effect in the intestinal epithelium, generating moderately to markedly 
increased plasma levels of acetaldehyde overall, reflecting intestinal intraepithelial levels.  
Ethanol exposure in this experimental design was based on previous experience using 
Aldh1b1-depleted mice and control wildtype mice under long-term (~1 year) treatment with 
20% ethanol in drinking water, in which intestinal tumour formation was observed within 
one year in both groups, indicating that long-term ethanol treatment of mice leads to 
intestinal tumour development (Müller et al., 2016).  
Mice received Tamoxifen treatment by daily i.p. injection for 4 consecutive days, to activate 
Cre-recombinase in a low proportion of Lgr5-expressing intestinal stem cells, as described in 
Chapter 3. In both Aldh1b1 conditional-knockout Msh2-LS mice and Aldh1b1 constitutive-
knockout Msh2-LS mice, body weights of the female and male mice didn’t significantly differ 
during the Tamoxifen treatment, showing successful drug administration and acceptance of 
the experimental procedure by the mice. Aldh1b1flox/flox Msh2-LS mice and Aldh1b1-/- Msh2-
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LS male mice showed statistically higher mean body weight compared with Aldh1b1flox/flox 
Msh2-LS mice and Aldh1b1-/- Msh2-LS female murine mean body weight at the same age (as 
expected due to normal sexual dimorphism for body weight observed in rodents).  On the 
fifth day after the last Tamoxifen i.p. injection, both Aldh1b1flox/flox Msh2-LS mice and 
Aldh1b1-/- Msh2-LS mice received 20% ethanol in drinking water or normal drinking water.  
EtOH_Aldh1b1fl/fl_Msh2fl KO female mice did not show abnormal behaviour or reduced body 
weight compared with H2O_Aldh1b1fl/fl_Msh2fl KO female mice, indicating good acceptance of 
the ethanol regime. EtOH_Aldh1b1fl/fl_Msh2fl KO and H2O_Aldh1b1fl/fl_Msh2fl KO male mice 
showed some variation in body weight most likely reflecting the low number of experimental 
mice in this experimental group. EtOH_Aldh1b1-/-_Msh2fl KO female and male mice did not 
show abnormal behaviour or significantly reduced body weight compared with 
H2O_Aldh1b1-/-_Msh2fl KO female and male mice, indicating good acceptance of the ethanol 
regime.  
In Aldh1b1flox/flox Msh2-LS mice, the liquid consumption per mouse was on average 12.83ml 
for H2O_Aldh1b1fl/fl_Msh2fl KO male mice, 13.4ml for EtOH_Aldh1b1fl/fl_Msh2fl KO male mice, 
12.87ml for H2O_Aldh1b1fl/fl_Msh2fl KO female mice, and 9ml for EtOH_Aldh1b1fl/fl_Msh2fl KO 
female mice. In Aldh1b1-/- Msh2-LS mice, the liquid consumption per mouse was on average 
10.4ml for H2O_Aldh1b1-/-_Msh2fl KO male mice, 10.5ml for EtOH_Aldh1b1-/-_Msh2fl KO male 
mice, 10.2ml for H2O_Aldh1b1-/-_Msh2fl KO female mice, and 11.5ml for EtOH_Aldh1b1-/-
_Msh2fl KO female mice. In both Aldh1b1flox/flox Msh2-LS mice and Aldh1b1-/- Msh2-LS mice, no 
significant differences were observed between any of the liquid consumption comparisons 
of ethanol-treated versus water-treated males or females.  
The cohorts of experimental mice were studied over time for evidence of intestinal (or other) 
tumour formation. As the study progressed, in both Aldh1b1flox/flox Msh2-LS mice and 
Aldh1b1-/- Msh2-LS mice, most of the ethanol-treated Msh2-LS mice displayed either anal 
prolapse or >20% reduction in body weight as common clinical signs of distress at various 
times and were culled for necropsy dissection. In Aldh1b1flox/flox Msh2-LS mice, 41.7% (5/12 
mice) of EtOH_Aldh1b1fl/fl_Msh2fl KO mice showed evidence of large intestinal 
hyperproliferation and adenoma formation (with 1 adenocarcinoma) within an average of 
4.5 months of ethanol treatment, compared with no hyperproliferation and no cases of large 
intestinal adenoma formation in H2O_Aldh1b1fl/fl_Msh2fl KO mice (0%, 0/12 mice) in the same 
time-period. EtOH_Aldh1b1fl/fl_Msh2fl KO mice showed a pattern of tumour distribution of one 
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or more large intestinal tumours mainly in the proximal colon and mid colon (total 21 
neoplasms; 14.3% of neoplasms were found in caecum, 38% in proximal colon, 23.8% in mid-
colon, 14.3% in distal colon and 9.6% in the rectum). The overall large intestinal tumour 
distribution pattern observed in EtOH_Aldh1b1fl/fl_Msh2fl KO mice was similar to that 
observed in EtOH_Msh2fl KO mice (total 36 neoplasms; 19.5% of neoplasms were found in 
caecum, 33.4% in proximal colon, 41.7% in mid-colon, 2.7% in distal colon and 2.7% in the 
rectum). However, in EtOH_Aldh1b1fl/fl_Msh2fl KO mice, ethanol-induced colonic adenomas 
occurred earlier, but not statistically significantly so, than in EtOH_Msh2fl KO mice (4.5 months 
on average compared with 6 months). However, EtOH_Aldh1b1fl/fl_Msh2fl KO mice showed 
statistically significantly higher numbers of tumours per mouse compared with EtOH_Msh2fl 
KO mice.  
In Aldh1b1-/- Msh2-LS mice, 66.7% (8/12 mice) of EtOH_Aldh1b1-/-_Msh2fl KO mice showed 
evidence of large intestinal hyperproliferation and adenoma formation within an average of 
6 months of ethanol treatment, compared with no hyperproliferation and no cases of large 
intestinal adenoma formation in H2O_Aldh1b1-/-_Msh2fl KO mice (0%, 0/12 mice) in the same 
time-period. EtOH_Aldh1b1-/-_Msh2fl KO mice showed a pattern of tumour distribution of one 
or more large intestinal tumours mainly in the proximal colon and mid colon (total 35 
neoplasms; 22.9% of neoplasms were found in caecum, 40% in proximal colon, 22.9% in mid-
colon, 0% in distal colon and 14.2% in the rectum). In EtOH_Aldh1b1-/-_Msh2fl KO mice, 
ethanol-induced colonic adenomas occurred at statistically significantly higher numbers per 
mouse than in EtOH_Msh2fl KO mice (35 neoplasms in 8/12 EtOH_Aldh1b1-/-_Msh2fl KO Msh2-
LS mice compared with 36 neoplasms in 15/23 EtOH_Msh2fl KO mice). As observed in 
Aldh1b1wt Msh2-LS mice, no small intestinal adenomas were seen in either the Aldh1b1flox/flox 
Msh2-LS or Aldh1b1-/- Msh2-LS mice, for both ethanol- and water-treated mice. 
EtOH_Aldh1b1-/-_Msh2fl KO mice showed a number of rectal adenomas, but these was not 
observed in EtOH_Msh2fl KO mice. Rectal tumours in human LS patients are uncommon, but 
occur later compared with right-sided neoplasms. Rectal adenomas are observed in LS 
patients mainly after a procedure on a previously diagnosed right-sided lesion (Lee et al., 
2001). 
A range of relevant control animal cohorts, including non-induced Aldh1b1flox/flox Msh2-LS 
mice, non-induced Aldh1b1-/- Msh2-LS mice and non-induced Msh2-LS mice, were also tested 
for comparison with tumour formation in these test cohorts, after long-term ethanol- or 
water-treatment. In the absence of Tamoxifen treatment, the Cre-recombinase is not 
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activated, preventing the loss of the conditional (floxed) Msh2 allele and thus, there is no 
MMR pathway abrogation in all of these non-induced control cohorts, together with no loss 
of the conditional Aldh1b1 allele in Lgr5 expressing intestinal epithelial stem cells and their 
daughter cells of Aldh1b1flox/flox Msh2-LS mice.  
It was hypothesised that without Cre activation, the Aldh1b1flox/flox Msh2-LS control mice 
should not present altered or harmful phenotypes, or show an increased intestinal tumour 
predisposition, or other tumour predisposition, compared with wild-type mice. In the 
Aldh1b1-/- Msh2-LS mouse model, the absence of Tamoxifen treatment prevents the loss of 
the conditional Msh2 allele in Lgr5-expressing intestinal epithelial stem cells, whereas the 
loss of Aldh1b1 expression is constitutive in all cells of the mouse.  It was hypothesised that 
without Cre activation, the Aldh1b1-/- Msh2-LS control mice should not show an increased 
dMMR-driven intestinal tumour predisposition, although it was hypothesised that they may 
show higher sensitivity to ethanol/acetaldehyde in the whole GI tract due to the constitutive 
loss of Aldh1b1 expression, compared with wild-type mice. The data shown here provide 
support for both of these hypotheses. The data related to wild-type control mice have 
already been discussed in Chapter 4 (4.3). 
 
In both Aldh1b1 conditional-knockout Msh2-LS mice and Aldh1b1 constitutive-knockout 
Msh2-LS mice, body weights of the female and male mice didn’t significantly differ during 
the corn oil treatment, showing successful drug administration and acceptance of the 
experimental procedures by the mice. EtOH_Aldh1b1fl/fl_Msh2fl and EtOH_Aldh1b1-/-_Msh2fl 
female and male mice did not show abnormal behaviour or reduced weight compared with 
H2O_Aldh1b1fl/fl_Msh2fl and H2O_Aldh1b1-/-_Msh2fl female and male mice, indicating good 
acceptance of the ethanol regime. However, the mild variations in the data distributions for 
the body weight curves for both non-induced Aldh1b1flox/flox Msh2-LS mice and non-induced 
Aldh1b1-/- Msh2-LS mice were influenced by the small numbers of mice coming from 
different litters and starting at different time points. 
In non-induced Aldh1b1flox/flox Msh2-LS mice, 43% (3/7 mice) of the EtOH_Aldh1b1fl/fl_Msh2fl 
mice showed zones of colonic crypt epithelial hyperproliferation mainly in the proximal and 
mid-colon, consistent with this previously described ethanol effect (Müller et al., 2016). 
However, none of the EtOH_Aldh1b1fl/fl_Msh2fl and H2O_Aldh1b1fl/fl_Msh2fl mice showed 
intestinal tumour formation. The tumour incidence in EtOH_Aldh1b1fl/fl_Msh2fl KO mice was 
statistically significantly higher compared with EtOH_Aldh1b1fl/fl_Msh2fl mice (p=0.0466). 
310 
 
In non-induced Aldh1b1-/- Msh2-LS mice, 33.4% (2/6 mice) of the EtOH_Aldh1b1-/-_Msh2fl 
mice showed zones of colonic crypt epithelial hyperproliferation mainly in the mid-colon, 
consistent with this previously described ethanol effect (Müller et al., 2016). However, none 
of the EtOH_Aldh1b1-/-_Msh2fl and H2O_ Aldh1b1-/-_Msh2fl mice showed intestinal tumour 
formation. The tumour incidence in EtOH_Aldh1b1-/-_Msh2fl KO mice was statistically 
significantly higher compared with EtOH_Aldh1b1-/-_Msh2fl mice (p=0.0073). 
 
The tumours and normal tissue samples from Aldh1b1flox/flox Msh2-LS mice and Aldh1b1-/- 
Msh2-LS mice were characterised by IHC, comparing samples from ethanol-treated and 
water-treated mice. IHC was used to investigate the expression of Msh2 in tumours and 
tissue samples from Tamoxifen-induced Aldh1b1flox/flox Msh2-LS mice, Tamoxifen-induced 
Aldh1b1-/- Msh2-LS mice, non-induced Aldh1b1flox/flox Msh2-LS mice and non-induced 
Aldh1b1-/- Msh2-LS mice. Tamoxifen treatment induced the loss of Msh2 expression in Lgr5+ 
expressing crypt epithelial stem cells scattered along the entire SI and LI. The Lgr5+ 
expressing stem cells, located at the bottom of the crypts, generate daughter cells that can 
expand to fill the entire crypt-villus epithelium in SI or entire crypt in the colon (Barker et al., 
2007; Wojciechowicz et al., 2014). In normal intestinal tissues, Msh2 was strongly expressed 
in crypt stem cells and transit amplifying cells in the small intestinal crypts, but Msh2 protein 
expression levels fade in the non-dividing differentiated SI villus cells, and similarly fade in 
the differentiated cells of the upper third of the colonic crypts (Tomé et al., 2013). 
In induced Aldh1b1flox/flox Msh2-LS mice, EtOH_Aldh1b1fl/fl_Msh2fl KO mice showed 43% Msh2-
negative small intestinal crypts and 17% Msh2-negative colonic crypts compared with 
H2O_Aldh1b1fl/fl_Msh2fl KO mice that showed 24% Msh2-negative small intestinal crypts and 
7% Msh2-negative colonic crypts. The percentage of Msh2-negative or dMMR crypts was 
statistically significantly higher in both SI and colon of EtOH_Aldh1b1fl/fl_Msh2fl KO mice 
(p=0.0056 and p=0.0006 respectively) compared with H2O_Aldh1b1fl/fl_Msh2fl KO mice, 
consistent with ethanol/acetaldehyde-mediated selection for survival of dMMR cells. The 
number of Msh2-negative crypts was higher in SI than in the colon in Aldh1b1flox/flox Msh2-LS 
mice, however although tumours were observed in the colon, no tumours formed in the SI.  
In induced Aldh1b1-/- Msh2-LS mice, EtOH_Aldh1b1-/-_Msh2fl KO mice showed 55.7% Msh2-
negative small intestinal crypts and 29% Msh2-negative colonic crypts compared with 
H2O_Aldh1b1-/-_Msh2fl KO mice that showed 28% Msh2-negative small intestinal crypts and 
10% Msh2-negative colonic crypts. The percentage of Msh2-negative or dMMR crypts was 
311 
 
statistically significantly higher in both SI and colon of EtOH_Aldh1b1-/-_Msh2fl KO mice 
(p<0.0001 for both SI and colon) compared with H2O_Aldh1b1-/-_Msh2fl KO mice, consistent 
with ethanol/acetaldehyde-mediated selection for survival of dMMR cells. The number of 
Msh2-negative crypts was higher in SI than in the colon in Aldh1b1-/- Msh2-LS mice, however 
although tumours were observed in the colon, no tumours formed in the small intestine.  
In induced Aldh1b1flox/flox Msh2-LS mice, the Msh2-negative crypts pattern in SI and colon is 
similar to the one observed in induced Msh2-LS mice (in EtOH_Msh2fl KO 43% Msh2-negative 
small intestinal crypts and 11.2% Msh2-negative colonic crypts compared with H2O_Msh2fl 
KO mice that showed 25.8% Msh2-negative small intestinal crypts and 5% Msh2-negative 
colonic crypts). By contrast, in induced Aldh1b1-/- Msh2-LS mice, the percentage of Msh2-
negative crypts is higher in both SI and colon compared with those in both EtOH_Msh2fl KO 
and H2O_Msh2fl KO mice. Given the significantly higher levels of plasma acetaldehyde in 
EtOH_Aldh1b1-/-_Msh2fl KO mice, this is consistent with the hypothesis that 
ethanol/acetaldehyde mediates selection, acting significantly via acetaldehyde-induced DNA 
damage, as shown by the y-H2AX and p53 IHC analyses, bringing about increased survival of 
dMMR cells in these mice (as explained in Chapter 4, Figure 4.58).  
All large intestinal adenomas tested from EtOH_Aldh1b1fl/fl_Msh2fl KO mice and 
EtOH_Aldh1b1-/-_Msh2fl KO mice showed Msh2-negative dysplastic glands, often surrounded 
by or admixed with Msh2-positive crypts showing reactive or hyperproliferative changes. 
This confirmed colonic adenomas arose from dMMR (Msh2-negative) crypts. This is 
consistent with observations from human LS patients that the risk of colonic tumour 
formation correlates with the size of the MMR-deficient crypt clusters that grow over time 
in affected patients, in line with observations by Wojciechowicz et al, (2014) (Kloor et al., 
2012; Shia et al., 2015). 
Immunohistochemical analysis of Msh2 expression in the intestinal tissue samples from non-
induced Aldh1b1flox/flox Msh2-LS control mice and non-induced Aldh1b1-/- Msh2-LS treated 
with either 20% ethanol in drinking water or normal / standard water, showed no Msh2-
negative crypts in either small or large intestinal mucosal epithelium, consistent with lack of 
induction of Cre activity with continued expression of full-length protein from the floxed 
Msh2 allele. 
IHC was performed to investigate Aldh1b1 murine protein expression. ALDH1B1 is a 
mitochondrial aldehyde dehydrogenase highly expressed in the intestinal epithelium, 
especially in the stem cells and transit-amplifying cells of the crypts of both small intestines 
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and large intestines, and has been proposed to play an important role in acetaldehyde 
detoxification in the intestines to protect stem and progenitor cells from acetaldehyde-
mediated damage (Stagos et al., 2010). In Aldh1b1flox/flox Msh2-LS mice, Tamoxifen-treatment 
induced the loss of Aldh1b1 expression, together with the loss of Msh2, in scattered Lgr5+ 
expressing intestinal crypt epithelial stem cells and their crypts, shown by IHC. Aldh1b1-
negative crypts were observed in the intestinal samples of both EtOH_Aldh1b1fl/fl_Msh2fl KO 
and H2O_Aldh1b1fl/fl_Msh2fl KO mice. Non-induced (no Tamoxifen treatment) Aldh1b1flox/flox 
Msh2-LS model mice treated with either 20% ethanol in drinking water or normal water 
showed no Aldh1b1-negative crypts in either SI and LI mucosa, consistent with lack of 
induction of Cre activity with continued expression of protein from the floxed Aldh1b1 allele. 
In induced Aldh1b1-/- Msh2-LS mice, Aldh1b1 is permanently inactivated in all tissues and 
cells (Tamoxifen treatment is not required to induce the loss of Aldh1b1 expression) and in 
both these mice and in non-induced Aldh1b1-/- Msh2-LS model mice, treated with either 20% 
ethanol in drinking water or normal water, IHC showed that all crypts were Aldh1b1-negative 
in both SI and LI mucosal epithelium, as expected. 
IHC was performed to investigate Ki-67 expression in intestinal tissue samples from 
Tamoxifen-induced Aldh1b1flox/flox Msh2-LS mice and Aldh1b1-/- Msh2-LS mice to determine 
proliferative activity. In normal large and small intestinal tissue, Ki-67 is expressed only in the 
proliferating cells at or near the base of crypts as previously reported (Johnston et al., 1989). 
In both Aldh1b1flox/flox Msh2-LS mice and Aldh1b1-/- Msh2-LS mice, the percentage of Ki-67-
positive cells per crypt was significantly higher in the colon in EtOH_Aldh1b1fl/fl_Msh2fl KO 
mice and EtOH_Aldh1b1-/-_Msh2fl KO mice compared with H2O_Aldh1b1fl/fl_Msh2fl KO mice and 
H2O_Aldh1b1-/-_Msh2fl KO mice respectively, confirming the presence of large regions of 
mucosal crypt epithelial hyperproliferation observed in histological sections of ethanol-
treated murine colons. The percentage of Ki-67-positive cells per crypt in SI of 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice and EtOH_Aldh1b1-/-_Msh2fl KO mice was mildly higher than 
in the SI of H2O_Aldh1b1fl/fl_Msh2fl KO mice and H2O_Aldh1b1-/-_Msh2fl KO mice respectively. 
These observations confirm the previously reported association of long-term ethanol 
treatment of mice and colonic mucosal epithelial hyperproliferation (Müller et al., 2016). 
We investigated the expression of β-catenin protein, an intracellular signal transducer in the 
Wnt signalling pathway (Cong et al., 2003), on tumours and tissue samples from Tamoxifen-
induced Aldh1b1flox/flox Msh2-LS mice and Tamoxifen-induced Aldh1b1-/- Msh2-LS mice. 
Normal colorectal mucosal crypt epithelium exhibited moderate membranous and weak 
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cytoplasmic staining for β-catenin, but absent nuclear localisation. In colonic tumours in the 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice and EtOH_Aldh1b1-/-_Msh2fl KO mice, immunohistochemical 
analysis of β-catenin showed a heterogeneous pattern with variable numbers of adenoma 
cells showing moderately to strongly positive β-catenin nuclear immunostaining due to 
accumulation and translocation of β-catenin into the nuclei. This pattern has been observed 
in human MMR-deficient CRC (Lugli et al., 2007). 
Ethanol metabolisms plays a major role in intestinal carcinogenesis (Seitz & Stickel, 2007), as 
described earlier in this chapter. Acetaldehyde is the first product of ethanol metabolism, 
and aldehydes are very reactive small molecules that can cause a wide range of DNA 
modifications. In normal conditions, acetaldehyde is oxidized to acetate by ALDHs. ALDH1B1 
is the major aldehyde dehydrogenase in the gastrointestinal epithelium (Stagos et al., 2010). 
In Aldh1b1 conditional-knockout Msh2-LS mouse model and Aldh1b1 constitutive-knockout 
Msh2-LS mice, lack of Aldh1b1 expression leads to increased plasma levels of acetaldehyde 
and accumulation of acetaldehyde-induced DNA damage. IHC was performed for y-H2AX and 
p53 to evaluate the DNA damage response in Aldh1b1 conditional-knockout Msh2-LS mice 
and Aldh1b1 constitutive-knockout Msh2-LS mice. Y-H2AX is a key co-ordinator of signalling 
and activator of DNA damage repair pathways and for this it is considered a specific 
molecular marker for monitoring DNA damage (Mah et al., 2010). In EtOH_Aldh1b1fl/fl_Msh2fl 
KO mice, a statistically significantly higher percentage of y-H2AX-positive cells in the colon 
(38.7%) was observed compared with H2O_Aldh1b1fl/fl_Msh2fl KO murine colon (0.5%). In both 
EtOH_Aldh1b1fl/fl_Msh2fl KO and H2O_Aldh1b1fl/fl_Msh2fl KO murine SI, no y-H2AX positive cells 
were observed.  
In EtOH_Aldh1b1-/-_Msh2fl KO mice, a statistically significantly higher percentage of y-H2AX-
positive cells in murine colon (46%) was observed compared with H2O_Aldh1b1-/-_Msh2fl KO 
murine colon (0.5%). The percentage of SI y-H2AX-positive cells was higher in EtOH_Aldh1b1-
/-_Msh2fl KO mice compared with H2O_Aldh1b1-/-_Msh2fl KO mice. In both 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice and in EtOH_Aldh1b1-/-_Msh2fl KO mice, colonic and caecal 
adenomas showed high levels of y-H2AX expression. 
The high expression of y-H2AX in EtOH_Aldh1b1fl/fl_Msh2fl KO and EtOH_Aldh1b1-/-_Msh2fl KO 
murine colonic mucosal epithelium is consistent with DNA damage induced by acetaldehyde, 
suggesting that acetaldehyde (more so than ethanol) mediates a significant genotoxic effect, 
predominantly on dMMR colonic mucosal epithelium rather than on dMMR small intestinal 
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mucosa, indicating that other protective mechanisms may be operative in the small intestinal 
epithelium, consistent with the lower incidence of small intestinal cancers compared with 
colonic cancers in human LS patients. This suggests that Msh2 has a key role in protecting 
the MMR-proficient colonic epithelial cells against this type of DNA damage, but Msh2 may 
not be the sole protective mechanism for small intestinal epithelial cells from acetaldehyde-
induced DNA damage. By contrast, the presence of y-H2AX-positive cells in EtOH_Aldh1b1-/-
_Msh2fl KO murine colonic mucosal epithelium confirms the important role of Aldh1b1 in 
protection of large intestinal epithelial cells from acetaldehyde-induced DNA damage.  
Upon DNA damage, increased p53 levels in response can be demonstrated 
immunohistochemically as a greater proportion of cells containing moderate to high (but 
variable) nuclear staining of p53 in individual cells (referred as p53 “wildtype pattern”) (Köbel 
et al., 2016; Lakin & Jackson, 1999). In Aldh1b1flox/flox Msh2-LS mice, the numbers of cells with 
either moderate or high levels of p53-positive nuclear staining per colonic crypt was 
significantly higher in EtOH_Aldh1b1fl/fl_Msh2fl KO mice (52.7%) compared with 
H2O_Aldh1b1fl/fl_Msh2fl KO mice (6.3%), consistent with ethanol/acetaldehyde-induced DNA 
damage.  The percentage of small intestinal p53-positive cells per crypt was higher in 
EtOH_Aldh1b1fl/fl_Msh2fl KO mice (21.7%) compared with H2O_Aldh1b1fl/fl_Msh2fl KO mice 
(3.3%).  
In Aldh1b1-/- Msh2-LS mice, the numbers of cells with either moderate or high levels of p53-
positive nuclear staining per colonic crypt was significantly higher in EtOH_Aldh1b1-/-_Msh2fl 
KO mice (47.5%) compared with H2O_Aldh1b1-/-_Msh2fl KO mice (3.3%), consistent with 
ethanol/acetaldehyde-induced DNA damage.  The percentage of small intestinal p53-
positive cells per crypt was higher in EtOH_Aldh1b1-/-_Msh2fl KO mice (20%) compared with 
H2O_Aldh1b1-/-_Msh2fl KO mice (4%). In both EtOH_Aldh1b1fl/fl_Msh2fl KO mice and 
EtOH_Aldh1b1-/-_Msh2fl KO mice, colonic and caecal adenomas showed high percentages of 
p53-positive cells, with variably moderate to high nuclear p53 positivity and some negative 
nuclei in a “p53 wildtype” pattern, indicative of widespread response to DNA damage, with 
no tumours showing either the “overexpression” or “null” patterns associated with Tp53 
mutation.  
Caspase-3 (Cas3) is a key executive member of the caspase cascade, with cysteine-aspartic 
acid protease activity, that acts as one of the key effectors of cell death by apoptosis. It 
requires proteolytic cleavage into 2 subunits that dimerize to create the active form, cCas3 
(Holubec et al., 2005; Talmon et al., 2010). Once activated, cCas3 is responsible for the 
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cleavage of key target proteins essential in cell proliferation and survival, and cCAS3 is 
involved in inducing DNA fragmentation, cell shrinkage, chromatin and cytoplasmic 
condensation and formation of apoptotic cells and bodies. Apoptotic bodies express ligands 
for phagocytic cell receptors for recognition by phagocytic cells or neighbouring cells 
(Elmore, 2007). In Aldh1b1flox/flox Msh2-LS mice, IHC analysis of cCas3 with quantification of 
cCas3-positive apoptotic bodies showed significantly higher numbers of cCas3+ apoptotic 
bodies in EtOH_Aldh1b1fl/fl_Msh2fl KO mice compared with very few or no detectable cCas3+ 
apoptotic bodies in H2O_Aldh1b1fl/fl_Msh2fl KO mice. In Aldh1b1-/- Msh2-LS mice, 
immunohistochemical analysis of cCas3 with quantification of cCas3-positive apoptotic 
bodies, showed significantly higher numbers of cCas3+ apoptotic bodies in EtOH_Aldh1b1-/-
_Msh2fl KO mice compared with very few or no detectable cCas3+ apoptotic bodies in 
H2O_Aldh1b1-/-_Msh2fl KO mice. The detection of cCas3+ apoptotic bodies is consistent with 
increased apoptosis associated with colonic epithelial exposure to ethanol/acetaldehyde, 
and it is hypothesised that this is mediated by those colonic epithelial cells with proficient 
MMR that can recognise severe ethanol/acetaldehyde-induced DNA damage triggering 
apoptosis. In both EtOH_Aldh1b1fl/fl_Msh2fl KO mice and EtOH_Aldh1b1-/-_Msh2fl KO mice, 
colonic and caecal adenomas showed very few or no detectable cCas3+ apoptotic bodies, 
indicating very few or rare apoptotic events in dMMR colonic tumours, consistent with 
inactivation of the MMR-mediated process by which ethanol/acetaldehyde-induced DNA 
damage is recognised leading to apoptosis. 
The increased DNA damage observed in EtOH_Aldh1b1fl/fl_Msh2fl KO mice and EtOH_Aldh1b1-
/-_Msh2fl KO mice large intestinal mucosal epithelium is consistent with the high levels of 
circulating acetaldehyde detected by plasma acetaldehyde assay. Statistically significantly 
higher plasma acetaldehyde levels were observed in EtOH_Aldh1b1fl/fl_Msh2fl KO mice and 
EtOH_Aldh1b1-/-_Msh2fl KO mice compared with H2O_Aldh1b1fl/fl_Msh2fl KO mice and 
H2O_Aldh1b1-/-_Msh2fl KO mice (p=0.0019 and p<0.0001, respectively). Furthermore, 
statistically significantly higher plasma acetaldehyde levels were observed in EtOH_Aldh1b1-
/-_Msh2fl mice compared with H2O_Aldh1b1-/-_Msh2fl mice, consistent with a greater effect 
due to constitutive loss of Aldh1b1 combined with ethanol exposure.  
In conclusion, we successfully introduced both the conditional-knockout Aldh1b1 allele 
(Aldh1b1flox/flox) and the constitutive Aldh1b1 knockout allele (Aldh1b1-/-) by cross-breeding 
into the Msh2-LS mouse model. Ethanol-treatment was shown to cause accumulation of high 
plasma levels of acetaldehyde in the Aldh1b1-/- Msh2-LS mice and lower, more moderate, 
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levels of plasma acetaldehyde in the Aldh1b1flox/flox Msh2-LS mice. Acetaldehyde was shown 
by immunohistochemical analysis of both y-H2AX and p53 to lead to an increased DNA 
damage response. Long-term ethanol-treatment was also observed to induce colonic crypt 
epithelial hyperproliferation, mostly in the proximal and mid colon, and this contributed to 
intestinal adenoma formation, indicating that ethanol/acetaldehyde can act as tumour 
promoter in these cells.  In both the Aldh1b1 conditional-knockout Msh2-LS model and 
Aldh1b1 constitutive-knockout Msh2-LS model, acetaldehyde-mediated DNA damage and 
carcinogenic effects appeared to be stronger than in the Aldh1b1 wild-type Msh2-LS mouse 
model, as both EtOH_Aldh1b1fl/fl_Msh2fl KO mice and EtOH_Aldh1b1-/-_Msh2fl KO mice showed 
increased numbers of precursor colonic crypt foci lesions and large intestinal adenomas 
(both colonic and caecal adenomas, with occasional progression to adenocarcinoma), 
compared with EtOH_Msh2fl KO mice. These results verified the key role of Aldh1b1 in 
protecting the large intestinal epithelial stem and progenitor cells from acetaldehyde-
induced DNA damage.  
This study produced strong evidence in support of the hypothesis that there is a 
gene/environment interaction between dMMR and ethanol/acetaldehyde, demonstrated 
most notably by the Aldh1b1 constitutive-knockout Msh2-LS mouse model. In Aldh1b1-/- 
MMR-proficient intestinal epithelial stem cells, acetaldehyde-induced DNA damage is likely 
to result in activation of the DNA mismatch repair pathway in the case of mild DNA damage 
or cell death by apoptosis in the case of severe DNA damage (Figure 6.92). By contrast, in 
Aldh1b1-/- MMR-deficient intestinal epithelial stem cells, significant acetaldehyde-induced 
DNA damage is not recognized by the DNA mismatch repair system, with no activation of 
either cell cycle arrest, DNA mismatch repair or apoptosis. The DNA-damaged Aldh1b1-/- 
MMR-deficient intestinal epithelial cells show inappropriate survival and subsequent 
proliferation. This leads to an increase of Aldh1b1-/- dMMR intestinal epithelial cells, 
observed as higher numbers of clusters of Aldh1b1-/- dMMR crypt foci, with elevated 
subsequent tumour formation with both right-sided and left-sided colonic adenomas and 




Figure 6.92: Schematic diagram of the proposed model of the MMR/acetaldehyde gene/environment 
interactions in Aldh1b1-/- MMR-proficient and Aldh1b1-/- MMR-deficient intestinal epithelial cells. 
Ethanol is metabolized to highly reactive acetaldehyde by ADHs in intestinal epithelium. Acetaldehyde 
is further oxidized to acetate by ALDHs, such as ALDH1B1 in intestinal epithelial stem cells and transit-
amplifying cells. In some epithelial cells, acetaldehyde can escape the metabolic pathway and induce 
various forms of DNA base damage, some of which would normally be recognised and repaired by the 
MMR system, or if unrepaired this base damage may induce replication errors, such as base 
mismatches or InDels, during S-phase of the cell cycle. In the Aldh1b1-/- MMR-proficient intestinal 
epithelial cell (red cell membrane), ethanol is metabolized to highly reactive acetaldehyde, with 
reduced oxidation to acetate due to the lack of Aldh1b1, leading to increased levels of highly reactive 
acetaldehyde that can damage DNA. The Aldh1b1-/- MMR-proficient intestinal epithelial cell is able to 
activate DNA mismatch repair, inducing cell cycle arrest to allow DNA repair. However, high levels of 
reactive acetaldehyde causing severe acetaldehyde-induced DNA damage may force the Aldh1b1-/- 
MMR-proficient intestinal epithelial cell to activate cell death by apoptosis. By contrast, the Aldh1b1-
/- MMR-deficient intestinal epithelial cell (green cell membrane) is unable to activate the MMR 
signalling pathway and so there is neither cell cycle arrest nor apoptosis, following increased 
acetaldehyde-induced DNA damage, resulting in aberrant survival of DNA-damaged cells and their 
subsequent proliferation. These proliferating Aldh1b1-/- MMR-deficient intestinal epithelial cells 
populate the crypt and expand further (by crypt fission) to form Aldh1b1-/- dMMR crypt foci. 
Stimulated by ethanol/acetaldehyde to undergo increased proliferation, these cells form 
hyperproliferative crypts whilst remaining subject to ongoing DNA damage. Thus, these Aldh1b1-/- 
dMMR cells can accumulate mutations reflecting a form of dMMR genomic instability, and are 
consequently at increased risk of tumour formation, thus explaining the acceleration of colonic 
adenoma formation and increased probability of evolution to adenocarcinoma. In the Aldh1b1flox/flox 
Msh2-LS model mice, scattered Aldh1b1flox/flox Msh2flox/- intestinal epithelial stem cells are induced by 
Tamoxifen-mediated Cre activation to become Aldh1b1-/- Msh2-/- MMR-deficient intestinal epithelial 




Chapter 7: Investigation of the effects of 
ethanol/acetaldehyde on defective Mismatch Repair colonic 
crypt foci precursors in the Msh2-LS models 
7.1 Introduction 
The mTmG reporter transgene was introduced through cross-breeding into the Msh2-LS 
mouse model, as previously described in Chapter 3. This Cre-mediated reporter construct 
confers a red fluorescence to cells of all tissues without Cre activation, due to whole body 
expression of mT. Upon Cre activation, Cre recombines the two LoxP sites surrounding the 
floxed mT allele and the adjacent polyadenylation site, thus excising this section of DNA, 
allowing expression of an mG (Chapter 3, Figure 3.3). In the modified version of the Msh2flox/-
; Lgr5CreERT2+/-; mTmG+/- mouse model (described in Chapter 3), the activation of Cre 
recombinase by Tamoxifen-treatment generates a Msh2 knockout allele (Msh2flox/OFF) and 
converts the same intestinal stem cells (and their daughter cells) to mG expression, 
generating dMMR intestinal stem cells that subsequently form dMMR crypts, which are 
marked by green fluorescent mG expression. In Chapter 3 (3.2.2.3), it was demonstrated that 
the dMMR crypt foci were positive for mG/GFP by performing IHC analyses of adjacent serial 
sections using anti-Msh2 antibody and anti-GFP antibody.  
In this chapter, the first aim was to use the mTmG transgene reporter system to monitor any 
changes in the number, size, or distribution of mG+ dMMR crypt foci following ethanol 
treatment of the mouse models over the time. The second aim was to investigate differences 
in gene expression patterns between ethanol-treated and water-treated Msh2-LS murine 
colonic and small intestinal epithelial cells to shed light on why hyperproliferative changes 
and adenoma formation occur in the colon, but not in the small intestine, in this Msh2-LS 
model and which signalling pathways are involved. 
In Chapter 4 and Chapter 6, evidence was provided that ethanol-treatment can cause tumour 
formation in the large intestinal mucosal epithelium, but not in the small intestine.  This 
suggested that Msh2 has a key role in protecting the pMMR colonic epithelial cells against 
some types of ethanol/acetaldehyde-induced DNA damage, but Msh2 may not be the sole 
protective mechanism for small intestinal epithelium cells from such DNA damage. 
The plan was to use FACS to sort mT-expressing red small intestinal and colonic epithelial 
cells (pMMR) and mG-expressing green small intestinal and colonic epithelial cells (dMMR) 
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from both ethanol-treated and water-treated murine colon, followed by extraction of RNA 
and gene expression analysis. However, due to COVID-19-related laboratory restrictions the 
latter experiment was not fully completed.  
 
7.2 Investigation of ethanol effects on mG-expressing dMMR colonic 
crypt foci in the Msh2-LS models 
7.2.1 Methods 
7-9 weeks old Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice were divided into 4 Groups: A-D 
(Figure 7.1). Group-A and Group-B mice received i.p. injections of 0.15mg Tamoxifen/g bw 
on day 1 and 0.1mg Tamoxifen/g bw on day 2, 3 and 4; on day 5 mice were provided with 
normal drinking water or 20% ethanol in drinking water, respectively.  Group-C and Group-
D mice received i.p. injections of 0.15mg corn oil/g bw on day 1 and 0.1mg corn oil/g bw on 
day 2, 3 and 4; on day 5 mice were provided with normal drinking water or 20% ethanol in 
drinking water, respectively. Group-A to Group-D mice were sacrificed after either 5 days or 
15 days of the ethanol or water regime. During the necropsy dissection procedure, small and 
large intestinal tissues were harvested, inverted on skewer as for preparation of Swiss-rolls, 
fixed in 10% NBF and kept on ice. The large and small intestines were opened longitudinally 
and flattened out as whole mount specimens on a transparent petri-dish, until fluorescent 
microscopic analysis of red mT and green mG fluorescent protein expression (as described in 
Material and Methods, 2.1.5). Images were acquired and analysed as described in Materials 
and Methods. The mT and mG protein expression detection was extended so that it was 
performed in all analyses of the experimental (tumour-watch) Aldh1b1-wild-type Msh2-LS 
mice, Aldh1b1-conditional-knockout Msh2-LS mice and Aldh1b1-constitutive-knockout 
Msh2-LS mice, in order to obtain data about changes in the dMMR colonic crypt foci in terms 
of their size, number and distribution over time. Following image acquisition of small and 
large intestines, tissues were prepared as Swiss-rolls and fixed in 10% NBF. They were 






Figure 7.1: Experimental treatment protocols and timelines for Group-A to -D using Msh2-LS mice. 
Animals in Group-A and Group-B received i.p Tamoxifen injections over 4 days (0.15mg Tamoxifen/g 
bw on day 1 and 0.1mg Tamoxifen/g bw on day 2, 3 and 4), followed by either standard/normal 
drinking water (Group-A) or drinking or water containing 20% ethanol (Group-B). Animals in Group-C 
and Group-D received i.p corn oil injections over 4 days (0.15mg corn oil/g bw on day 1 and 0.1mg 
corn oil/g bw on day 2, 3 and 4), followed by either standard/normal drinking water (Group-C) or 











7.2.2.1 Investigation of ethanol effects on mG-expressing dMMR colonic crypt foci after 5 
or 15 days of ethanol or water regimes 
The proportional area (as a percentage) of colonic mucosa composed of mG-expressing crypt 
foci relative to the total area of mG and mT fluorescent protein expression (percentage green 
area) was quantified in Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- (Msh2-LS) mice after 4 i.p. 
Tamoxifen injections and either 5 days of 20% ethanol in drinking water regime or 5 days of 
normal drinking water regime (Figure 7.2). There was a statistically significant increase in the 
percentage green area, combining number and size of crypt foci containing mG-expressing 
cells, along the large intestinal tract of 5-day ethanol-treated Msh2-LS mice compared with 
5-day water-treated Msh2-LS mice (p=0.0003). Moreover, the ethanol-treated Msh2-LS mice 
showed a statistically significantly higher percentage area of mG-expressing crypt foci in the 
proximal colon than in the distal colon (p=0.0384) (Figure 7.2). Images of Msh2-LS murine 
small intestine were acquired after 5 days of either ethanol- or water-treatment regimes 
(Figure 7.3), but quantification of the mG+ villlus/crypt foci was technically much more 
difficult due to the extensive and often confluent mG+ villus/crypt foci with some partially 
mG+ villi, and the complicated folded structure of the small intestinal villi in 3-dimensions, 
including partially fluorescent green and partially fluorescent red villi that were folded and 
twisted.  
The percentage area of mG+ crypt foci relative to the total area of mT and mG fluorescent 
protein expression was measured in Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice after 4 i.p. 
Tamoxifen injections and either 15 days of 20% ethanol in drinking water or 15 days of 
normal drinking water (Figure 7.4). There was a larger and statistically significant increase in 
the percentage area of crypt foci containing mG-expressing cells along the large intestinal 
tract of 15-day ethanol-treated Msh2-LS mice compared with 15-day water-treated Msh2-LS 
mice (p<0.0001), more so proximally than distally (p=0.004) (Figure 7.4). Images were 
acquired of Msh2-LS murine small intestine after 15 days of either ethanol- or water-
treatment regimes (Figure 7.5), but the quantitative analysis was technically difficult as 
previously explained. 
Detection of mG+ crypt foci and quantification of the percentage green area was evaluated 
in the large intestinal tissue samples from non-induced (no Tamoxifen treatment) Msh2-LS 
model mice after 4 i.p. corn oil injections and either 15 days of 20% ethanol in drinking water, 
or 15 days of normal drinking water, but these mice showed no mG+ colonic crypt foci (Figure 
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7.6), consistent with lack of induction of Cre activity with continued expression of mT 
fluorescent red protein from the mTmG construct (presumably together with continued 
expression of Msh2 protein from the floxed Msh2 allele) in this tissue.  
Higher magnification images were taken during mT and mG protein detection to obtain a 
better understanding of the cellular localisation of mG expression within intestinal crypts, 
using the Leica MZ FLIII fluorescence stereomicroscope (Figure 7.7-7.8), showing highly-
magnified images of small intestinal mucosa with mG+ cells in strips along the SI villi (Figure 
7.8). By contrast, highly-magnified images of Msh2-LS control (no ethanol treatment) murine 
colon were unable to provide a sufficiently detailed views of the mG+ crypt foci (Figure 7.7). 
Subsequently, these murine colonic crypts were examined using a confocal microscope to 
obtain more fine-detailed images of the distribution of mG+ cells within the crypts (Figure 











Figure 7.2. A) Fluorescence stereomicroscopic analysis of the mT and mG fluorescent protein expression in whole-mount colonic samples of Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/- mice after 5 days of either 20% ethanol in drinking water (top row) or 5 days of normal water (row below). Representative fluorescent images of the mT & 
mG/GFP detection in the proximal colon (left) and distal colon (right). B) The percentage green areas were statistically significantly higher in ethanol-treated Msh2-LS 
(EtOH_Msh2fl KO) murine whole colon, proximal colon and distal colon compared with water-treated Msh2-LS (H2O_Msh2fl KO) murine colon equivalents. Students t 
Test; ***p=0.0003; **p=0.0020; *p=0.0277. The percentage green areas were statistically significantly higher in EtOH_Msh2fl KO murine proximal colon compared with 
EtOH_Msh2fl KO murine distal colon. Students t Test; ∆p=0.0384. Images taken using the Leica MZ FLIII fluorescence stereomicroscope at 2.5X magnification/1x objective 




Figure 7.3. Fluorescence stereomicroscopic analysis of the mT and mG fluorescent protein expression 
in whole-mount small intestinal samples of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice after 5 days of 
either 20% ethanol in drinking water (top row) or 5 days of normal water (row below). Representative 
fluorescent images of the mT & mG/GFP detection in the proximal small intestine (left) and distal small 
intestine (right). Images taken using the Leica MZ FLIII fluorescence stereomicroscope at 2.5X and 3.6X 




Figure 7.4: A) Fluorescence stereomicroscopic analysis of the mT and mG fluorescent protein expression in whole-mount colonic samples of Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/- mice after 15 days of either 20% ethanol in drinking water (top row) or 15 days of normal water (row below). Representative fluorescent images of the mT & 
mG/GFP detection in the proximal colon (left) and distal colon (right). B) The percentage green areas were statistically significantly higher in ethanol-treated Msh2-LS 
(EtOH_Msh2fl KO) murine whole colon, proximal colon and distal colon compared with water-treated Msh2-LS (H2O_Msh2fl KO) murine colon equivalents. Students t 
Test; ****p<0.0001; **p=0.0029. The percentage green areas were statistically significantly higher in EtOH_Msh2fl KO murine proximal colon compared with 
EtOH_Msh2fl KO murine distal colon. Students t Test; ∆∆p=0.0040. Images taken using the Leica MZ FLIII fluorescence stereomicroscope at 2.5X magnification/1X 




Figure 7.5: Fluorescence stereomicroscopic analysis of the mT and mG fluorescent protein expression 
in whole-mount small intestinal samples of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-mice after 15 days of 
either 20% ethanol in drinking water (top row) or 15 days of normal water (row below). Representative 
fluorescent images of the mT & mG/GFP detection in the proximal small intestine (left) and distal small 
intestine (right). Images taken using the Leica MZ FLIII fluorescence stereomicroscope at 2.5X 




Figure 7.6. Fluorescence stereomicroscopic analysis of the mT and mG fluorescent protein expression 
in whole-mount colonic samples of non-induced (no Tamoxifen treatment) Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/-mice after 15 days of either 20% ethanol in drinking water (top row) or 15 days of normal 
water (row below). Representative fluorescent images show only mT expression (with no mG/GFP 
detection) in the proximal colon (left) and distal colon (right). Images taken using the Leica MZ FLIII 





Figure 7.7: Representative images of mT and mG fluorescent protein expression in whole-mount colon 
samples of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- control (no ethanol treatment) mice. Images taken 
using the Leica MZ FLIII fluorescence stereomicroscope at 2.5X (A), 4X (B), 6.3X (C) and 8X (D) 




Figure 7.8: Representative images of mT and mG fluorescent protein expression in whole-mount small 
intestinal samples of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- control (no ethanol treatment) mice, showing 
green strips of green mG+ epithelium partially lining otherwise red mT+ villi. Images taken using the 
Leica MZ FLIII fluorescence stereomicroscope at 2.5X (A) and 8X (B) magnification/1X objective (bar at 




Figure 7.9: Two representative images (A and B) of mT and mG fluorescent protein expression in 
whole-mount large intestinal mucosa samples of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice (no ethanol 
treatment). The images show the distribution of green mG+ cells in Cre-activated colonic crypts and 
adjacent surface epithelium of Msh2-LS murine colon (in selected crypts with cells that express mG). 
In contrast, some of the adjacent crypts, lamina propria cells and smooth muscle cells of the 
muscularis mucosae express red mT fluorescent protein. Images taken using the Nikon A1R point 















7.2.2.1 Investigation of ethanol effects on mG-expressing colonic crypt foci with 
fluorescence microscopy in Aldh1b1 wild-type Msh2-LS mice, Aldh1b1 conditional-
knockout Msh2-LS mice and Aldh1b1 constitutive-knockout Msh2-LS mice. 
The combined areas of mT and mG fluorescent protein were detected by fluorescence 
microscopy and quantified using an ImageJ algorithm in all analyses of the Aldh1b1wt Msh2-
LS mouse model, Aldh1b1flox/flox Msh2-LS mouse model and Aldh1b1-/- Msh2-LS mouse model 
experiments, in order to obtain data about changes in the mG+ colonic crypt foci size and 
number, measured as percentage green area, as well as their distribution over time under 
ethanol or water treatment regimes. Small groups (n=3) of mice were used to investigate the 
changes at 5 days and 15 days, whereas after these times single mice in tumour-watch 
studies were analysed at longer timepoints. The mG+ crypt foci were quantified in both 
EtOH_Msh2fl KO and H2O_Msh2fl KO murine colonic samples and there was a peak of 
percentage green area around the first 15 days of ethanol- or water-treatment (30.9% and 
19%, respectively).  Subsequently, the percentage of green areas were broadly stable over 
the following weeks showing a gentle increase over time with some variability towards the 
end of the experiment, at around 30 to 50 weeks. EtOH_Msh2fl KO murine colon showed 
statistically significantly higher percentage green areas than H2O_Msh2fl KO murine colon 
(Figure 7.10).  In Aldh1b1flox/flox Msh2-LS mice, quantification of the mG+ colonic crypt foci in 
both EtOH_Aldh1b1fl/fl_Msh2fl KO and H2O_Aldh1b1fl/fl_Msh2fl KO mice showed a steady 
increase in percentage of green area reaching a high peak around 11-12 weeks of ethanol-
treatment (39.9%). By contrast, this high peak was not observed in the 
H2O_Aldh1b1fl/fl_Msh2fl KO murine colon, which showed a pattern very similar to that seen in 
H2O_Msh2fl KO mice. In Aldh1b1flox/flox Msh2-LS murine colon, the percentage green areas 
decreased after 12 weeks to stabilize over the subsequent weeks, with a small increase 
towards the end of the experiment with some mild variability. EtOH_Aldh1b1fl/fl_Msh2fl KO 
colon showed statistically significantly higher percentage green areas than 
H2O_Aldh1b1fl/fl_Msh2fl KO murine colon equivalents (Figure 7.11). In EtOH_Aldh1b1-/-_Msh2fl 
KO mice, measurement of the mG+ colonic crypt foci showed a similar trend to that observed 
in EtOH_Msh2fl KO mice, in which after the peak seen around 15 days of ethanol-treatment, 
the percentage green areas settle to a more stable trend with a mild increase over the 
subsequent weeks towards the end of the experiment. EtOH_Aldh1b1-/-_Msh2fl KO murine 
colon showed statistically significantly higher percentage green areas than H2O_Aldh1b1-/-




Figure 7.10: Quantification of green fluorescent crypt foci in large intestinal mucosal epithelium of 
Aldh1b1wt Msh2-LS mice treated with either 20% ethanol in drinking water or normal drinking water 
for various periods of time (x-axis). Percentage green areas were measured in whole-mount 
specimens of Aldh1b1wt Msh2-LS murine whole colonic samples (A), with separate examination of 
proximal colon (B), and distal colon (C). Ethanol-treated Aldh1b1wt Msh2-LS (EtOH_Msh2fl KO) murine 
colon showed statistically significantly higher percentage green areas than in water-treated Aldh1b1wt 
Msh2-LS (H2O_Msh2fl KO) murine colon equivalents; 2-way-ANOVA test analysis, ****p<0.0001 vs. 




Figure 7.11: Quantification of green fluorescent crypt foci in large intestinal mucosal epithelium of 
Aldh1b1flox/flox Msh2-LS mice treated with either 20% ethanol in drinking water or normal drinking 
water for various periods of time (x-axis). Percentage green areas were measured in whole-mount 
specimens of Aldh1b1flox/flox Msh2-LS murine whole colonic samples (A), with separate examination of 
proximal colon (B), and distal colon (C). Ethanol-treated Aldh1b1flox/flox Msh2-LS 
(EtOH_Aldh1b1fl/fl_Msh2fl KO) murine colon showed statistically significantly higher percentage green 
areas than in water-treated Aldh1b1flox/flox Msh2-LS (H2O_Aldh1b1fl/fl_Msh2fl KO) murine colon 
equivalents; 2-way-ANOVA test analysis, ****p<0.0001 and ***p=0.0001 vs. water (data shown as 




Figure 7.12: Quantification of green fluorescent crypt foci in large intestinal mucosal epithelium of 
Aldh1b1-/- Msh2-LS mice treated with either 20% ethanol in drinking water or normal drinking water, 
for various periods of time (x-axis). Percentage green areas were measured in whole-mount 
specimens of Aldh1b1-/- Msh2-LS murine colonic samples (A), with separate examination of proximal 
colon (B), and distal colon (C). Ethanol-treated Aldh1b1-/- Msh2-LS (EtOH_Aldh1b1-/-_Msh2fl KO) murine 
colon showed statistically significantly higher percentage green areas than in water-treated Aldh1b1-
/- Msh2-LS (H2O_Aldh1b1-/-_Msh2fl KO) murine colon equivalents; 2-way-ANOVA test analysis, 




7.2.2.2 Immunohistochemical characterization of mG-expressing intestinal crypt 
foci in Aldh1b1 wild-type Msh2-LS mice after long-term ethanol treatment 
To test whether the expression of mG/GFP observed by fluorescence microscopic detection, 
following Cre activation, correlated with the loss of Msh2 expression, IHC analyses were 
performed using anti-Msh2 antibody and anti-GFP antibody on intestinal tissue serial 
sections that were almost adjacent to each other. Small intestine, caecum and colon serial 
(or near serial) sections were cut from Tamoxifen-induced Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- 
mice and immunostained for both mG/GFP and Msh2 proteins.  
Small intestinal tissue samples of Msh2-/- mice were used as Msh2-null controls and GFP-
negative expression controls; and SI tissue samples of Tamoxifen-induced mTmG+/+ mice as 
Msh2-positive and GFP-positive expression controls (Figure 3.9). The lack of DAB-brown 
staining for both anti-Msh2 and anti-GFP IHC in the Msh2-/- SI tissues confirmed complete 
loss of Msh2 expression and lack of mG/GFP expression (Figure 3.9 A-B) in the Msh2-null 
negative control tissues. The presence of DAB-brown staining in the mTmG+/+ SI tissues 
confirmed presence of Msh2 expression throughout the SI tissue and GFP expression in some 
Cre-activated crypts (Figure 3.9 C-D) in the mTmG+/+ positive control tissues.  
The IHC analysis of Msh2 in Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- murine intestinal tissues 
showed lack of DAB-brown staining in some crypts scattered along the length of small 
intestinal mucosa, caecal mucosa and colonic mucosa (Figure 7.13, 7.14, 7.15). The exact 
same crypts appeared positive for DAB-brown staining after immunohistochemical detection 
of mG/GFP on the almost adjacent serial sections from the same Msh2flox/-; Lgr5CreERT2+/-; 
mTmG+/- murine intestinal tissue (Figure 7.13, 7.14, 7.15), confirming that the same small 
intestinal crypts, caecal crypts and colonic crypts had lost Msh2 protein expression and 
gained mG/GFP expression. 
The immunohistochemical detection of Msh2 in large intestinal adenomas (both colonic and 
caecal) from Msh2-LS mice showed lack of DAB-brown staining (Figure 7.16), however after 
IHC staining for mG/GFP, the same crypts displayed either weak or no DAB-brown staining in 






Figure 7.13: Representative images showing the comparison between mG/GFP and Msh2 
immunostaining of almost adjacent serial sections of large intestinal mucosal epithelium of Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mice treated with Tamoxifen to activate Cre in scattered Lgr5+ stem cells and 
their crypts. The same hyperproliferative crypt is positive for mG/GFP (A) and negative for Msh2 (B) 
(red ovals). Images taken using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP 
Viewer software at 20X magnification (bar at lower left indicates 100um). 
 
 
Figure 7.14: Representative images showing the comparison between mG/GFP and Msh2 
immunostaining of almost adjacent serial sections of caecal mucosal epithelium of Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mice treated with Tamoxifen to activate Cre in scattered Lgr5+ stem cells and 
their crypts. The same crypt foci are positive for mG/GFP (A) and negative for Msh2 (B) (red ovals). 
Images taken using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 





Figure 7.15: Representative comparison between mG/GFP and Msh2 immunostaining of almost 
adjacent serial sections of small intestinal mucosal epithelium of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- 
mice treated with Tamoxifen to activate Cre in scattered Lgr5+ stem cells and their crypts. The same 
crypts, villi and part-villi are positive for mG/GFP (A) and are negative for Msh2 (B) (red arrows). 
Images taken using the Hamamatsu Nanozoomer and analysed with the Hamamatsu NDP Viewer 







Figure 7.16: Representative adenoma images show the comparison between Msh2 and mG/GFP 
immunostaining of almost adjacent serial sections of a caecal adenoma (A and B) and a large intestinal 
adenoma (C and D) from Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice treated with Tamoxifen to activate 
Cre in scattered Lgr5+ stem cells and their crypts that may progress to form adenomas. In the caecal 
adenoma, the same crypt foci are negative for Msh2 (A) and positive for mG/GFP (B) (red ovals), 
however the GFP staining appears weak in some crypts. In the large intestinal adenoma those dMMR 
dysplastic crypt foci that are negative for Msh2 (C) are also negative for mG/GFP (D) (red ovals), 
consistent with GFP mutation resulting in lack of expression (GFP was expressed elsewhere in this 
section in non-dysplastic crypts). Images taken using the Hamamatsu Nanozoomer and analysed with 








7.3 FACS sorting of mT- and mG-expressing epithelial cells from small 
and large intestines from the Msh2-LS mouse model 
7.3.1 Methods 
7-9 weeks old Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- mice were divided into two groups. Group-
A mice received i.p. injections of 0.15mg Tamoxifen/g bw on day 1 and 0.1mg Tamoxifen/g 
bw on day 2, 3 and 4; on day 5 mice were provided with normal drinking water for 1.5 
months. By contrast, Group-B received i.p. injections of 0.15mg Tamoxifen/g bw on day 1 
and 0.1mg Tamoxifen/g bw on day 2, 3 and 4; but on day 5 the Group-B mice were provided 
with 20% ethanol in drinking water for 1.5 months (Figure 7.17). During the necropsy 
dissection procedure, morphologically normal-appearing small and large intestinal tissues 
were harvested, and soaked in cold PBS and kept on ice. Samples of small and large epithelial 
cells were isolated by FACS from fresh tissue following the protocol described in Materials 
and Methods, using anti-EpCAM antibody to detect epithelial cells. Disaggregated samples 
of ethanol-and water-treated Msh2-LS murine small and large intestinal epithelial cells were 
sorted as EpCAM positive populations in 4 groups: mT-expressing events, mG-expressing 
events, double-positive mT+mG+ expressing events and double-negative null-mT/null-mG 
expressing events, using the FACSAria II with BD Accuri C6 analyser (IGMM FACS facility). 








Figure 4.17: Experimental treatment protocols and timelines for Group-A (water-treated) and -B 
(ethanol-treated) mice, showing 4 days of i.p. injections of Tamoxifen, followed by either 
standard/normal drinking water (Group-A) or drinking or water containing 20% ethanol (Group-B). 























The FACS sorting of the ethanol- and water-treated Msh2-LS large and small intestinal 
samples did not show any quantitative and qualititative differences between the cell 
populations, due to loss of cell viability during experimental preparation procedures. 
EpCAM+ cells were subdivided into 4 groups, mT+/mG- cells, mT-/mG+ cells, double positive 
mT+/mG+ cells and double-negative mT-/mG- cells. The mT+/mG- cells or mT-/mG+ cells 
were the result of correct detachment of the intestinal epithelial cells (without or with prior 
Cre activation, respectively). The number of mT+/mG- cells was higher than the number of 
mT-/mG+ cells. Some cells that were negative for both mT and mG were detected during the 
FACS sorting, as a result of loss of both mT and mG expression. Some cells (or cell groups) 
that were positive for both mT and mG were detected during the FACS sorting, as a result of 
expression of both mT and mG, most probably due to doublets or larger clusters of mixed 
cells (Figure 7.18).  
All 4 groups of cell samples were collected from each sorted specimen. RNA extraction was 
performed and resulting RNA samples were stored at -80֯C. Due to COVID-19-related 











Figure 7.18: Representative graphs of the FACS sorting analysis reports. Ethanol-treated Msh2-LS 
murine large intestine (A), water-treated Msh2-LS murine large intestine (B), ethanol-treated Msh2-
LS murine small intestine (C), and water-treated Msh2-LS murine small intestine were selectively 
sorted according to their positivity for EpCAM (antigen positive cells=APC pos) in 4 different groups: 
RFP+ cells (RFP only), cells positive for both RFP and GFP (RFP GFP), cells negative for both RFP and 
GFP (neg) and GFP+ cells (GFP only). (LI=large intestine, SI=small intestine, RFP= red fluorescent 









In this chapter, expression of fluorescent green mG or fluorescent red mT proteins from the 
mTmG transgene reporter system was used to monitor any changes in the number, size, or 
distribution of crypt foci that were dMMR, following ethanol (compared with water) 
treatment of the mouse models over time. It was previously demonstrated (in Chapter 3) 
that the same crypts are both negative for Msh2 (confirming that they are dMMR) and 
positive for mG/GFP immediately following Cre-mediated activation in the Msh2-LS mouse 
model, and this was confirmed again by the data shown in this chapter for all three of the 
Aldh1b1wt Msh2-LS, Aldh1b1flox/flox Msh2-LS and Aldh1b1-/- Msh2-LS murine models (data not 
shown for all cases). Thus, mG expression can be used as a marker to detect and measure 
percentage green areas of dMMR cells and crypts in these models immediately following Cre 
activation by Tamoxifen. Long-term studies were also used to follow the natural history of 
these dMMR crypts as they proliferate to form dMMR crypt foci along with their subsequent 
potential for evolution to neoplasms over longer periods of time in single mice in the tumour-
watch study. 
To study the early effects of ethanol/acetaldehyde on dMMR crypts and crypt foci, 
experimental groups were set up to monitor changes after 5 days or 15 days of either 20% 
ethanol in drinking water or normal water. Statistically significant increases in the percentage 
green areas, combining number and size of crypt foci containing mG-expressing cells, were 
observed along the large intestinal tract for both 5-day and 15-day ethanol-treated Msh2-LS 
mice compared with 5-day and 15-day water-treated Msh2-LS mice, more so in proximal 
colon than distal colon, matching the pattern of adenoma distribution. Following the peak 
around the 15-day timepoint, these percentage green area differences between ethanol- 
and water-treated Msh2-LS mice stabilised and continued over the longer term, up to 50 
weeks, with some variability in the 30-50 week data.  
Images of mG+ villi/crypts in the Msh2-LS murine small intestine were acquired after 5 days 
and 15 days of either ethanol- or water-treatment regimes, but quantification of the mG+ 
villlus/crypt foci was technically difficult due to the extensive and often confluent mG+ 
villus/crypt foci and the more complicated folded structure of the small intestinal mucosa in 
3-dimensions. However, highly-magnified images of small intestinal mucosa showed the 
cellular localisation of mG+ cells sometimes in strips along the SI villi and this was 
corroborated by the anti-GFP IHC stains of Msh2-LS small intestine sections that showed 
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partial coverage of villi by strips of mG+/GFP+ and Msh2- epithelial cells. The murine colonic 
crypts were examined using a confocal microscope to obtain more high-powered and fine-
detailed images of the distribution of mG+ cells within the colonic crypts. This revealed that 
the fluorescent green crypt foci observed with the stereomicroscope consisted of whole 
colonic crypts, either singly or in crypt clusters, that were fully occupied by mG+/GFP+ cells, 
with mG+/GFP+ cells present on the table surface epithelium of the colon. This was 
corroborated by the anti-GFP IHC stains of Msh2-LS colon sections that showed mostly whole 
crypts or groups of crypts containing mG+/GFP+ and Msh2- epithelial cells. These 
appearances are consistent with scattered colonic crypt Lgr5+ stem cells undergoing Lgr5-
driven Cre-mediated concurrent inactivation of the floxed allele of Msh2 and change from 
mT to mG expression, with rapid monoclonal conversion of the crypts, such that whole crypts 
appear positive for mG expression within 5-15 days. Following further exposure to ethanol 
and its metabolite acetaldehyde, subsequent crypt fission leads to formation of mG+ crypt 
foci within a few weeks and these continue to expand over time at variable rates. 
The detection and quantification of mT and mG fluorescent protein by fluorescence 
microscopy was extended to all analyses of the Aldh1b1wt Msh2-LS, Aldh1b1flox/flox Msh2-LS, 
and Aldh1b1-/- Msh2-LS murine model tumour-watch experiments, in order to obtain data 
about changes in the mG+ dMMR colonic crypts and crypt foci over longer periods of time 
under long–term ethanol- or water-treatment regimes.  In all three mouse models, the 
ethanol-treated murine colon showed statistically significantly higher percentage green 
areas than water-treated murine colon. The PGA followed very similar trends in all 3 
experimental mouse models, in which after reaching a peak around 15 days (or longer, 11-
12 weeks, in the Aldh1b1flox/flox Msh2-LS model), the PGA stabilises over the following weeks 
showing a mild increase over time with some variability towards the end of the study period. 
In Aldh1b1flox/flox Msh2-LS mice, the early peak was higher and this may be consistent with 
combined inactivation in individual cells of MMR and Aldh1b1 expression with increased 
levels of intracellular acetaldehyde conferring an increased survival selective advantage 
upon dMMR cells (relative to MMR-proficient cells that can still undergo cell cycle arrest or 
apoptosis following DNA damage, as described in Chapter 6, Figure 6.92), with subsequent 
increased acetaldehyde-driven proliferation resulting in a relatively higher and longer early 
peak of mG+/dMMR crypt foci.  
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The PGA of dMMR crypt foci trends over time showed a high early peak that decreased after 
15-30 days (11-12 weeks for the Aldh1b1flox/flox Msh2-LS model) followed by subsequent 
stabilisation with a mild increase over time rather than a continually increasing level of PGA 
over time. Possible explanations for this include a time-related immune response to the early 
expansion of dMMR/mG+ crypts, with a reduction in dMMR/mG+ crypt foci occurring 
perhaps due to immune attack against the more immunogenic dMMR crypt cells that may 
present more frameshift peptides (Seth et al., 2018). This would require future 
immunological studies to evaluate whether greater numbers of infiltrating T lymphocytes 
could be found around dMMR crypt foci at the appropriate timepoints. However there is 
evidence of an immune response with infiltrating CD8+ and other lymphocytes and myeloid 
cells within and around adenomas shown in Chapter 4, 4.4.2.6. Another explanation might 
be that dMMR/mG+ crypt cells, including stem cells that populate the whole crypt, may 
acquire inactivating mutations in the mG/GFP gene sequence, resulting in loss of mG 
expression. Evidence for this was observed in the IHC analyses of adenomas for Msh2 and 
mG/GFP expression. In addition to confirming the co-localization in the same crypts or crypt 
foci showing gain of mG expression and loss of Msh2 expression, IHC for Msh2 and mG/GFP 
showed evidence of a partial or complete lack of GFP expression in some large intestinal 
adenomas, consistent with acquired mutations in mG/GFP. 
MMR-deficient cells are characterized by hypermutability (increased mutation rate by 100x 
– 1000x due to uncorrected mismatches) and microsatellite instability (MSI, variation in 
length of repetitive or microsatellite sequences, due to uncorrected insertion/deletion loops 
or InDels), with MSI confirmed in the Msh2-LS murine adenomas described in Chapter 4, 4.6 
(Kloor et al., 2012).  Analysis of the pCA-mTmG plasmid sequence (used to generate mTmG 
reporter mice) revealed the presence of several repetitive DNA coding sequences in the 
membrane-targeted EGFP (mG/GFP) gene sequence that are highly likely to act as targets for 
InDel mutations that are not repaired in mismatch repair-deficient cells (Figure 7.19). These 
are likely to confer susceptibility of the mG/EGFP gene to inactivating frameshift mutations, 
including within dMMR crypt stem cells in the Msh2-LS model, particularly following 
ethanol/acetaldehyde exposure. Subsequent investigations could include targeted DNA 
sequencing of the mG gene in those colonic adenoma glands (microdissected) that show loss 




As a result of the induced loss of Msh2 expression with abrogation of MMR in the Aldh1b1wt 
Msh2-LS, Aldh1b1flox/flox Msh2-LS and Aldh1b1-/- Msh2-LS murine model intestinal epithelial 
stem cells (and subsequently whole crypts and crypt foci), there will be an increased risk of 
InDel mutations in repetitive sequences in large numbers of genes that contain exonic 
repetitive DNA sequences, as well as microsatellite sequences between genes, thus 
generating expression of InDel mutated proteins or truncated proteins, that are fragmented 
to frameshift peptides that can be presented as antigenic epitopes on MHC molecules to 
trigger an immune attack against the dMMR cells. In a previous chapter (Chapter 4) dMMR 
tumours from the Msh2-LS mouse model were shown to have MSI, functionally confirming 
this deficiency in mismatch repair. The observation of loss of mG/GFP immunostaining in 
some adenomas in these models indicate that the mTmG transgene reporter can be used 
effectively for short-term studies (perhaps up to 12-15 weeks, although further studies are 
required to map these changes more precisely in time) of Cre-mediated DNA recombination 
in the Msh2-LS models, but in the context of Cre-induced inactivation of the mismatch repair 
system, the mTmG transgene system appears to become a less reliable system to monitor 
changes in mG+ dMMR crypt foci over longer periods of time due to the proposed time-
related acquisition of InDel mutations in the mG/GFP gene (Figure 7.20). 
In conclusion, a model is proposed (set out in a schematic diagram in Figure 7.20) to show 
the effects on colonic crypts and crypt foci of the mismatch repair pathway/acetaldehyde 
gene/environment interactions. These MMR/acetaldehyde interactions are likely to have 
significant effects on both MMR-proficient and MMR-deficient cells and crypts scattered 
along the large intestinal mucosa. Following ethanol ingestion and its metabolic conversion 
to acetaldehyde with acetaldehyde-induced DNA base damage, MMR-proficient intestinal 
stem cells and crypt daughter cells are able to activate DNA mismatch repair of the (MMR-
recognised) base damage, leading to either cell cycle arrest, to allow repair of mild DNA 
damage, or apoptosis in the case of unrepairable severe DNA damage. However, following 
loss of the second Msh2 allele (in the Msh2-LS model), MMR-deficient stem cells and their 
crypt daughter cells are unable to activate the MMR pathway  and so neither cell cycle arrest 
nor apoptosis can be triggered, resulting in aberrant survival of DNA-damaged cells and their 
subsequent proliferation (mostly acetaldehyde-induced colonic crypt cell proliferation, as 
shown in previous chapters). The proliferating dMMR stem cells populate crypts (detected 
as mG-positive appearing crypts in the Msh2-LS model colon under fluorescent microscopy 
and shown as green dots on the red background in the schematic diagram), and these crypts 
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expand further, by crypt fission, to form dMMR crypt foci or clusters. MMR-deficient stem 
cells and crypts have MSI resulting in accumulation of InDel mutations in microsatellite or 
repeat sequences, leading to both activation of an increased immune response to frameshift 
peptides and loss of expression of mG/GFP, as the mG gene contains many repetitive 
sequences. This mutational inactivation of mG generates colonic crypts and crypt foci that 
lack expression of both mG and mT and would thus be transparent (represented as black 
dots in the third panel of the schematic diagram). Such transparent crypts and crypt foci 
would allow red fluorescent light from the underlying mT-expressing tissue (lamina propria, 
muscularis mucosae, submucosa and muscularis propria) below to shine through and hence 
should also appear red on fluorescence microscopy, but negative on immunstaining for 
mG/GFP.  This process of dMMR crypt foci expansion would be enhanced by continued 
exposure over time to acetaldehyde, increasing DNA damage with selective survival and 
proliferation of dMMR cells and crypts, only partially balanced by some crypt loss from 
immune attack, with an increasing risk of these precursors forming neoplasms (adenomas) 














Figure 7.19: The mG/EGFP gene sequence (from the mTmG reporter construct DNA sequence) 
contains 8 repetitive (microsatellite) sequences (highlighted in yellow), which are summarised in a 
table of the microsatellite repeats showing their position within the EGFP gene, number of repetitions 
and the repeated sequence. Mononucleotide (e.g. AAAAAA or TTTTTT), dinucleotide (e.g. TGTGTG) 
and trinucleotide (e.g. AACAACAAC or TCATCATCA) repeats are known to be more susceptible to  InDel 
mutations in MMR-deficient cells in Lynch Syndrome tumours and their precursors, rendering the 
mG/EGFP gene particularly susceptible to mutational inactivation in dMMR crypt stem cells in the 




Figure 7.20: Schematic diagram of the proposed model of the effects on crypt foci of MMR/acetaldehyde gene/environment interactions in both MMR-proficient (mG-
/mT+ red cells/crypts constituting the red background of the large intestinal mucosa) and MMR-deficient (mG+/mT- green cells/crypts scattered along the large 
intestinal mucosa, shown as green dots) cells. Upon acetaldehyde (AcAld) exposure (following ethanol (EtOH)  ingestion and its metabolism to acetaldehyde), the 
pMMR intestinal cells (with red cell membranes) are able to activate DNA mismatch repair of the (MMR-recognised) base damage, bringing about either cell cycle 
arrest (mild DNA damage) or apoptosis (severe DNA damage). By contrast, the dMMR cells (with green cell membranes) are unable to activate the MMR pathway 
(following Cre-mediated inactivation of Msh2, indicated by the red cross through Msh2) and so, neither cell cycle arrest nor apoptosis are triggered, resulting in
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aberrant survival of DNA-damaged cells and their subsequent proliferation. The proliferating 
mG+/dMMR stem cells populate crypts (shown as green dots on the red background, first panel), and 
these crypts expand further (by crypt fission) to form mG+/dMMR crypt foci or clusters (second panel), 
with more mG+/dMMR crypt foci in the proximal than the distal colon. These mG+/dMMR cells have 
MSI resulting in accumulation of InDel mutations in microsatellite or repeat sequences, leading to 
both activation of an increased immune response to frameshift peptides and loss of expression of 
mG/GFP (as the mG gene contains many repetitive sequences) (mG- /mT- crypt foci are represented 
as black/transparent dots in the third panel). This process is enhanced by continued exposure to 
acetaldehyde over time increasing DNA damage with selective survival and proliferation of dMMR 
cells and crypts, only partially balanced by some crypt loss from immune attack, with increasing risk 






















Chapter 8: Final Discussion, Future Work & Summary 
8.1 Ethanol/Acetaldehyde induces colonic neoplasms in a Lynch 
Syndrome mouse model 
In this project the overarching objective was to investigate whether there is a 
gene/environment interaction between ethanol/acetaldehyde and dMMR, that may cause 
an acceleration of dMMR-driven intestinal tumour formation. Aims included determining 
whether ethanol/acetaldehyde can increase the number and size of precursor lesions and 
colonic adenomas, whether these adenomas can progress to invasive adenocarcinoma, and 
whether MMR plays a role in protecting intestinal epithelial cells from 
ethanol/acetaldehyde-induced DNA damage. 
The Msh2-LS mouse model, created by Wojciechowicz et al., (2014), was combined with the 
mTmG transgene reporter, generated by Dr. Lou, Stanford University (Muzumdar et al., 
2007). This modified version of the Msh2-LS mouse model was successfully generated to 
establish a colony of Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- model mice. In the Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/- mouse model, the activation of Cre recombinase by Tamoxifen-
treatment induced recombination between two inverted loxP sites flanking Msh2 exons 12 
and 13 in the floxed Msh2 allele and also between the loxP sites flanking the mT sequence in 
the mTmG transgene. This was shown to generate a Msh2 knockout allele (Msh2flox/OFF) and 
convert the same intestinal stem cells to mG expression, forming dMMR intestinal stem cells 
that subsequently form dMMR crypts, which are marked by green fluorescent mG 
expression.  That these two events occurred in the same cells/crypts was confirmed by IHC 
for both Msh2 and GFP expression on adjacent serial sections of intestinal tissue, showing 
colocalization in the same cells/crypts of mG expression and the loss of Msh2 expression.  
The Msh2flox/-; Lgr5CreERT2+/-; mTmG+/- model mice (Msh2-LS mice) were used to investigate 
the effects of long-term ethanol treatment on intestinal tumour formation and progression. 
Long-term ethanol treatment of the Tamoxifen-induced Msh2-LS mice showed evidence of 
large intestinal hyperproliferation and adenoma formation (with 5 adenocarcinomas) in 65% 
(15/23 mice) of the EtOH_Msh2fl KO mice, over an average of 6 months of ethanol treatment. 
This is in stark contrast to the H2O_Msh2fl KO mice, none of which developed intestinal 
tumours over the same time period, with only 1 colonic adenoma observed at 15 months 
(4%, 1/23).  
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In previous experiments by our group reported by Müller et al., (2016), Aldh1b1-depleted 
mice and WT control mice treated with long-term ethanol showed intestinal tumour 
formation after 1 year in both groups. In Wojciechowicz et al., (2014), Tamoxifen-induced 
Msh2flox/-; Lgr5CreERT2+/- mice (without any further treatment) showed intestinal tumour 
formation within an average of 19 months. Long-term ethanol-treatment of the Tamoxifen-
induced Msh2-LS mice provided evidence of ethanol-induced colonic adenoma formation 
that occurred at higher numbers and at a much earlier time, consistent with ethanol-
mediated acceleration of dMMR-driven large intestinal tumour formation. 
The EtOH_Msh2fl KO mice showed a pattern of tumour distribution of one or more large 
intestinal tumours mainly in the proximal colon and mid colon. A similar pattern is observed 
in human LS patients, in which colonic tumour formation occurs more in the caecum, 
ascending colon and transverse colon regions (proximal colon), than in the descending colon, 
sigmoid colon and rectum (distal colon), compared with sporadic colorectal tumours that are 
predominantly distal in location. Rijcken et al. (2008), described 50% of colonic adenomas in 
human LS cases were found in the proximal colon, compared with 26% of sporadic 
adenomas. In addition, proximal LS adenomas progressed to high-grade dysplasia more 
frequently than distal LS adenomas, and also more showed high-grade dysplasia than larger 
distal adenomas (Rijcken et al., 2008). Adenomas in LS familial cases were smaller when 
compared with sporadic adenomas, and proximal LS familial adenomas ≥ 5 mm showed more 
severe dysplasia than larger proximal sporadic adenomatous polyps (Lynch et al., 2009). 
 
Here, ethanol-treatment of the combined Msh2-LS and mTmG mouse model, which was 
designed to study intestinal tumour formation associated with defective DNA mismatch 
repair (with Tamoxifen-induced Lgr5-driven Cre activation occurring in small and large 
intestines, as Lgr5 is an intestinal stem cell-specific gene) (Barker et al, 2008), has been 
characterised to show that it represents a good model of human LS in terms of the formation 
and location of adenomas, with some progressing to adenocarcinomas, only in the colon (not 
in the small intestine), and these predominantly form in the proximal and mid colon. No small 
intestinal adenomas were seen in the water- or ethanol-treated Msh2-LS mice, similar to the 






8.2 Ethanol/Acetaldehyde increases mismatch repair-deficient crypt 
foci that act as precursors in the pathogenesis of colonic neoplasms in 
this Lynch Syndrome mouse model 
 
Msh2 immunohistochemical analysis of Msh2-LS murine intestines showed inducible loss of 
Msh2 expression in scattered large intestinal crypts and small intestinal crypts and villi. A 
statistically significantly higher number of dMMR crypt foci were observed in ethanol-treated 
murine colons compared with water-treated murine colons. However, the number of dMMR 
crypt/villus foci appeared to be higher in EtOH_Msh2fl KO murine SI than in colon even though 
no SI tumours were observed. All large intestinal adenomas from EtOH_Msh2fl KO mice 
showed Msh2-negative dysplastic glands, often surrounded by or admixed with Msh2-
positive non-dysplastic crypts showing reactive or hyperproliferative changes. This 
confirmed that colonic adenomas arose from dMMR (Msh2-negative) crypt precursors. This 
is consistent with observations from human LS patients that the risk of colonic tumour 
formation correlates with the number and size of the MMR-deficient crypt clusters that 
expand over time in affected LS patients (Kloor et al., 2012; Shia et al., 2015; Wojciechowicz 
et al., 2014). The complete abrogation of MMR activity in these crypt foci was confirmed by 
the presence of Msh6-negative crypts (detected by IHC) scattered along both SI and colon of 
Tamoxifen-induced Msh2-LS mice in a very similar frequency and pattern as Msh2-negative 
crypts, as Msh6 is the heterodimeric binding partner of Msh2 and loss of Msh2 is considered 
to lead to destabilisation and loss of Msh6, but retention of Mlh1 expression, as confirmed 
in this study (Poulogiannis et al., 2010). Microsatellite instability was also shown in adenomas 
arising in the Msh2-LS mouse model, validating functional loss of the MMR pathway. 
The positive Ki67 immunostaining in elongated large intestine crypts confirmed the presence 
of extended hyperproliferative zones identified morphologically on routine H&E stains. The 
proliferation marker Ki67 showed statistically significant higher expression levels in 
EtOH_Msh2fl KO murine colon compared with ethanol-treated murine SI and compared with 
H2O_Msh2fl KO murine intestinal tissues (both colon and SI). These observations confirm the 
previously reported association of long-term ethanol treatment of mice and colonic mucosal 
epithelial hyperproliferation, likely to act as a tumour promoter  in the initiator-promoter 
model of carcinogenesis (Müller et al., 2016; Scott et al., 1984).  
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β-catenin is a Wnt signalling pathway intermediate and its nuclear localisation by 
immunostaining is a useful biomarker of colorectal neoplasms (Cong et al., 2003). Colonic 
adenomas and adenocarcinomas from EtOH_Msh2fl KO mice showed a heterogeneous 
pattern with variable numbers of adenoma cells showing moderately to strongly positive β-
catenin nuclear immunostaining, due to accumulation and translocation of β-catenin into the 
nuclei of dysplastic cells. This pattern supports heterogeneous activation of the Wnt 
signalling pathway in these tumours and has been observed in human MMR-deficient CRC 
(Lugli et al., 2007), more often in association with activating mutations in the β-catenin 
encoding gene CTNNB1 than APC mutations in LS patients (Ahadova et al., 2016; Fukushima 
et al., 2001; Mirabelli-Primdahl et al., 1999).  
Following ethanol treatment, a significant DNA damage response was 
immunohistochemically detected using antibodies against yH2AX, a DNA damage marker, 
(Siddiqui, 2015) and p53, which showed the “wild-type pattern” observed previously in 
response to DNA damage (Köbel et al., 2016). Increased levels of yH2AX and “wild-type 
pattern” nuclear p53 immunostaining were observed in EtOH_Msh2fl KO murine large 
intestine compared with H2O_Msh2fl KO murine large intestine, and also compared with 
almost no to very low expression in ethanol-treated Msh2-LS small intestine. This suggests 
that Msh2 / MMR plays a key role in protecting the MMR-proficient colonic epithelial cells 
against this type of DNA damage, but Msh2 appears not to be the sole protective mechanism 
for small intestinal epithelial cells from ethanol/acetaldehyde-induced DNA damage. 
The increased DNA damage observed in EtOH_Msh2fl KO murine large intestinal mucosal 
epithelium was consistent with the statistically significantly higher levels of circulating 
plasma acetaldehyde detected in these mice compared with H2O_Msh2fl KO mice by plasma 
acetaldehyde assay. Acetaldehyde is a highly reactive molecule able to cause a wide range 
of DNA modifications (Seitz & Stickel, 2007). In the absence of MMR some of these DNA 
lesions are not recognised and repaired. Loss of MMR pathway function results in dMMR 
with hypermutability (increased mutation rate by 100x – 1000x due to uncorrected 
mismatches) and MSI (manifested by variation in length of repetitive microsatellite 
sequences due to uncorrected insertion/deletion loops). More importantly dMMR results in 
reduced susceptibility to either cell cycle arrest or apoptosis induced by those types of DNA 
damage recognised by the MMR system (Poulogiannis et al., 2010; Seth et al., 2018; Toft et 
al., 1999). Thus, unrepaired acetaldehyde-induced DNA damage in dMMR cells that fail to 
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arrest or die are likely to result in both an increased mutation rate and aberrant survival with 
an increased risk of neoplasm formation. 
The immunohistochemical analysis of cCAs3, a key effector of cell death by apoptosis 
(Holubec et al., 2005; Talmon et al., 2010), showed significantly higher numbers of apoptotic 
bodies in colons from EtOH_Msh2fl KO mice compared with no detectable cCas3+ apoptotic 
bodies in colons from H2O_Msh2fl KO mice, consistent with increased apoptosis associated 
with pMMR colonic epithelial cell exposure to ethanol/acetaldehyde (only scattered crypts 
are defective for MMR in this model, the majority are proficient for MMR as seen by the 
large area of red fluorescent pMMR crypts compared with the smaller area of green dMMR 
crypts). The almost complete lack of detection of apoptotic bodies in large intestinal tumours 
from Msh2-LS mice is consistent with the inability of dMMR cells to activate cell death by 
apoptosis following DNA damage of MMR-recognisable type. Furthermore, MSI was 
detected using a panel of microsatellite markers in colonic adenomas from EtOH_Msh2fl KO 
mice, functionally confirming abrogation of the mismatch repair system in these adenomas. 
Detection of infiltrating immune cells (by IHC pilot studies) in the intestinal adenomas of 
EtOH_Msh2fl KO mice supports an immune response against dMMR adenoma cells. Defective 
MMR with MSI causes mutations in protein coding repetitive DNA sequences that are likely 
to result in production of FSPs (Sæterdal et al., 2001). Such FSPs are novel antigens and elicit 
both humoral and cellular immune responses, which are seen as TILs around the dMMR 
crypts in LS patients as well as in dMMR cancers, both sporadic and due to LS (M. Linnebacher 
et al., 2001; Reuschenbach et al., 2010; Seth et al., 2018a).  
The data provide evidence that ethanol and its metabolite acetaldehyde act as tumour 
promoters causing proliferation of colonic epithelium and can also select for aberrant 
survival of dMMR cells, via loss of MMR-recognised DNA damage-induced apoptosis. This 
aberrant survival and proliferation of DNA-damaged dMMR colonic epithelial cells is likely to 
lead to an increased probability of acquisition and fixation of DNA mutations, including some 
affecting tumour driver genes, explaining the accelerated colonic adenoma formation.  
Hence, there is evidence for a selective advantage of the dMMR/ethanol/acetaldehyde 
interaction, as a gene/environment interaction, that is consistent with accelerated colonic 
adenoma development and further progression to adenocarcinoma (in some cases) in 
EtOH_Msh2fl KO mice. The hyperproliferation process is observed mostly in the proximal colon 
and mid colon, but not in the small intestine, and is proposed to be a key driver of the 
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location of tumour formation at these sites in this Msh2-LS model, very similar to the 
anatomical tumour distribution seen in human Lynch Syndrome patients. 
Early in these studies, we attempted to further accelerate dMMR-driven intestinal 
tumorigenesis in Msh2-LS mice by adding a TMZ treatment (described by Wojciechowicz et 
al., 2014) to the long-term ethanol treatment. The aim was to accelerate intestinal tumour 
formation to 2-4 months to reduce the experimental time period, in contrast to the 1 year 
of ethanol treatment required for intestinal adenoma formation in WT and Aldh1b1-
depeleted mice (Müller et al., 2016), and the 1.5 years or longer for intestinal adenoma 
development in otherwise untreated Msh2-LS model mice (Wojciechowicz et al., 2014). The 
immunohistochemical analysis of Msh2, Ki67 and β-catenin of tumour and normal intestinal 
tissue of TMZ- and ethanol-treated Msh2-LS mice confirmed the carcinogenic properties of 
TMZ, which is known to be a powerful DNA methylating agent and carcinogen. TMZ was 
shown to confer proliferative advantage upon established dMMR crypt foci with selection 
for survival and expansion in the Msh2-LS murine intestines that led to intestinal tumour 
formation (Wojciechowicz et al., 2014). However, the carcinogenic properties of TMZ were 
too potent in these experiments, inducing early-occurring extra-intestinal tumours 
(independent of dMMR), predominantly thymic lymphomas, that masked any carcinogenic 
ethanol effects upon the intestines. The intestinal data obtained were inconclusive as TMZ 
was too potent a carcinogen to allow exploration of the intestinal tumour-promoting and 
DNA-damaging effects of ethanol and its major metabolite acetaldehyde, in combination 
with deficient MMR. For this reason, it was decided to discontinue the experimental use of 
TMZ in combination with ethanol in the Msh2-LS mouse model and to focus solely on the 













8.3 Inactivation of Aldh1b1 allowed exploration of the effects of 
acetaldehyde on DNA damage and its interaction with deficient 
mismatch repair during intestinal tumourigenesis in Lynch Syndrome 
mouse models 
 
Both the conditional-knockout Aldh1b1 allele (Aldh1b1flox) and the constitutive-knockout 
Aldh1b1 allele (Aldh1b1-) were introduced into the Msh2-LS mouse model to further 
investigate the gene/environment interaction between acetaldehyde and dMMR, in the 
context of formation of precursor lesions, adenomas and adenocarcinomas. The Msh2flox/-; 
Lgr5CreERT2+/-; mTmG+/-; Aldh1b1flox/flox colony and the Msh2flox/-; Lgr5CreERT2+/-; mTmG+/-; 
Aldh1b1-/- colony were established and used in long-term ethanol treatment tumour-watch 
experiments for up to one year, with the expected changes in Msh2 and Aldh1b1 protein 
expression confirmed by IHC detection of Msh2 and Aldh1b1. In Aldh1b1flox/flox Msh2-LS mice, 
41.7% (5/12 mice) of EtOH_Aldh1b1fl/fl_Msh2fl KO mice showed evidence of large intestinal 
hyperproliferation and adenoma formation (with 1 adenocarcinoma) within an average of 
4.5 months of ethanol treatment, compared with no hyperproliferation and no cases of large 
intestinal adenoma formation in H2O_Aldh1b1fl/fl_Msh2fl KO mice (0%, 0/12 mice) over the 
same time-period. In Aldh1b1-/- Msh2-LS mice, 66.7% (8/12 mice) of EtOH_Aldh1b1-/-_Msh2fl 
KO mice showed evidence of large intestinal hyperproliferation and adenoma formation 
within an average of 6 months of ethanol treatment, compared with no hyperproliferation 
and no cases of large intestinal adenoma formation in H2O_Aldh1b1-/-_Msh2fl KO mice (0%, 
0/12 mice) over the same time-period. As observed in Aldh1b1wt Msh2-LS mice, no small 
intestinal adenomas were seen in either the Aldh1b1flox/flox Msh2-LS or Aldh1b1-/- Msh2-LS 
mice, for both ethanol- and water-treated mice.   
The EtOH_Aldh1b1fl/fl_Msh2fl KO mice showed a pattern of tumour distribution of one or more 
large intestinal tumours mainly in the proximal colon and mid colon and in some cases in the 
distal colon, whereas EtOH_Aldh1b1-/-_Msh2fl KO mice showed one or more tumours in the 
proximal and mid colon as well as in the rectum (distal colonic or rectal tumours were not 
observed in EtOH_Msh2fl KO mice). In both EtOH_Aldh1b1fl/fl_Msh2fl KO mice and 
EtOH_Aldh1b1-/-_Msh2fl KO mice, ethanol-induced colonic adenomas occurred at statistically 
significantly higher numbers of adenomas per mouse than in EtOH_Msh2fl KO mice.  
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There were high plasma levels of acetaldehyde in the Aldh1b1-/- Msh2-LS mice and lower, 
more moderate levels of plasma acetaldehyde in the Aldh1b1flox/flox Msh2-LS mice. 
Acetaldehyde-induced DNA damage response was detected by immunohistochemical 
analysis of both yH2AX and p53 (showing the “wild-type pattern”), with high expression of 
yH2AX and nuclear p53 immunostaining in both EtOH_Aldh1b1fl/fl_Msh2fl KO and 
EtOH_Aldh1b1-/-_Msh2fl KO murine large intestine, compared with H2O_Aldh1b1fl/fl_Msh2fl KO 
and H2O_Aldh1b1-/-_Msh2fl KO murine large intestine. Lower yH2AX and nuclear p53 
expression was observed in EtOH_Aldh1b1fl/fl_Msh2fl KO and EtOH_Aldh1b1-/-_Msh2fl KO 
murine small intestine. This revealed that acetaldehyde (more so than ethanol) mediated a 
significant DNA-damaging effect, mainly on dMMR colonic mucosal epithelium rather than 
on dMMR small intestinal mucosa, indicating that other protective mechanisms appear to be 
operative in the small intestinal epithelium, consistent with the much lower incidence of 
small intestinal cancers compared with colonic cancers in human LS patients. This suggests 
that Msh2 has a key role in protecting the MMR-proficient colonic epithelial cells against this 
type of DNA damage. Measurement of plasma acetaldehyde showed that the inactivation of 
Aldh1b1 led to increased levels of acetaldehyde in the blood, and this likely reflected 
increased acetaldehyde in intestinal epithelial cells causing more acetaldehyde-mediated 
DNA damage. Some acetaldehyde-mediated DNA damage, unrecognised in dMMR cells, was 
associated with increased numbers of intestinal crypt foci in both EtOH_Aldh1b1fl/fl_Msh2fl 
KO and EtOH_Aldh1b1-/-_Msh2fl KO mice. The evidence suggests that these increased dMMR 
crypt foci act as precursors in dMMR-driven intestinal tumour formation, explaining in part 
the increased numbers of colonic adenomas per mouse in this model. These results verified 
the key role of Aldh1b1 in protecting the large intestinal epithelial cells, particularly the stem 
and progenitor cells that have the highest levels of Aldh1b1 expression, from ethanol-derived 
acetaldehyde-induced DNA damage, consistent with previous observations by our group 
(Müller et al., 2016).  
This study produced strong evidence in support of the hypothesis that there is a 
gene/environment interaction between dMMR and acetaldehyde, demonstrated most 
notably by the Aldh1b1 constitutive-knockout Msh2-LS mouse model. The data provide 
evidence in support of the proposed models (Figures 8.1 to 8.5) that in Aldh1b1-/- MMR-
deficient intestinal epithelial stem cells, significant acetaldehyde-induced DNA damage is not 
recognized by the DNA mismatch repair system, with no activation of either cell cycle arrest 
or apoptosis. The DNA-damaged Aldh1b1-/- MMR-deficient intestinal epithelial cells are 
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proposed to undergo inappropriate survival and subsequent proliferation, compared with 
Aldh1b1-/- MMR-proficient cells. This is proposed to confer a selective advantage upon the 
Aldh1b1-/- dMMR intestinal epithelial stem cells that leads to more efficient monoclonal crypt 
conversion (Figure 8.1) and crypt expansion by crypt fission (Figures 8.2-8.3), observed as 
higher numbers of clusters of Aldh1b1-/- dMMR crypt foci. This is further proposed to confer 
an elevated risk of subsequent tumour formation with both right-sided and left-sided colonic 
adenomas and occasional adenocarcinomas developing in these mice. In the Aldh1b1flox/flox 
Msh2-LS model mice, scattered Aldh1b1flox/flox Msh2flox/- intestinal epithelial stem cells are 
induced by Tamoxifen-mediated Cre activation to become Aldh1b1KO MMR-deficient 
intestinal epithelial stem cells and these respond to ethanol exposure in a similar way to 
Aldh1b1-/- MMR-deficient intestinal epithelial stem cells, with a survival selective advantage 
over the surrounding Aldh1b1wt intestinal epithelial stem cells, including those in the same 
crypts, thus making monoclonal crypt conversion by these cells more likely (Figure 8.1).  The 
surrounding Aldh1b1wt intestinal epithelial crypts and other intestinal cell types (lamina 
propria and smooth muscle cells) would be able to metabolise more acetaldehyde to acetate 
leading to relatively lower levels of acetaldehyde in the intestinal tissues compared with 





Figure 8.1: Schematic diagram of the proposed model of acetaldehyde-mediated selection for 
monoclonal conversion by dMMR colonic crypt stem cells following ethanol exposure in the 
Tamoxifen-induced Cre-activated Aldh1b1wt Msh2-LS mouse model (top row) and the Tamoxifen-
induced Cre-activated Aldh1b1-/- Msh2-LS mouse model (bottom row) over time (shown as a black 
horizontal arrow). In the Aldh1b1wt Msh2-LS mouse model (top row), Tamoxifen induced Cre-
activation in scattered Lgr5+ colonic stem cells converts them to dMMR/mG+ stem cells (green cells, 
first seen at the crypt base of the second crypt from the left in the top row). Ethanol is metabolised to 
acetaldehyde (at low intracellular levels in the Aldh1b1wt mice), and there is preferential selection for 
survival of dMMR/mG+ stem cells containing acetaldehyde-induced DNA damage over pMMR/mT+ 
stem cells (red cells containing the word ‘stem”) containing acetaldehyde-induced DNA damage. This 
is because pMMR/mT+ stem cells can recognise acetaldehyde-induced DNA damage (of MMR-
recognisable type) and either undergo cell cycle arrest or apoptosis, whereas dMMR/mG+ stems can 
not do this. This acetaldehyde-driven selective advantage for green dMMR/mG+ stem cells allows 
them to replace the red pMMR/mT+ stem cells and populate the crypt with their daughter cells over 
time, gradually leading to monoclonal conversion of the entire crypt with green dMMR/mG+ cells 
(shown in the sixth crypt). This process is proposed to occur earlier in the Aldh1b1-/- Msh2-LS mouse 
model (complete monoclonal crypt conversion is shown occurring by the fourth crypt in the bottom 
row), supported by the evidence of more green crypts observable in Aldh1b1-/- Msh2-LS mice 
compared with Aldh1b1wt Msh2-LS mice. Under ethanol exposure, the Aldh1b1-/- dMMR/mG+ cells are 
proposed to have an increased selective advantage over the pMMR /mT+ cells due to the higher 
intracellular levels of acetaldehyde that mediate DNA damage, leading to earlier or faster monoclonal 
crypt conversion (to be verified by future experiments). In the Aldh1b1flox/flox Msh2-LS model mice, 
scattered Aldh1b1flox/flox Msh2flox/- intestinal epithelial stem cells are induced by Tamoxifen-mediated 
Cre-activation to become Aldh1b1-/- Msh2-/- MMR-deficient intestinal epithelial stem cells and thus the 
dMMR/mG+ monoclonal crypt conversion occurs in a similar way to that described for the Aldh1b1-/- 





Figure 8.2: Schematic diagram of the proposed model of the selective effects of MMR/acetaldehyde 
gene/environment interactions on dMMR/mG+ crypts and their expansion to form crypt foci in the 
Aldh1b1wt Msh2-LS mouse model (upper panels) and the Aldh1b1-/- Msh2-LS mouse model (lower 
panels) over time (horizontal black arrow) during ethanol exposure. The dMMR/mG+ crypts (mG+/mT- 
green crypts scattered along the large intestinal mucosa, shown as green dots on the red background 
in the left-sided panels) are shown progressing to dMMR/mG+ expanded crypt foci (illustrated as two, 
three or more clustered green dots in the right-sided panels) over time. The data shows that this 
process occurs to a greater extent in Aldh1b1-/- Msh2-LS (lower panels) compared with the Aldh1b1wt 
Msh2-LS mice (upper panels). This crypt expansion process is proposed to occur via crypt fission 
(examples of bifid crypts undergoing crypt fission were observed histologically and this is shown in the 
lower panels). The more rapid expansion of dMMR/mG+ crypt foci by crypt fission in Aldh1b1-/- Msh2-
LS mice is proposed to result from higher intracellular acetaldehyde levels conferring a greater 
selective advantage of acetaldehyde-exposed dMMR/mG+ stem cells for survival and proliferation, 
that are triggered to initiate the process of crypt fission. The mG-/mT+ red cells/crypts constitute the 
red background of the large intestinal mucosal epithelial surface. (Prx=proximal colon; Dst=distal 





Figure 8.3: Representative image of a colonic crypt undergoing crypt fission (red oval) in a background 
of colonic epithelial hyperproliferative change in ethanol-treated Msh2-LS mice. Image taken from 
scanned slide files with the Hamamatsu Nanozoomer NDP Viewer software at 20X magnification (bar 
at lower left indicates 100µm).   
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8.4 The mTmG transgene reporter system allowed investigation of the 
effects of ethanol on mG-expressing dMMR crypt foci precursors in the 
Lynch Syndrome mouse models 
The mTmG transgene reporter system was used to monitor any changes in the number, size, 
or distribution of crypt foci that were dMMR, following ethanol (compared with water) 
treatment of the mouse models over time. The detection of mT and mG fluorescent proteins 
after 5 days or 15 days of either ethanol or water treatment showed a statistically significant 
increase in the number and size of mG expressing colonic crypt foci in ethanol-treated mice 
compared with water-treated mice. Furthermore, the treatment of Msh2-LS mice with 
ethanol increased the number of mG expressing dMMR crypt foci in a time dependent 
manner. By contrast, the number of dMMR crypt foci didn’t increase under normal drinking 
water treatment. Ethanol increased mG expressing dMMR crypt foci in the colon, suggesting 
ethanol/acetaldehyde-mediated selection for expansion of dMMR crypt foci (Figures 8.2-
8.3).  
The detection and quantification of mT and mG fluorescent protein was extended to all 
analyses of the Aldh1b1wt Msh2-LS, Aldh1b1flox/flox Msh2-LS, and Aldh1b1-/- Msh2-LS murine 
model tumour-watch experiments, in order to obtain more data about changes in the mG+ 
dMMR colonic crypts and crypt foci over longer periods of time under long–term ethanol- or 
water-treatment regimes. The PGA of dMMR crypt foci showed similar trends over time with 
a high early peak that decreased after 15-30 days for the Msh2-LS model (11-12 weeks for 
the Aldh1b1flox/flox Msh2-LS model) followed by subsequent stabilisation with a mild increase 
over time, rather than a continually increasing level of PGA-detected dMMR foci over time. 
Also the IHC for Msh2 and mG/GFP showed evidence of a partial or complete lack of GFP 
expression in some large intestinal adenomas, consistent with acquired mutations in 
repetitive sequences in the mG/GFP gene. Analysis of the pCA-mTmG plasmid sequence 
revealed the presence of several repetitive sequences in the membrane-targeted EGFP 
(mG/GFP) gene sequence that are highly likely to act as targets for InDel mutations that are 
not repaired in mismatch repair-deficient cells. This mutational inactivation of mG would 
generate colonic crypts and crypt foci that lack expression of both mG and mT (Figures 8.4 
and 8.5). The resulting transparent crypts and crypt foci appear red under the fluorescent 
microscope due to the detection of red fluorescent light from the underlying mT-expressing 
tissue. However, they were negative on immunostaining for mG/EGFP. Furthermore, there 
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may be a time-related immune response to the early expansion of dMMR/mG+ crypts, with 
a reduction in dMMR/mG+ crypt foci occurring perhaps due to immune attack against the 
more immunogenic dMMR crypt cells that may present more frameshift peptides (Seth et 
al., 2018). This would require future immunological studies to evaluate whether greater 





In conclusion, a model is proposed (set out in schematic diagrams in Figures 8.4-8.5) to show 
the effects on colonic crypts and crypt foci of the mismatch repair pathway/acetaldehyde 
gene/environment interactions. In the Aldh1b1wt Msh2-LS mouse model, following ethanol 
ingestion and its metabolic conversion to acetaldehyde, but before acetaldehyde is fully 
metabolised to acetate, there is some acetaldehyde-induced DNA base damage. MMR-
proficient intestinal stem cells and crypt daughter cells are able to activate DNA mismatch 
repair of the (MMR-recognised) base damage, leading to either cell cycle arrest, to allow 
repair of mild DNA damage, or apoptosis in the case of unrepairable severe DNA damage. 
However, following loss of the second Msh2 allele, MMR-deficient stem cells and their crypt 
daughter cells are unable to activate the MMR pathway and so neither cell cycle arrest nor 
apoptosis can be triggered, resulting in aberrant survival of DNA-damaged cells and their 
subsequent proliferation (mostly acetaldehyde-induced colonic crypt cell proliferation). The 
proliferating dMMR stem cells have both a survival advantage (apoptosis blocked by dMMR) 
and a proliferative advantage (cell cycle arrest inhibited by dMMR) during 
ethanol/acetaldehyde exposure and thus can rapidly populate crypts by monoclonal crypt 
conversion (detected as mG-positive cells filling the whole crypt, which appears as a green 
area/dot (on a red background) on the colonic mucosal surface of the mTmG Msh2-LS model 
colon under fluorescent microscopy, represented as green dots on the red background in the 
schematic diagram in Figures 8.1 to 8.5). During ongoing ethanol/acetaldehyde exposure, 
the proliferative advantage allows these green dMMR crypts to expand further, by crypt 
fission, to form dMMR crypt foci or clusters (Figure 8.2 and 8.3), with more of them observed 
proximally than distally in the colon, consistent with the acetaldehyde-induced epithelial 
hyperproliferation occurring more proximally than distally (Figures 8.4 and 8.5).  
These dMMR cells/crypts can accumulate mutations from continued exposure to 
ethanol/acetaldehyde reflecting a form of dMMR genomic instability. MMR-deficient stem 
cells and crypts have MSI resulting in accumulation of InDel mutations in microsatellites or 
repeat sequences in coding exons; this is proposed to lead to both activation of an increased 
immune response to frameshift peptides (presented on major histocompatibility class I 
molecules on the surface of the affected cells) and loss of expression of mG/GFP green 
fluorescent protein, as the mG gene contains many repetitive sequences. This mutational 
inactivation of mG generates colonic crypts and crypt foci that lack expression of both mG 
and mT and should be transparent, but would appear red on fluorescence microscopy due 
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to transmission of red light from mT-expressing tissues underneath, although they appear 
negative on immunostaining for mG/EGFP.  This process of dMMR crypt foci expansion would 
be enhanced by continued exposure over time to acetaldehyde, increasing the amounts of 
DNA damage with selective survival and proliferation of dMMR cells and crypts, only partially 
balanced by some crypt loss from immune attack, with an increasing risk of neoplasm 
formation and progression as mutations accumulate. 
 In the Aldh1b1-/- Msh2-LS murine model colon (Figure 8.5), ethanol is metabolized to highly 
reactive acetaldehyde, with much reduced oxidation to acetate due to the lack of Aldh1b1 
enzymic activity. This causes a marked increase in acetaldehyde levels in the colonic stem 
cells. High levels of reactive acetaldehyde causing severe acetaldehyde-induced DNA 
damage (of MMR-recognised type) may force the Aldh1b1-/- MMR-proficient colonic 
epithelial cells to activate cell death by apoptosis. This is not the case in Aldh1b1-/- MMR-
deficient colonic epithelial cells that are unable to activate the MMR signalling pathway and 
so there is neither cell cycle arrest nor apoptosis, following increased acetaldehyde-induced 
DNA damage, resulting in aberrant survival of more severely DNA-damaged cells and their 
subsequent proliferation, also driven by increased levels of acetaldehyde. Aldh1b1-/- MMR-
deficient colonic epithelial cells proliferate and expand to form higher numbers of Aldh1b1-
/- dMMR crypt foci, with an elevated risk of accelerated tumour formation, observed as 
higher numbers of colonic adenomas per mouse, with both right-sided and left-sided colonic 
adenoma formation. This process of Aldh1b1-/- dMMR crypt foci expansion would be 
enhanced by continued exposure over time to high levels of acetaldehyde, increasing DNA 
damage with an increasing risk of neoplasm formation and progression to invasive 
adenocarcinoma as mutations accumulate, particularly if these mutations occur in neoplastic 
driver genes.  
The schematic diagrams in Figures 8.1 to 8.5 are also representative of what occurs in 
individual colonic stem cells following Tamoxifen-mediated Cre activation in Aldh1b1flox/flox 
Msh2-LS model mice, as this results in inactivation of both copies of Aldh1b1 and loss of the 
second Msh2 allele as well as conversion from mT to mG expression, resulting in mG+ 
Aldh1b1-null, dMMR stem cells that populate crypts to full monoclonal crypt conversion, 
form crypt foci by crypt fission, and although the circulating levels of acetaldehyde are not 
as high as in the constitutive knockout Aldh1b1-/- Msh2-LS mice, it is proposed that there are 
increased intracellular levels of acetaldehyde conferring a similarly increased risk of 




Figure 8.4: Schematic diagram of the proposed model of the effects on cells, crypts and crypt foci of MMR/acetaldehyde gene/environment interactions in both MMR-
proficient cells (mG-/mT+ red cells/crypts constituting the red background of the large intestinal mucosa) and MMR-deficient cells (mG+/mT- green cells/crypts 
scattered along the large intestinal mucosa, shown as green dots) over time (black horizontal arrow) during ethanol exposure. Cells/crypts that lose both mG and mT 





Figure 8.5: Schematic diagram of the proposed model of the effects on cells, crypts and crypt foci of MMR/acetaldehyde gene/environment interactions in both 
Aldh1b1-/- MMR-proficient cells (mG-/mT+ red cells/crypts constituting the red background of the large intestinal mucosa) and Aldh1b1-/- MMR-deficient cells (mG+/mT- 
green cells/crypts scattered along the large intestinal mucosa, shown as green dots) over time (black horizontal arrow) during ethanol exposure. Cells/crypts that lose 
both mG and mT expression are shown in black. (Prx=proximal colon; Dst=distal colon; EtOH=ethanol; AcAld=Acetaldehyde).
368 
 
8.6 Future work 
This project has characterised the Msh2-LS mouse model and provided evidence for a 
gene/environment interaction between dMMR and ethanol/acetaldehyde, causing 
acceleration of dMMR-driven intestinal tumour formation upon ethanol exposure, but there 
are still many details that need further investigation. 
The immune system has an important role in tumour incidence, prognosis and response to 
immunotherapy in LS patients (Gonzalez et al., 2018). The pilot experiment performed on 
caecal adenomas of Msh2-LS mice provided evidence of an immune response with infiltrating 
CD8+ and other lymphocytes and myeloid cells within and around adenomas. Further 
investigation of the immune response in the Msh2-LS mouse model would give a better 
understanding of which infiltrating immune cells are present around dMMR crypt foci 
precursors over the time following expansion of individual dMMR crypts to dMMR crypt foci/ 
clusters and subsequent evolution to intestinal tumours. This may help to elucidate the 
nature of the interaction between dMMR intestinal cells and the immune response in the 
context of the three step process of elimination, equilibrium and escape (Dunn et al., 2004; 
Seth et al., 2018). This could be performed with a more extensive investigation of the 
infiltrating immune cells by IHC comparing normal intestinal tissue with early and late dMMR 
crypt foci and tumours from the Msh2-LS mouse model either treated with 20% ethanol in 
drinking water or normal water.  
Improved knowledge of the gene expression patterns in large intestinal epithelium and small 
intestinal epithelium of both MMR-proficient cells and MMR-deficient cells, with and without 
ethanol exposure, would offer improved understanding about why hyperproliferative 
changes and adenoma formation occur in the colon, but not in the small intestine in this 
Msh2-LS model and which signalling pathways are involved. This could be done by 
performing RNA sequencing analysis on the RNA extracted from the mT-expressing red small 
intestinal and colonic epithelial cells (pMMR cells) for comparison with RNA-seq data from 
the mG-expressing green small intestinal and colonic epithelial cells (dMMR cells), from both 
ethanol-treated and water-treated Msh2-LS mice. RNA has already been extracted from 
these samples following FACS-sorting of the ethanol- and water-treated Msh2-LS large and 
small intestinal epithelial samples (described in Chapter 7). In addition, adjacent pMMR 
crypts and early dMMR crypts (identified by IHC staining for Msh2) could be micro-dissected 
(by laser capture microdissection) and analysed by RNA and DNA extraction for sequencing 
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to allow comparison to determine signalling pathway changes and mutation changes that 
occur at the earliest stages of dMMR monoclonal crypt conversion. 
Furthermore, generation of an organoid model system from isolated small and large 
intestinal stem cells of the Msh2-LS mouse model may shed light on the subsequent 
responses and effects of DNA MMR following ethanol/acetaldehyde-induced DNA damage 
and other types (e.g. Temozolomide, other aldehydes) of DNA damage induced in vitro. 
Analysis of gene expression in such organoids may reveal the molecular mechanisms and 
pathways that become activated under ethanol treatment (and other genotoxic agents) in 
the presence and absence of DNA MMR.  
DNA sequencing and RNA sequencing could be performed in both the organoid model and in 
the Msh2-LS murine colonic crypt foci, adenomas and adenocarcinomas, to investigate the 
most prevalent driver mutations in tumourigenesis and signalling pathways in this model and 
to distinguish those gene mutations that occur early in adenomagenesis from those that 
occur late in this process, which may reveal some actionable gene mutations that may be 
investigated in human LS patients. 
 
8.7 Summary 
In this study, evidence is provided that shows that: 
 The Msh2-LS mouse model is a good model of human Lynch Syndrome. Loss of MMR 
occurs in scattered stem cells, crypts and crypt foci along the small and large 
intestines. However, with long-term ethanol treatment, tumour formation is only 
seen in the colon (mainly in the proximal and mid colon, following the locational 
distribution of ethanol-induced epithelial hyperproliferation) and not seen in the 
small intestine, closely mirroring human LS intestinal tumour distribution. 
 Msh2 has a key role in protecting the MMR-proficient colonic epithelial cells against 
ethanol/acetaldehyde-induced DNA damage, but there appear to be other 
protective mechanisms in addition to mismatch repair in small intestinal epithelial 
cells protecting against acetaldehyde-induced DNA damage. 
  Ethanol/acetaldehyde induces regions of hyperproliferation of the large intestinal 
mucosal epithelium (mostly in the proximal and mid-colon) and this contributes, 
most likely through the process of tumour promotion, to acceleration of dMMR-
driven intestinal adenoma formation compared with water-treated controls. 
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 Ethanol/acetaldehyde promotes survival and proliferation of aberrant dMMR large 
intestinal epithelial cells/crypts over the MMR-proficient colonic epithelial 
cells/crypts. In this way, it increases the number and size of precursor dMMR lesions 
and elevates the risk of progression to either adenoma or invasive adenocarcinoma. 
 Aldh1b1 has a key role of in protecting the large intestinal epithelial stem cells and 
crypts from acetaldehyde-induced DNA damage, demonstrated in the increased 
colonic neoplasm formation in both Aldh1b1fl/fl Msh1-LS and Aldh1b1-/- Msh2-LS 
models compared with Aldh1b1wt Msh2-LS model following ethanol exposure. 
 There is strong evidence for a gene/environment interaction between dMMR and 
acetaldehyde acting via selection for reduced apoptosis, decreased cell cycle arrest, 
increased DNA damage in addition to dMMR-mediated hypermutation, and colonic 
epithelial hyperproliferation, collectively contributing to the acceleration of dMMR-
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Appendix 1          
 
 
Supplementary Figure 2.1: The left panel shows an electrophoretic gel photograph with representative 
results for the PCR genotyping assay DNA products for Msh2wt Msh2- and Msh2flox alleles (genotypes 
shown above the lanes). In this assay, the Msh2flox (Msh2 flox) allele produces a 460bp band (upper 
single band indicating fl genotype), whereas the Msh2 wild-type (wt or +) allele produces a 389bp band 
(lower single band indicating + genotype), whereas the heterozygous state is shown by the presence 
of both bands (two bands of 460bp and 389bp indicating fl/+ genotype). The right panel shows 
representative results for the PCR genotyping assay DNA products for the Mshwt (+) and Msh2- alleles 
(Msh2- or -). In this assay, the Msh2- allele produces a 194bp band (upper single band indicating - 
genotype) and wt allele produces a 164bp band (lower single band indicating + genotype), whereas 
the heterozygous state is shown by the presence of both bands (194bp and 164bp indicating +/- 







Supplementary Figure 2.2: The electrophoretic gel photograph shows representative results for the 
PCR genotyping assay for presence of the Cre allele. Presence of the Cre allele is shown by a 1000bp 
band (“Pos”, which can be either Cre+/- or Cre+/+), whereas the absence of a band indicates that Cre is 
not present (“Neg” or Cre-/-) (M=DNA ladder, bp= base pair). 
 
 
Supplementary Figure 2.3: The electrophoretic gel photograph shows representative results for the 
PCR genotyping assay for presence of the mTmG allele. The mTmG allele produces a 250bp band 
(“mut”, mTmG+/+), whereas the absence of this allele produces a 330bp band (“Neg”, mTmG-/-), and 





Supplementary Figure 2.4: The 3 electrophoretic gel photographs show representative results for the 3 separate PCR genotyping assays for Aldh1b1wt, Aldh1b1flox 
and Aldh1b1-alleles. In the first panel (left), the Aldh1b1tm1a allele produces a 445bp band (“tm1a” or “KnockOut Ready” or “KOR”, single band indicating tm1a/tm1a 
genotype), the Aldh1b1flox allele produces a 1000bp band (“flox”, single band indicating “flox/flox” genotype), the Aldh1b1- allele is shown by the absence of a band 
(absent band indicating -/- genotype), and the wild-type Aldh1b1wt allele produces a 775bp band (“wt”, single band indicating a Aldh1b1wt/wt genotype). In the 
second panel (centre), the Aldh1b1flox allele produces a 218bp band (“Pos”, single band indicating “flox/flox” genotype) and the Aldh1b1 wild-type allele is shown by 
the absence of a band (“Neg/wt”). In the third panel (right), the Aldh1b1- allele produces a 177bp band (“Pos”, single band indicating a Aldh1b1-/-  genotype) and the 










Supplementary Figure 2.5: Photomicrographs illustrating the immunohistochemistry antibody 
technical controls performed with the absence of the primary (or the secondary) antibody against 
Msh2, Msh6, Mlh1, Pms2, Ki-67, Aldh1b1, y-H2AX, p53, cCas3 (cleaved Caspase-3) and B-catenin 
proteins. IHC performed with antibody diluent and no primary antibody (left column) and/or 
secondary antibody (right column) using either normal small intestine or normal colon murine tissue. 
Images taken from IHC stained sections scanned using the Hamamatsu Nanozoomer and analysed 
with the Hamamatsu NDP Viewer software at 20X magnification, showing no evidence of positivity for 







Supplementary Table 3.1: Tabular representation of the inter-cross to generate the Msh2-LS mouse 
model experimental subjects. A) Inter-cross between Msh2 flox/flox and the Msh2+/-; Lgr5CreERT2 +/- 





Supplementary Table 3.2: Tabular representation of the inter-cross to introduce the mTmG transgene 
into the Msh2-LS mouse model. A) Cross-breeding between Msh2flox/-; Lgr5CreERT2+/- and mTmG+/+ 






Supplementary Figure 4.1: Immunohistochemical analysis of Pms2 protein expression in caecal 
mucosal epithelium of Msh2-LS mice treated with either 20% ethanol in drinking water (A) or normal 
/ standard water (B). Images taken from Pms2 IHC stained sections scanned using the Hamamatsu 
Nanozoomer and analysed with the Hamamatsu NDP Viewer software at 10X and 20X magnification, 
showing no evidence of nuclear positivity for Pms2 protein (bar at lower left indicates 250μm, bar in 
red rectangle indicates 100μm).   
 
 















































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 6.1: Tabular representation of the generation of the Aldh1b1 conditional-knockout Msh2-LS mouse model experimental subjects. Representation 


























































































































































































































































































































































Supplementary Table 6.2: Tabular representation of the generation of the Aldh1b1 conditional-knockout Msh2-LS mouse model experimental subjects. Representation 







Supplementary Table 6.3: Tabular representation of the generation of the Aldh1b1 constitutive-knockout Msh2-LS mouse model experimental subjects. Representation 
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Supplementary Table 6.4: Tabular representation of the generation of the Aldh1b1 constitutive-knockout Msh2-LS mouse model experimental subjects. Representation 
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Abstract
Lynch syndrome (LS) is characterised by predisposition to colorectal, endometrial, and other cancers and is caused by
inherited pathogenic variants affecting the DNAmismatch repair (MMR) genesMLH1, MSH2, MSH6, and PMS2. It is
probably the most common predisposition to cancer, having an estimated prevalence of between 1/100 and 1/180.
Resources such as the International Society for Gastrointestinal Hereditary Cancer’s MMR gene variant database, the
Prospective Lynch Syndrome Database (PLSD), and the Colon Cancer Family Register (CCFR), as well as pathological
and immunological studies, are enabling advances in the understanding of LS. These include defined criteria by which
to interpret gene variants, the function of MMR in the normal control of apoptosis, definition of the risks of the var-
ious cancers, and the mechanisms and pathways by which the colorectal and endometrial tumours develop, including
the critical role of the immune system. Colorectal cancers in LS can develop along three pathways, including flat
intramucosal lesions, which depend on the underlying affected MMR gene. This gives insights into the limitations
of colonoscopic surveillance and highlights the need for other forms of anti-cancer prophylaxis in LS. Finally, it
shows that the processes of autoimmunisation and immunoediting fundamentally constrain the development of
tumours in LS and explain the efficacy of immune checkpoint blockade therapy in MMR-deficient tumours.
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Introduction
Lynch syndrome (LS), previously called hereditary non-
polyposis colorectal cancer (HNPCC), is probably the
most common major cause of inherited susceptibility to
cancer, with an estimated prevalence in the general pop-
ulation of between 1/100 and 1/180 [1]. LS is charac-
terised by predisposition to a range of cancers,
involving most frequently the colorectum and endome-
trium, and also many other organ sites including ovary,
stomach, small intestine, hepatobiliary tract, pancreas,
urinary tract, prostate, brain, and sebaceous skin tumours
[2,3].
LS is caused by constitutional (germline) pathogenic
variants affecting one of four genes encoding the DNA
Mismatch Repair (MMR) system components: MLH1,
MSH2, MSH6, and PMS2, and hence the current com-
monly accepted diagnostic definition of LS is carrying
such a variant [1,4–8]. However, although we acknowl-
edge that there is an opinion that LS can only be diag-
nosed in such individuals once cancer has been
diagnosed, this is contrary to the hereditary polyposes,
which are characterised by the macroscopic syndromic
feature of multiple pre-malignant tumours [9]. Allied to
this, a major purpose of diagnosis of a cancer-
predisposing condition is to identify those who would
benefit from surveillance and prophylactic surgery to
prevent cancer [5]. Hence, our view is that it is inconsis-
tent and to a degree cruel to discriminate against LS by
expecting such individuals to develop cancer in order
to be diagnosed with the condition, especially as cancer
does not always occur [2,3,10]. As we discuss later on,
the definition of LS could, and perhaps should, therefore,
move to one that incorporates recently identified specific
microscopic and molecular pre-malignant syndromic
features.
DNAMMR recognises and repairs mismatched bases
(e.g. C opposite T) and insertions or deletions in repeti-
tive sequences. In LS patients, this MMR gene constitu-
tional variant, when combined with an acquired second
pathogenic variant due to somatic mutation in the wild-
type allele of the same MMR gene, results in the com-
plete loss of MMR pathway function in the affected
cells. Deficiency of MMR (dMMR) leads to hypermut-
ability, resulting in an increase in the mutation rate by
100- to 1000-fold due to uncorrected base mismatches,
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and to microsatellite instability (MSI) due to variation in
the lengths of repetitive sequences (e.g. AAAAAAA…
or CACACACA…. or similar, known as microsatellites)
due to uncorrected insertion/deletion loops that are
prone to occur as DNA replication errors in repetitive
sequences [11]. However, crucially, dMMR does not
simply fail to repair mismatches, it elicits a reduced sus-
ceptibility to apoptosis induced by DNA damage recog-
nised by the MMR pathway [11–14].
The International Society for Gastrointestinal Heredi-
tary Cancer (InSiGHT) was the first expert group to
define pathogenicity of gene variants according to an
agreed set of criteria based upon Bayesian probability,
using the five-tier classification system of Plon et al
[4,15–17]. In this system, Class 5 variants are patho-
genic and Class 4 likely pathogenic, with Class 3 being
variants of uncertain significance (VUS), and Classes
2 and 1 being likely benign and benign respectively.
InSiGHT maintains the world reference database of var-
iants observed inMMR genes, as Leiden Open Variation
Databases (LOVDs), which are now linked to ClinVar as
part of the ClinVar-ClinGen partnership, and accord-
ingly, 82% of the Class 4 and 5 variants listed affect
MLH1 and MSH2, with 13% affecting MSH6 and 5%
PMS2 [16,18–20]. It should be noted that these patho-
genic variants are mostly from cases ascertained by fam-
ily history. As more cases of LS are ascertained from
systematic testing of cancer cases and incidentally from
gene panel testing, more patients will be identified with
pathogenic variants in MSH6 and PMS2, and thus the
proportions due to the different MMR genes will
alter [6].
All types of variants are seen as pathogenic: non-
sense, frameshift, splice-site, missense, insertion–dele-
tion, and large deletions/rearrangements, the largest so
far being a 10 Mb inversion affectingMSH2 and which
is visible cytogenetically [21–23]. Approximately 60%
of all putative pathogenic missense mutations causing
LS actually disrupt splicing and are thus, in effect, trun-
cating [24]. Up to 3% of LS cases are due to variants
involving the 30 end of the EPCAM gene (immediately
adjacent to MSH2), that result in hypermethylation of
the MSH2 promoter or partial deletion of MSH2
[25,26]. Another infrequent but important cause of LS
is constitutional methylation of the MLH1 promoter,
which occurs in 1–2% of cases [27–29]. This is usually
sporadic in nature, so it is neither inherited nor herita-
ble, and relatives are therefore not at risk. However, in
a small number of patients, the hypermethylation may
be secondary to a large deletion involving LRRFIP2,
the gene upstream of MLH1, and it is the deletion that
is the pathogenic variant: The methylation is secondary
[29]. Given the risks to relatives it is therefore impor-
tant to distinguish such cases, and this is achieved by
testing both the tumour and constitutional DNA, and
finding MLH1 promoter methylation in both, perhaps
in the context of an LS family history. It has to be borne
in mind that approximately 15% of sporadic colon can-
cers are also dMMR due to somatic, so acquired, epi-
mutation of both MLH1 alleles by promoter
hypermethylation [30]. This is a function of such
tumours arising from right-sided serrated lesions
[31]. A similar proportion of sporadic endometrial can-
cers also have biallelic hypermethylation ofMLH1, and
as with colon cancers a small proportion are due to con-
stitutional methylation plus a somatic mutation in the
normal MLH1 allele [27,28,32,33].
Other genetic conditions relating to Lynch syndrome
Muir-Torre syndrome (MTS) is a descriptive diagnosis
of an individual in which both skin sebaceous neoplasms
(and keratoacanthoma-like lesions) and a ‘visceral’ car-
cinoma of any sort has occurred [34,35]. It is a frequently
seen combination in LS. Indeed, on close inspection
many, perhaps most patients with LS who have had a
carcinoma probably have a sebaceous skin lesion and
thus MTS [36,37]. However, MTS is also seen in other
heritable predispositions, for example, MUTYH-
associated adenomatous polyposis, or it may be spo-
radic, so although a marker of possible LS, MTS is not
diagnostic [38,39]. Notably, although sebaceous lesions
and hyperplasia are often rightly a cause for concern
regarding LS and a patient with sebaceous lesions and
a visceral cancer warrants testing, it should be noted that
in the absence of a family or personal history of LS-
associated cancer they are at low risk and do not warrant
testing [40,41].
Individuals may inherit pathogenic variants in both
copies of a DNA MMR gene. When both are in the
same gene it causes constitutional mismatch repair
deficiency (CMMR-D) syndrome. CMMR-D is a clas-
sic recessive DNA repair disorder typically charac-
terised by childhood-onset leukaemia, lymphoma, and
colorectal and brain cancers, but also, in contrast to
LS, some patients may have multiple colorectal adeno-
mas [42–44]. Signs suggestive of neurofibromatosis
type 1 also often occur, such as café-au-lait macules
and cutaneous neurofibromata, plus other features such
as immune deficiency [45]. In CMMR-D patients,
abnormal MMR immunohistochemistry (IHC) is seen
in both normal and tumour cells (hence the necessity
always to test all four markers) and it is possible to
detect constitutional MSI in, for example, blood
[46,47]. Patients with CMMR-D due to MSH6 or
PMS2 variants may show milder disease and later
onset [48]. Comprehensive diagnostic criteria and care
pathways have been published [7,45].
Patients may also be found who have pathogenic var-
iants in more than one MMR gene, so-called digenic
LS. It is not clear if this is more severe than LS due to
a pathogenic variant in one gene, but it has clear implica-
tions for clinical genetic counselling. However, LS
patients can and do co-inherit other forms of predisposi-
tion to cancer (or indeed any other genetic condition),
and if this is suspected should be pursued [49].
Finally, Turcot syndrome, a combination of colorectal
cancer or adenomas and central nervous system tumours,
with dominant or recessive inheritance, is another histor-
ical descriptive diagnosis that has been related to
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LS. However, it is now known that it can be due to
CMMR-D, familial adenomatous polyposis (FAP), and
probably other conditions, and so as an ambiguous term
it should be abandoned [42,44,50].
DNA mismatch repair mechanisms
The MMR pathway is a highly evolutionarily conserved
mechanism responsible for the correction of base mis-
matches (e.g. C or G opposite T or A) and insertion/dele-
tion loops (occurring in repetitive sequences such as
AAAAAA … or CACACACA … due to insertion or
deletion of an extra repeat unit during stalled DNA rep-
lication of these repetitive sequences). Such stalling is
probably mostly due to replication-associated errors,
but is also caused by DNA damage due to oxidative
stress, lipid peroxidation, base deamination, methyla-
tion, and alkylation [51].
A base mismatch or single nucleotide insertion/dele-
tion error is recognised by the MutSα complex, which
is composed of MSH2 and MSH6 proteins. Insertion/
deletion loops of 2–8 nucleotides are recognised by the
alternative complex MutSβ, composed of MSH2 and
MSH3 proteins. MutSα complex activation is character-
ized by ATPase activity, which is important for the inter-
action with the mismatchedDNA and initiation of repair.
The binding of MutSα stimulates ATP hydrolysis, lead-
ing to a conformational change that subsequently trig-
gers the recruitment of a second complex MutLα,
composed of MLH1 and PMS2 proteins. The tetrameric
complex, by sliding on the DNA, searches for the single-
strand DNA mismatch on the new strand (daughter
strand). This in turn activates proliferating cell nuclear
antigen (PCNA) and replication factor C (RFC). MutLα
possesses an intrinsic ATP-stimulated endonuclease
activity that requires activation by PCNA in order to cre-
ate an incision in the recently synthesised daughter
strand (containing the error). The incision step is fol-
lowed by the recruitment of exonuclease 1 (EXO1) that
removes the newly synthesised DNA strand up to and
beyond the mismatch or loop. DNA polymerase δ re-
synthesises the DNA, whereas ligase 1 seals the remain-
ing nick [52].
TheMMRpathway is involved in a signalling cascade
that leads to cell cycle arrest and/or apoptosis, if DNA
damage has occurred previously [53]. It has been
observed that MMR-deficient cells fail to recruit
ataxia-telangiectasia mutated (ATM) and ATM and
Rad3-related (ATR); and this prevents p53 phosphoryla-
tion in response to DNA damage [12,54]. The underly-
ing mechanisms by which MMR proteins promote
DNA damage–induced cell cycle arrest and apoptosis
have not been fully elucidated. Two models have been
hypothesised: The futile cycling model and the direct
damage signalling model. In the futile cycling model,
MMR recognises the mismatches triggering the excision
of the newly synthesized strand, although the persistent
offending damage on the template strand cannot be
excised. MMR initiates futile repair cycles, eventually
resulting in the formation of DNA double-strand breaks
and thus activating the ATM/ATR/p53 signalling path-
way to activate cell cycle arrest and/or apoptosis
[55]. In the direct damage signalling model, MutSα
and MutLα directly recruit ATM/ATR and cause cell
cycle arrest and/or apoptosis [56].
A crucial consequence of this is that the low back-
ground level of DNA damage in normal cells may stim-
ulate MMR and thus inhibit the cell cycle, or if severe
even stimulate apoptosis, and so net cell turnover does
not reach its theoretical maximum. However, if MMR
deficiency should occur in such cells, there is no such
limitation by stalling of the cell cycle or activation of
apoptosis and net cell division increases in an uncontrol-
lable fashion, allied to which as a secondary phenome-
non the mutation rate increases, which is manifest as
MSI and/or abnormal MMR IHC. This is very useful
diagnostically, but it is important to appreciate that it is
not the increased mutation rate per se that is driving
the carcinogenic process, and neither does it make ade-
nomas progress any quicker than usual [14]. However,
because mutations are strongly biased towards repetitive
DNA sequences in dMMR cells, this has profound con-
sequences for the biology of such tumours and patients
with LS due to the strong immunological responses this
elicits [57,58]. The critical consequences of this are man-
ifest in how LS tumours develop and potentially evade
the immune system [59].
Notably, someMMR gene variants are associated with
abnormal MMR IHC in tumours but not MSI, and vice
versa [4,15]. In addition, only one of 149 PMS2 patho-
genic variants causative of LS is a missense mutation
[18]. However, many other PMS2 missense variants
are seen in CMMR-D (a recessive DNA repair disorder),
which is consistent with common, but not complete,
overlap between loss of DNA (MMR-recognised) dam-
age repair and apoptotic functions of MMR [18,60,61].
Lynch syndrome databases
In addition to the MMR gene variant database main-
tained by InSiGHT, there are other phenotypic databases
aimed at understanding the precise risks that LS patients
face. Initial estimates were liable to ascertainment bias
and thus tended to overestimate by being necessarily ret-
rospective. The penetrance and expressivity of MMR
pathogenic variants differs in LS patients according to
theMMR gene, age, sex and environmental/lifestyle fac-
tors [62]. Several lifestyle factors, such as smoking,
alcohol, obesity, are associated with an increased risk
of sporadic cancer and have been suggested to have sim-
ilar effects in LS patients. Therefore, as it is fundamental
to quantify accurately the risks of developing cancer for
LS patients, in order to provide adequate data for surveil-
lance and care, as well as understand the underlying biol-
ogy, the PLSD was established in 2012 by the Mallorca
Group of InSiGHT [2,63]. The PLSD collects data on LS
patients from expert centres and registries worldwide;
these patients are thus undergoing colonoscopic surveil-
lance with polypectomy and may also be having thera-
peutic or prophylactic surgery. It therefore provides
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information on the natural history of the disease course
and the effects of interventions and lifestyle factors.
The PLSD is linked to the InSiGHT MMR LOVD: All
patients on the PLSD must have a Class 4 or 5 MMR
variant, so pathogenic or likely pathogenic according
to the InSiGHT classification [4,15]. The PLSD includes
basic information on pathogenic genetic variants, sex,
and age, plus information such as cancers or pre-cancers
diagnosed, age at diagnoses, age at prophylactic surgical
removal of organs, and information on pre-cancers.
Every patient is followed as an individual, as the family
history is ignored so as not to introduce bias, and the
database now has >50 000 patient-years of observations
[10]. The PLSD website is public and allows anyone to
determine the risks to an individual of an LS-associated
cancer in an interactive graphical form according to their
affected gene, age, gender, and whether previously
affected by cancer [63]. Risks of LS-associated cancers
to age 75 are summarised in Table 1; those for PMS2
affecting both sexes are combined due to the smaller
numbers available, and numbers have been rounded
throughout for clarity [10].
Important parallel efforts have been made in defining
risks in Lynch syndrome by the CCFR and the Interna-
tional Mismatch Repair Consortium (IMRC)
[64,65]. The CCFR is an international consortium of
six institutes in the United States, Canada, and
Australasia formed as a resource to support studies on
the aetiology, prevention, and clinical management of
colorectal cancer, and utilises a form of modified segre-
gation analysis to minimise retrospective ascertainment
bias [65,66]. It currently has data on >42 500 individuals
from >15 000 families on its records and has made sig-
nificant advances in demonstrating how environmental
and lifestyle factors affect cancer risks in LS, such as
smoking, increased body mass index, and alcohol con-
sumption [67–69]. By contrast, reduced cancer risk is
seen with, for example, hormone replacement therapy,
vitamin and mineral supplements, nonsteroidal anti-
inflammatory drug (NSAID) use, and parity, but there
is no change in risk associated with oral contraceptive
use [70,71]. The IMRC is a worldwide collaboration of
more than 115 investigators from 59 centres, with
20 000 individuals with LS from 8800 families, facili-
tated by InSiGHT and the Collaborative Group of the
Americas on Inherited Gastrointestinal Cancer (CGA-
IGC) [64,72].
Finally, is the initiative to determine the effects of
aspirin prophylaxis on LS patients, although this is a
series of clinical trials rather than a database. Remark-
ably, the CAPP2 trial has shown that only 2–4 years of
treatment with 600 mg/d of aspirin significantly reduces
the risk of colorectal cancer up to more than 10 years
post treatment, and likely also reduces the risks of other
Table 1 Average risks of Lynch syndrome–associated cancers to age 75 years
Males
Cancer type MLH1 MSH2 MSH6 PMS2
Any cancer 71% [63–81%] 75% [66–86%] 42% [25–67%] See below
Colorectal (bowel) 57% [49–68%] 51% [41–65%] 18% [8–43%] See below
Stomach, small bowel, bile duct, gallbladder, and pancreas 22% [16–30%] 20% [14–28%] 8% [3–30%] See below
Ureter and kidney 5% [3–10%] 18% [13–25%] 2% [<1–24%] See below
Urinary bladder 7% [4–13%] 13% [8–21%] 8% [3–30%] See below
Prostate 14% [9–22%] 24% [17–33%] 9% [3–31%] 5% [<1–68%]
Brain 0.7% [<1–5%] 8% [4–15%] 2% [<1–24%] See below
Females
Cancer type MLH1 MSH2 MSH6 PMS2
Any cancer 81% [74–88%] 84% [77–91%] 62% [47–78%] See below
Colorectal (bowel) 48% [41–57%] 47% [39–55%] 20% [12–41%] See below
Endometrium 37% [30–47%] 49% [40–61%] 41% [29–62%] 3% [5–50%]
Ovaries 11% [7–20%] 17% [12–31%] 11% [4–39%] 3% [<1–43%]
Stomach, small bowel, bile duct, gallbladder, and pancreas 11% [7–17%] 13% [9–19%] 4% [3–30%] See below
Ureter and kidney 4% [2–8%] 19% [14–27%] 6% [2–27%] See below
Urinary bladder 5% [3–11%] 8% [5–14%] 1% [<1–23%] See below
Brain 2% [<1–5%] 3% [1–8%] 1% [<1–23%] See below
Both Sexes combined
Cancer type PMS2
Any cancer 34% [19–60%]
Colorectal (bowel) 10% [3–41%]
Stomach, small bowel, bile duct, gallbladder, and pancreas 4% [1–34%]
Ureter and kidney 4% [<1–34%]
Urinary bladder <1% [0–31%]
Brain <1% [0–31%]
Data from the Prospective Lynch Syndrome Database (PLSD) [10,63].
Note that the individuals studied are under colonoscopic surveillance and may have had prophylactic or therapeutic surgery, which is allowed for in the estimates.
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LS cancers, although this is less certain. Notably, side-
effects possibly attributable to aspirin were at a low rate
and actually slightly more common, although non-sig-
nificantly, in the placebo compared to treatment arm
[73–75]. A follow-up randomised double-blind dose
non-inferiority trial, CaPP3, is now in progress to deter-
mine the optimum dose of aspirin for long-term prophy-
laxis [76].
Pathology of Lynch syndrome cancers
Typical histological features of LS tumours are best
exemplified by colorectal cancer (CRC), which often
shows a combination of the presence of prominent
tumour-infiltrating lymphocytes, Crohn-like peritu-
moural lymphoid aggregates, poor differentiation, fre-
quently with areas of mucinous and/or signet-ring cell
patterns, sometimes with a medullary growth pattern
[77,78]. These characteristics can be seen in both Lynch
syndrome CRC and sporadic dMMR bowel cancers but
are not sufficiently specific to distinguish them from
MMR-proficient (pMMR) cancers.
Fewer data have been published about non-colorectal
LS-associated cancers. LS-associated endometrial can-
cers can be seen more frequently than sporadic cancers
in the lower uterine segment, are mostly of the endome-
trioid type, and are often with poor differentiation, solid
or dyscohesive, with prominent tumour-infiltrating lym-
phocytes and Crohn-like peritumoural lymphoid aggre-
gates [79–84]. LS-associated ovarian cancers are
typically of endometrioid or clear cell type, with some
tumour-infiltrating lymphocytes [79,80,85,86]. LS-
associated gastric carcinomas are mostly of the
intestinal-type with fewer diffuse-type, and rarely of
mucinous type, and an associated immune gastritis is
reported [87–90]. LS-associated small intestinal adeno-
carcinomas often display mucinous, signet-ring cell, or
medullary differentiation, with tumour-infiltrating lym-
phocytes and Crohn-like reactions, as do ampullary ade-
nocarcinomas [91]. LS-associated pancreatic cancers are
mostly acinar cell carcinomas and medullary carcino-
mas [92].
Testing for Lynch syndrome cancers
Testing of (usually selected) patients with CRC, endome-
trial cancer, and/or other types of LS-associated cancer is
recommended by many guidelines and organisations,
generally starting with testing the tumours for either the
presence of MSI or the absence (or abnormal expression)
of mismatch repair proteins. There is no consensus
regarding whether MMR immunohistochemistry or
MSI testing is the better first test in colorectal cancers
as they have similar test performance characteristics in
detecting LS: Sensitivity of MSI is 88 ~ 100% and IHC
73 ~ 100%, with specificity of MSI 68 ~ 84% versus
IHC 78 ~ 98% [93,94]. They may be used serially, or in
combination [93–97]. However, evidence is now emerg-
ing that IHC may be the preferred option when testing
endometrial cancers (systematic testing of which is now
under consideration by the UK National Institute for
Health and Care Excellence (NICE) as a recent UK study
has shown that while MSI and IHC have similar specific-
ity (83.7 versus 81%), MSI has only 56.3% sensitivity
compared to 100% for IHC [82,83].
MMR IHC is the better option for small biopsies, can-
cers with a low tumour cell proportion, or intense inflam-
matory reaction. Subsequent testing forMLH1 promoter
hypermethylation and somatic (rather than constitu-
tional/germline) mutations can be used to clarify the risk
of inherited pathogenic variants in suspected LS
patients. MLH1 promoter hypermethylation testing
may be used as an alternative to BRAF V600E mutation
analysis in colonic cancers [98–100]. The use of larger
targeted gene mutation panels (or whole exome/genome
sequencing) that includes MMR tumour testing with
mutation analyses is becoming more widespread [101].
Immunohistochemical staining for the four major
DNA mismatch repair proteins (MLH1, MSH2, MSH6,
and PMS2) is probably the most common test to screen
CRCs and other tumours for dMMR [93,95,97]. The
nuclear expression of all four proteins suggests mis-
match repair proficiency with microsatellite stability
[102–104]. Loss or abnormality of nuclear staining for
any of the proteins indicates dMMR and suggests the
most likely MMR gene involved [103,104]. Loss of
MSH2 alone or loss of both MSH2 and MSH6 suggests
that a mutation or abnormality in MSH2 is most likely.
Similarly, loss of MLH1 alone or loss of both MLH1
and PMS2 suggests an underlying mutation, abnormal-
ity, or promoter methylation in MLH1. Combined loss
of both MSH2 and MSH6 (or of both MLH1 and
PMS2) reflects the heterodimeric binding of MSH2 with
MSH6 (or of MLH1 with PMS2) in the mismatch repair
complex MutSα (or of MutLα), such that loss of the first
protein partner generates instability and loss of the sec-
ond [37]. Usually, there is nuclear staining in the nuclei
of both tumour cells and adjacent normal epithelial cells,
stromal cells, and lymphocytes.
In a dMMR tumour due to MSH2 mutation, there is
loss of nuclear MSH2 and MSH6 and intact staining
for MLH1 and PMS2. In a dMMR tumour due to
MLH1 mutation, there is loss of nuclear MLH1 and
PMS2 and intact staining for MSH2 and MSH6. This
pattern of combined MLH1 and PMS2 loss could be
seen either in a sporadic tumour (most commonly due
toMLH1 promoter methylation) or in LS due to constitu-
tionalMLH1mutation. CorrectMMR IHC interpretation
requires adequate internal control staining of the adja-
cent stromal and lymphoid cells to confirm good fixation
of the tissue region [102,103]. Patchy intact nuclear
staining may occur due to variable fixation, tissue hyp-
oxia, or unequal antibody diffusion [105,106]. Cytoplas-
105,106]. Cytoplasmic staining may occur, but if
nuclear staining is lost, this is considered abnormal, indi-
cating dMMR [107].Weak, patchy nucleolar staining, or
sometimes absence of MSH6 has been described in rec-
tal tumours following neoadjuvant treatment without
MSI or a mutation confirmed by molecular testing
[108,109]. Notably, heterogeneous staining or loss of
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MSH6 can be due to a secondary (non-germline)
acquired somatic mutation in theMSH6 codingmononu-
cleotide tract [110,111]. Approximately 3–10% of LS-
associated dMMR tumours show no abnormality on
IHC testing (presumably because of variants that disrupt
normal MMR protein function but nonetheless enable
protein detection by IHC) [112].
Testing DNA extracted from tumours for MSI
involves investigating the presence of extra alleles (lon-
ger or shorter) at a microsatellite locus compared with
normal microsatellite length determined from normal tis-
sue or blood from the same individual [113]. Microsatel-
lites vary in their propensity to show instability, and thus
the frequency with which the same microsatellite is
altered varies in different tumour types. Instability is
more likely to be observed at mononucleotide repeats
(e.g. AAAAA …) than at dinucleotide repeats (e.g.
CACACA …). Microsatellite loci or markers used in
colonic cancer MSI testing are known to have reduced
sensitivity at detecting MSI in non-colonic cancers,
including endometrial, small intestinal, or gastric can-
cers; in tumours from LS patients with MSH6 or PMS2
mutations; and in colonic adenomas [114]. Therefore, a
proportion of LS-associated tumours may not appear to
have MSI using the standard test but might be identified
by abnormal MMR immunohistochemistry.
The efficacy of MMR IHC and MSI may be signifi-
cantly enhanced by testing more than one tumour from
the same individual or family, particularly if there are
tumours that are multiple or rarely seen in LS (e.g. colo-
rectal adenomas, small intestinal cancers, hepatobiliary,
upper urinary tract, and cutaneous sebaceous tumours)
[15,115]. Consistent IHC abnormality of one mismatch
repair protein in more than one tumour from an individ-
ual or family represents very good evidence for variant
pathogenicity [15,116]. Some CRCs due to MUTYH-
associated polyposis (MAP) or proofreading
polymerase-associated polyposis (PPAP) may exhibit
MSI and/or abnormal IHC due to somatically acquired
MMR gene mutations.
Approximately 13–15% of sporadic colonic cancers
have dMMR, usually due to epigenetic silencing of both
alleles of MLH1 by promoter hypermethylation. Hence,
although overall unselected dMMR colonic cancers
have a relatively poor positive predictive value for LS,
because the proportion of colonic cancers with MSI
due to LS varies with age this can be exploited clinically.
In individuals younger than the age of 57, more than half
of all dMMR colonic cancers will be due to LS, whereas
over this age less than half will be, although even at age
70 approximately 25% dMMR colonic cancers will be
due to LS (Figure 1) [8,104,117]. In contrast, pMMR
has a good negative predictive value for LS. Further tests
(BRAF mutation and MLH1 methylation tests) are
required for MLH1-negative cancers to distinguish
between LS and sporadic origin [93,94,96]. Another
important practice point is that rectal cancers are distinct
from colonic cancers in the diagnosis of LS. Because
sporadic colonic cancers with dMMR arise largely from
right-sided serrated lesions, sporadic rectal cancers with
dMMR are correspondingly rare, if they occur at all, and
hence a rectal cancer with dMMR at any age must be
considered to be due to LS until proven otherwise
[118,119].
The activating missense variant BRAF p.V600E
occurs in sporadic colonic cancers with dMMR, but
not in those due to LS; therefore, BRAF p.V600E is
highly predictive of the tumour being of sporadic origin
rather than LS [31,93,94,96,120]. However, sporadic
tumours may occasionally occur in patients with LS, so
the absence of BRAF p.V600E does not definitively
diagnose LS but does indicate that LS is more likely.
Alternatively, detection ofMLH1 promoter hypermethy-
lation in a colonic cancer provides good, although not
unequivocal, evidence that the tumour is sporadic in ori-
gin, as occasional sporadic tumours do occur in LS and
constitutionalMLH1 promoter methylation can be found
in a small proportion of patients with LS [28,29]. BRAF
p.V600E testing is only of use in distinguishing CRCs; it
has no utility in, for example, endometrial cancer.
LS is definitively diagnosed following tumour testing
by constitutional/germlineMMRgene sequencing to iden-
tify a pathogenic constitutional variant [4–6,121]. Patients
with digenic LS,who have inherited pathogenic variants in
more than oneMMR gene, are occasionally seen (andmore
will be as gene panel testing becomes prevalent), but it is
unclear if their risks are increased over those patients with
a pathogenic variant in oneMMRgene. It is often useful to
have samples frommore than one individual in the family,
because case segregation studies may be required to deter-
mine pathogenicity or whether an individual is a pheno-
copy [4,15]. If the family shows evidence of hereditary
transmission of LS but no point mutation is found, tests
for large-scale mutations, such as deletion of a whole exon
(or more), can be performed; 12–40% of pathogenic vari-
ants are of this type [21,23,122–127]. LS-related tumour
types that are rare in the general population and thus have
a high predictive value for LS, such as small intestinal and
Figure 1. Probability by age that a colonic cancer with dMMR is due
to Lynch syndrome. The graph shows the probability by age that a
colonic cancer with dMMR is due to Lynch syndrome
[8,104,117]. Note that this does not apply to rectal cancers, because
right-sided serrated lesions that give rise to sporadic dMMR colonic
cancers do not occur in the rectum; hence a rectal cancer with
dMMR is due to LS until proven otherwise [118,119].
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hepatobiliary cancer, upper urinary tract and bladder
(under age 60) transitional cell carcinoma, or skin seba-
ceous adenoma/carcinomas, are therefore worth testing
[40]. Synchronous ormetachronous bowel cancers are also
significant, as is the development of any two LS-related
tumours (e.g. CRC and endometrial cancer), and all such
cases warrant testing for LS.
Neoplastic precursors in Lynch syndrome
When LS was being defined in the early 1990s, the only
known pathway to CRC was based on the work of
Dukes, Bussey, and Morson on FAP. First was Dukes’
concept of ‘simple tumours and cancer’ in 1925 as part
of his system for the staging of rectal cancer in FAP, fol-
lowed by the adenoma to carcinoma pathway in 1958
[128–130]. Naturally, the reasonable assumption was
that the same pathway applied in LS and colonoscopic
surveillance to remove premalignant adenomas would
thus be beneficial in LS.When early data started to come
in on the efficacy of surveillance in LS, it became obvi-
ous that there was a large number of interval cancers,
and, moreover, these occurred despite the interval
between colonoscopies being steadily reduced to less
than 3 years and sometimes even less than 1 year,
because it appeared that LS cancers developed much
more rapidly than sporadic ones, assuming they all arose
from adenomas [6,131]. Moreover, because of the
increased mutation rate (the MSI) observed in LS can-
cers, allied with the prevailing concept that genomic
instability characterised all cancer, it was further
assumed that this must be what was driving a faster
adenoma-carcinoma progression, although not all
parties were convinced [11,14,132]. In addition,
although dMMR adenomas could be found in LS
patients, further doubts were raised when aspirin treat-
ment failed to reduce the incidence of adenomas
(although it later reduced that of CRCs), and results from
the PLSD became available [2,73,116,133,134]. LS
patients on colonoscopic surveillance at various inter-
vals could finally be compared [133]. Remarkably,
within the limits measurable, colonoscopy did not
appear to reduce the rate at which colorectal cancers
were arising in LS patients, despite it being associated
with a significant reduction in mortality and, in addition,
stage was not related to the interval since last
colonoscopy—completely the opposite of population
screening programmes, which are based primarily on
adenoma removal [2,133–135]. What was going on?
Although LS patient survival is certainly improved by
colonoscopic surveillance, enabling earlier diagnosis
and a degree of downstaging, together this mass of evi-
dence was leading to the conclusion that a pathway inde-
pendent of adenomas must be occurring, and moreover,
a pathway in which precursors were less obvious on
colonoscopy [94].
At about the same time, it was discovered that LS
patients harbour an enormous number of dMMR crypts
in the colorectum (~1/cm2 mucosa, so ~10 000 crypts/
patient), which are not dysplastic, and yet LS patients
only go on to eventually develop between zero and per-
haps one, two, or three cancers [136,137]. Could these
be leading to cancers, perhaps by an occult route? This
was answered shortly afterwards by the finding of flat
intramucosal cancers in which the Wnt pathway was
activated by mutations not in APC, as in classical adeno-
mas, but in beta-catenin; indeed mutations in repetitive
coding sequences, exactly as predicted, would result
from dMMR [138]. It is intriguing that subsequent work
to sequence LS cancers has shown that some 61% of
APC mutations are predicted to occur after MMR defi-
ciency occurs, as they are found in repetitive sequences,
exactly as would be expected in dMMR tumours. Hence,
a proportion of these beta-catenin–mutant flat lesions
acquire secondary APC mutations, thence to become
polypoid adenomas and subsequently cancers
[139,140]. Thus, it is now understood that there are at
least three pathways to CRCs in LS, not including spo-
radic colonic cancer due to a right-sided sessile lesion,
which are occasionally observed (Figure 2). The first
pathway is via sporadic adenomas that acquire second-
ary dMMR. The second pathway is via flat cancers
within the mucosa that arise directly from dMMR crypts,
and the third pathway is LS-specific adenomas that arise
from these flat lesions due to secondary APC mutations
[139]. Hence, a proportion of LS CRCs arise from flat
lesions, which are inherently more difficult to detect,
let alone remove on colonoscopy, explaining at least in
part the apparent high rate of interval cancers, but also
removing the need to invoke a faster progression rate
in LS. Building on this, it has been shown that the can-
cers in patients with LS due to PMS2 mutations arise
largely along pathway 1 (i.e. from sporadic adenomas),
going further to explain why patients with pathogenic
PMS2 variants have only a small increased risk of
CRC [142]. It is interesting that very recently it has been
found that pathway 2 predominates over pathway 3 in
patients with pathogenic MLH1 variants, but pathway
3 predominates over pathway 2 in those with MSH2
pathogenic variants [143]. These fascinating findings
have clear implications for future surveillance strategies,
which of necessity must now also include modalities
such as aspirin prophylaxis and vaccines to address the
inherently limited efficacy of colonoscopy and increased
risks of cancers in LS at sites other than the large bowel,
which are becoming the predominant cause of mortality
in LS patients under surveillance [2,3].
It is of note that a number of observers have now
found dMMR glands in morphologically normal endo-
metrium from LS patients, which in turn has implica-
tions for the understanding of LS carcinogenesis in that
organ [146].
Immune escape of Lynch syndrome neoplasms
The early general observations of large local tumours
and a lower rate of metastasis, together with a strong
immune reaction to LS cancers such as increased tumour
infiltrating lymphocytes (TIL) and tertiary lymphoid
structures (TLS; also termed Crohn-like peritumoural
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lymphoid aggregates or follicles), later backed up by
gene expression signatures characteristic of immune cell
activation, all indicate an important role for the immune
system in LS [57,147,148]. However, this needs to be
put in the context of the normal immune architecture in
the bowel. Gut-associated lymphoid tissue (GALT)
comprises both isolated and aggregated lymphoid folli-
cles in both the small and large intestines. Humans have
approximately 30 000 isolated lymphoid follicles (ILFs)
scattered throughout the large and small intestine, but
especially in the colon [149]. ILFs vary in their distribu-
tion within the large and small intestines, may be muco-
sal or sub-mucosal, and at their simplest may consist
of a single follicle, with or without some T cells
[150,151]. They are considered to be the main source
of immune priming in the colon and fromwhere Crohn’s
disease originates, and they have specialised follicle-
associated epithelium (FAE), which overlies a
subepithelial dome containing numerous macrophages,
dendritic cells, T and B lymphocytes, and special antigen
sampling microfold/M/cells [152,153]. The FAE has a
crucial role in the initiation of the mucosal and systemic
immune responses [154]. However, the relationship
between Crohn-like follicles in LS and ILF in normal
colon is not completely clear. In LS, the follicles are gen-
erally peritumoural and not located inside cancers, and,
although they do not have FAE, they do have T cells,
B cells, and germinal centres [58,155]. Whether they
are induced de novo, as in chronic inflammation, or
develop from submucosal ILFs remains to be deter-
mined [156]. Crohn-like follicles/TLS are found in
CRCs apart from LS; however, the frequency/number
is highest in LS patients compared to sporadic dMMR
and pMMR CRCs, which is not simply related to
age [58].
In recent years, there has been a growing interest in
TLSs in a variety of cancers including CRC, in particular
as prognostic indicators of cancer progression and
responses to immunotherapy [153,157]. In hepatocellu-
lar carcinoma, intratumoral TLSs correlated with a lower
risk of early relapse after surgery [158]. In sarcoma, mel-
anoma, and renal cell carcinoma, both intratumoural
location and the presence of B cells (but not T cells),
and particularly germinal centres, correlate with
improved outcomes to checkpoint blockade immuno-
therapy [159–161]. Further studies of the location, cellu-
lar composition, and presence of germinal centres in
TLS in hereditary dMMR may therefore shed light on
their role in LS.
In dMMRcells, predictablemutations can and do occur
in repetitive protein coding sequences and result in frame-
shift peptides (FSPs) [162–164]. Such FSPs are novel
antigens and elicit both humoral and cellular immune
responses, which are seen as TILs around the dMMR
crypts in LS patients as well as in dMMR cancers, both
sporadic and due to LS [136,144,163,165]. In the face of
such responses, how is it possible for tumours, let alone
cancers, to develop in LS? The answer lies in the three-
step process of elimination, equilibrium, and escape
[59,166]. Cells generating FSPs, presented on their sur-
face by MHC-I, are subjected to attack by cytotoxic T
lymphocytes (CTLs), resulting in elimination. However,
cells that randomly acquire activating mutations in PD-
L1before they are eliminated can hold the immune system
to a local standstill (activating the PD-1 – PD-L1 immune
checkpoint)—the process of equilibrium. Subsequently, if
before being eliminated these cells manage to acquire
inactivating mutations in MHC-I or MHC-II (HLA clas-
ses I & II) that abrogate presentation of FSPs on their sur-
face, they are then able to escape the immune system, at
least locally. Given the huge number of dMMR crypts in
an LS patient, but that the average LS patient manifests
between zero and one, two, or three CRCs, it is clear that
the process of elimination must be highly efficient, giving
a different perspective on cancer biology [2,139].
A number of different escape mechanisms have been
observed. The most common, seen in approximately
30%of dMMRCRCs, ismutation of beta-2-microglobulin
Figure 2. Pathways to colorectal cancer in Lynch syndrome. There
are three pathways to dMMR colorectal cancers in LS
[138,139]. Pathway 1: Classic sporadic adenomas, initiated by
Wnt pathway activation due to mutations in APC (APCm), acquired
dMMR through somatic mutation of the remaining normal MMR
allele (MLH1m, MSH2m, MSH6m, or PMS2m). This can occur at any
stage of the adenoma, from early through to adenoma-carcinoma
transition. Pathway 3: Crypts that have acquired dMMR due to
somatic mutation of the normal MMR allele are not dysplastic,
but if they undergo somatic mutation of beta-catenin (CTNNB1m),
which activates theWnt pathway, they become flat carcinomas that
later acquire mutations in TP53 (TP53m), an otherwise rare event in
dMMR CRCs [138,141]. Pathway 2: A proportion of Pathway
3 lesions acquire secondary APCmutations and thus become polyp-
oid adenomas. Because of this unique combination of somatic
events, these Pathway 2 adenomas are, as far as is known, specific
to LS (hence ‘Lynch-specific dMMR adenomas’). Regarding path-
ways 2 and 3 in their original proposal, Ahadova and colleagues
remark: ‘For better visibility, pre-malignant lesions that do not
develop into cancer are not included in the diagram, because their
number greatly exceeds the number of carcinomas’ [139]. Pathway
1 predominates in patients with LS due to PMS2 pathogenic vari-
ants, whereas CTNNB1-mutant tumours are more likely in MLH1
patients and APC-mutant tumours are more likely in MSH2 and
MSH6 patients [142,143]. Note that sporadic colonic cancers that
arise from serrated lesions with MLH1 deficiency due to somatic
biallelic hypermethylation of the MLH1 promoter can and do occur
in LS, albeit perhaps less often due to the enhanced immunity in LS
patients against dMMR cells because of chronic autoimmunisation
from the novel frameshift peptides generated from dMMR crypts
[31,57,59,136,139,144,145].
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(B2M), which prevents MHC-I presentation of FSPs. This
was an early observation, the full significance of which is
only now apparent [145,167–170]. The outgrowth of such
B2M mutant clones is a prime example of cancer immu-
noediting, which has been further related to variation in
host immune function, for example, mucosal density of
FOXP3-positive regulatory T cells, indicating that such
factors may be additional modifiers of LS [171]. It is nota-
ble that B2Mmutations in dMMR cancers are significantly
associated with an almost zero rate of metastasis and thus
indicate highly favourable prognosis [172,173]. In addi-
tion to mutations in B2M, mutations of CIITA or RFX5
are seen in approximately 20% of dMMR CRCs and pre-
ventMHC-II antigen presentation, whereas approximately
10% of dMMR CRCs have mutations of TAP1 or TAP2,
which are antigenic peptide transporters responsible for
antigen presentation, thus also preventing antigen presen-
tation on the cell surface [174,175]. In such ways, tumour
cells escape the attention of the host’s immune system,
both locally and in the circulation, but are in turn liable to
attack with help from immunotherapy, such as anti-PD-1
or PD-L1 immune checkpoint blockade [176,177].
The full variety of mechanisms by which tumours, and
dMMR tumours in particular, manage to evade the immune
systemhasyet to bedetermined.Undoubtedly, the colorectal
microbiome plays an important part in the process of CRC
development in LS as well as sporadically [178]. Intrigu-
ingly, the immune response to dMMR CRCs in the form
of the development of high endothelial venules (HEVs)
responsible for trafficking lymphocytes into lymphoid folli-
cles/TLS is stronger in LS patients than in sporadic dMMR
colonic cancers, and especially high HEV densities in B2M-
mutant tumours support the concept of immunoediting dur-
ing tumour evolution [58]. Such higher HEV densities in
B2M-mutant tumours imply that under strong immunoselec-
tive pressure created by immune cells recruited via HEVs,
tumour cells that have lostMHCclass I antigens gain growth
advantage due to immunoediting, thus revealing amajor role
of HEVs in enhancing the immunoselective pressure on
highly immunogenic cancers. Taken together with the high
numbers of dMMR crypts in LS and the low numbers of
CRCs that actually manifest, these findings all point toward
a longer process of immunoediting in LS CRCs, possibly
due to the pre-existing dMMR crypts immunising LS
patients against their own propensity to cancer, and explain-
ing the higher proportion ofB2Mmutations in LS compared
to sporadic CRCs [58,136,137]. However, these HEVs gen-
erally recruit naïve lymphocytes from the blood into tissues
and HEV-containing Crohn-like aggregates are generally
seen in a peritumoural location in both pMMR and dMMR
cancers, so our understanding of HEV and TLS in LS is as
yet incomplete [58,155,179].
Conclusions
The major carcinogenic effect of dMMR is to reduce
apoptosis and increase the net cell turnover rate. The
raised mutation rate per se is of little or no consequence,
but the bias to frameshift mutations in repetitive
sequences caused by dMMR is of fundamental conse-
quence, first in auto-immunising LS patients to FSPs
and second in thus modifying the evolution of dMMR
cancers by immunoediting.
That some MMR gene variants are associated with
abnormal MMR IHC in tumours, but not MSI, and vice
versa, plus the observation of, for example, certain
PMS2 variants in cases of CMMR-D but not LS, chal-
lenges the concept of in vitro functional tests in assessing
variant pathogenicity [4,15,18,60,61]. Which function
should be tested: DNA repair, or apoptosis, or both?
[4,180–182]. We would therefore advise caution in the
interpretation of such assays until this is clarified.
It is now understood that there are three main path-
ways to CRC in LS, including via sporadic adenomas,
but also via occult intramucosal dMMR crypts and then
beta-catenin-mutant flat cancers, which are directly inva-
sive, some of which acquire secondaryAPCmutations to
become polypoid [138,139]. Moreover, the likelihood
that tumours follow particular pathways is related to
the underlying gene affected by a pathogenic variant,
and hence the variation in expression of LS starts to be
explained andmay lead to surveillance protocols becom-
ing more tailored to genotype [3,10,142,143].
Currently, LS is defined by an individual carrying a
pathogenic variant in an MMR gene, but interpretation
of variants as pathogenic often requires tests on tumours
for dMMR [4,6]. As part of the interpretational process,
tests of MMR function may be performed in vitro, but
this too is problematic and interpretation cannot be
based solely on such analyses [4,180–182]. However,
recent advances in understanding the pathways and
responses to cancer in LS bring the possibility of alter-
native means of diagnosing LS independent of cancer
itself, indeed perhaps even an alternative definition
involving the immune system. The nature of the intense
immune response to cancers in LS, manifest as the
stronger HEV response seen in individuals with LS
from an early age (16 years) allied to specific T- and
B-cell responses to FSPs can be considered syndromic
features characteristic of LS [58,163,165]. In addition,
the dMMR crypts seen in the normal large bowel
mucosa and the dMMR glands seen in normal endome-
trium can also be considered syndromic features charac-
teristic of LS [136]. So, all taken together we may be
approaching a definition of LS in molecular terms, in
which the development of cancer, although of great
importance clinically, is not necessary to achieve diag-
nosis. This in turn may enable the classification as path-
ogenic of many variants in MMR genes, and MSH6 and
PMS2 in particular, which is currently problematic due
to their reduced penetrance.
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